Can clinical presentation predict response to a non-surgical chronic disease management program for hip and knee osteoarthritis? by Eyles, Jillian
i 
 
 
 
Can clinical presentation predict response to a non-surgical chronic disease management 
program for hip and knee osteoarthritis? 
 
Jillian Eyles BAppSc(Phty) 
 
 
 
A Thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy 
Northern Clinical School, Sydney Medical School 
Faculty of Medicine and Health 
The University of Sydney 
2019 
  
ii 
 
Supervisors’ Statement 
As supervisors of Jillian Eyles’ doctoral work, we certify that we consider her Thesis 
“Can clinical presentation predict response to a non-surgical chronic disease management 
program for hip and knee osteoarthritis?” sufficiently well presented to be examined and 
certify that it does not exceed the prescribed word limit or any extended word limit for which 
prior approval has been granted. 
 
 
Professor David J Hunter 
Institute of Bone and Joint Research, The Kolling Institute of Medical Research,  
Northern Clinical School, Sydney Medical School, Faculty of Medicine and Health,  
The University of Sydney, Australia, Rheumatology Department, Royal North Shore Hospital 
 
        Date 1st March, 2019 
 
Dr Kathryn Mills 
Faculty of Medicine and Health Sciences 
Macquarie University, Sydney, Australia 
 
        Date 1st March, 2019 
 
iii 
 
Dr Barbara R Lucas 
Physiotherapy Department, Royal North Shore Hospital, 
The Kolling Institute of Medical Research, John Walsh Centre for Rehabilitation Research, 
Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and 
Health, The University of Sydney, Australia 
 
        Date 1st March, 2019 
 
iv 
 
Candidate’s Statement 
 
I, Jillian Eyles, hereby declare that this submission is my own work and that it contains no 
material previously published or written by another person except where acknowledged in the 
text. Nor does it contain material which has been accepted for the award of another degree. 
 
I, Jillian Eyles, understand that if I am awarded a higher degree for my Thesis entitled  
“Can clinical presentation predict response to a non-surgical chronic disease management 
program for hip and knee osteoarthritis?” being lodged herewith for examination, the Thesis 
will be lodged in the University library and be available immediately for use. I agree that the 
University Librarian (or in the case of a department, the Head of the Department) may supply 
a photocopy or microform of the Thesis to an individual for research or study or to a library. 
 
        Date 1st March, 2019 
 
v 
 
 
Table of contents 
Acknowledgements ......................................................................................... xii 
Publications and Presentations ..................................................................... xiv 
Abstract .......................................................................................................... xxi 
Abbreviations ..............................................................................................xxiii 
Chapter One: Thesis introduction ................................................................... 2 
1.1. The burden of osteoarthritis ............................................................................................... 2 
1.2. Non-surgical interventions for hip and knee osteoarthritis ........................................... 3 
1.3. Osteoarthritis management programs ............................................................................... 4 
1.3.1. Outcomes of osteoarthritis management programs ................................................ 5 
1.3.2. Responders and non-responders ................................................................................ 6 
1.3.3. Worsening outcomes following OAMPs ................................................................... 8 
1.3.4. Predictors of ‘response’ and ‘worsening’ following OAMPs .................................. 8 
1.4. Osteoarthritis self-management attitudes and capabilities ............................................. 9 
1.5. Aims of this Thesis ............................................................................................................. 11 
1.6. Thesis outline ...................................................................................................................... 11 
1.7. Ethical approvals ................................................................................................................ 15 
Chapter Two: Thesis Methods ........................................................................ 17 
2.1. The Osteoarthritis Chronic Care Program Model of Care ........................................... 17 
2.2. Definition of ‘response’ ...................................................................................................... 20 
2.3. Definition of worsening ..................................................................................................... 22 
2.4. Regression models .............................................................................................................. 24 
2.4.1. Multivariable logistic regression ............................................................................... 24 
2.4.2. Multivariable linear regression ................................................................................. 25 
2.5. The COSMIN systematic review method ........................................................................ 26 
2.6. Rasch Modelling ................................................................................................................. 27 
Chapter Three: Targeting care: tailoring non-surgical management 
according to clinical presentation .................................................................. 34 
3.1. Abstract ................................................................................................................................ 34 
3.2. Introduction ........................................................................................................................ 35 
3.3. Body Mass Index ................................................................................................................ 36 
3.4. Psychological factors .......................................................................................................... 42 
3.5. Muscle Strength .................................................................................................................. 46 
vi 
 
3.6. Tibiofemoral Joint Alignment .......................................................................................... 49 
3.7. Radiographic and MRI Assessment ................................................................................. 53 
3.8. Inflammation ...................................................................................................................... 61 
3.9. Other clinical characteristics that may predict response to intervention.................... 66 
3.10. Summary ............................................................................................................................. 67 
3.11. Addendum .......................................................................................................................... 70 
Chapter Four: Does clinical presentation predict response to a non-surgical 
chronic disease management program for participants with end-stage hip 
and knee OA? .................................................................................................. 77 
4.1. Abstract: ............................................................................................................................... 77 
4.2. Introduction: ....................................................................................................................... 78 
4.3. Materials and Methods: ..................................................................................................... 79 
4.3.1. Study design ................................................................................................................ 79 
4.3.2. Intervention ................................................................................................................. 80 
4.3.3. Outcome measures ..................................................................................................... 81 
4.3.4. Statistical analyses ...................................................................................................... 84 
4.4. Results .................................................................................................................................. 87 
4.5. Discussion ........................................................................................................................... 94 
Chapter Five: Can we predict those with OA who worsen following a chronic 
disease management program? .................................................................... 105 
5.1. Abstract .............................................................................................................................. 105 
5.2. Introduction ...................................................................................................................... 107 
5.3. Patients & methods .......................................................................................................... 109 
5.3.1. Participants and data collection .............................................................................. 109 
5.3.2. Outcome Measures ................................................................................................... 110 
5.3.3. Definitions of worsening ......................................................................................... 112 
5.3.4. Statistical Analysis .................................................................................................... 113 
5.4. Results ................................................................................................................................ 114 
5.4.1. Definition of worsening outcomes ......................................................................... 118 
5.4.2. Multivariate Models ................................................................................................. 119 
5.5. Discussion ......................................................................................................................... 121 
Chapter Six: Instruments assessing attitudes toward or capability regarding 
self-management of osteoarthritis: a systematic review of measurement 
properties ...................................................................................................... 132 
6.1. Abstract .............................................................................................................................. 132 
6.2. Introduction ...................................................................................................................... 134 
6.3. Methodology ..................................................................................................................... 137 
6.3.1. Terminology .............................................................................................................. 137 
vii 
 
6.3.2. Review protocol ........................................................................................................ 137 
6.3.3. Literature search ....................................................................................................... 138 
6.3.4. Eligibility criteria ...................................................................................................... 139 
6.3.5. Data extraction.......................................................................................................... 140 
6.3.6. Methodological quality evaluation of the studies ................................................. 141 
6.3.7. Evaluation of measurement property result.......................................................... 143 
6.3.8. Data synthesis ........................................................................................................... 143 
6.4. Results ................................................................................................................................ 143 
6.4.1. Measurement property results and “best evidence synthesis” ............................ 151 
6.5. Discussion ......................................................................................................................... 160 
6.6. Conclusion ........................................................................................................................ 166 
Chapter Seven: Is the Patient Activation Measure a valid measure of 
osteoarthritis self-management attitudes and capabilities? Results of a Rasch 
analysis .......................................................................................................... 172 
7.1. Abstract: ............................................................................................................................. 172 
7.2. Background: ...................................................................................................................... 174 
7.3. Methods: ............................................................................................................................ 176 
7.3.1. Participants ................................................................................................................ 176 
7.3.2. Data ............................................................................................................................ 177 
7.3.3. Statistical analysis ..................................................................................................... 180 
7.4. Results: ............................................................................................................................... 186 
7.5. Discussion: ........................................................................................................................ 197 
7.6. Conclusion ........................................................................................................................ 201 
Chapter Eight: Examining patient activation as a predictor of short-term 
outcomes following an osteoarthritis chronic disease management program
....................................................................................................................... 207 
8.1. Abstract .............................................................................................................................. 207 
8.2. Introduction ...................................................................................................................... 209 
8.3. Methods ............................................................................................................................. 212 
8.4. Results ................................................................................................................................ 216 
8.5. Discussion ......................................................................................................................... 227 
Chapter Nine: Thesis discussion and future directions ............................... 233 
9.1. Summary of Thesis findings............................................................................................ 233 
9.2. Strengths and limitations of this Thesis ........................................................................ 244 
9.3. Future directions .............................................................................................................. 248 
9.4. Final Remarks ................................................................................................................... 250 
References ..................................................................................................... 251 
viii 
 
Appendices.................................................................................................... 268 
Appendix 1. Search strategy........................................................................................................ 268 
Appendix 2: Quality criteria for rating the results of measurement properties ................... 271 
Appendix 3: Targeting care: tailoring non-surgical management according to clinical 
presentation.’ ................................................................................................................................ 273 
Appendix 4: Does clinical presentation predict response to a non-surgical chronic disease 
management program for participants with end-stage hip and knee OA? .......................... 274 
Appendix 5: Can we predict those with OA who worsen following a chronic disease 
management program? ............................................................................................................... 275 
Appendix 6: Instruments assessing attitudes toward or capability regarding self-
management of osteoarthritis: a systematic review of measurement properties. ................ 276 
 
ix 
 
Tables 
Table 4.1 Participant demographics................................................................................................. 90 
Table 4.2 OACCP participant referrals ........................................................................................... 92 
Table 4.3 Univariable analyses .......................................................................................................... 93 
Table 4.4 Multivariable model .......................................................................................................... 93 
Table 5.1 Participant demographics............................................................................................... 117 
Table 5.2 Univariable analyses for three definitions of worsening ............................................ 119 
Table 5.3 Multivariable models for three definitions of worsening ........................................... 120 
Table 6.1 Definitions of measurement properties ........................................................................ 142 
Table 6.2 Levels of evidence for the quality of the measurement property ............................... 145 
Table 6.3 Content comparison of instruments ............................................................................. 147 
Table 6.4 Characteristics of included studies ................................................................................ 148 
Table 6.5 Measurement property results: internal consistency, reliability, measurement error 
and structural validity. ............................................................................................................ 152 
Table 6.6 Measurement property results: construct validity, cross-cultural validity, and floor 
and ceiling effects. .................................................................................................................... 155 
Table 6.7 Measurement property synthesis using COSMIN rating, quality criteria and levels 
of evidence ................................................................................................................................ 157 
Table 7.1 PAM-13 items and mean response scores .................................................................... 179 
Table 7.2 Participant characteristics .............................................................................................. 187 
Table 7.3 Item fit statistics for the PAM-13 .................................................................................. 192 
Table 7.4 Item fit statistics for the PAM-13 following removal of items .................................. 194 
x 
 
 195 
Table 7.5 Correlations between Patient Activation Measure-13 scores and other variables .. 197 
Table 8.1 Characteristics of participants. ...................................................................................... 218 
Table 8.2 Change in PAM-13, pain and function baseline to 12 and 26- weeks ...................... 220 
Table 8.3 Linear regression analyses; change in WOMAC pain Wk0 to Wk12 ....................... 223 
Table 8.4 Linear regression analyses; change in WOMAC function Wk0 to Wk12 ................ 224 
Table 8.5 Linear regression analyses; change in WOMAC pain Wk0 to Wk26 ....................... 225 
Table 8.6 Linear regression analyses; change in WOMAC function Wk0 to Wk26 ................ 226 
xi 
 
Figures 
 
Figure 3.1 Clinical characteristics associated with response to nonsurgical management ........ 69 
Figure 4.1 Study flowchart ................................................................................................................ 89 
Figure 5.1 Study Flowchart ............................................................................................................. 116 
Figure 5.2 Variability of worsening explained by the model ...................................................... 126 
Figure 6.1 Flowchart of the selection and inclusion of studies ................................................... 146 
Figure 7.1 Responses across items of the PAM-13 ....................................................................... 189 
Figure 7.2 Person: item map of study participants and PAM-13 item ...................................... 191 
Figure 7.3 Person: item map of study participants and PAM-13: removal of item ................. 195 
Figure 8.1 Flow diagram of study participants ............................................................................. 217 
xii 
 
Acknowledgements 
 
Christopher, I cannot thank you enough for the love and support you have tirelessly shown 
me, especially over the past six years of my candidature. I am blessed that you are my best 
friend, an exceptional partner in life and a wonderful father to our children. Despite both of 
us leading extremely busy lives, we still manage to have amazing adventures together. I pledge 
to you that the next adventure will not be another PhD! I love you, I can’t wait to see what we 
are going to do next. To my extraordinary children Brayden and Lachlan. You are both 
clever, funny and kind, therefore I am the luckiest mother in the world. You were so young 
when I started on this journey (Lachlan three, Brayden five) you have probably forgotten 
what it is like to have a mother who is not a ‘crazy PhD Mum’. Thank you both for your 
patience and understanding when I was sitting in front of the computer day, night and every 
weekend. These last few months you have both offered me endless support and kindness for 
which I will always be grateful. I love you both so much and look to enjoying our journey 
together as you continue to grow and learn. Never forget that you can do anything- reach for 
the stars! 
 
Mum and Dad, you have always been my greatest advocates and have always told me that I 
can do anything. Well, look what happened! Thank you for your abundant love, support and 
encouragement. I love and respect you both so much. I also love and respect my beautiful, 
brave sister Alison and gorgeous, strong niece Isabelle, your support has been so important to 
me. The last few years have been extremely tough for you both. I miss Dave terribly, but I 
xiii 
 
can’t even begin to imagine how much you both miss him. To Marie, Daryl and the extended 
Large/Eyles clan, thank you for your continued love and support. 
 
David, Kat and Barb I am so appreciative of your guidance during my PhD candidature. Your 
support and mentorship have been exceptional. David, you are a great leader, it is such an 
honour to work with you and I can’t thank you enough for the many, many opportunities you 
have offered me. You make me believe that anything is possible. Kat, you are an amazing 
mentor. I enjoy getting over-excited about study design, outcome measures and statistics with 
you immensely, but our friendship is way more fun! Barb, you believed in me from the very 
beginning and advocated strongly that I should embark on this PhD adventure. Thank you 
for being a wonderful friend, mentor and colleague.  
 
To my fantastic friends Joce, Manuela Sarah and Matt, I could not have done this without 
you, you have all been there for me, every day, especially in the last few months. I am so 
grateful for your friendship and support. Bec, Lisa and Jess, you have all exercised with me to 
help keep me sane and listened to me when I needed you to. Thank you for your precious 
friendships and for being my fitness buddies. To my fabulous group of friends- you know 
who you are- thank you for believing in me and tolerating my limited social contact for the 
last six years. I am so grateful you are still talking to me! And I look forward to spending 
more time with you. Lastly, my colleagues, many of you are also dear friends to me. You have 
seen my every day, celebrated my successes, commiserated with me in my defeats, encouraged 
and supported me to the last through this time. Thank you all. 
xiv 
 
Publications and Presentations  
 
Published works from this Thesis: 
1. Eyles, JP, Hunter, DJ, Meneses, S, Collins, N, Dobson, F, Lucas, BR, Mills, K. Instruments 
assessing attitudes toward or capability regarding self-management of osteoarthritis: a 
systematic review of measurement properties. Osteoarthritis and Cartilage 
2017;25(8):1210-22. 
2. Eyles JP, Mills K, Lucas BR, Williams MJ, Makovey J, Teoh L, et al. Can we predict those 
with osteoarthritis who will worsen following a chronic disease management program? 
Arthritis Care Res (Hoboken). 2016;68(9):1268-77. 
3. Eyles JP, Lucas BR, Patterson JA, Williams MJ, Weeks K, Fransen M, et al. Does clinical 
presentation predict response to a nonsurgical chronic disease management program for 
endstage hip and knee osteoarthritis? J Rheumatol. 2014;41(11):2223-31. 
4. Eyles J, Lucas BR, Hunter DJ. Targeting care: tailoring nonsurgical management according 
to clinical presentation. Rheum Dis Clin North Am. 2013;39(1):213-33. 
 
Work from this thesis submitted for publication 
1. Eyles, JP, Ferreira, M Mills, K, Lucas, BR Robbins, SR Williams, M, Lee, H Appleton, S, 
Hunter, DJ. Is the Patient Activation Measure a valid measure of osteoarthritis self-
management attitudes and capabilities? Results of a Rasch analysis. BMC Health Quality 
of Life Outcomes. Submitted 7th July, 2018. 
 
xv 
 
Co-authored works arising from osteoarthritis research during the period of candidature: 
1. Mills K, Eyles JP, Martin MA, Hancock MJ, Hunter DJ. Exploratory study of 6-month 
pain trajectories in individuals with predominant patellofemoral osteoarthritis: a cohort 
study. JOPST. 2018:1-38. 
2. Leech RD, Eyles J, Batt ME, Hunter DJ. Lower extremity osteoarthritis: optimising 
musculoskeletal health is a growing global concern: a narrative review. BJSM 2018. (in 
press) 
3. Riordan E, Robbins S, Deveza L, Duong V, Oo WM, Wajon A, et al. Radial subluxation in 
relation to hand strength and radiographic severity in trapeziometacarpal osteoarthritis. 
Osteoarthritis Cartilage. 2018.(in press) 
4. Duong V, Bennell KL, Deveza LA, Eyles JP, Hodges PW, Holden MA, et al. Attitudes, 
beliefs and common practices of hand therapists for base of thumb osteoarthritis in 
Australia (The ABC Thumb Study). Hand Therapy. 2017;23(1):19-27. 
5. Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating 
osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167-75. 
6. Paterson KL, Hunter DJ, Metcalf BR, Eyles J, Duong V, Kazsa J, et al. Efficacy of intra-
articular injections of platelet-rich plasma as a symptom- and disease-modifying 
treatment for knee osteoarthritis - the RESTORE trial protocol. BMC musculoskeletal 
disorders. 2018;19(1):272. 
7. Liu X, Eyles J, McLachlan AJ, Mobasheri A. Which supplements can I recommend to my 
osteoarthritis patients? Rheumatology (Oxford, England). 2018;57(suppl_4):iv75-iv87. 
xvi 
 
8. Castro-Dominguez F, Melo L, Eyles JP. Models of healthcare delivery for osteoarthritis. 
Reumatologia clinica. 2018 (in press). 
9. Melo L, Schrieber L, Eyles J, Deveza LA, Meneses SRF, Hunter DJ. Comparison of 
physical examination performance of medical students trained by musculoskeletal versus 
non-musculoskeletal specialists. Int J Rheum Dis. 2017;20(4):451-9. 
10. Deveza LA, Hunter DJ, Wajon A, Bennell KL, Vicenzino B, Hodges P, et al. Efficacy of 
combined conservative therapies on clinical outcomes in patients with thumb base 
osteoarthritis: protocol for a randomised, controlled trial (COMBO). BMJ Open. 
2017;7(1) 
11. Zhang X, Eyles JP, Makovey J, Williams MJ, Hunter DJ. Is the effectiveness of 
patellofemoral bracing modified by patellofemoral alignment and trochlear morphology? 
BMC Musculoskelet Disord. 2017;18(1):168. 
12. Teoh LSG, Eyles JP, Makovey J, Williams M, Kwoh CK, Hunter DJ. Observational study 
of the impact of an individualized multidisciplinary chronic care program for hip and 
knee osteoarthritis treatment on willingness for surgery. Int J Rheum Dis. 
2017;20(10):1383-92.  
13. Murphy NJ, Eyles J, Bennell KL, Bohensky M, Burns A, Callaghan FM, et al. Protocol for 
a multi-centre randomised controlled trial comparing arthroscopic hip surgery to 
physiotherapy-led care for femoroacetabular impingement (FAI): the Australian 
FASHIoN trial. BMC Musculoskelet Disord. 2017;18(1):406 
xvii 
 
14. Mills KA, Naylor JM, Eyles JP, Roos EM, Hunter DJ. Examining the Minimal Important 
Difference of Patient-reported Outcome Measures for Individuals with Knee 
Osteoarthritis: A Model Using the Knee Injury and Osteoarthritis Outcome Score. J 
Rheumatol. 2016;43(2):395-404. 
15. Murphy NJ, Eyles JP, Hunter DJ. Hip Osteoarthritis: Etiopathogenesis and Implications 
for Management. Advances in therapy. 2016;33(11):1921-46. 
16. Yu SP, Williams M, Eyles JP, Chen JS, Makovey J, Hunter DJ. Effectiveness of knee 
bracing in osteoarthritis: pragmatic trial in a multidisciplinary clinic. Int J Rheum Dis. 
2016;19(3):279-86. 
 
Presentations of work arising from this Thesis 
Invited international presentations 
1. Eyles JP, Novel models of service delivery for osteoarthritis management. Invited 
presentation at OARSI Pre-congress workshop: Update on Osteoarthritis Management 
Programs. Liverpool, UK April 2018. 
 
2. Eyles JP, Measurement of outcomes and their evaluation. Invited presentation at OARSI 
Pre-congress workshop: Osteoarthritis chronic disease management programs: 
implementing best practice. Amsterdam, Netherlands April 2016. 
 
 
xviii 
 
International meetings 
1. Eyles JP, Mills K, Lucas BR, Robbins SR, O'Connell RL, Williams M, Lee H, Appleton S, 
Hunter DJ. Is patient activation associated with changes in symptoms following an 
osteoarthritis management program? Osteoarthritis Research International Congress 
Accepted for presentation April 2019.  
2. Eyles JP, Ferreira M, Mills K, Lucas BR, Robbins SR, Williams M, et al. Does the patient 
activation measure provide a meaningful measure of OA self-management? Osteoarthritis 
and Cartilage. 2018;26:S235-S6. Osteoarthritis Research International Congress April 
2018, Liverpool UK. 
3. Eyles JP, Hunter DJ, Meneses S, Collins N, Dobson F, Lucas B, et al. Measurement 
Properties of Instruments Assessing Attitudes and Capabilities Regarding Osteoarthritis 
Self-management: A Systematic Review. Osteoarthritis and Cartilage. 2017;25:S347. 
Osteoarthritis Research International Congress April 2017, Las Vegas USA. 
4. Eyles JP, Mills K, Lucas BR, Williams MJ, Makovey J, Teoh L, et al. Can we predict those 
who report worsening despite participation in a programme based on OARSI guidelines 
for non-surgical management of hip and knee OA? Osteoarthritis and Cartilage. 
2016;24:S474-S5. Osteoarthritis Research International Congress April 2016, Amsterdam 
Netherlands. 
 
 
 
 
xix 
 
National meetings 
1. Eyles JP, Mills K, Lucas BR, Robbins SR, O'Connell RL, Williams M, Lee H, Appleton S, 
Hunter DJ. Examining patient activation as a predictor of outcomes following the 
OACCP. Musculoskeletal Network Forum, Royal Prince Alfred Hospital, Sydney 
February 2019. 
2. Eyles JP, Hunter DJ, Meneses S, Collins N, Dobson F, Lucas BR, Mills K. Instruments 
assessing attitudes towards and/or capabilities regarding self-management of 
Osteoarthritis; a systematic review of measurement properties. Sydney Musculoskeletal, 
Bone & Joint Health Alliance Scientific meeting. Sydney October 2017.  
3. Eyles JP, Lucas BR, McConnell R, Williams MJ, Hunter DJ. Do symptoms of depression 
moderate the association between weight loss and response of overweight participants to a 
chronic care programme for hip & knee OA? Momentum 2017 Physiotherapy 
Conference, ICC Sydney, October 2017. 
4. Eyles JP, Hunter DJ, Meneses S, Collins N, Dobson F, Lucas BR, Mills K. Which 
instrument best measures patient attitudes and capabilities regarding osteoarthritis self-
management? Momentum 2017 Physiotherapy Conference, ICC Sydney, October 2017. 
5. Eyles JP, Hunter DJ, Meneses S, Collins N, Dobson F, Lucas BR, Mills K. Instruments 
assessing attitudes toward or capability regarding self-management of osteoarthritis: a 
systematic review of measurement properties. New Horizons Conference, UTS Sydney, 
2016. 
xx 
 
6. Eyles JP, Hunter DJ, Meneses S, Collins N, Dobson F, Lucas BR, Mills K. Instruments 
assessing attitudes towards and/or capabilities regarding self-management of 
Osteoarthritis- a systematic review of measurement properties. Allied Health Forum, 
RNSH, Sydney 2016. 
7. Eyles JP, Mills K, Handcock M, Martin M, Hunter DJ. Can patients with patellofemoral 
osteoarthritis be sub-grouped at baseline? Journal of Science & Medicine in Sport. 
December 2015 Volume 19, Supplement, Page e86. Sports Medicine Australia conference 
Gold Coast Qld, October 2015 
8. Eyles JP, Lucas BR, Patterson JA, Williams MJ, Weeks K, Fransen M, Hunter DJ.  ‘Does 
Clinical Presentation Predict Response to a Nonsurgical Chronic Disease Management 
Program for Endstage Hip and Knee Osteoarthritis?’ 2014 Osteoarthritis Forum at the 
Kolling Institute of Medical Research, Sydney. 
9. Eyles J, Mills K, Handcock M, Martin M, Hunter D. Can patients with patellofemoral 
osteoarthritis be sub-grouped at baseline? Journal of Science and Medicine in Sport. 
2015;19:e86. Sports Medicine Australia Conference, October 2015. 
  
xxi 
 
Abstract  
 
Osteoarthritis (OA) is a leading cause of global disability. International guidelines make clear 
recommendations for evidence-based OA management. However, there is considerable 
discrepancy between these recommendations and the actual care received by patients. 
Osteoarthritis management programs (OAMPs) aim to address this evidence-practice gap. 
There is evidence that some participants improve in pain and function following OAMPs, 
however, others fail to accomplish these gains. The ability to predict patient outcomes would 
enable targeting these programs at those people most likely to demonstrate improvement. 
This Thesis addresses the question: ‘Can clinical presentation predict response to an OAMP?’ 
Five studies were conducted to address this question.  
 
Two longitudinal cohort studies were conducted to examine the relationships between 
participant characteristics and changes in pain and function following 26 weeks of an OAMP. 
Significant predictors of response were found to include: sex; knee as treatment joint (vs hip); 
and total joint arthroplasty (TJR) waitlist status. However, the regression models used were 
not sufficiently sensitive to correctly classify ‘responders’ or ‘worseners’. 
 
We were also interested in examining patients’ attitudes and capabilities towards OA self-
management as a construct that could potentially predict OAMP outcomes. Before we 
examined these relationships, we conducted a systematic review (third study) that aimed to 
identify the instrument assessing OA self-management attitudes and capabilities with the 
xxii 
 
“best” measurement properties. From this review, little extant measurement property 
evidence was found to recommend any instrument.  
 
The fourth study examined the measurement properties of the Patient Activation Measure 
(PAM-13) based on its good face validity. We conducted a cross-sectional cohort study that 
provided evidence of adequate measurement properties to support the use of PAM-13 to 
measure OA self-management capabilities in this population. The fifth study examined the 
relationships between PAM-13 and changes in pain and function. Surprisingly, the PAM-13 
scores were not associated with changes in pain or function following 12 or 26 weeks of the 
OAMP.  
 
It is difficult to determine who will improve or worsen in an OAMP. It does not seem to be 
based on participants’ self-management attitudes or capabilities, although this could be due to 
the measure we used rather than the construct. Variables found to be significantly associated 
with outcomes were Timed-Up-and-Go and employment status. Although these findings 
were statistically significant, the evidence from a single clinical cohort study is insufficient to 
translate into clinical practice. Hence, these findings should be replicated in larger cohorts.  
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Chapter One: Thesis introduction 
1.1. The burden of osteoarthritis 
Symptomatic osteoarthritis (OA) is often defined by the presence of pain and/or stiffness in a 
joint, coupled with structural changes seen on imaging. The experience of pain and/or 
stiffness often prompts people to seek treatment for their OA. The nature, severity and impact 
of osteoarthritis symptoms vary greatly between individuals and change over time (1). 
Osteoarthritis is a highly prevalent condition (2, 3). The knee, hip and hand joints are the 
most commonly affected sites of OA (4).  OA prevalence is influenced by multiple factors 
including age, sex, cultural background and type of employment. The prevalence of OA has 
been reported to be between 7% and 16% for lower limb OA (5, 6) and 7 and 15% for hand 
OA (7).  
 
Osteoarthritis is not only highly prevalent, it is a severely disabling condition. Of 291 
conditions included in the global burden of disease study, hip and knee OA together ranked 
as the 11th highest contributor to global disability (8). This is particularly worrisome given 
that in the presence of an aging population, and increasing rates of obesity, the prevalence of 
OA and its projected burden, are projected to increase dramatically (3). The financial burden 
of OA is also substantial to both individuals and the economy. Furthermore, these costs 
increase with disease severity (9). The overall impact of OA also needs to be considered 
within the context of multimorbidity; OA is one of the most common comorbidities of people 
already living with chronic conditions such as heart disease, diabetes or cancer (10). Not only 
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is the health management of people with complex multimorbidity more difficult, the ensuing 
health outcomes of these people may be worse (11).  
 
1.2. Non-surgical interventions for hip and knee osteoarthritis 
In order to address the needs of those suffering with this chronic, disabling condition, 
international management guidelines have been developed to recommend evidence-based 
care for OA. These guidelines are in broad agreement regarding their recommendations of 
efficacious non-pharmacological and pharmacological treatments for management of hip and 
knee OA (12). There is relative consensus amongst these guidelines that hip and knee OA 
management should be tailored to the individual and include the following three core 
effective, non-surgical, non-pharmacological interventions.  
i) Self-management and OA education: Education and support for OA self-management are 
consistently considered cornerstones of OA treatment (12, 13), despite providing modest 
treatment effects when used in isolation (14, 15). 
 ii) Exercise: Land-based exercise has been found to provide moderate treatment effects in the 
short term for both pain and function (16) in knee OA, and slightly smaller, short-term 
treatment effects have been found in hip OA (17).  
 iii) Weight loss interventions: Weight loss is consistently recommended as a core intervention 
in management guidelines for people with hip or knee OA who are overweight or obese (12, 
13). In people with knee OA who are obese, weight loss has been demonstrated to provide 
moderate treatment effects for pain and function. These outcomes improve further when the 
weight loss is greater than 5% of baseline bodyweight (18).  
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In addition, OA management guidelines recommend that these three core, non-
pharmacological OA interventions may be supported by judicious and regularly monitored 
use of pharmacological agents (13). Other evidence-based adjunctive treatments also 
recommended, as required, include : psychological interventions such as pain coping skills or 
management of psychological symptoms (19); referral to a physiotherapist if the patient is 
weak or stiff; walking aids and other assistive devices (20); braces, taping and specialised 
footwear (21) in the presence of joint malalignment (13).  
 
1.3. Osteoarthritis management programs 
Despite the existence of clear, evidence-based recommendations for OA management, their 
implementation into clinical practice has been limited (22). Considerable discrepancy persists 
between the recommendations and the actual care that is received by OA patients in 
Australia. The Caretrack study estimated that only 43% of Australians with OA received 
evidence-based care (23), which is consistent with international evidence (24, 25). The 
reasons for this evidence-practice gap are complex. One contributing factor is that there 
remains a perception amongst healthcare providers that OA is merely a ‘normal part of the 
ageing process’. This perception is exacerbated when patients present with OA within the 
context of competing demands imposed by multimorbidity, particularly in the presence of 
perceived ‘more serious’ conditions such as cardiovascular disease and cancer (26). When OA 
care is provided it is often limited to pharmacological treatments alone, and non-
pharmacological treatments such as exercise and weight loss are underutilised or overlooked 
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entirely (25). In response to these challenges, models of OA care have been developed and 
implemented over the past 15 years to attempt to close this evidence-practice gap (22).  
 
Implemented models of OA care can be referred to as OA management programs (OAMPs). 
As there is no published definition of what constitutes an OAMP, for the purposes of this 
Thesis, an OAMP is defined as a model of evidence-based, non-surgical OA care that has 
been implemented in a real-world setting providing the following four components:  
a. Individualised OA care 
b. Provided as a package of care with longitudinal reassessment and treatment progression 
c. Two or more components of the core, non-surgical, non-pharmacological interventions 
(i.e. self-management and OA education; exercise; weight loss interventions) 
d. Optional evidence-based adjunctive treatments as required. 
Published international OAMPs differ markedly in their models of service delivery and 
implementation across a range of healthcare systems (22). However OAMPs include the core 
components previously described in common of i) education and support for self-
management, ii) exercise; and generally offer various combinations of other evidence-based 
therapies such as: weight loss interventions; psychological support; review of analgesics; 
assistive devices and braces (22).  
 
1.3.1. Outcomes of osteoarthritis management programs 
There is some evidence in previous literature to support the efficacy or value of OAMPs in 
terms of improvements in pain and functional ability (27-30). The focus of this Thesis, 
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however, was not on efficacy, but on the relationships between clinical characteristics and 
outcomes following participation in an OAMP. If clinical characteristics were found to be 
associated with OAMP outcomes, this knowledge could be used to direct services to people 
likely to improve following participation. In an era where the delivery of evidence-based care 
is demanded within an environment of growing economic rationalism, the ability to predict 
outcomes to intervention would enable identification of people with OA most likely to benefit 
from an OAMP and improve resource allocation. Further, people identified as unlikely to 
improve, or likely to worsen despite treatment, may be targeted for adjunctive therapies that 
may improve their chances of success e.g. cognitive behavioural therapy or motivational 
counselling. Therefore, the overarching research question of this Thesis was:  
‘Can clinical presentation predict response to a non-surgical chronic disease management 
program for hip and knee osteoarthritis?’.  
 
1.3.2. Responders and non-responders  
 
The first aim of this Thesis was to determine if “baseline clinical characteristics were 
associated with the outcomes of an OAMP”. One method of reporting outcomes following OA 
interventions is to present the proportion of people who achieve a pre-defined threshold for 
change in the outcome(s) of interest. Participants who achieve this threshold of improvement 
in an outcome can be classified as ‘responders’ and those who did not as ‘non-responders’. 
There are few previous studies that have reported outcomes following OAMPs in terms of the 
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proportion of participants who were ‘responders’, and these used varying definitions of 
‘response’ (27, 29, 30) . One study that adopted this approach was a randomised controlled 
trial that compared a patient self-management program- “the Enabling Self-Management and 
Coping of Arthritic Knee Pain Through Exercise (ESCAPE-knee pain) program” with usual 
primary care in the United Kingdom (27). A pre-defined threshold to classify participants as 
responders was set at 15% of the Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) function score (27). Sixty-one percent of participants were classified as 
responders immediately following the intervention and 54% of all participants maintained 
this at the six-month follow up (27). Furthermore, two cohort studies reported outcomes 
from a Dutch stepped-care model for hip and knee OA. The first study defined the responder 
threshold using the Outcome Measures in Rheumatology- Osteoarthritis Research Society 
International (OMERACT-OARSI) response criteria (31). The authors reported that 47% of 
participants were responders at 12-weeks (30). The second study used the threshold of pain 
Numeric Rating Scale (NRS) ≤4 to indicate the threshold for responders to the intervention 
(29). Twenty-nine percent of participants with complete data were responders according to 
this threshold (29). 
 
 The rationale for the definition of responder for our cohort studies is discussed in detail in 
the Thesis methods in Chapter Two. In brief, we used the threshold of treatment response 
described by Angst et al (2002) that was developed in a prospective cohort study of 
participants with hip and knee OA engaged in a multimodal rehabilitation intervention (32). 
This threshold included: a relative change greater or equal to 18% (100 × (change of 
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score/baseline score); and an absolute change of 9 points improvement of WOMAC global 
scores at 26-week assessment compared to baseline. We classified cohort participants as 
responders and non-responders in Chapter Four of this Thesis. 
 
1.3.3. Worsening outcomes following OAMPs 
In addition to the concept of responders and non-responders, it is important to consider that 
people can report worsening outcomes despite their participation in OAMPs. There is little 
evidence available in the current literature that addresses worsening outcomes following 
OAMPs. Further, there is a paucity of evidence available to support the use of a suitable 
threshold of worsening. In Chapter Five of this Thesis, we compared three different 
thresholds of worsening following participation in an OAMP and examined the relationships 
of these thresholds with baseline clinical characteristics. The thresholds of worsening and the 
rationale for the choice of these thresholds is also described in Chapter Two. 
 
1.3.4. Predictors of ‘response’ and ‘worsening’ following OAMPs 
Few strong predictors of response to OAMPs have been identified in previous studies. Four 
previous studies, which attempted to identify baseline predictors of response to three discrete 
OA management programs, did not find consistent predictors of response (29, 30, 33, 34). 
Furthermore, we were unable to find any studies in the literature concerned with the clinical 
characteristics associated with worsening outcomes following an OAMP. The study in 
Chapter Five was therefore undertaken to investigate characteristics that were associated with 
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worsening outcomes. It compared three different thresholds of worsening, following 
participation in an OAMP, and examined the relationship of worsening with baseline clinical 
characteristics.  
 
1.4. Osteoarthritis self-management attitudes and capabilities 
Self-management is a general term used to describe an individual’s ability to manage the 
physical and psychological symptoms, treatments, consequences and lifestyle changes 
required to live with their condition (35). As stated earlier in section 1.3 of this chapter, a core 
intervention of OAMPs is to support participants to self-manage their OA. It follows that OA 
self-management attitudes and capabilities may be associated with the ensuing clinical 
outcomes following participation in an OAMP. We hypothesized that better attitudes towards 
and/or capabilities regarding self-management of OA at baseline would be associated with 
improved outcomes following participation in an OAMP.  
 
To test this hypothesis, it was necessary to identify a suitable instrument to measure attitudes 
towards and/or capabilities regarding self-management of OA. Measures of this construct 
have not been widely used to report OAMP outcomes, and there is no ‘gold standard’. The 
second aim of this Thesis was therefore to “identify a suitable standardised instrument that 
could be used to measure OA self-management attitudes and/or capabilities.” To make a 
recommendation on the “best” measure of OA self-management attitudes and capabilities, it 
was necessary to consider the measurement property or psychometric evidence available for 
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instruments measuring the construct in the population of interest. Measurement properties 
provide information on the performance of an instrument such as construct and structural 
validity, reliability, sensitivity, responsiveness and feasibility within a given setting (36, 37). 
Chapter Six comprises a systematic review that synthesized the available measurement 
property evidence for instruments assessing OA self-management attitudes and capabilities.  
 
The third aim of this Thesis was “to test the measurement properties of an instrument 
measuring OA self-management attitudes and capabilities in people living with OA.” The 
Patient Activation Measure (PAM-13), identified in the systematic review, was selected as a 
potential instrument for further investigation. The measurement properties of the PAM-13 
were tested in a cross-sectional study described in detail in Chapter Seven.  
 
The fourth aim of this Thesis was “to determine if OA self-management attitudes and 
capabilities predict response to an OAMP”. We tested the hypothesis that that better attitudes 
towards and/or capabilities regarding self-management of OA, measured on the PAM-13, at 
baseline, would be associated with improved outcomes following participation in an OAMP 
in Chapter Eight. In this longitudinal cohort study, we examined the relationship between 
patient activation (PAM-13 scores) and changes in pain and function. 
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1.5.  Aims of this Thesis 
To recap, the overarching research question of this Thesis was:  
‘Can clinical presentation predict response to a non-surgical chronic disease management 
program for hip and knee osteoarthritis?’.  
There were four specific aims of this Thesis that addressed this question: 
I. To determine if baseline clinical characteristics were associated with outcomes of the 
OACCP (Chapters Three, Four and Five) 
II. To identify a suitable standardised instrument to measure OA self-management 
attitudes and/or capabilities (Chapter Six) 
III. To test the measurement properties of an instrument measuring OA self-management 
attitudes and capabilities in people living with OA (Chapter Seven) 
IV. To determine if OA self-management attitudes and capabilities predict response to the 
OACCP (Chapter Eight) 
 
1.6. Thesis outline 
The Thesis is arranged in nine chapters, each written so that they can be read independently. 
The University of Sydney permits published manuscripts arising from the candidature to be 
included in the Thesis. Six chapters of this Thesis consist of papers that were submitted for 
publication. Four of these chapters have been published with the remaining two currently 
under review. Each of these six chapters addresses one of the four specific aims. 
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Following on from the Thesis introduction comprising Chapter One, the methods used in 
this Thesis are described in Chapter Two. This chapter provides a broad overview of data 
collection for the four cohort studies and statistical techniques used to model potential 
predictors of outcomes following an OA management program (OAMP). There is an 
emphasis on less commonly-used methodologies including the COnsensus-based Standards 
for the selection of health Measurement Instruments (COSMIN) initiative methodology for 
systematic reviews of outcome measurement instruments and Rasch statistical modelling to 
test the measurement properties of outcome measurement instruments. 
 
The first aim of this Thesis was to identify baseline characteristics that were associated with 
“response” to an OAMP. To address this aim we first conducted a literature review to 
determine if clinical characteristics had been shown to be associated with response to OAMPs 
in previous work. The body of literature addressing predictors of response to OAMPs was 
very limited. To broaden the depth of our knowledge of the literature, we conducted a 
narrative review to summarise existing evidence of predictors of response to any nonsurgical 
interventions (pharmacological and non-pharmacological) for OA. This review is presented 
as Chapter Three and also considered whether the authors defined a threshold for ‘response’ 
within the analyses. It is presented as published in the Rheumatic Clinics of North America 
(38).  
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The study presented in Chapter Four was a prospective, longitudinal, clinical cohort study 
that examined the relationships between baseline characteristics of OA management program 
participants and positive response to the intervention. We hypothesised that “it would be 
possible to predict participants likely to “respond” to the program using baseline demographic, 
psychological, disease-related and functional performance variables” (39). This study is 
presented as published in The Journal of Rheumatology (39).  
 
The second prospective, longitudinal, clinical cohort study presented in Chapter Five 
investigated participant characteristics associated with worsening outcomes following 
participation in an OA management program. We hypothesised that: “the same participants 
with similar demographic, psychological, disease-related and functional performance predictor 
variables would be identified as ‘worse’ across three definitions of worsening”. It is presented as 
published in Arthritis Care and Research (40). 
 
The second aim of this Thesis was to identify a suitable standardised instrument to measure 
OA self-management attitudes and/or capabilities. This aim was addressed with the 
systematic review in Chapter Six presented as published in Osteoarthritis and Cartilage (41). 
The aims of the systematic review were to: 
“i) identify studies reporting measurement properties of instruments assessing attitudes toward 
and/or capabilities regarding self-management of OA;  
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ii) systematically critique the studies evaluating instruments using the Consensus-based 
Standards for the selection of Health Measurement Instruments (COSMIN) tool: and  
iii) synthesize the evidence available with the possibility of making rudimentary 
recommendations concerning the best evidence-based instruments…”(41). 
 
One instrument identified from the systematic review, deemed worthy of further 
investigation, was the Patient Activation Measure 13 (PAM-13). The PAM-13 measures self-
reported knowledge, skill, and confidence for self-management of one’s health (42). Although 
there was limited extant measurement property evidence for this instrument, it was chosen 
because it appeared to have adequate face validity to justify further testing in an OA 
population. The third aim of this Thesis was to test the measurement properties of an 
instrument measuring OA self-management attitudes and capabilities in people living with 
OA. Chapter Seven presents the cross-sectional cohort study undertaken to examine the 
measurement properties of the PAM-13 presented in this Thesis as submitted to BMC Health 
Quality of Life Outcomes (under review).  
 
After adequate measurement properties were established for the PAM-13 in Chapter Seven, 
the fourth aim of this Thesis was to determine if OA self-management attitudes and 
capabilities were associated with changes in pain and function following participation in an 
OAMP. Chapter Eight describes a longitudinal cohort study. Finally, Chapter Nine provides 
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a summary of the principal findings of this Thesis, discusses the implications of these findings 
and proposes directions for future research.  
 
1.7. Ethical approvals  
Ethical approval was obtained for Chapters Four and Five from the NSW Population and 
Health Services Research Ethics Committee AUREI Reference HREC/12/CIPHS/63. Cancer 
Institute NSW Reference Number 2012/08/413.  
Ethical approval for Chapters Six and Seven was provided by Human Research Ethics 
Committees (HREC): 
Hunters Hill Hospital NSPHEC 2016-LNR-007; Mount Wilga Hospital NSPHEC 2017-LNR-
005 and Northern Sydney Local Health District reference: RESP/16/11, HREC reference: 
LNRl16/HAWKE/14.  
The remaining chapters did not require ethical approval. 
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Chapter Two: Thesis Methods 
 
Detailed methodology regarding each of the studies contained within this Thesis are included 
within the discrete chapters reporting them. The purpose of this chapter is to provide brief 
overview of the main methodological considerations of this PhD work including:   
2.1  The Osteoarthritis Chronic Care Program- the OAMP that is the main focus of this 
Thesis; 
2.2 Definition of response; 
2.3 Definition of worsening; 
2.4 Regression models: logistic and linear multivariable regression; 
2.5 COnsensus-based Standards for the selection of health Measurement Instruments 
(COSMIN) initiative methodology for systematic reviews of outcome measurement 
instruments and; 
2.6 Rasch modelling. 
2.1. The Osteoarthritis Chronic Care Program Model of Care 
The Osteoarthritis Chronic Care Program (OACCP) was developed and implemented by the 
Musculoskeletal Network of the Agency for Clinical Innovation (ACI); a pillar of the New 
South Wales (NSW) Ministry of Health, Australia. The OACCP model of care was based on 
the chronic care model (CCM) (43), a proactive healthcare delivery system that enables 
patients to self-manage their condition. This CCM was supported by a coordinated team of 
health care providers with appropriate clinical expertise, all underpinned by suitable health 
information technology systems (44). Using CCM principles the OACCP aimed to support 
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participants with hip and knee OA to reduce their pain, increase their function and quality of 
life through provision of a combination of evidence-based interventions delivered by a 
multidisciplinary team.  
 
In this model of care, the OACCP Musculoskeletal (MSK) coordinator was an experienced 
Physiotherapist or Exercise Physiologist with expertise in the management of OA and the 
central health professional who coordinated the care of OACCP participants. At the first 
program visit the MSK coordinator conducted a detailed assessment, provided participants 
with education about their condition and supported participants to set goals for the 
management of their OA and any comorbidities. The assessment and goal setting was based 
on the HealthChange Australia Model of Health Change™ (45). This model addressed 
important aspects of behaviour facilitating long-term behaviour change including; building 
motivation; identifying and addressing barriers and facilitators to health behaviours; and 
establishing the patient-practitioner relationship (46). This model also informed behaviour-
change strategies developed in partnership with participants.  
 
Participants were also prescribed an individualised exercise program incorporating both 
strength and cardiovascular training, which was progressed at scheduled face-to-face 
reassessments at 12-, 26-, and 52-weeks. Following their first OACCP visit, participants 
attended a multidisciplinary clinic for consultation with a rheumatologist and a selection of 
other health care professionals according to their individual clinical needs. Some examples of 
multidisciplinary clinic consultation included:  
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• a dietitian review to manage weight loss in participants who were overweight/obese 
• an occupational therapy review for those requiring assistive devices  
• a social work review for participants requiring psychosocial support  
• an orthotist review for those presenting with knee joint malalignment to consider 
bracing interventions.  
The effects of these management strategies were measured using standardised clinical 
outcomes at baseline, 12, 26 and 52 weeks of the OACCP (47). This enabled evaluation of 
clinical outcomes at a patient level, and of OACCP outcomes at group level. 
 
The OACCP model of care has been implemented at various public teaching hospitals in 
NSW and is considered a state-of-the-art program for OA management. There are also 
programs at two private metropolitan hospitals. These programs are based on the OACCP 
model of care but are known as the Osteoarthritis Management Program (OAMP). The 
OACCP study sites included in this Thesis were Royal North Shore Hospital, and 
Wollongong Hospital (both public facilities) whilst the OAMP study sites were Hunters Hill 
Private and Mount Wilga Private Hospitals. Given that all sites implemented the OACCP 
model of care, all public and private sites are referred to generally as the OACCP throughout 
this Thesis.
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2.2. Definition of ‘response’ 
One of the important methodological considerations of this Thesis was to define the 
threshold used to indicate that a participant was a ‘responder’ in the longitudinal cohort study 
described in Chapter Four. Three thresholds of response identified in previous literature 
were considered 
(1) The OMERACT-OARSI response criteria. This required either:  
“Improvement in pain or in function ≥ 50% and absolute change ≥ 20 points, or;  
Improvement in at least two of the following: 
• Pain ≥ 20% absolute change ≥ 10 points 
• Function ≥ 20% absolute change ≥ 10 points 
• Patients’ global assessment ≥ 20% absolute change ≥10 points” (31). 
(2) The minimal clinically important improvement (MCII) proposed by Tubach et al (2005). 
This was globally defined as “the smallest change in measurement that signifies an important 
improvement in a patient’s symptom” (48). More specifically the MCII was defined as 
follows: 
“For knee and hip OA, MCII for absolute (and relative) changes were, respectively, (a) -19.9 
mm (-40.8%) and -15.3 mm (-32.0%) for pain on a visual analogue scale; (b) -18.3 mm (–
39.0%) and -15.2 mm (-32.6%) for patient’s global assessment on a visual analogue scale; (c)  -
9.1  (-26.0%)  and  -7.9  (-21.1%)  for  Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC)  function subscale score.” (48).  
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(3) The threshold proposed by Angst et al. (2002). This was based on the concept of the 
minimal clinically important difference (MCID), which can be can be defined as the smallest 
difference in scores of the variable concerned that is considered beneficial by participants of 
the intervention (49). This MCID required a relative change greater or equal to 18% (100 × 
(change of score/baseline score) and an absolute change of 9 points improvement of 
WOMAC global scores at 26-week assessment compared to baseline (32). 
 
Of the three thresholds considered above, both the OMERACT-OARSI response criteria and 
the thresholds proposed by Tubach et al. (2005) were relatively stringent, requiring large 
improvements in outcomes to indicate a response. These thresholds were proposed to 
determine the efficacy of pharmacological therapies in randomised controlled trials. In these 
contexts, it was necessary to set large thresholds to account for the larger treatment effects 
required to justify the risks of side-effects associated with drug therapies (31, 48). The study 
described in Chapter Four of this Thesis did not require such a large threshold of 
improvement to indicate a positive response as the OACCP interventions were relatively safe, 
and their efficacy had already been tested. Hence, we chose the third threshold of response 
proposed by Angst et al. (2002). This threshold was developed in a prospective cohort study 
of participants with hip and knee OA engaged in a multimodal rehabilitation intervention 
(32). It was based on a similar intervention to the OACCP, with comparable expected 
treatment effects and a lower risk profile (compared with OA drug trials). Further details of 
this definition and how it was applied are presented in Chapter Four.
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2.3. Definition of worsening 
The aim of the study in Chapter Five was to investigate baseline characteristics that predicted 
the worsening of symptoms associated with the treated joint experienced by participants of 
the OACCP. There were relatively few studies that described thresholds used to indicate 
symptomatic worsening of the treated joint. Given the uncertainty regarding an appropriate 
threshold, we decided to compare three different definitions to test if predictors of worsening 
were similar across the definitions:   
(1) Worsening based on the study by Angst et al. (2002). This MCID for worsening was 
9.6 points absolute and 21% relative-change in the WOMAC Global score. This 
threshold was derived from the same study used for the threshold for response 
described in Chapter Four (32), which investigated a comprehensive rehabilitation 
intervention for hip and knee OA.  
(2) Worsening based on a transition question proposed by Jordan et al. 2009. The 
transition question was proposed as a suitable indicator of worsening following 
criticism of the use of pre/post patient-reported outcomes (PROs), such as the 
WOMAC, in the measurement of OA self-management education program 
effectiveness (50). Interview data was considered to represent the gold standard 
outcome of this study, however, the responses to the PROs were found to be a poor 
reflection of the interview data (50). It was proposed that this dissonance was possibly 
due to ‘response shift’ whereby a change in the participants’ perspective occurred 
following engagement in such programs (50). Further, a single transition question was 
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found to be more reflective of the interview data (50). The transition question 
required participants to report the global magnitude and direction of change 
experienced regarding the treatment joint using a 5 point Likert scale (5=much worse; 
1=much better) following the intervention (50). Participants were asked at OACCP 
reassessments “Compared with when I started this program, my hip/knee has…”: 
“much improved”, “moderately improved” “slightly improved”, “not changed”, 
“slightly worse”, “moderately worse”, or “much worse”. In the absence of evidence for 
an ideal cut-off for change on the transition question that is meaningful to 
participants, the threshold “moderately worse” was chosen in an attempt to ensure 
that participants were reporting a change that was important to them (51).  
(3) Worsening based on a composite outcome. This outcome included either or both 
WOMAC Global score MCID and transition question definitions of worsening. This 
composite outcome was chosen to reflect clinical practice whereby concerns would be 
raised if a patient declared their joint was feeling moderately worse following 
treatment or if considerably worse PRO scores were obtained. The composite 
outcome reflected the dual importance of the two clinical outcomes with the added 
benefit that it increased the power of the analysis by combining two outcomes of 
common aetiology (52).  
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2.4. Regression models 
2.4.1. Multivariable logistic regression  
Logistic regression modelling was used to test the relationships between baseline 
characteristics and dichotomous response outcomes in Chapters Four and Five. To make 
sure that the models were adequately powered, we ensured that there were at least ten 
predictors per event. This also avoided overfitting the model with too many predictors (53). 
For both studies, the first modelling step examined the association between each of the 
predictor variables and their response using univariable logistic regression analyses.  
 
The methods used to determine the base multivariable model differed in Chapters Four and 
Five. The multivariable modelling in Chapter Four used a forced entry technique. This 
involved all the variables being entered into the base model. In contrast, the procedure to 
determine the base model in Chapter Five involved considering the results of the univariable 
analyses that were conducted for each of the three definitions of worsening. To enable 
interpretation and comparison of results between the composite definition and the single-
outcome definitions of worsening, variables exhibiting odds with p <0.2 that trended in the 
same direction across a minimum of two definitions were included in the base models for all 
three definitions of worsening (52).  
 
After base models had been established, the analyses proceeded similarly for both studies. In 
an iterative manner, the variable associated with the largest P-value was removed from the 
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base model until only variables with P ≤ 0.05 remained. To control for confounding, the 
regression coefficients of the remaining variables were checked on removal of each variable 
from the model and in the presence of a change of 10% or more the variable was retained. 
Possible interactions were tested by combining variables, and then testing the relationship 
between the combined variable and the outcome variables. The Hosmer-Lemeshow 
goodness-of-fit test was used to test how well the chosen models fit the data; a p-value of 
>0.05 indicated the model fit was adequate (54). Further specific details of how the modelling 
steps were applied are described in Chapters Four and Five. 
 
2.4.2. Multivariable linear regression  
In the study comprising Chapter Eight, linear regression modelling was used to examine 
relationships between baseline PAM-13 scores and changes in WOMAC pain and function 
scores of participants with knee OA following 12 and 26 weeks of the OACCP. The decision 
to use linear regression modelling was partially a pragmatic one. The sample size required to 
analyse data using logistic regression is larger than what is required to run adequately 
powered linear regression analyses (53-55). The variables used in the analyses were normally 
distributed, an important assumption of linear regression, making it possible to examine the 
size and direction of the effect patient activation, along with other variables of interest, on 
changes in pain and function. Only data from people who chose the knee joint as their 
treatment joint was used in the analyses. This decision was made because there were four 
times the number of people with knee OA in the cohort compared to those with hip OA. 
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Hence, the smaller mixed sample for this study was unrepresentative of people with hip OA. 
This could have led to difficulties in generalising the results of the study to people with hip 
OA. 
 
The first step of linear regression modelling was unadjusted analysis with simple linear 
regression to study relationships between baseline variables and WOMAC Pain and Function 
change scores. In the second step, models included an adjustment for baseline WOMAC 
Pain/Function scores to test whether the baseline score was associated with the covariates and 
the outcome scores at 12- and 26 weeks. Variables with a P-value of ≤ 0.1 were included as 
candidate variables in multivariable models which were built using a backward selection, 
forced entry technique. We used the more conservative threshold of P ≤ 0.1 because this 
study had a much smaller sample size, we wanted to avoid overfitting the regression model 
with too many variables and hence maintain adequate statistical power (55). In a similar 
manner to the techniques used in Chapter Four, at each step, the least significant variable (p-
value<0.05) was removed from the base model and the beta coefficients were checked. If the 
coefficients changed by ≥ 10% the variable was retained in the model as a confounder, if not it 
was removed. Further details of these analyses are documented in Chapter Eight. 
 
2.5. The COSMIN systematic review method  
The COnsensus-based Standards for the selection of health Measurement Instruments 
(COSMIN) initiative method for performing systematic reviews of measurement property 
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studies (56) was used to guide the systematic review in Chapter Six of this Thesis. The 
COSMIN initiative aims to: “improve the quality of studies on measurement properties by 
developing methodology and practical tools for assessing measurement properties” (57) . 
 
Briefly, a taxonomy of measurement properties was provided by the COSMIN initiative (58) 
and a search filter provided to capture all studies concerned with these measurement 
properties (59). The COSMIN initiative has devised a method to determine the 
methodological quality of measurement property studies (60) and developed a checklist of 
criteria for good measurement properties to rate the measurement property results for each 
instrument (61). The quality ratings of the study methodology and the quality of the 
measurement property results for each instrument were combined to provide a best evidence 
synthesis. A more detailed explanation of the COSMIN initiative methodology for systematic 
reviews used in this Thesis is provided in Chapter Six. 
 
2.6. Rasch Modelling 
Chapter Seven examined the measurement properties of the PAM-13 in a cohort of OA 
management program participants. The PAM-13 was developed by Hibbard et al. (2005) 
using Rasch modelling (42). A Rasch analysis was used to test the fit of our data to the 
expected model and provide measurement property evidence for the PAM-13 in a sample of 
people living with OA. The Rasch model (RM) is a specific item response theory 
measurement model that is used to develop instruments and is capable of scaling raw 
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observed scores (measuring a latent trait) into linear variables. A “latent trait” refers to a 
construct that cannot be observed directly (e.g. the mathematics ability of a child) (62). The 
RM provides a mathematical framework against which the fit of data from another sample 
can be compared to quantify how well it fits the test (62).  
 
The RM assumes that responses to the test items are affected by the ability of the person and 
the difficulty of the item (62). A RM describes the probability of success (in the case of PAM-
13 that an item will be ‘agreed’ with) based on the difference between the ability of the person 
(person ability) and the difficulty of the item to achieve (item difficulty) (62). ‘Person ability’ 
is calculated using the number of items of the instrument that a person agreed with. ‘Item 
difficulty’ is estimated using the number of persons in the sample who agreed with an item.  
 
Essential requirements of the RM include adequate data-model fit and confirmation of 
unidimensionality. Measures of fit, namely infit, outfit and standardised fit, are used to 
confirm that the instrument conforms to RM requirements and to indicate how accurately or 
predictably data fit the model (63). Unidimensionality refers to one dimension or attribute of 
the subject being measured at a time. This is a requirement of the RM to enable items of an 
instrument to become more difficult with each subsequent item (62). A particular type of 
Principal Components Analysis (PCA), unique to RM, is used to provide evidence of 
unidimensionality (63).  The study comprising Chapter Seven used the partial credit model 
to examine model-data fit, tested the assumption of unidimensionality and interpreted Rasch 
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analysis results for the PAM-13. More detailed description of the methods used are described 
in that Chapter. 
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Chapter Three: Targeting care: tailoring non-surgical management 
according to clinical presentation 
 
3.1. Abstract 
This review summarizes the evidence available for patient characteristics that have been 
analysed as potential predictors of response to non-surgical interventions for patients with 
hip and knee OA. The specific variables targeted for this review include: body mass index, 
psychological factors, muscle strength, tibiofemoral alignment, radiographic changes and 
signs of inflammation. Several studies provide moderate to good evidence of potential 
predictors of response to non-surgical treatments, while areas for future research are 
illuminated. 
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3.2. Introduction 
The activity limitation attributed to osteoarthritis (OA) places it within the world’s top 10 
most disabling conditions (64). Globally OA affects approximately 18.0% of women and 9.6% 
of men over 60 years of age (65). In 2003 the annual costs of OA and other rheumatic 
conditions was an estimated $128 billion to the United States economy (66). These enormous 
costs are projected to rise steeply with the steadily increasing prevalence of rheumatic 
conditions (66).  
 
This prevalent, expensive, disabling disease is incurable, so it follows that current treatments 
focus on symptomatic relief. Commonly reported treatment goals for this group include 
reductions in joint pain, stiffness, activity limitation, participation restriction, and 
improvements in quality of life and well-being. To assist clinicians in achieving these goals 
with their patients, numerous international evidence-based guidelines for management of hip 
and knee OA have become available (67-72). There is uniformity in most of the 
recommendations made by the guidelines (73) and agreement that conservative management 
of hip and knee OA should combine both non- pharmacological and pharmacological 
treatment modalities (67-72).  
 
The recommendations made in the guidelines for management of hip and knee OA are 
broad. For example: the evidence-based, expert consensus guidelines from the Osteoarthritis 
Research Society International (OARSI) (2008) include no fewer than 20 recommendations 
for the non-surgical management of hip and knee OA (74), however, the treatments are not 
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arranged systematically to indicate the order of priority in which they should be undertaken. 
With so many recommended management options tabled, it would be advantageous to know 
which treatments are most likely to be effective for the individual with hip or knee OA 
according to clinical presentation. 
 
This review examines the evidence available for identification of clinical characteristics which 
predict patient response to nonsurgical treatments for hip and knee OA. The summation of 
this evidence may assist clinicians to target treatments most likely to benefit patients 
according to clinical presentation, and identify areas for further research  
 
3.3. Body Mass Index 
Obesity is a known risk factor for the development of arthritis (75) and is a strong predictor 
for long-term progression of the disease (76). There is evidence that obesity is a risk factor for 
knee OA, however, the relationship between obesity and the risk of developing hip OA is less 
clear (77, 78). International guidelines nonetheless recommend weight reduction in people 
with hip and knee OA who are overweight or obese (68, 71, 73, 79). There is strong evidence 
that weight loss is an effective treatment for knee OA, yet little evidence exists regarding 
weight loss as an effective treatment for obese patients with hip OA.  
 
It seems reasonable that body mass index (BMI) may be a clinical characteristic that is 
predictive of response to weight loss interventions, surprisingly evidence exists that it does 
not. A post hoc analysis of a randomised controlled trial (RCT) involving 111 overweight 
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veterans with knee OA, investigated nine clinical characteristics as possible predictors of 
weight change between baseline, 16 and 32 weeks. The minimum amount of weight loss 
required to define treatment responder was not provided. Multi-regression analysis revealed 
that BMI was not predictive of weight loss in response to the interventions for overweight 
veterans with knee OA (80). The external validity of this study was limited by confining 
recruitment of participants to veterans. 
 
Two studies found that BMI was not predictive of response to a Dutch multi-modal, stepped 
care model of pain management for hip and knee OA. Snijders and colleagues (2011) 
investigated the efficacy of the Dutch model in a cohort of 183 participants with hip and knee 
OA (30). The model combined pharmacological and non-pharmacological treatments. Two 
possible definitions of positive treatment response were described: (i) Outcome Measures in 
Rheumatoid Arthritis Clinical Trials/ Osteoarthritis Research Society International 
(OMERACT-OARSI) Responder Criteria and (ii) patient reported numeric rating scale 
(NRS) for pain ≤ 4. At 12-week reassessment, 86 patients were responders according to 
definition (i), and 71 fulfilled definition (ii). BMI was one of eleven potential predictors of 
response included in analyses, and was not a significant predictor of response to this program 
(30), however, the study was underpowered to identify true predictors of response. A more 
recent study utilized the same Dutch model, focussing specifically on a stepped-care protocol 
used to progress the use of acetaminophen and non-steroidal anti-inflammatory drugs 
(NSAIDs) at standardised intervals according to patient-reported pain levels (29). The 
definition of treatment responder was patient-reported NRS pain ≤ 4, 100 participants met 
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this target. The study was underpowered to analyse 13 patient characteristics, including BMI, 
as possible predictors of response. Further research is required to determine whether BMI is 
predictive of positive treatment response achieved by participants of this multi-modal 
stepped-care model of pain management. 
 
Two well-powered studies were identified examining the potential of BMI as a predictor of 
response to Cyco-Oxygenase-2 (COX-2) inhibitors. Bingham et al. (2011) pooled the results 
of two similar RCT’s comparing the efficacy of Etoricoxib and Celecoxib to placebo (81). The 
OMERACT-OARSI Responder Criteria determined that 562 participants were responders to 
the COX-2 inhibitors following 12 weeks of the intervention. BMI was one of 16 variables 
analysed as potential predictors of response, BMI failed to predict positive treatment response 
to the COX-2 inhibitors (81). Similar results were found by Detora et al. (2001) combining 
the results of three 6 week RCT’s comparing the COX-2 inhibitor Rofecoxib with placebo in 
1501 patients with hip and knee OA (82). Responder criteria were not defined. Patient data 
was analysed according to subgroups representing 14 baseline characteristics including BMI. 
Analysis of covariance failed to identify any baseline measures associated with treatment 
response (82). To date, good evidence exists that baseline BMI does not predict the response 
of patients with hip and knee OA treated with COX-2 inhibitors. 
 
A single study explored BMI as a predictor of response to intra-articular corticosteroid (CSI) 
for management of hip OA. Robinson et al. (2007) followed 120 patients with hip OA for 12 
weeks following CSI (83). Participants were classified as responders to the CSI at 12 weeks if 
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>15% reduction in baseline WOMAC pain sub-scale was achieved, 48 participants met this 
criterion. Logistic regression determined that BMI, one of 14 variables analysed, was not a 
significant predictor of response to hip CSI (83) however the study was underpowered to 
detect true predictors of treatment response.  
 
Four cohort studies were identified exploring possible predictors of response to intra-
articular (IA) hyaluronic acid derivatives for hip and knee OA. Short-term efficacy and 
tolerability of IA Hylan G-F 20 were assessed in 4253 patients with symptomatic knee OA 
(84). Responder criteria were not defined, the primary outcome was pain measured at 
baseline and 3 weeks on a 4-point Likert scale. At three-weeks post IA Hylan G-F20, 88.4% of 
patients assessed their pain as better or much better. Logistic regression of 7 potential 
predictors of short-term pain reduction determined that underweight patients were more 
likely to report reduced knee pain than their obese counterparts. The method of recruitment 
threated the validity of this evidence; the authors invited 840 orthopaedic surgeons to who 
report on at least five consecutive patients receiving Hylan G-F 20 for relief of knee OA pain, 
introducing significant selection bias.  
 
Longer term outcomes of patients with knee OA receiving IA Hylan G-F were explored in the 
following three cohort studies (85-87). A retrospective cohort of 155 patients with knee OA 
was reassessed 7-14 months following IA Hylan G-F 20 (85). The definition of responder was 
not specified. Analysis of 16 possible predictors found that BMI was not a significant 
predictor of patient satisfaction, though this study was underpowered to identify the possible 
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predictors, and the retrospective design was prone to significant recall bias. Longer term 
outcomes of Hylan G-F 20 were also studied in a small cohort of 32 patients with mild to 
moderate knee OA 6 months following IA Hylan G-F 20 (86). Clinical response was defined 
using the OMERACT-OARSI “high improvement” criteria, only 15 participants were 
responders, and 8 variables, including BMI, were investigated as predictors of response, 
leaving the study underpowered to detect significant predictors. BMI was not significantly 
correlated to patient response. A prospective cohort study examining 84 patients with knee 
OA for 6 months following knee IA Hylan G-F20 found that Short Form -36 health survey 
scores for were significantly improved at 6 months post injections (87). Responder criteria 
were not described. Three factors including the subjects’ percentage above ideal body weight 
were analysed for correlations with positive treatment outcomes seen on the Short Form-36 
health survey: Physical Function, Role-Physical and Role-Emotional categories. The subjects’ 
percentage above ideal body weight was not predictive of improvements. The high number of 
patients lost to follow up (23%) affected the validity of this study. Evidence for BMI and % 
above ideal bodyweight as clinical characteristics predictive of longer-term response to knee 
IA Hylan G-F20 was inconclusive due to low validity and power. 
 
BMI was not a significant predictor of response of people with hip OA to IA Hylan G-F20. 
Migliore et al. (2008) evaluated 250 patients with hip OA who received intra-articular Hylan 
G-F20 (88). Treatment response was defined as a ≥30% improvement in baseline Lequesne 
scores or NSAID usage at 6 months, the number of participants classified as responders was 
unclear. Ten possible predictors of treatment response were analysed, BMI was not a 
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significant predictor of response to hip IA Hylan G-F 20 (88). The large number of drop-outs 
(42%) affected the validity of this study. 
 
Patients with a lower BMI may be more likely to experience a reduction in chronic knee pain 
following treatment with glucosamine sulphate. A prospective correlational study of 39 
participants with chronic knee pain followed patients receiving 1.5g daily glucosamine 
sulphate for 12 weeks (89). Participants were not required to have been diagnosed specifically 
with OA, affecting the external validity of this study. The definition of treatment responder 
was not described and 7 patient characteristics were examined to as potential predictors of 
reduction of pain rated on a VAS. The study was underpowered to determine the effects of 7 
potential predictors.  
 
To date, most of the evidence suggests that BMI is not a consistent predictor of response to 
non-surgical treatments for people with hip and knee OA. Some evidence exists that BMI is 
not predictive of response to a weight loss program in overweight veterans with knee OA 
(80). There is good evidence that BMI does not predict response to COX-2 inhibitors for hip 
and knee OA management (81, 82). The evidence is weak that BMI is not predictive of 
treatment response to either a multi-modal stepped-care pain management model (29, 30), 
hip CSI (83), hip IA Hylan G-F20 (88), or glucosamine for chronic knee pain (89). The 
evidence for BMI as a predictor of response to knee IA Hylan G-F is weak and conflicting 
(84-87). Further research is required to determine whether BMI is a clinical characteristic that 
can foretell response to non-surgical treatments for people with hip and knee OA.
Chapter 3 
42  
 
3.4. Psychological factors 
Complex interactions exist between psychological factors and perceived symptoms of OA. 
Compared with their peers, people with OA report increased prevalence of depression and 
depressed mood (90). The intensity of perceived OA pain has been demonstrated to be 
predictive of depression severity in this cohort (90). Poor mental health has been associated 
with worse overall hip and knee OA pain and deterioration in mental health has been found 
to precede short-term exacerbations of OA pain (91). Treatment of depression in people with 
arthritis appears to improve depressive symptoms, reduce OA pain, improve function and 
quality of life (92) and therefore is an important consideration in the management of OA. 
 
Many treatments prescribed for hip and knee OA management, particularly exercise, weight 
loss programs and medications; require active participation from the patient. The compliance 
with and efficacy of these treatments may be influenced by the individual’s mental state to 
affect rehabilitation outcomes. The prospective cohort study “Predictors for response to 
rehabilitation in patients with hip or knee OA” (34) featured 250 patients with hip and knee 
OA who participated in a 3- 4 week multimodal rehabilitation program combining exercise 
therapy, hydrotherapy, relaxation strategies, distraction techniques, patient education, 
manual therapy, thermotherapy, and electrotherapy. Participants were assessed at baseline 
and 6 months following the program. Three different definitions of treatment responder were 
used: (i) the minimal clinically important difference (MCID) (18%) improvement shown on 
the WOMAC, (ii) improvement on the Transition scale, and (iii) MCID improvement on 
WOMAC and improvement on the Transition scale. The transition scale was described as a 
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measure of the current state of health of the OA joint compared with its state 6 months earlier 
(34). There were 21 personal, lifestyle and psychological measures investigated as potential 
predictors of the three definitions of responder. Depression and anxiety were evaluated using 
the Hospital Anxiety and Depression Scale, mental health was assessed using the mental 
component of the SF-36. The absence of depressive symptoms was determined to be a strong 
predictor of all three of the responder definitions suggesting that depression may hinder the 
achievement of positive treatment outcomes of patients with hip and knee OA following a 3-
4- week rehabilitation program. This study did not attempt to answer the question as to why 
they did not achieve the same results as their non-depressed counterparts, but we could 
hypothesize that perhaps those patients with depression have more difficulty complying with 
a comprehensive rehabilitation program. This is an interesting area for further research (34). 
 
The presence of depression may affect the ability of overweight people with OA to lose 
weight. A post hoc analysis of an RCT aimed to identify predictors of positive treatment 
response resulting from weight loss interventions for 111 overweight veterans with knee OA 
(80). Veterans were randomized into groups receiving 24 weeks of nutritional counselling, a 
home exercise program, a combination of both or usual care. There were no differences in 
weight loss between intervention groups and 9 variables were investigated as possible 
predictors of weight change between baseline, 16 and 32 weeks of the RCT. The amount of 
weight loss required to indicate successful treatment response was not indicated. Symptoms 
of depression were evaluated using The Centre for Epidemiologic Studies Depression Scale 
which measured 20 items to achieve a score out of 60. The presence of depression was 
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indicated by a score ≥ 16. The absence of depression was the only independent predictor of 
weight loss at 16 weeks and 32 weeks (80). This study did not define treatment responder; 
however, it did suggest that depressive symptoms may limit the ability of veterans to lose 
weight. 
 
Depression and anxiety did not seem to predict treatment response of patients with knee OA 
to CSI. A small study of 59 patients with knee OA receiving CSI examined 10 possible 
predictors of a favourable response, defined as a ≥ 15% reduction of pain rated on VAS, to 
injection of methylprednisolone acetate (93). The Hospital Anxiety and Depression score at 
baseline was not found to consistently predict treatment response. Given that 59 patients 
were used to investigate 10 predictors of response, this study was underpowered to detect 
meaningful effects of the potential predictors. 
 
Mental health scores did not seem to predict response to a combined non- pharmacological 
and pharmacological pain management program. Predictors for response to analgesics were 
explored in relation to a cohort study of 347 patients investigating treatment outcomes of a 
stepped model of care for hip and knee OA. The model initially offered education, lifestyle 
and weight loss advice, physiotherapy, acetaminophen, then progressed to other medications 
at intervals as guided by a pain numerical rating score (29). Treatment response was defined 
as achievement of pain NRS ≥4, there were 100 responders. Thirteen possible predictors of 
response were explored including mental health. The Short Form-36 (SF-36) questionnaire 
was used to assess health-related quality of life and the mental component summary (MCS) 
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scores of the SF-36 were used to reflect mental health. Mental health rated by the MCS was 
not a significant predictor of response to the stepped model of pharmacological pain 
management for patients with hip and knee OA, however, this study was underpowered to 
analyse 13 possible predictors.  
 
Self-reported participant mood failed to predict treatment outcome in a small cross- over 
RCT of 11 patients with osteoarthritis receiving two different NSAIDs (94). During two 
treatment periods of four weeks duration participants received ketoprofen and piroxicam. A 
4- week wash-out period followed the initial drug treatment prior to commencement of the 
second drug. Participants were classified as treatment responders if they showed ≥30% 
improvement of 5 of the 7 variables measured at baseline including; pain, tenderness, 
swelling, patient and physician global assessments, acute-phase protein levels and disability. 
There were 20 baseline variables explored as possible predictors of response including mood, 
assessed using an 18-item questionnaire. Mood was not a significant predictor of treatment 
outcome; however, the small sample size of this study leaves it underpowered to detect 
meaningful effects of the predictors investigated. 
 
In summary, two well-designed, adequately powered studies used specific measures of 
depression that were predictive of response to intervention (34, 80). Both studies 
demonstrated the relationship between the absence of depressive symptoms and positive non- 
pharmacologic treatment outcomes. The treatments investigated in these studies included a 
comprehensive rehabilitation program and weight loss interventions. These treatment 
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modalities require high levels of active participation of the patients involved, which may be 
affected by the presence of depressive symptoms. Interestingly, the three studies investigating 
drug therapy regimes, perhaps not requiring such a high level of active participation by the 
subjects, consistently found different measures of psychological factors incapable of 
predicting treatment response (29, 93, 94). Two of these studies were underpowered (93, 94), 
and the third that was inadequately powered did not measure depression specifically. 
 
3.5. Muscle Strength 
In view of the biomechanical influence and protective functions of skeletal muscles 
surrounding joints, muscle weakness is considered to be an important possible factor in the 
development and progression of OA. Evidence for the significance of muscle strength in the 
pathogenesis of OA remains unclear (95, 96). Higher quadriceps strength may have a 
protective effect against the development of symptomatic OA (96). Whether muscle weakness 
precedes the onset of OA, or if it is a feature of already established disease seen on X-ray, or is 
only related to the onset of pain and other symptoms, is an area for further research.  
 
The evidence for the role of muscle strength in the progression of OA is varied. Limited 
evidence exists to support muscle strength as a predictor of knee OA progression (76). Yet, 
over time, people with knee OA who have greater quadriceps strength report less pain and 
superior functional ability compared to their weaker counterparts (97). Quadriceps strength 
has been studied widely in relation to knee OA, however muscles around the hip stabilising 
the pelvis also have an effect on adduction forces around the knee that may result in increased 
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compression of the medial compartment (98) and influence the pathogenesis and progression 
of OA. Hip OA has also been associated with significantly reduced lower limb muscle 
strength (99), however limited evidence is available to explain the role of hip and thigh 
musculature in the development and progression of the disease. Further research is required 
to explain this possible relationship.  
 
Treatments for hip and knee OA have long included specific exercises designed to strengthen 
muscles surrounding the joints involved. High-level evidence exists regarding the reduction 
of pain and dysfunction in knee OA through therapeutic exercises (100). The evidence for the 
efficacy of exercise in hip OA to date is less convincing (101) yet exercise is often prescribed. 
Wright et al. (2011) published a study aiming to identify baseline characteristics of patients 
with hip OA likely to respond favourably to Physical Therapy interventions (102). As part of 
a larger RCT, 91 patients were randomised to groups receiving manual therapy, exercise 
therapy, a combination of both or usual care. The OMERACT-OARSI responder criteria 
determined treatment responders. Ten variables were analysed as predictors of treatment 
response. Measures of muscle strength using a hand-held dynamometer were not predictive 
of treatment success. Only 22 of the 68 participants were responders which left the study 
underpowered to identify predictors of response (102).  
 
There has been recent interest in the nature of lower limb muscle weakness in people with 
knee OA. Decreased quadriceps strength in knee OA has been attributed to both loss of 
muscle cross-sectional area (103) and reduced ability to activate the muscles (104). In a 
Chapter 3 
48  
 
cohort of 111 subjects taken from a larger RCT, baseline ability to activate quadriceps was 
examined as one of 9 possible predictors of changes in strength of the muscle following a 6 -
week exercise program for subjects with knee OA. Primary outcome measures were 
quadriceps strength and quadriceps activation, measured using a burst-superimposition 
maximum isometric quadriceps torque test, however a definition of treatment response was 
not identified. Although lower quadriceps activation was associated with lower strength, the 
baseline quadriceps activation did not predict the magnitude of gain in quadriceps strength 
following exercise therapy (105). These results suggest that patients with OA should benefit 
from strengthening exercises regardless of baseline quadriceps activation.  
 
Baseline muscle strength does not seem to predict the degree of symptomatic relief achieved 
following a weight loss program in obese people with knee OA. The 192 participants, who 
were part of larger RCT, were randomised to two different dietary interventions. A significant 
response to the interventions included the OMERACT-OARSI responder criteria and 
improvement on Knee Injury and Osteoarthritis scores (KOOS). Although weight loss was 
achieved in most of the subjects, only 64% achieved the OMERACT- OARSI responder 
criterion. There were 23 variables investigated as possible predictors of response to the weight 
loss programs, including measurements of baseline hamstrings and quadriceps strength using 
isometric dynamometry. Baseline muscle strength was not predictive of symptomatic relief in 
response to the weight loss program (106). The study was underpowered to detect significant 
predictors from a possible 23 variables. 
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One study investigated muscle strength as a predictor of response to a pharmacological agent. 
Jones et al. (1996) performed a cross-over RCT comparing CSI with saline (placebo) in 59 
subjects with knee OA (93). Ten possible predictors of treatment response were analysed. 
Treatment response defined as ≥ 15% decrease in pain rated on a visual analogue scale, was 
not predicted by baseline quadriceps strength measured using a commercial strain gauge. 
This study was significantly underpowered to analyse 10 predictors of response. 
 
Further research into the role of muscle strength in the pathogenesis of OA and subsequent 
progression of the disease may be helpful in refining recommendations for therapies aimed at 
OA prevention and further joint deterioration as a consequence of OA. To date, muscle 
strength has not been demonstrated to predict response to non-surgical interventions for hip 
and knee OA  
 
3.6. Tibiofemoral Joint Alignment 
Varus (bow-legged) or valgus (knock-kneed) tibiofemoral joint alignments are clinical 
characteristics observed in some people with knee OA. Joint alignment impacts the 
distribution of load borne by the medial and lateral compartments of the articular surface of 
the knee. Static knee alignment is conventionally determined using full- length weight-
bearing radiographs of the lower limb with knees extended. Lines are drawn from the centre 
of the femoral head to the talus through the middle of the femoral and tibial shafts to indicate 
the loadbearing mechanical axis, then measurements made of various angles subtended from 
where those lines intersect (107-109). Neutral alignment is commonly defined as 0-2 degrees 
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of varus (110) meaning that in a normal knee the mechanical axis passes medial to the knee 
joint resulting in 60-70% of weight-bearing forces to pass through the medial articular surface 
(111). Varus malalignment results in higher loads borne through the medial compartment of 
the knee, whereas increased compressive forces through the lateral articular surface 
accompany valgus malalignment.  
 
Dynamic knee alignment can be assessed using three dimensional (3-D) gait analysis. In 
varus knees, the measurement of knee adduction moment during the stance phase of walking 
is an indirect measure of joint compressive forces sustained within the medial tibiofemoral 
joint compartment (109, 112, 113). Static and dynamic alignment are important to consider 
in view that altered distribution of forces placed through the joint surface may lead to damage 
of articular structures, possibly increasing the risk of OA development or worsening existent 
disease.  
 
It remains unclear whether knee joint malalignment precedes incident knee OA (107, 108), 
however varus alignment considered to be a significant predictor of knee OA disease 
progression (76). Knee malalignment has been demonstrated to interact with other risk 
factors for OA progression, increasing the likelihood of disease acceleration. Possible 
interactive factors include greater quadriceps strength (114), the stage of disease observed in 
the individual (115) and obesity (108).  
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The evidence for the relationship between knee malalignment and reported OA symptoms 
remains unclear (115, 116). Nevertheless, some non-surgical treatments in OA management 
guidelines aim to reduce pain and dysfunction associated with tibiofemoral malalignment. 
Orthotic bracing, shoe wedges and muscle strengthening are recommended with a view to 
improving the biomechanics of the joint (69-72). Several studies have investigated knee joint 
alignment as a predictor response to non-surgical management of OA. An RCT by Lim et al. 
(2008) examined the effect of a 12-week quadriceps strengthening program on knee 
adduction moment, pain, and function in 107 subjects with knee OA. Knee alignment was 
assessed on radiographs and participants stratified according to whether they had more 
neutral (< 5 degrees) or more varus (≥5 degrees) alignment. Specific responder criteria were 
not described. Patients in the strengthening group achieved significant improvements in 
strength regardless of alignment. Self-reported function, performance measures and knee 
adduction moment determined using 3-D gait analysis were unchanged by the intervention 
in both alignment groups. Pain, assessed using the WOMAC pain subscale, was significantly 
improved in the strengthening group subset that was more neutrally aligned. Neutral knee 
joint alignment may mediate improvements in knee OA pain following a 12-week quadriceps 
strengthening program (117). 
 
Immediate changes in static alignment and knee adduction moment were not predictive of 
response to lateral wedge insoles at 3 months. A cohort of forty volunteers with knee OA were 
provided with laterally wedged insoles to assess the immediate effects of the insoles on knee 
OA pain, knee adduction moment and static alignment (109). The lateral wedges immediately 
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reduced knee adduction moment calculated using 3-D gait analysis and walking pain 
measured using the WOMAC pain subscale, but had no effect on static alignment as 
determined on full-length leg radiographs. Alignment was defined as the angle subtended by 
the intersection of the femoral and tibial mechanical axes. Varus malalignment was 
determined when the angle was <180 degrees with valgus indicated by >180 degrees. After 3 
months of wearing the insoles, significant improvements in pain and function persisted. A 
definition of treatment responder was not utilised; 10 predictors at baseline of outcome to 
intervention at 3 months were explored. Neither immediate changes in static alignment or 
knee adduction moment were predictive of decreased pain and improvement in function 3 
months following the intervention (109). The size of this cohort limited the ability of this 
study to identify true predictors of response to the intervention. 
 
A larger RCT of 192 obese subjects with knee OA allocated patients to two different weight 
loss interventions (106). Knee joint alignment was assessed using a ‘Plug-in Gait model’ with 
a six-camera stereophotogrammetric system and markers on anatomic landmarks. A knee 
was categorised as varus when the alignment was > 0 degrees, and valgus if < 0 degrees. 
Baseline knee alignment was one of 23 variables examined as possible predictors, however, it 
failed to predict improvements in Knee Injury and Osteoarthritis Outcome Scores (KOOS) or 
achievement of OMERACT- OARSI Responder Criterion following weight loss interventions 
(106). In view that only 64% of patients were treatment responders according to OMERACT-
OARSI criterion, the study was underpowered to detect effects of significant predictors. 
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It is interesting to consider the definitions of knee malalignment utilised in the three studies 
discussed above. Lim et al. (2007) employed a more extreme definition of ≥5 degrees to 
indicate varus malalignment (117). In contrast to the two other studies they categorized 
subjects to knee malalignment groups if the mechanical axis did not appear as a straight line 
(106, 109). This may have increased the severity of malalignment observed within the 
participants assigned to the varus group investigated by Lim and colleagues, compared to the 
subjects categorized to knee malalignment groups in the other studies. Participants with varus 
malalignment studied by Lim et al. (2007) did not experience improvements in pain following 
strength-training, while the neutrally-aligned reported significant pain reduction (117). 
Perhaps the higher severity of varus malalignment was key to the determination of knee joint 
alignment as a predictor of outcome to intervention in this study. Future research considering 
knee malalignment as a predictor of treatment response to conservative treatments should 
consider carefully the definition of joint alignment. 
 
3.7. Radiographic and MRI Assessment 
The presence of radiographic osteophytes (OP) and joint space narrowing are commonly 
used to diagnose OA. These features are combined to determine radiographic disease severity 
according to scoring systems such as the Kellgren and Lawrence grade (KLG) (118). Despite 
known limitations, radiographs are inexpensive, accessible and easy to interpret, so are 
commonly used in research for classification of subjects to determine eligibility and for 
stratification of samples according to radiographic severity. Radiographic joint space width 
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(JSW) or minimum joint space width (mJSW) is recommended for use in clinical trials, 
however, MRI is preferred particularly for assessment of cartilage morphology (119). 
 
Relatively few papers analyse radiographic severity of hip and knee OA as possible predictors 
of response to non-surgical, non-pharmacological treatments. Two of the three papers 
identified doing so examined the ability of radiological and MRI OA severity to predict 
response to weight loss interventions. A small RCT of 30 obese female participants with knee 
OA compared two dietary weight loss interventions (120). Within the intervention group, 
90% of participants achieved clinically significant weight reduction of >10%, and 33% had a 
50% improvement in knee OA symptoms. A strict definition of treatment responder was not 
provided. Structural joint damage was assessed at baseline using both the KLG classification, 
and low field MRI (0.2T) to assess various measures of cartilage abnormalities, bone marrow 
lesions (BML’s) effusions and synovitis of the medial, lateral and patellofemoral 
compartments of the knee. Five baseline radiographic characteristics and clinical outcomes 
following the weight loss interventions were investigated for correlations. None of the 
imaging variables were able to forecast symptomatic response to treatment (120) however this 
study was likely underpowered to identify significant predictors. 
 
A second RCT randomized 192 obese patients with knee OA into 8 weeks of two 
experimental dietary interventions (106). Results were calculated for the entire cohort as the 
method of weight loss was not relevant for this analysis. OA symptoms were evaluated at 
baseline and 16 weeks using the OMERACT- OARSI Responder Criteria and changes in 
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KOOS. High field MRI was assessed using the Boston-Leeds Osteoarthritis of the Knee Score 
(BLOKS) to measure joint damage at baseline. Conventional radiography determined the 
baseline KLG and minimum Joint Space Width (mJSW). MRI and radiographic measures 
failed to find any relationship between variables assessing knee structural damage and 
symptomatic improvements following the dietary interventions (106). Only 64% of patients 
were treatment responders according to OMERACT-OARSI criterion, therefore this study 
may also be insufficiently powered to detect effects of 23 potential predictors. 
 
A third study examining the ability of radiographic features to predict response to non-
surgical, non-pharmacological interventions was conducted by Hinman et al (2008) (109). A 
cohort of 40 patients with knee OA wore full length 5- degree lateral wedge insoles for 3 
months. Improvements were observed in WOMAC pain and function subscales following the 
intervention. Tibiofemoral OA severity was assessed at baseline using the KLG scoring 
system. Following analysis of 10 possible predictors of outcome, greater disease severity 
indicated by higher KLG scores were predictive of worse pain at 3 months. This study did not 
define responder criteria, and the small sample size reduced the ability to identify predictors 
of response to lateral wedge insoles. 
 
Two studies examine radiographic severity using KLG as potentially predictive of response to 
interventions combining both non-pharmacological and drug therapies for hip and knee OA. 
Both investigated cohorts of patients with hip and knee OA participating in a Dutch multi-
modal, stepped-care pain management program (29, 30). During the 12-week program 
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subjects received standardised non-pharmacological management and pain relieving 
medications prescribed and altered at set intervals depending on self-reported pain at 
reassessment. The definition of positive treatment response in the initial cohort of 183 
patients was fulfilment of either the OMERACT-OARSI Responder Criteria or NRS ≤ 4 (30). 
The later study of 347 subjects required NRS ≤ 4 at 12 weeks to indicate successful response 
to the intervention (29). Both studies analysed OA severity as determined by KLG scores as 
possible predictors of positive treatment outcomes. The first study tested 11 possible 
predictors of response to intervention and found that disease severity did not forecast 
improvements in overall pain and function as a result of the 12-week pain management 
program. (30). In the second study, 13 predictors were tested for correlation with treatment 
response at the 4 different steps of the treatment model. Greater OA severity was 
independently associated with a higher chance of pain relief achieved in response to use of 
acetaminophen (29). This correlation was discovered because unlike the first study, the 
predictors of response were tested at each of the separate steps of the program. There were 59 
responders to acetaminophen (paracetamol), so the study was underpowered to test 13 
predictors. Although the evidence is tenuous, this finding lends support to the 
recommendations made by international OA management guidelines to trial acetaminophen 
as a first line pharmacological treatment of hip and knee OA (67-72), even in those patients 
with severe disease. 
 
Evidence to the contrary was presented by Case et al. (2003) in the results from a double-
blind, placebo-controlled RCT comparing the efficacy of acetaminophen and diclofenac 
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sodium for pain management of knee OA (121). Eight-two patients were randomized to 3 
groups receiving either one of the drugs or placebo. The primary outcome at baseline, 2 and 
12 weeks was the WOMAC scale. The diclofenac sodium group alone achieved significant 
improvement (≥20%) in all 3 WOMAC subscales following the intervention. The subjects 
were stratified according to pre-study medication, baseline pain and disease severity indicated 
by KLG, in order to identify subsets of patients that were consistent in response to the 
treatments. None of the sub-groups consistently demonstrated a preferential response to 
acetaminophen or diclofenac sodium. This study suffered from a high number of dropouts 
(>25%). Three of the five subjects who withdrew from the diclofenac sodium treatment arm 
(n=25) did so as a result of adverse effects. Despite the evidence presented in this paper for 
the superior efficacy of diclofenac sodium, the relatively high risk of unwanted side effects 
lends further weight to the OA treatment guidelines recommending a trial of acetaminophen 
prior to commencing NSAID therapy (67-72) and it can be presumed that this follows 
regardless of radiographic severity.  
 
Four articles were identified investigating radiological predictors of response to CSI for hip 
OA. Of these, only one reported that radiographically determined disease severity was a 
significant predictor of positive response to steroid injection (122). This retrospective cohort 
study reviewed radiographs, radiology reports and medical records of 361 patients who had 
received fluoroscopically guided IA 80 mg depomedrol or methylprednisolone with 
bupivacaine. The definition of treatment responder was a 50% decrease in pain reported on a 
visual analogue scale (VAS). Immediate positive response to injection was evident in 68.2% of 
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hips and delayed response were apparent in 71.4%. OA severity was measured at baseline 
using KLG classification and the grades were split into groups for analysis. Multivariate 
regression determined that radiographic severity of OA was an independent predictor of 
treatment response. Patients with advanced disease were much more likely to experience both 
immediate and delayed onset of pain relief. The authors suggested that people with advanced 
hip OA are likely to achieve better response to CSI than those with mild or moderate disease 
(122). Although a good number of participants were recruited, these inferences should be 
considered cautiously in view of the inherent risk of bias associated with the retrospective 
cohort design of this study. 
 
In contrast, Robinson et al. (2007) utilizing a similar fluoroscopically guided injection of 
methylprednisolone and bupivacaine into the hip joint of 120 people with hip OA concluded 
that radiographically determined OA severity was not predictive of response to intervention 
(83). This cohort study assessed symptomatic response to 40 mg and 80mg dosages of the 
steroid. A decrease in the WOMAC pain by >15% was considered to indicate positive 
treatment response, 75 patients were classified as responders at 6 weeks. The authors 
concluded that the higher dose (80mg) of methylprednisolone was more effective and lasted 
longer. Twelve possible predictors of treatment response included KLG scoring. Forward 
logistic regression found that KLG was incapable of predicting reduced pain in response to 
hip CSI (83). This study was underpowered to detect predictors of response among 12 
variables. 
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Similar conclusions were made regarding a small prospective cohort of 27 patients with hip 
OA  assessed at baseline, 2, 12 and 26 weeks following hip IA lignocaine and 
methylprednisolone (123). The main outcome measure was pain measured on VAS. The 
degree of radiological severity according to KLG classification and mJSW had no significant 
bearing on the reported pain relief following hip steroid injection, however, the small sample 
size decreased the power to detect significant predictors. The fourth RCT compared 
ultrasound-guided CSI to IA hyaluronic acid, saline (control), and standard care (no 
injection) in 77 subjects with hip OA (124). Response to treatment was delineated by the 
OMERACT-OARSI Responder Criteria, there were 14 responders to steroid injection. CSI 
was significantly more effective than the 3 other treatments. Univariate regression analysis 
determined that of 5 predictors analysed, radiographic severity using Croft grading and 
mJSW were not predictive of treatment response to CSI, however, the study was 
underpowered to analyse 5 predictors (124). Further research is required to explore the value 
of radiographic and MRI clinical characteristics indicating disease severity as potential 
predictors of response to hip CSI.  
 
Three cohort studies attempted to identify radiographic characteristics of patients with hip 
and knee OA that were predictive of treatment response to IA Hylan G-F 20(85, 86, 88). 
Migliore et al. (2008) followed 250 patients who received US-guided IA hylan G-F 20 into OA 
hips (88). Treatment response was defined as an improvement of ≥30% Lequesne index or 
NSAID use. Significant improvements were reported for all outcome measures at 3,6, 9 and 
12 months when compared to baseline. Multivariable regression analysis of 8 baseline 
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variables determined that KLG was unable to predict treatment response (88). A high number 
of dropouts limited the validity of this study. The second study followed a small cohort of 32 
patients with mild to moderate knee OA for 6 months following knee IA Hylan G-F 20 (86). 
The OMERACT-OARSI “High improvement” responder criteria for OA were utilized to 
define responders to treatment. Fifteen participants met the responder criteria. Eight 
predictors of treatment response were explored, including mJSW which was not predictive of 
positive response to Hylan G-F 20 injection (86). The study was underpowered and limited by 
the exclusion of patients with severe OA. Conrozier et al. (2003) (85) studied a cohort of 155 
patients across the spectrum of mild through to severe knee OA. Knee joint space loss in a 
single compartment seen on radiograph and meniscal calcinosis noted on MRI scans were 
predictive of a good outcome to knee IA Hylan GF-20. The definition of treatment responder 
was not utilised in this retrospective cohort, (85). Weak evidence exists that knee joint space 
loss in a single compartment and meniscal calcinosis may predict response to IA Hylan G-F 
20, and this warrants further research. 
 
Bennett et al. (2007) (89) investigated the symptomatic response of 39 subjects with chronic 
knee pain treated with 1.5g oral Glucosamine sulphate for 12 weeks. Primary outcome 
measures at baseline and 3 months included pain VAS rated on movement, VAS for 
restriction in function and patient-rated global change score. These outcomes were all found 
to be significantly improved at 12 weeks but the responder criteria were not specified. Seven 
possible predictors of reduced pain and improved functional ability were analysed using 
regression modelling. The authors concluded that lower levels of PFJ osteophytes, BMI and 
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functional self-efficacy, were predictors of successful glucosamine treatment. The presence of 
osteophytes within the medial and lateral compartments of the tibiofemoral joint was not 
correlated with response to the intervention (89).The study was underpowered to identify 
true predictors of response and participants did not require formal diagnosis of OA, so these 
results must be viewed accordingly. 
 
Overall, there was weak evidence that radiographic measures of OA severity may have 
predictive value in the identification of potential responders to lateral wedged insoles (109), 
CSI (122) and glucosamine sulphate. MRI assessment was predictive of response in a single 
study concerned with knee Hylan G-F 20 injections (85). A greater number of studies exist 
that were unable to predict response to treatment based on radiographic disease severity or 
MRI. There is good evidence that KLG scores are not predictive of response to hip CSI (83). 
Further research is required to clarify the roles radiography and MRI perform as clinical 
characteristics that predict response to non-surgical treatment for hip and knee OA. 
 
3.8. Inflammation 
Abnormal progressive remodelling of joint tissues occurs in response to local inflammatory 
processes arising within osteoarthritic joints (125). Physical examination may reveal clinical 
signs such as presence of joint swelling, effusion and heat. With recent improvements in 
imaging techniques, synovial hypertrophy has become a surrogate marker of local 
inflammation within a joint.  
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Signs of inflammation were examined as potential predictors of response to weight loss 
interventions for participants with knee OA. The clinical cohort described by Gudbergsen et 
al. (2012) participated in a 4 month dietary intervention (106). Responders were required to 
fulfil the OMERACT-OARSI responder criteria. Joint damage severity was assessed on MRI 
using the BLOKS which included scoring for synovitis and effusion. Although synovitis and 
effusion were not predictive of OMERACT-OARSI response, there was some evidence that 
the effusion score correlated with changes in the KOOS ADL score from baseline to 4 
months. Responder criteria for the KOOS score were not provided. There were 23 variables 
assessed as potential predictors of response, 123 patients were responders, therefore this study 
was insufficiently powered for this many predictors. The presence of inflammatory markers 
such as effusion and synovitis requires further investigation as predictors of symptomatic 
response to weight loss interventions for overweight patients with OA. 
 
Systemic pharmacological agents such as NSAID’s and COX-2 inhibitors are prescribed for 
their analgesic properties and also to reduce inflammatory activity in affected joints. Two 
studies found that the presence of swelling was not predictive of response to these drug 
therapies. The data of three 6 week RCT’s comparing rofecoxib with placebo were combined 
to analyse the consistency of response of patients with hip or knee OA classified into 
subgroups determined by 14 demographic and disease factors (82). Three outcome measures 
were analysed in relation to the subgroups; Pain walking on flat surface (WOMAC), Patient 
Global Assessment of Response to Therapy, and Global Assessment of Disease Status. The 
definition of treatment responder was not provided. Overall, the subgroups did not show 
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consistent interactive effects with all three outcome measures. The absence of knee swelling of 
participants with knee OA significantly correlated with improved scores on the Patient Global 
Assessment of Response to Therapy, but not the 2 remaining outcome measures (82). 
Another study investigated swelling among numerous possible predictors of response of 
patients with OA and rheumatoid arthritis to ketoprofen and piroxicam (94). The trial was 
very small with 11 participants with OA, so was underpowered to determine significant 
predictors of response (94). Further investigation into signs of inflammation as possible 
predictors of response to NSAID’s and COX-2 inhibitors would be helpful to the clinician 
attempting to tailor pharmacological management according to clinical presentation.  
 
Intra-articular corticosteroids aim to directly reduce inflammatory processes occurring 
within joint tissues. An RCT by Chao et al. (2010) examined inflammatory characteristics 
assessed on ultrasound (US) as predictors of response to intra-articular corticosteroid 
injection for knee OA (126). Participants were categorised as ‘inflammatory’ if synovial 
hypertrophy (synovitis) with or without effusion was detected on grayscale US examination 
of the affected knee(s) at baseline. Within the intervention group 16 patients presented with 
synovitis on US, and 18 did not. At 4 weeks there were no significant differences between the 
inflammatory and non-inflammatory subgroups. Significantly lower WOMAC pain scores of 
the non-inflammatory sub-group at 12 weeks suggested that those without inflammatory 
characteristics experienced prolonged beneficial effects from corticosteroids. The presence of 
effusion had no influence on response to corticosteroid injection (126). 
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The presence of hip joint synovitis on US assessment of patients with hip OA was predictive 
of treatment response to CSI. An RCT compared standard care (no injection), injection of 
normal saline (placebo), non-animal stabilised hyaluronic acid and methylprednisolone 
acetate (124). Of the participants receiving CSI, 14 participants were classified as responders 
according to the OMERACT-OARSI criteria. The authors concluded that synovitis was 
predictive of response at 4 and 8 weeks following injection, however, this study was 
underpowered to establish clear associations between the 5 variables analysed as possible 
predictors. In contrast, Robinson et al (2007) found that evidence of hip synovitis and 
effusion on US were not predictive of clinical response to intra-articular methylprednisolone 
injection (83). The cohort study defined response to intervention as >15% reduction in 
baseline WOMAC pain score at 6 and 12 weeks following injection. This study was also 
underpowered to identify predictors of response. Further research using greater numbers of 
subjects is required to explore US determined inflammatory characteristics as predictors of 
response to CSI of osteoarthritic hips. 
 
Inflammatory characteristics identified on physical examination of patients with knee OA 
failed to predict response to CSI. The presence of local inflammation indicated by knee joint 
fluid, local heat, synovial thickening and stiffness were explored as possible predictors of 
response to intra-articular methylprednisolone in an RCT of 59 participants with 
symptomatic knee OA (93). No predictors of response were identified, perhaps a result of this 
study being underpowered. Pendleton et al. (2008) examined similar clinical signs of 
inflammation; presence of heat, effusion and synovial thickening in addition to the presence 
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of effusion and synovitis on knee US, as predictors of improvements in baseline WOMAC 
pain scale 1 and 6 weeks following CSI (127). The presence of heat was associated with 29% 
greater reduction in night pain, otherwise clinical and US inflammatory signs were not 
predictive of response. The study was underpowered and did not publish any measures of 
data variability. Adequately powered well-designed research is necessary to determine 
whether clinical and US signs of inflammation are predictive of outcomes following CSI for 
knee OA. 
 
Moderate effusion was associated with good outcome following intra-articular injection with 
Hylan G-F 20 in patients with symptomatic OA. Conrozier et al (2003) followed a cohort of 
155 patients who received three intra-articular hylan G-F 20 injections and were evaluated 7-
14 months later (85). Treatment outcomes included patient satisfaction, safety, changes in 
pain and function which were assessed on 4-point Likert scales. This study was limited by the 
lack of validated outcome measures and the retrospective study design. 
 
Only one study investigated signs of inflammation as predictive of outcome to non-surgical, 
non-pharmacological intervention. There is weak evidence that that synovitis and effusion 
seen on MRI are unable to predict response to weight loss in patients with OA (106). 
Numerous studies were concerned with signs of inflammation as predictors of outcomes to 
pharmacological agents, but few were sufficiently powered. Some evidence exists that knee 
joint swelling may predict good outcomes from rofecoxib (82) and that patients without 
synovitis observed on US experience prolonged pain relief following CSI injection compared 
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to those patients with knee OA presenting with synovitis (126). The evidence for synovitis on 
US as a predictor of response for outcomes following hip CSI is conflicting (83, 124). There is 
little evidence to support the use of clinical inflammatory signs as predictors of response to 
CSI for knee OA (93, 127) . Further research is required to determine whether signs of 
inflammation are useful predictors of response to conservative therapies for people with hip 
and knee OA. 
 
3.9. Other clinical characteristics that may predict response to intervention 
For the purposes of this review, we selected patient characteristics that we deemed interesting 
to examine as potential predictors of outcome to interventions for people with hip and knee 
OA. There is a wider range of presenting features than those covered here, analysed as 
potential predictors of response and further discussed in the literature. Among the articles 
identified through literature searches for our chosen predictors, age and gender were 
commonly analysed as potential predictors of response to intervention, but appeared to hold 
little predictive capacity overall. Four well-powered studies investigating predictors of 
response to; COX-2 inhibitors (20, 21), a rehabilitation program (32), and exercise therapy 
(45) provided moderate to good evidence that age was not a powerful predictor of response to 
these interventions. Further investigation of age as a predictor of response to alternative 
interventions for patients with hip and knee OA is justified.  
 
One adequately powered study determined female gender to be a characteristic predictive of 
treatment success following participation in a rehabilitation program (34). In contrast, three 
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well-powered studies found gender not predictive of treatment success for COX-2 inhibitors 
and exercise therapy (81, 82, 105). Additional research into gender as a predictor of treatment 
response to different non-surgical modalities is required. 
 
Pain and function WOMAC subscales are often used as primary outcome measures in OA 
research. Of the studies extracted from literature searches performed around our chosen 
predictors, two well-designed studies examined WOMAC pain and function scores as 
predictors of response to COX-2 inhibitors. One found that that baseline WOMAC pain was 
not predictive of response to Etoricoxib and Celecoxib. Lower levels of function on the 
WOMAC decreased the odds of response to the drugs, but the difference in WOMAC 
function scores between responders and non-responders was not clinically significant (81). 
The second study concluded that baseline WOMAC function was not predictive of response 
to Rofecoxib (82). Although baseline WOMAC pain and function scores were not predictive 
of response to COX-2 inhibitors, these measures may prove to be interesting predictors of 
response to different non-surgical interventions in other research. 
 
3.10. Summary 
This review identified and summarized the evidence available for particular features of 
clinical presentation exhibited by people with hip and knee OA that were predictive of 
response to non-surgical interventions. The studies are summarized in Figure 3.1. Good 
evidence exists that BMI is not predictive of response to COX-2 inhibitors for hip and knee 
OA (81), and moderate evidence presented that BMI does not predict weight reduction 
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following weight loss interventions for overweight people with knee OA (80). There is some 
evidence to suggest that the absence of depressive symptoms predicts successful outcomes 
from both weight loss interventions in overweight people with knee OA (80) and a 3-4 week 
rehabilitation program for participants with hip and knee OA (34). Moderate evidence was 
cited that quadriceps muscle activation was not predictive of improvements in quadriceps 
strength attained by participants with knee OA during a strengthening program (105). 
Patients with medial knee OA who were neutrally aligned were more likely than their more 
varus aligned counterparts to achieve significant pain relief following a quadriceps 
strengthening program (117). Evidence was lacking for any radiographic or MRI changes that 
were significant predictors of response to non-surgical interventions, however, patients with 
knee OA presenting without inflammatory characteristics on US (synovitis) were more likely 
to experience prolonged benefit from CSI than inflammatory patients (126).  
 
The practice of analysing patient characteristics as potential predictors of response to 
interventions is becoming increasingly popular. Researchers attempting to identify predictors 
of clinical response to non-surgical treatments for hip and knee OA require the use of larger 
sample sizes, or restriction of the number of variables analysed such that 10-15 responders are 
studied per possible predictor (128). Identification of further characteristics capable of 
predicting response to intervention would indeed provide clinicians with additional tools to 
tailor non-surgical care of patients with hip and knee OA according to their clinical 
presentation. 
 
Chapter 3 
69  
 
Figure 3.1 Clinical characteristics associated with response to nonsurgical management 
BMI: Body mass index; CSI: Corticosteroid injection; KLG: Kellgren-Lawrence grade; mJSW: minimum joint 
space width; MRI: magnetic resonance imaging; NSAIDs: Non-steroidal anti-inflammatory drugs 
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3.11. Addendum 
Since the publication of this review (2013), subsequent studies have examined predictors of 
response to non-surgical treatments for OA. For the purposes of the research questions of this 
Thesis, we were most-interested in studies concerned with predictors of outcomes following 
non-surgical, non-pharmacological interventions such as OA self-management and 
education, exercise and weight loss. We conducted further literature searches and identified 
three studies concerned with predictors of response to these interventions published 
subsequent to the review. 
 
The first study by French et al. (2014) based on secondary analyses from an RCT examined 
patient baseline characteristics as predictors of OMERACT-OARSI responder criteria 
following a course of physical therapy for hip OA (129). Although four predictors of response 
were identified (male sex, lower levels of baseline self-reported physical function, pain, 
anxiety, and depressive symptoms), the low predictive ability of the model did not provide 
strong evidence that these variables could adequately predict which patients would be 
responders (129). 
 
In the second study, Skou et al. (2014) followed a clinical cohort that participated in a 
combined education and neuromuscular exercise intervention for hip and knee OA. The 
study aimed to determine if improvements in participant pain (visual analogue scale) and 
quality of life (EQ-5D) were associated with the following: 
i) physical performance and self-efficacy at three months, or  
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ii) change measured in physical performance and self-efficacy at three months (130). Self-
efficacy was defined by the authors as “a person’s belief in his or her ability to succeed in a 
given situation” and was measured using the Arthritis Self-Efficacy scale (pain and other 
symptoms scale), physical function was measured using the 30-second chair stand test (130). 
The changes in self-efficacy and the 30-second chair stand test from baseline to three months 
were associated with one-year improvement in pain. The 30-second chair stand test and self-
efficacy at three months were also associated with one-year improvement in pain. Self-
efficacy at three months was associated with improvement in quality of life at 12 months. 
 
The third study by Taylor et al. (2018), hypothesised that changes in self-efficacy, perceived 
pain control, and pain catastrophizing mid-way through a multifaceted intervention for hip 
and knee OA would predict changes in physical functioning measured on the WOMAC 
function scale at 12 months (131). The intervention included telephone-delivered weight 
management, physical activity, and cognitive-behavioural pain management for veterans with 
OA, in addition to patient-specific treatment recommendations delivered to the primary care 
providers (PCP) in the study. The control group received usual care from their PCPs. Self-
efficacy was measured on the Arthritis Self-Efficacy scale (eight-item scale), pain control was 
derived from two items of the Coping Strategies Questionnaire and catastrophising was 
assessed using the Pain Catastrophizing Scale. Changes in self-efficacy and perceived pain 
control partially mediated improvements in physical functioning (compared to usual care 
controls) at 12 months however, catastrophising did not (131). 
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It is interesting to note that two of the studies described above found that changes in self-
efficacy were associated with changes in symptoms following interventions that combined 
several components of non-surgical, non-pharmacological care (130, 131). Although these 
studies involved different interventions, outcome variables and subscales used to measure 
self-efficacy, changes in self-efficacy were associated with changes in the outcomes. The 
authors of these studies recommended that interventions shown to support patient self-
efficacy (e.g. education, development of self-management skills) should be considered when 
delivering treatments to people with OA (130, 131). Considering these relatively recent 
results, it would be helpful to validate these findings in future research and consider targeting 
self-efficacy in the design of OA interventions. These studies were not concerned with the 
association between baseline self-efficacy and clinical outcomes, rather changes in 
characteristics following periods of treatment were examined. Hence, the relationships 
between baseline self-efficacy and improvements in pain and function following non-surgical, 
non-pharmacological interventions have not yet been studied and should be considered in 
future research. 
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Chapter Four: Does clinical presentation predict response to a non-surgical 
chronic disease management program for participants with end-stage hip 
and knee OA? 
4.1. Abstract: 
Objective: To identify baseline characteristics of participants who will respond favourably 
following 6 months participation in a chronic disease management program for hip and knee 
osteoarthritis (OA). 
 
Methods: This prospective cohort study assessed 559 participants at baseline and following 6 
months of participation in the Osteoarthritis Chronic Care Program. Response was defined as 
the minimal clinically important difference (MCID) of an 18% and 9-point absolute 
improvement in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) 
global score. Multivariate logistic regression modelling was used to identify predictors of 
response. 
 
Results: Complete data were available for 308 participants, those who withdrew within the 
study period were imputed as non-responders. Three variables were independently associated 
with response; signal joint (knee vs hip), gender and high level of comorbidity. Index joint 
and gender were significant in the multivariate model however, the model was not a sensitive 
predictor of response.  
Conclusions: Strong predictors of response to a chronic disease management program for hip 
and knee OA were not identified. The significant predictors that were found should be 
considered in future studies. 
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4.2. Introduction: 
Osteoarthritis (OA) is placed within the world’s top 10 most disabling conditions (64). 
According to the recent global burden of disease estimates, musculoskeletal disorders rank 
second only to mental and behavioural disorders in overall contribution to years lived with a 
disability (YLD) (132). A large proportion of YLDs attributed to musculoskeletal disorders 
results from hip and knee OA, estimated at over 17 million YLDs worldwide (132). 
Treatments for this disabling, prevalent, and incurable disease focus on symptomatic relief. 
Numerous international evidence-based guidelines for management of hip and knee OA have 
become available (67-72). There is consistency in most of the recommendations made by the 
guidelines (73) and agreement that non-surgical management of hip and knee OA should 
combine both non- pharmacological and pharmacological treatment modalities (67-72). 
However, the recommendations are numerous and are not arranged systematically to indicate 
the order of priority in which treatments should be undertaken or which combinations of 
modalities should be used. Faced with a plethora of choices, it would be helpful for clinicians 
to be able to base treatment decisions on the identification of specific clinical presentations 
that foretell greater likelihood of success following implementation of an individual or 
combination of treatments. In an era where the delivery of quality care is being promoted 
coupled with finite resources, the ability to predict outcome/s to intervention would allow 
clinicians to prioritize those who will redeem the greatest benefit. 
 
There is a growing body of evidence for clinical characteristics that predict response to non-
surgical interventions for participants with hip and knee OA (38). Four previous studies have 
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attempted to identify predictors of response to programs involving combinations of non-
surgical interventions (29, 30, 33, 34) however consistent predictors of response were not 
found. All four treatment protocols involved strategies for self-management of OA including 
dietary advice, two studies provided weight loss advice if indicated (29, 30) and all were of 
relatively short duration ranging from 3 to 12 weeks (29, 30, 33, 34). To our knowledge 
studies reporting outcomes or predictors of response to longer duration self-management 
programs do not exist. The aim of our research was to determine participant characteristics 
predictive of favourable outcomes following participation in a longer term non-surgical 
chronic disease management program for hip and knee OA. We hypothesized that it would 
be possible to predict participants likely to respond to the program using baseline 
demographic, psychological, disease related and functional performance variables.  
 
4.3. Materials and Methods: 
4.3.1. Study design 
This observational clinical cohort study followed consecutive participants of the 
Osteoarthritis Chronic Care Program (OACCP) from two teaching hospitals in New South 
Wales (NSW), Australia over a period of six months. The OACCP was developed by the 
Agency for Clinical Innovation Musculoskeletal Network in response to the growing 
recognition of the need for a non-surgical care program for people awaiting elective hip or 
knee total joint arthroplasty (TJA). Participants with symptomatic and radiographic hip and 
knee OA were recruited for the OACCP at Royal North Shore/ Ryde and Wollongong 
Hospitals from TJA waiting lists or referral by Rheumatologists, Orthopaedic Surgeons and 
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General Practitioners. This equates to a doctor diagnosis of OA which provides good face 
validity (133). People with a diagnosis of knee or hip OA were eligible for the OACCP at 
initial assessment if they had pain in the affected knee/hip on most days of the past month 
(47). Participants who had completed a reassessment at 26 weeks (within 140-225 days 
following initial assessment) were included in the analysis (see Figure 4.1). There were no 
exclusion criteria for the OACCP, however, participants who did not return for their 26 week 
assessment, or who were reassessed outside 140-225 days following initial assessment, were 
considered for imputation as non-responders. Participants imputed as non-responders 
included; those who underwent TJA more than 90 days (and less than 225 days) following 
initial assessment, those discharged on medical advice or participants who cited 
dissatisfaction with the program as their reason for discharge. Those receiving TJA within 90 
days of initial assessment were excluded from analysis on the basis that there was insufficient 
time to determine if they responded to the OACCP. The remaining participants without a 
complete 26-week assessment within 140-225 days were excluded from the regression 
analysis. 
 
4.3.2. Intervention 
The OACCP aimed to reduce pain, increase function and quality of life of participants with 
hip and knee OA through provision of access to relevant health professional to support self-
management and long term behaviour change. At initial assessment the Musculoskeletal 
(MSK) Coordinator engaged participants to set goals around the management of their OA 
and comorbidities (134). The MSK Coordinator was a specialised MSK Physical Therapist; all 
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participants were prescribed an individualised exercise program that focused on 
strengthening muscles around affected joints, increasing physical activity levels and other 
exercises depending on clinical presentation. These programs were reviewed and progressed 
at 12, and 26 weeks into the program. All participants were provided with education about 
their OA and any identified comorbidities. 
 
Following initial assessment participants were referred to members of the multi-disciplinary 
team (MDT) according to clinical need. If participants required medication review they were 
referred to a rheumatologist or pain clinical nurse consultant. Intra- articular injections were 
not part of the treatment provided. A dietitian provided interventions when indicated to 
assist participants with weight loss and/or comorbidity management. Participants requiring 
assessment of efficiency and safety of functional tasks were referred to an occupational 
therapist. Psychosocial interventions and linkage with community support services were 
provided by a social worker as required. Some participants with tibiofemoral or 
patellofemoral joint malalignment were referred to an orthotist for application of knee 
bracing or foot orthoses. Participants were also referred to health care providers outside the 
MDT for other interventions (e.g. hydrotherapy, diabetes education, psychology etc.) as 
required. 
 
4.3.3. Outcome measures 
During a structured interview at initial assessment, the MSK co-ordinator recorded 
demographic and comorbidity data. Demographic data included: gender, date of birth, 
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referral source, residential status, language spoken at home, employment and level of 
education. Signal joint, the predominant site of OA, was determined by clinical examination, 
patients’ symptoms and radiographic evidence of disease. All physical measures performed at 
initial and 26-week assessments were performed using a standardised protocol (47) including: 
height, weight, waist and hip circumferences and Body Mass Index (BMI). Disease-specific 
self-report measures administered at 0 and 26 weeks included the Hip Dysfunction and 
Osteoarthritis Score (HOOS) or Knee Injury and Osteoarthritis Score (KOOS) according to 
the signal joint. The Depression Anxiety Stress 21 Scale (DASS 21) was used to measure these 
3 negative emotional states at initial and 26 week assessments. The Six Minute Walk Test 
(6MWT) was completed at baseline and 26 weeks.  
 
HOOS, KOOS and WOMAC  
The validated, disease specific HOOS (135) and KOOS (136) require participants to use 5- 
point Likert scales to rate their: Symptoms, Stiffness, Pain, Physical Function, Recreational 
Activities and Quality of Life. The HOOS and KOOS subsume all of the WOMAC questions 
enabling conversion into WOMAC scores (137, 138). The WOMAC subscales for pain, 
stiffness and function were calculated by summation of the numerical responses provided by 
the WOMAC questions within the HOOS and KOOS. The WOMAC subscores were 
combined to calculate a WOMAC Global score= 100- (sum of pain + stiffness + function 
items) × 100/96. Normalised WOMAC Global Scores were used reflecting the convention 
that 100 indicated no problems and 0 indicated severe problems (78, 137). 
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Depression, Anxiety and Stress Scale 21 item version (DASS 21) 
Using a 4-point Likert scale, the DASS 21 asks participants to rate how much 21 separate 
statements applied to them over the past week. The DASS 21 provides subscores to indicate 
the presence or absence of symptoms of depression, anxiety and stress and has previously 
been shown to predict the diagnostic presence of depression and anxiety in older adults (139). 
We were concerned primarily with the depression sub scores; with 0-9 indicating no 
depressive symptoms, 10-13 mild, 14-20 moderate, 21-27 severe and greater than 28 severe 
symptoms (140). The DASS depression subscores were categorized into low depressive (0-13) 
versus high depressive (≥14) groups for the regression analyses. 
 
Modified Self-Administered Comorbidity Questionnaire 
This questionnaire asks participants ‘has your doctor told you that you have any of the 
following problems’ listing 21 commonly reported conditions plus an ‘other’ category to 
indicate comorbidities not included on the list. Response is indicated using ‘yes’ or ‘no’. This 
questionnaire was adapted from ‘The Self-Administered Comorbidity Questionnaire’ (141) 
and is scored by counting ‘yes’ responses to indicate the number of comorbidities experienced 
by the participant. The number of comorbidities variable was categorised into low (0-2), high 
(3-5) and very high (≥6) groups for the analyses. 
 
Six Minute Walk Test (6MWT) 
The 6MWT is recommended by the Osteoarthritis Research Society International to assess 
long distance walking and aerobic capacity for participants with hip and knee OA (142). 
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Participants were asked to walk as quickly as they could for 6 minutes on a flat 25m track with 
no corners (143) and the distance walked was recorded in metres. Baseline measurement of 
oxygen saturation, heart rate and perceived exertion (Borg Scale) were taken prior to and at 
test completion. Participants with respiratory or cardiac concerns had measures taken at one 
minute intervals during the test which was discontinued for the following: chest pain or 
discomfort, mental confusion, lack of coordination, dizziness, intolerable dyspnea, leg 
cramps, extreme muscle fatigue, persistent oxygen saturation < 85%, other clinically 
warranted reasons. 
 
Pain Visual Analogue Scale 
Participants were asked to rate their average pain on the day of assessment using a visual 
analogue scale (0 indicated no pain and 10 the most pain imaginable). The pain VAS was 
categorised into low pain (VAS 0-5) and high pain (VAS 6-10) for the regression analyses. 
 
4.3.4. Statistical analyses 
Definition of Responder 
Participants were dichotomized according to response or non-response at 26 week 
assessment with respect to treatment based on the notion of Minimal Clinically Important 
Difference (MCID) which according to Roman Jaeschke can be defined as “the smallest 
difference in score in the domain of interest which patients perceive as beneficial and which 
would mandate, in the absence of troublesome side effects and excessive cost, a change in the 
patient's management”(49). The MCID used was first developed by Angst et al (2002) (32) to 
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reflect the treatment effect considered to be clinically relevant to a comprehensive 
rehabilitation intervention for participants with OA of the lower extremities. This MCID 
required a relative change greater or equal to 18% (100 × (change of score/baseline score) and 
an absolute change of 9 points improvement of WOMAC global scores at 26 week assessment 
compared to baseline. Using an MCID comprising of both relative and absolute change 
standardised the amount of improvement required to achieve response across the spectrum of 
disease severity. Hence participants with very low global WOMAC scores were not classified 
as responders for small absolute changes in score compared with those whose baseline scores 
were higher. Participants who demonstrated improvements in WOMAC global scores at 26 
weeks of greater or equal to 18% with an absolute change in score greater than or equal to 9 
were categorised as responders (32), those who did not were non-responders. By this 
definition, participants who presented with baseline WOMAC global scores of > 91 (could 
not achieve a 9-point difference) or 0 or >84 (could not achieve relative difference of 18%) 
could not meet the requirements of the MCID and hence were excluded from the analysis. 
Participants censored at their 26 week follow up due to TJA performed at least 90 days after 
their initial assessment and within the 26 week assessment window (≤225 days) were imputed 
into the analysis as non-responders. Participants who withdrew from the OACCP due to 
dissatisfaction with the program or following medical advice were also imputed as non-
responders.  
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Predictor Variables and Power Calculations  
The potential predictor variables were chosen following literature review (38) and discussion 
amongst this study’s authors. The MSK Co-ordinators collecting the data at both study sites 
were blinded to which variables were to be analysed as predictors of response. Eight baseline 
predictor variables were identified a priori for consideration in the model: BMI, pain VAS, 
DASS Depression sub score, signal joint, 6MWT, age, gender and number of comorbidities. 
The power calculation was set to include at least 10 ‘responders’ per predictor variable (53, 
144). Previous studies have reported 34- 47% of participants with hip or knee OA may be 
expected to satisfy responder criteria following non-surgical multi-modal interventions (30, 
34). A sample of 267 was considered sufficient to accommodate 8 predictor variables.  
 
Regression Analyses 
Univariate logistic regression analyses examined the association between each of the predictor 
variables and response, continuous variables were categorised when necessary to meet 
linearity requirements. All variables were entered into a multivariate binary logistic 
regression model, the least significant predictor was removed at each step of the modelling 
until only significant variables remained. To control for confounding, when any variables 
associated with response in the univariate analyses were removed from the model, the 
regression coefficients of the remaining variables were checked for a change in 10% or more 
and if so were retained. Testing for interactions was performed by combining variables of 
interest. SPSS version 21 was used for all statistical analyses.  
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Ethics approval was granted by the NSW Population and Health Services Research Ethics 
Committee AUREI Reference HREC/12/CIPHS/63. Cancer Institute NSW Reference 
Number 2012/08/413.  
 
4.4. Results 
Of 559 patients consecutively referred to the Wollongong and Royal North Shore/ Ryde 
Hospitals OACCP July 2011 to December 2013, 475 participants had completed their 26 week 
assessment as shown in Figure 4.1. There were 145 participants excluded because their 26-
week assessment occurred outside the assessment range. A further 16 participants were 
excluded with incomplete HOOS or KOOS, 6 were unable to complete the 6MWT due to 
high BP or backpain and 84 did not return for follow up assessment. There were 308 
participants with complete datasets remaining for the analysis, a further 74 were imputed as 
non-responders: 55 discharged from the OACCP after TJA 90-225 days following initial 
assessment, 16 withdrew due to dissatisfaction with the program and 3 ceased due to medical 
advice. 
 
The baseline demographics of included participants, those excluded due to missing or 
assessments outside the 26-week range (n=167) and those who did not return for follow up 
assessment (n=84) are summarised in Table 4.1. The included and excluded groups were 
homogenous in most respects. Approximately 90% were referred from elective TJA waiting 
lists; the wait time for TJA in NSW Hospitals is around 12 months. The majority of 
participants were of similar age, lived at home with an able person, spoke English, were 
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retired and overweight. Participants reported similar baseline pain, the majority had 0-5 
comorbidities and did not finish high school.
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Figure 4.1 Study Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ø Participants with incomplete 26 week assessment or 26 week assessment outside 140-225 days or receiving 
joint replacement surgery within 90 days of initial assessment ØØ Participants who underwent TJA more than 
90 days (and less than 225 days) following initial assessment, or were discharged on medical advice or who cited 
dissatisfaction with the program as the reason for their discharge. *HOOS or KOOS at either 0 or 26 weeks were 
incomplete so that WOMAC Global scores could not be calculated. #6MWT results were unavailable because 
participants were unable to complete the test: five due to high blood pressure and one with back pain.
Total participants with 26 
week assessment n=475 
Complete records 
n=308 
Participants with 26 
week assessment outside 
140-225 days n=145 
Included (26 week assessment 
within 140-225 days) n=330 
Excluded: Incomplete 
data n=22 
HOOS/KOOS* 
incomplete  
n=16 
6MWT# 
incomplete n=6 
Non-responders 
n=289 
 
Responders n=84 
Total participants who 
completed initial 
assessments n = 559 
Participants with no 
follow up assessment 
completed n=84 
ExcludedØ n=98 
 
Imputed into analysis 
as non-responders 
ØØn=27 
ExcludedØ n= 57  
Imputed into analysis as 
non- respondersØØ n=47 
Excluded: Global 
WOMAC=0 or Global 
WOMAC>84 n=9 
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Table 4.1 Participant demographics  
Baseline characteristics Included  
n = 313 
Excluded 26wk not 
within 140-225 days 
or missing data 
 n= 162 
Excluded no follow-
up assessment  
n= 84 
P value ˅ 
 
Female (%) 62 59 48 0.067 
Age (y), Mean (SD) 68.5 (9.25) 69.0 (9.92) 68.0 (10.85) 0.76 
Signal joint knee (%) 
Signal joint knee (%) responders 
Signal joint knee (%) non-responders 
77 
83 
75 
65  68 0.022 
On Elective Joint Replacement List (%) 88 90 86 0.68 
Residence: 
At home with able person (%) 
Home alone (%) 
Other‡ (%) 
 
64 
28 
8 
 
68 
22 
10 
 
68 
21 
11 
 
0.46 
Speaks English* (%) 90 92 88 0.61 
Employment: 
Not currently employed† (%) 
Currently employed^ (%) 
 
86 
14 
 
82 
18 
 
84 
16 
0.60 
 
Education (%) 
Finished secondary school or higher¤ (%)  
Did not finish secondary school° (%)  
 
30 
60 
 
29 
71 
 
32 
68 
0.94 
BMI (weight(kg)/height (m)2, Mean (SD) 
BMI knees (weight(kg)/height (m)2, Mean 
(SD) 
BMI hips (weight(kg)/height(m)2, Mean 
(SD) 
31.9 (6.88) 
32.52 (7.12) 
 
30.03 (5.84) 
32.0 (6.57) 
 
 
31.7 (6.36) 0.94 
Pain VAS, Mean (SD) 5.5 (1.84) 5.7 (1.74) 5.7 (2.20) 0.65 
Number of comorbidities 
Low (0- 2) (%) 
High (3- 5)(%) 
Very high (≥6) (%)  
Missing 
 
54 
39 
8 
 
44 
51 
5 
 
 
43 
42 
10 
5 
 
WOMAC global score#, Mean (SD), Range 
WOMAC global score knees, Mean (SD) 
WOMAC global score hips, Mean (SD) 
WOMAC global score for ‘Responders’, 
Mean (SD), Range 
WOMAC global score for ‘Responders’ 
knees, Mean (SD), Range 
WOMAC global score for ‘Responders’ hips, 
Mean (SD), Range 
WOMAC global score ‘Non-responders’, 
Mean (SD), Range 
43.4 (19.39), 0- 100 
44.2 (19.66) 
40.7 (18.34) 
33.8 (18.06), 1-79 
 
35.6 (18.65), 1, 79 
 
25.1 (11.71), 6, 47 
 
47.4 (18.51), 4- 100 
  
38.4 (17.17), 0- 90 
40.8 (18.59) 
33.6 (12.96) 
41.3 (21.72), 3- 98 
41.5 (21.23) 
40.8 (23.23) 
0.027 
6 Minute Walk Test (m) Mean (SD) 337.4 (118.52) 324.3 (120.51) 323.5 (114.51) 0.44 
 
 
 
 
 
‡ Other includes residence at hostel or residence with non-able person. * Participants who did not speak English 
(approximately 10%) required the use of an interpreter. † Not currently employed includes participants who reported they were 
retired, performed home duties and other. ^ Currently employed includes participants who reported engaging in full/part-time/ 
volunteer work. ¤ Includes participants who reported finishing secondary school, tertiary certificate or university graduate. ° 
Includes participants who did not finish secondary school, and those who reported no formal schooling. # The WOMAC global 
scores are a transformed score calculated from the HOOS and KOOS, 100 indicates no problems and 0 indicates extreme 
problems. ˅Independent ANOVA or chi-squared statistic comparing included participants with the 2 other groups. 
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There were proportionally more males in the excluded group with no follow-up assessment 
(p=0.07) and the included group reported a higher proportion of knees to hips than the 
excluded groups (p=0.02). The mean baseline WOMAC global scores were significantly 
different (p=0.03) however the greatest difference in mean scores was 5.2 points which is not 
very clinically important.  
 
The referrals to health care providers recorded for included and excluded participants are 
summarised in Table 4.2. All participants were assessed by a Physical Therapist and provided 
with a graded exercise program, around half were referred to a dietitian, 30-40% to a 
rheumatologist and 20-30% to an occupational therapist or a social worker. Approximately 
20% of participants were referred to providers within and 40% outside the local health 
district.  
 
Of 308 included participants with complete datasets, 9 were omitted from analysis because 
their baseline WOMAC was too high (>84) or zero so were unable to achieve a response. Of 
the 299 participants with complete datasets, 84 (28%) were responders according to the 
MCID. Results of the univariate regression analyses are shown in Table 4.3. Compared to 
females, males were less likely to be responders OR 0.5 (95% CI 0.31, 0.88). There was strong 
evidence that participants with knee OA were more likely to be responders than those with 
hip OA OR 2.1 (95% CI 1.10, 3.88). Compared to those with a low number (≤2) there was 
evidence that participants with a very high number of comorbidities (≥6) were more likely to 
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Table 4.2 OACCP participant referrals  
 
Healthcare Provider Type 
Included participants 
n=300  
Participants without 
follow up imputed as 
non-responders n=74 
Excluded 
participants n=185 
OACCP Multidisciplinary team 
OACCP Physical Therapist* (%) 
OACCP Dietitian* (%) 
OACCP Rheumatologist# (%) 
OACCP Occupational Therapist* (%)  
OACCP Social Worker# (%) 
OACCP Orthotist# (%) 
Othert (%) 
 
100 
53.7 
40.4 
28.4 
19.4 
23.7 
16 
 
100 
55.7 
46.3 
36.6 
28.5 
17.8 
12.9 
 
100 
41.3 
31.1 
30.5 
13.8 
13.5 
10.7 
Other health providers within the local 
health district± (e.g. Hydrotherapy, 
exercise groups) (%) 
 
21 
 
20.3 
 
19.4 
 
Other health providers outside the 
local health district˅ (e.g. GP, 
hydrotherapy, diabetes educator, 
exercise groups) (%) 
 
42 
 
39.2 
 
39.2 
* Available at both OACCP sites. # Available at Royal North Shore Hospital OACCP only this rheumatologist 
saw patients in the OACCP clinic, they did not refer participants to the OACCP. t Other may include pain CNC 
at Wollongong Hospital and education sessions at both sites. ± Other healthcare providers within the local health 
district may include hydrotherapy, exercise groups, falls clinic, Physiotherapist, pulmonary rehabilitation, 
smoking cessation, Geriatrician.˅ Other healthcare providers outside the local health district may include 
General Practitioner, hydrotherapy, exercise groups, diabetes clinic, Orthopaedic Surgeon, Psychologist, 
Geriatrician, Physiotherapist, Dietitian, falls clinic, pain clinic, Social Worker, Orthotist, smoking cessation, 
pulmonary and cardiac rehabilitation.  
 
be responders OR 2.2 (95% CI 0.99, 4.95). The other baseline variables were not 
independently associated with response. 
 
All potential predictor variables were entered into the base multivariate model. No significant 
interactions between the variables were found. Following elimination of non-significant 
variables, the final model (Table 4.4) contained both signal joint (χ2LR = 4.49, P <0.05) and 
Gender (χ2LR = 4.95 , P <0.05). Participants with the knee as the signal joint had almost twice  
the log odds of being responders compared with those with hip OA (adjusted OR 1.92 (95% 
CI 1.02, 3.62)).
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Table 4.3 Univariable analyses  
Variable  Unadjusted OR (95% 
C.I) 
P 
Age  0.9 (.071, 1.20) 0.539 
Gender Female Reference  
 Male 0.5 (0.31, 0.88) 0.015 
Signal joint Knee 2.1 (1.10, 3.88) 0.023 
 Hip Reference  
Comorbidity Low (0-2)  Reference  
 High (3-5)  0.8 (0.47, 1.37) 0.414 
 Very high (≥6) 2.2 (0.99, 4.95) 0.053 
Depression*  ≤13 Reference  
 ≥14 1.2 (0.68, 1.98) 0.592 
Pain † 0-5 Reference  
 6-10 1.2 (0.72, 1.92) 0.526 
BMI‡  1.0 (0.98, 1.05) 0.329 
6MWTⱢ  1.0 (1.0, 1.0) 0.755 
*Depression measured using the Depression component of the Depression Anxiety Stress Scales 
†Pain measured using Visual Analogue Scale (self-rated 0 no pain, 10 worst pain). ‡BMI Body Mass Index 
calculation 𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 (𝑘𝑘𝑊𝑊)
𝐻𝐻𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 (𝑚𝑚)2. ⱢDistance participants are able to walk on flat ground during 6-minute walk test 
 
 
Table 4.4 Multivariable model  
Variable β-
Coefficient 
P-value Adjusted 
OR 
95% CI 
Constant -1.496    
Gender -0.594 0.029 0.55 0.32, 0.94 
Signal Joint Knee 0.651 0.045 1.92 1.02, 3.62 
# The base adjusted or multivariate model included age, gender, index joint, comorbidity, depression, pain, BMI 
and 6MWT. 
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Compared to women, men were less likely to be responders adjusted OR 0.55, (95% CI 0.32, 
0.94). The very high number of comorbidities group was not significantly associated with 
response in the multivariate model (p=0.07) and removal did not have a confounding effect 
on the remaining variables. The model fit the data well using the Hosmer-Lemeshow 
goodness- of- fit test (χ2 = 3.03, 3 DF, P = 0.21) however the model was unable to predict any 
participants as responders (Sensitivity 0%, specificity 100%).  
 
4.5. Discussion  
To our knowledge, this was the first study attempting to identify predictors of response 
following longer term (six months) participation in a chronic disease management program 
for hip and knee OA. The relatively low response rate (28%) was not surprising considering 
the severity of disease in this sample indicated by the large proportion of participants on TJA 
waiting lists (around 90%). Assuming that participants on TJA waiting lists would have 
clinically and radiographically significant disease, it may be expected that given the natural 
history of the disease, without intervention the majority of participants would stay the same 
or worsen over a period of six months. A similar response rate was reported by Weigl et al. 
(2006) using a less stringent definition of response (≥ 18% improvement in global WOMAC 
score) six months following a three to four-week rehabilitation program for participants with 
hip and knee OA (34).  
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The univariate analysis and the multivariate model adjusting for gender found participants 
with signal joint the knee had almost twice the log odds of being responders compared to 
those referred with hip OA OR 1.92 (95% CI 1.02, 3.62). Although signal joint is not a 
significant predictor of response in the literature (29, 30, 34), this finding makes sense in the 
clinic. A central aim of the OACCP was to increase physical activity. There is evidence that 
participants with knee OA experience reduced pain and improvement in physical function 
following land-based therapeutic exercise (100) however the evidence for such benefits is 
weaker in those with hip OA (101). Perhaps the participants with knee OA derived higher 
levels of therapeutic benefit from the exercise prescribed by the Physical Therapist of the 
OACCP so were more likely to respond than those with hip OA. Included participants with 
knee OA had a higher mean BMI (32.52 kg/m2) than those with hip OA (30.03 kg/m2) seen in 
Table 4.1. Given that a common goal for OACCP participants was to lose weight, and that 
participants with knee OA were more overweight, it was hypothesized that these people 
would be more likely to respond to interventions that involved weight loss. Interestingly BMI 
was not an independent predictor of response, and it was not significant in the multivariate 
model when adjusted for the signal joint. This confirms previous findings that BMI was not 
predictive of responsiveness to weight loss or multimodal non-pharmacological and 
pharmacological interventions for participants with hip and knee OA (29, 30, 80). 
 
Gender was a univariate predictor of response that remained significant in the multivariate 
model adjusting for signal joint OR 0.54 (0.31, 0.95). Men had half the log odds of being 
responders as women, a result that is difficult to explain. The literature yields conflicting 
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results: female gender was predictive of response to a rehabilitation program for hip and knee 
OA (34), however gender was not significantly associated with response in other previous 
predictor studies (29, 30).  
 
Compared to participants with a low number of comorbidities (0-2), participants with a very 
high number of comorbidities (>6) were independently associated with response OR 2.2 
(0.99, 4.95). A very high number of comorbidities was not significantly associated with 
response when adjusting for gender and signal joint, so number of comorbidities was 
removed from the model.  
 
The absence of depression has been identified previously as a predictor of response to a 3-4 
week inpatient multimodal rehabilitation intervention (34) and positive outcomes from a 
weight loss program in overweight veterans with knee OA (80). The absence of depression 
was not a significant predictor of response in the present study. Participants reporting 
depressive symptoms on the DASS depression subscale were referred for treatment as 
required. The treatment of depression in people with arthritis has been shown to reduce pain, 
depressive symptoms, improve function and quality of life (92). The treatment of depression 
as an adjunct to the other multidisciplinary interventions in our study may have diminished 
the negative effect depressive symptoms had on response to treatment.  
 
There is a potential limitation regarding the results for DASS depression in this study related 
to dichotomising the DASS depression variable into low and high depressive symptom 
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groups. The published clinical thresholds were chosen to characterise the degree of severity of 
depressive symptoms relative to the population (140). The threshold used to indicate 
moderate depression or greater was chosen to mark more serious depressive symptoms. 
Although this method was clinically meaningful, collapsing the groups from five to two 
categories would have led to ‘data loss’ which may have limited the results from the analyses 
of this variable. 
Age was not a predictor of response to the OACCP. Most studies include age in their list of 
potential predictor variables to control for the effects of confounding. Previous evidence for 
age as a predictor of response is conflicting. Higher age was a predictor of response to a 
multimodal stepped-care model for participants with hip and knee OA (29) and a Physical 
Therapy intervention for patients with hip OA (102) however was insignificant in other 
predictor studies (30, 34). The 6MWT was not predictive of response and while functional 
performance measures have not been widely used in previous prediction studies, one study 
found the self-paced 40-metre walk test predictive of response to physical therapy 
interventions for patients with hip OA (102). A recent systematic review rated the 40-metre 
walk test as the best walk test based on the limited evidence available (145) and perhaps it 
would have been a more useful predictor of response for our study. This is an interesting area 
for future research. 
 
Notable strengths of this study design included: the large sample size, the follow-up period 
was clinically meaningful and the potential predictor variables were identified a priori 
through literature and peer review with due consideration to not overfitting the model with 
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excessive degrees of freedom. The potential predictors included a broad mix of disease, 
psychological, physical and demographic variables. In order to minimise bias the data was 
collected prospectively by the MSK co-ordinators who were blinded to which variables were 
to be analysed as predictors. This clinical cohort study captured data from a real-life clinic. 
The participants required doctor diagnosis of OA which provides good face validity but may 
present potential limitations as different symptom labels for OA may exist between 
independent medical practitioners (133). Recruited largely from TJA waiting lists many 
participants of the OACCP were censored when their date for TJA came up. Excluded 
participants reported worse global WOMAC scores at baseline compared to included 
participants. To control for selection bias, participants who had experienced at least 90 days 
on the OACCP and had surgery within the 26-week window (≤ 225 days) were imputed as 
non-responders in addition to those who discontinued the OACCP citing dissatisfaction with 
the program or withdrew under medical advice. The transformed baseline Global WOMAC 
score (100 indicates no problems and 0 indicates extreme problems) was significantly lower 
in responders compared to non-responders (p<0.05), and although there is marked overlap 
between groups, the mean difference of 10 points may suggest some regression towards the 
mean. 
 
A control group was not used in this study, so it could be argued that it is impossible to 
distinguish between predictors of response to the chronic disease management program and 
natural progression of the disease. Previous studies concerned with progression of OA 
indicate a slow evolution and progression of the disease over time (146). Given that the vast 
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majority of patients were on the waiting list for TJA indicating end-stage disease, it would be 
unlikely that the natural course of OA in these participants would allow improvement in 
symptoms sufficient to achieve the MCID over a period of six months. However this does 
limit the generalizability of the results of our study to those with severe OA. A previous study 
reported that compared to participants not waiting for surgery, patients on the waitlist for 
knee TJA experienced smaller improvements that were not as lasting in response to 
participation in a chronic disease management program (33). It would be interesting in future 
research to investigate a more heterogeneous sample of participants to enable analysis of 
referral for TJA as a potential predictor of response.  
 
We can only assume that referral for TJA was a proxy measure of disease severity in this 
study. Future research should include a standardised measure of structural disease severity. 
Higher radiographic severity of knee and hip OA measured using the Kellgren-Lawrence 
Grading Scale (KLG) was a predictor of response to acetaminophen as part of a Dutch 
multimodal stepped-care model (29). Conversely, an earlier study investigating predictors of 
response to the same intervention found that KLG grade was not associated with a more 
stringent definition of response (30). It would be interesting to investigate whether 
radiographic severity is associated with response to the longer term chronic disease 
management program. Another predictor variable in the literature associated with response 
was a history of previous non-surgical interventions. Two studies reported history of previous 
non-surgical therapies as associated with good response to rehabilitation programs for 
participants with hip or knee OA(33, 34), this should be addressed in future studies 
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concerned with prediction of response to chronic disease management programs for hip and 
knee OA. 
 
In conclusion, response to intervention could not be predicted using the variables studied in 
this sample following 6months participation in the OACCP. Although significant predictors 
of response were identified, the model was not sensitive. The significant predictors of this 
study should be considered for future research and alternative variables for investigation have 
been highlighted. It is possible that an alternative battery of variables could be more useful for 
prediction of response to this intervention. If response can be predicted, it may enable 
clinicians to better tailor management of hip and knee OA according to clinical presentation. 
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Chapter Five: Can we predict those with OA who worsen following a chronic 
disease management program? 
 
5.1. Abstract 
Objective: To identify predictors of worsening symptoms and overall health of the treated hip 
or knee joint following 26-weeks of a non-surgical chronic disease management program for 
hip and knee osteoarthritis (OA) and examine the consistency of these predictors across three 
definitions of worsening. 
 
Methods: This prospective cohort study followed 539 participants of the program for 26-
weeks. The three definitions of worsening included: symptomatic worsening based on a 
change in Western Ontario and McMaster Universities Arthritis Index Global score 
(WOMACG) measuring pain, stiffness and function, a Transition scale that asked about the 
overall health of the treated hip or knee joint, and a Composite outcome including both. 
Multivariable logistic regression models were constructed for the three definitions of 
worsening.  
 
Results: Complete data were available for 386 participants: mean age 66.3 years, 69% female, 
85% knee joint as primary complaint (signal joint), 46% waitlisted for total joint arthroplasty 
(TJA). TJA waitlist status, signal joint, Six-Minute-Walk-Test (6MWT), depressive 
symptoms, pain and age were independently associated with at least one definition of 
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worsening. TJA waitlist status and 6MWT remained in the multivariate models for the 
Transition and Composite definitions of worsening.  
 
Conclusion: Participants reporting worsening on the transition scale did not consistently 
meet the WOMACG definition of worsening symptoms. TJA waitlist status was predictive of 
the Composite definition of worsening, a trend apparent for the Transition definition. 
However, variables that predict worsening remain largely unknown, further research is 
required to direct comprehensive and targeted management of patients with hip and knee 
OA. 
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5.2. Introduction 
Osteoarthritis (OA) is a well-known cause of significant disability (64, 147). Current evidence 
promotes tailored treatments combining non-pharmacological and pharmacological non-
surgical modalities for symptomatic management of knee and hip OA (72, 148, 149). It would 
be naïve to assume that everybody will benefit from a similar program of non-surgical 
interventions, hence it is important to identify participants likely to report symptomatic 
worsening despite ‘usual’ non-surgical regimens so that alternative therapeutic options may 
be considered.  
 
Longitudinal studies have examined predictors of hip and knee OA progression: deterioration 
in radiographic features, symptoms or progression to total joint arthroplasty (TJA) (76, 150-
153). Attempts have been made to identify thresholds of pain, function and structural severity 
to provide a surrogate measure of need for TJA for use in clinical trials (154, 155). Elusive 
thus far, these thresholds could be useful to triage participants of non-surgical self-
management programs so that those who may potentially derive more benefit from TJA may 
be escalated to surgery. Extant thresholds indicative of symptomatic worsening following a 
rehabilitation program for hip and knee OA (32) have not been applied extensively in the 
literature. Yet the ideal threshold for “worsening” may be useful: first, to interpret clinical 
findings of individual patients and second to derive predictors of worsening in groups of non-
surgical program participants. Predictors may be used to triage referrals for interventions 
unlikely to confer benefit, placing unnecessary burden on the health-care system and patients. 
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In the absence of a robust clinical definition of “worsening” we have compared two 
definitions existing in the literature. The first is based on a threshold of change in Western 
Ontario and McMaster Universities Osteoarthritis Index Global score (WOMACG) derived 
from participants of a rehabilitation intervention (32). The second is the response to a 
transition question measuring the overall amount and direction of change the individual has 
undergone regarding their joint following the intervention (50). This method has been 
suggested following recent questioning of the utility of pre/post patient reported outcomes 
(PRO’s) to measure efficacy of self-management education programs, possibly due to 
response shift prompted by change in the participants’ perspective following engagement in 
such programs (50). A third definition of worsening was used in this study: a composite 
outcome including either or both WOMACG and transition definitions. The composite 
outcome was chosen to reflect the dual importance of the two clinical outcomes and to 
increase the power of the analysis by combining two outcomes of common aetiology (52).  
 
The objective of this study was to identify baseline participant characteristics predictive of 
three different definitions of symptomatic worsening following 26-weeks participation in a 
non-surgical chronic disease management program for hip and knee OA and examine the 
consistency of predictors for the definitions. Previous studies have identified age, body mass 
index (BMI) and pain intensity as predictors of radiographic progression and TJA of knee 
(76, 150-152) and hip OA (152, 153). As such, these were pragmatically chosen as potential 
predictors of worsening following participation in the OACCP. TJA waitlist status was also 
selected based on evidence that some patients report deterioration in health status following 
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≥6 months wait for TJA (156). Additional predictors included: signal joint, gender, number of 
comorbidities, a functional performance measure (6MWT) and presence of depression, 
which have all been previously associated with response to non-surgical rehabilitation 
programs for hip and knee OA (34, 39, 102). We hypothesized that the same participants with 
similar demographic, psychological, disease-related and functional performance predictor 
variables would be identified as ‘worse’ across three definitions of worsening.  
 
5.3. Patients & methods 
5.3.1. Participants and data collection 
This study comprised a cohort of consecutive participants with symptomatic and 
radiographic hip and knee OA recruited for the Osteoarthritis Chronic Care Program 
(OACCP) at Royal North Shore Hospital (RNSH). Participants were recruited directly from 
RNSH and Ryde Hospital (New South Wales, Australia) TJA waitlists or referral by 
rheumatologists, orthopaedic surgeons and general practitioners. People with a diagnosis of 
knee or hip OA were eligible if they reported pain in the affected knee/hip on most days of the 
past month (39). Data were included from participants who had completed at least 140 days 
in the program, there were no exclusion criteria. Ethics approval for analysis of OACCP 
clinical data was provided by the NSW Population and Health Services Research Ethics 
Committee AUREI Reference HREC/12/CIPHS/63 Cancer Institute NSW Reference Number 
2012/08/413.  
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The objectives of the OACCP were to reduce pain, increase function and quality of life of 
participants through provision of tailored interventions delivered by a multidisciplinary team 
including; a physical therapist, rheumatologist, dietitian, occupational therapist, social worker 
and orthotist. At initial assessment an experienced musculoskeletal physical therapist (MJW) 
provided participants with education about their OA and associated comorbidities, set 
patient-oriented goals, prescribed behavioural modification strategies and an exercise 
program. The exercise program comprised of strength and cardiovascular training and was 
progressed at 12, 26 and 52-week reassessments. Participants then attended a 
multidisciplinary clinic for consultation with a rheumatologist and a selection of other health 
professionals according to their individual clinical needs.  
 
5.3.2. Outcome Measures 
Demographic data were recorded at baseline. Signal joint, the predominant site of OA, was 
determined by clinical and radiographic examination. Anthropometric measures were 
performed using a standardised protocol (47) including: height, weight, waist and hip 
circumferences and Body Mass Index (BMI). Participants rated their average pain on the day 
of assessment using a 10-cm VAS (0 indicated no pain and 10 the most pain imaginable) 
(157). 
 
The validated, disease-specific Hip disability and Osteoarthritis Outcome Score (HOOS)(135) 
and Knee injury and Osteoarthritis Outcome Score (KOOS)(158) require participants to rate 
their: Symptoms, Stiffness, Pain, Physical Function, Recreational Activities and Quality of Life 
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on 5-point Likert scales. These questionnaires subsume the WOMAC questions enabling 
conversion: WOMACG= (sum of pain + stiffness + function items) × 100/96 (78, 137).  
 
The Depression, Anxiety and Stress Scale 21 item version (DASS-21) asks participants to rate 
how much 21 separate statements applied to them over the past week using a 4-point Likert 
scale. Subscores indicate the presence/absence of symptoms of depression, anxiety and stress 
(159). Participants were dichotomised into: those with depression sub-scores 0-9 with no 
depressive symptoms and those ≥10 with signs of depression (159). 
 
A modified version of the Self-Administered Comorbidity Questionnaire (141) quantified the 
number of comorbidities experienced by each participant. Participants were asked to respond 
‘yes’ or ‘no’ to: ‘has your doctor told you that you have any of the following problems’ 
followed by a list of 21 commonly reported conditions plus an ‘other’ category. We 
categorised the number of comorbidities into low (0-1), moderate (2-3) and high (≥4) groups.  
 
The 6MWT is recommended to assess long distance walking and submaximal aerobic 
capacity (142). Participants were asked to walk as quickly as possible for 6-minutes on a flat 
25m track with no corners (143), the distance walked recorded in metres. Measurement of 
oxygen saturation, heart rate and perceived exertion were taken prior to and at test 
completion. Participants with respiratory or cardiac comorbidity had measures at 1-minute 
intervals the test was discontinued if participants reported concerning symptoms.  
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At reassessments participants were asked a transition question to rate their signal joint health 
status compared with prior to starting the program: “Compared with when I started this 
program, my hip/knee has…” on a 7-point scale: “much improved”, “moderately improved” 
“slightly improved”, “not changed”, “slightly worse”, “moderately worse”, or “much worse”.  
 
5.3.3. Definitions of worsening 
WOMAC Global (WOMACG) definition of worsening: The minimal important difference 
(MID) is the smallest difference in scores of the variable considered to be beneficial or 
detrimental by participants (160). MID thresholds for worsening of 9.6 points absolute and 
21% relative-change in WOMACG were previously determined for a comprehensive 
rehabilitation intervention for hip and knee OA (32) .We termed this threshold the 
“WOMACG definition of worsening”. A similar threshold has been used previously to 
indicate meaningful symptomatic worsening of participants on TJA waitlists (156). 
 
Transition definition of worsening: In addition to pre/post-intervention assessment 
questionnaires, a transition scale is recommended to assess efficacy of self-management 
education programs (50). Thus, the second definition of worsening was defined by transition 
scale participant response “moderately worse” or “much worse”. In the absence of evidence 
for an ideal cut-off for change on the transition question that is meaningful to participants 
(51), we decided that “slightly worse” was not an adequate threshold for worsening in an 
attempt to ensure that participants were reporting a change that was important to them.  
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Composite definition of worsening: The final definition of worsening was based on combined 
criteria of 9.6 points absolute and 21% relative change in WOMACG scores or “moderately 
worse” or “much worse “on the transition scale. This was chosen to reflect the dual 
importance of self-reported worsening of symptoms and self-reported overall deterioration of 
the signal joint.  
 
5.3.4. Statistical Analysis 
Power calculations were based on evidence that 25% of patients waitlisted for TJA worsened 
≥9.6 WOMACG points over 6-months (156). Given that only half of the OACCP participants 
were on TJA waitlists we extrapolated that around 12.5% of the sample would report 
worsening. Further, all participants received interventions for their OA, we expected that the 
majority of participants would report no change or improvements following the intervention 
and therefore estimated 10% of participants would ‘worsen’. A sample of 500 participants was 
considered sufficient to include 3-5 variables in the final model assuming 10 participants 
reported worsening per predictor variable (53, 144). 
 
As series of regression analyses were conducted in SPSS (Version 22.0, Armonk NY: IBM 
Corp, USA). For each model, the dependent variable was “worsening” and was based on 
dichotomisation of participants into two groups: worse and not-worse using each definition of 
worsening. Independent predictor variables were identified a priori and the physical therapist 
collecting data was blinded to which variables were analysed as predictors of worsening. 
Chapter 5 
114  
 
Missing 26-week assessment data from patients who were not lost to follow-up had their 12-
week assessment data carried forward, similar to intention-to-treat analysis. Further, the 
6MWT results were standardized to ensure the scale (m) was comparable with the other 
variables (161).  
 
Univariate logistic regression analyses examined the odds of an OACCP participant 
worsening when each predictor variable was present. Subsequently, multivariate regression 
models were built for each definition of worsening. Variables exhibiting odds with p <0.2 that 
trended in the same direction across a minimum of two definitions were included in the base 
model for all three definitions of worsening. This method enabled interpretation and 
comparison of results between the composite definition and the single-outcome definitions 
(WOMACG and transition definitions)(52). The least significant predictor was removed at 
each step of the modelling until only significant variables remained. The regression 
coefficients of the remaining variables were checked on removal of each variable from the 
model and in the presence of a change of 10% or more the variable was retained. Testing for 
interactions was performed by combining variables of interest. The validity of each model was 
assessed using Hosmer-Lemeshow goodness-of-fit and the predictive-ability of the model was 
assessed by calculation of sensitivity and specificity. 
 
5.4. Results 
Of 539 participants consecutively enrolled in the OACCP March 2012 to July 2014, 153 were 
excluded due to missing data or the presence of a floor/ceiling effect whereby they could not 
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achieve the WOMACG definition (Figure 5.1). Reasons for missing data included: 
undergoing TJA, medical advice, moving interstate and illness or death.  
 
Included and excluded participants were of similar age, were overweight and reported low to 
moderate number (0-3) of comorbidities (Table 5.1). Higher proportions of excluded 
participants were on TJA waitlists, presented with hips as the signal joint and demonstrated 
depressive symptoms. Fewer excluded participants finished secondary school (p=0.018) and 
their mean WOMACG scores were higher (p<0.001). Excluded patients exhibited worse 
6MWT results and higher baseline pain-VAS although the mean difference was within 
measurement error for both outcomes (162). In the multidisciplinary OACCP clinic, most 
participants (95%) saw a rheumatologist, 75% were referred to a dietitian, 55% to an 
occupational therapist, 50% to a social worker and 50% to an orthotist. 
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Figure 5.1 Study Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excluded participants with baseline 
WOMACG = 0 (cannot get worse 
by relative definition) n = 2 
 
Participants with missing 26 wk 
WOMAC with wk12 carried 
forward n = 93 
 
Participants with complete baseline 
26wk WOMAC or 12wk score 
carried forward n = 413 
Excluded participants with baseline 
WOMACG > 82.6 (cannot get 
worse by definition) n = 24 
Excluded participants with missing 
DASS depression score data 
n = 1 
 
Participants with complete baseline 
26wk WOMAC or 12wk score 
carried forward n = 386 
Eligible participants enrolled in the 
OACCP Feb 2012 to July 2014 
n=539 
 
Participants with complete baseline 
& 26 wk WOMAC 
n=320 
Excluded participants with missing 
baseline or 12 and 26 WOMAC 
data n = 126 
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Table 5.1 Participant demographics  
Baseline                                                                                                                                      
Characteristics                                                                                                                                                                                            
Included 
n = 386
Excluded: missing 
data£ n = 153             
Pv 
Female (%) 69  63 0.242 
Age, years, mean (SD) 66.3 (9.97) 65.8 (11.35) 0.620 
Signal joint knee (%) 85 73 0.006 
On TJA waitlist (%) 46 59 0.008 
Residence 
Lives alone‡ (%) 
 
28 
 
29 
 
0.694 
Speaks English* (%) 93 89 0.146 
Engaged in paid employment^ (%) 31 28 0.573 
Education 
Finished secondary school or higher∞ (%) 
Did not finish secondary school˚ (%) 
 
57 
43 
 
46 
54 
 
0.018 
BMIϱ, mean (SD) 30.0 (6.47) 32.1 (7.17) 0.001 
Pain VAS, mean (SD) range 0-10 4.1 (2.17) 5.4 (2.58) <0.001 
6MWTϪ, mean (SD) 421.6 (111.72) 380.7 (129.13) 0.001 
Depressive symptoms: DASS depression subscale (≥14) (%) 35 48 0.005 
Number of comorbidities 
Low (0-1) % 
Moderate (2-3) % 
High (≥4) % 
 
39 
39 
22 
 
32 
41 
27 
0.233 
Baseline WOMACG#, mean (SD) range 49.1 (18.09) 3.1, 8.3 61.7(23.67) 0, 97.9 <0.001 
Baseline WOMACG those who got worse vs not worse, mean 
(SD)  
WOMACG 
Worse, mean (SD)          n = 34 
Not worse, mean (SD)   n = 352 
(CI difference in means ), P 
                         
Transition     
Worse, mean (SD)         n = 34 
Not worse, mean (SD)  n = 352 
(CI difference in means), P 
 
Composite 
Worse, mean (SD)         n = 56 
Not worse, mean (SD)  n = 330 
(CI difference in means), P 
 
 
 
38.4 (16.34) 
50.2 (17.93) 
(-18.02, -5.45), <0.01 
 
 
58.3 (17.31) 
48.3 (17.94) 
(3.69, 16.32), 0.002 
 
 
49.3 (19.91) 
49.1 (17.79) 
(-4.91, 5.38), 0.929 
  
 
 
 
 
 
Data in bold face are statistically significant. £ Missing data include those participants with missing 0, 12 or 26 week WOMACG data 
(n=126), those whose wk0 WOMACG equalled 0 (n= 2), those with wk0 WOMAC G >82.6 and missing DASS depression data (n=1). 
‡ Lives alone reported by participants. Living with others included living with able/non-able bodied person, hostel or aged care 
residential facility. * Participants who did not speak English (about 7%) required the use of an interpreter. ^ Currently employed 
includes participants who reported engaging in full/part time paid work. ∞Included participants who reported finishing secondary 
school (final year), or university degree. ° Includes participants who did not finish secondary school, and those who reported no 
formal schooling. WOMAC: Western Ontario and McMaster Universities Arthritis Index; # WOMACG: WOMAC Global Scores 
calculated from the HOOS and KOOS: 0 indicates no problems and 100 indicates extreme problems. WOMACG: WOMAC Global 
scale minimal clinically important difference for worsening: 9.6 points absolute and 21% relative change in WOMAC Global scores 
compared to baseline. Transition: transition question definition of worsening; participant response was “moderately worse” or “much 
worse”. Composite: composite definition of worsening; 9.6 points absolute and 21% relative change in WOMAC Global scores 
compared to baseline OR transition question response as “moderately worse” or “much worse”. v Independent ANOVA or chi-
squared statistic comparing included & excluded participants. VAS: visual analogue scale (cm) ; BMIϱ: body mass index(kg/m2). 
6MWT Ϫ: Six minute walk test (m). DASS: Depression Anxiety Stress Scale. TJA: Joint replacement surgery. OR: Odds ratio. CI: 
Confidence interval. 
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5.4.1. Definition of worsening outcomes 
The 386 participants with complete datasets were included in the regression analyses. Of 
these 34 (9%) reported worsening according to the WOMACG definition, 34 (9%) met the 
criteria for worsening for the Transition definition and 56 (15%) for the Composite 
definition. Only 12 participants met all three definitions of worsening. According to both the 
Transition OR 2.7 (95%CI 1.26, 5.62) and Composite OR 2.2 (95%CI 1.22, 3.91) definitions, 
OACCP participants waitlisted for TJA had more than twice the odds of reporting worsening. 
There was a trend that those with signal joint knees had lower odds of reporting worsening 
(Table 5.2). The standardised 6MWT was significantly associated with the Transition 
definition and trended towards significance for the Composite definition of worsening 
whereby farther walking distance indicated reduced odds of worsening OR 0.7 (95%CI 0.46, 
0.99).  The results of the univariate analyses differed when the WOMACG worsening 
definition was applied; participants reporting depressive symptoms were less likely to worsen.  
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Table 5.2 Univariable analyses for three definitions of worsening 
Independent variable WOMACG 
Unadjusted OR 
(95%CI) 
P Transition 
Unadjusted OR 
(95%CI) 
P Composite 
Unadjusted OR 
(95%CI) 
P 
Age 1.0 (.99, 1.08) 0.062 1.0 (0.99, 1.10) 0.114 1.0 (1.00, 1.07) 0.028 
Sex                                             
male                                                   
female                                     
 
ref 
1.1 (0.50, 0.23) 
 
 
0.895 
 
ref 
1.6 (0.78, 3.29) 
 
 
0.199 
 
ref 
1.3 (0.70, 2.28) 
 
 
0.477 
Signal joint                                    
hip                                                   
knee 
 
ref 
1.0 (0.39, 2.84) 
 
 
0.922 
 
ref 
0.5 (0.20, 1.04) 
 
 
0.063 
 
ref 
0.5 (0.27, 1.07) 
 
 
0.078 
Pain VAS 1.0 (0.83, 1.15) 0.820 1.2 (1.04, 1.45) 0.017 1.1 (1.00, 1.24) 0.203 
Number of comorbidities          
low                                                    
moderate                                                    
high 
 
ref 
1.3 (0.63, 2.88) 
0.5 (0.17, 1.73) 
 
0.274 
0.443 
0.302 
 
ref 
0.9 (0.43, 1.1) 
0.6 (0.21, 1.68) 
 
0.605 
0.845 
0.323 
 
ref 
1.1 (0.60, 2.05) 
0.6 (0.26, 1.41) 
 
0.365 
0.753 
0.244 
Depression                                  
no depression                                                    
any depression 
 
ref 
0.3(0.11, 0.79) 
 
 
0.015 
 
ref 
1.4 (0.66, 2.77) 
 
 
0.409 
 
ref 
0.6 (0.35, 1.22) 
 
 
0.180 
6MWT 1.1 (0.72, 1.5 ) 0.791 0.7 (0.46, 0.70) 0.033 0.8 (0.57, 1.03) 0.079 
BMI 1.0 (0.95, 1.06) 0.989 1.0 (0.91, 1.02) 0.226 1.0 (0.93, 1.02) 0.351 
TJA Waitlist       
on list                                                      
not on list 
 
ref 
1.4 (0.67, 2.73) 
 
 
0.404 
 
ref 
2.7 (1.26, 5.62) 
 
 
0.011 
 
ref 
2.2 (1.22, 3.91) 
 
 
0.009 
WOMAC: Western Ontario and McMaster Universities Arthritis Index; WOMACG: WOMAC Global scale 
MCID for worsening: 9.6 points absolute and 21% relative change in WOMAC Global scores compared to 
baseline. Transition: transition question definition of worsening; participant response was “moderately worse” 
or “much worse”. Composite: composite definition of worsening; 9.6 points absolute and 21% relative change in 
WOMAC Global scores compared to baseline OR transition question response as “moderately worse” or “much 
worse”. ref: reference category for logistic regression. VAS: visual analogue scale DASS: Depression Anxiety 
Stress Scale. 6MWT: Standardised six-minute walk test. BMI: body mass index (kg/m2). TJA: Joint replacement 
surgery. OR: Odds ratio. CI: Confidence interval. P: p-values in bold face if p<0.2, one of the criteria for entry 
into the multivariate model 
 
 
5.4.2. Multivariate Models 
The final model for the WOMACG definition retained only presence of depressive symptoms 
OR 0.30 (95%CI 0.11, 0.79) (Table 5.3). The final multivariable model for the Transition 
definition contained TJA waitlist, 6MWT and signal joint however these predictors did not 
attain statistical significance (Table 5.3). The final multivariable Composite definition model 
retained TJA waitlist OR 1.91 (95%CI 1.04, 3.51) and 6MWT OR 0.81 (95%CI 0.60, 1.13). 
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According to the Composite definition; participants on TJA waitlists had almost twice the 
odds of worsening. The 6MWT was a confounder; OR 0.8 (95%CI 0.57, 1.03), although as the 
CI crossed zero, we can interpret this as having little or no effect. The Composite definition 
model fit the data well using the Hosmer-Lemeshow goodness- of- fit test: (χ2 = 8.68, 2 DF, p 
= 0.37), however was only capable of explaining 5% of the variance in demonstrating 
worsening (Figure 5.2). No model could predict worsening on all 3 definitions together. 
Although the best model was specific, correctly identifying participants who did not worsen, 
it lacked sensitivity so failed to identify those who had worsened.  
 
Table 5.3 Multivariable models for three definitions of worsening 
Definition of 
worse 
Worse      
n (%) 
Predictors β-coefficient P Adjusted 
OR 
95% CI 
WOMACG  34 (9) Constant 
Depression           
 
-2.04 
-1.21 
 
0.015 
 
0.30 
 
0.11, 0.79 
Transition 34 (9) Constant 
TJA Waitlist 
Signal Joint Knee 
6MWT 
 
-1.14 
 0.65 
-0.54 
-0. 34 
 
0.114 
0.238 
0.092 
 
1.91 
0.58 
0.071 
 
 
0.86, 4.29 
0.24, 1.43 
0.48, 1.06 
Composite 56 (14.5) Constant 
TJA Waitlist 
6MWT 
-1.47 
 0.65 
-0.19 
 
0.036 
0.231 
 
1.91 
0.83 
 
1.04, 3.51 
0.60, 1.13 
WOMACG: WOMAC Global scale MCID for worsening: 9.6 points absolute and 21% relative change in 
WOMAC Global scores compared to baseline. Transition: transition question definition of worsening; 
participant response was “moderately worse” or “much worse”. Composite: composite definition of worsening; 
9.6 points absolute and 21% relative change in WOMAC Global scores compared to baseline OR transition 
question response as “moderately worse” or “much worse”. TJA: Total joint arthroplasty6MWT: Standardised 
six-minute walk test. OR: Odds ratio. CI: Confidence interval. 
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5.5. Discussion 
This study aimed to identify participant characteristics predictive of three definitions of 
worsening following 26-weeks participation in the OACCP. We hypothesized that the same 
participants with similar demographic, psychological, disease-related and functional 
performance predictor variables would be identified as ‘worse’ across three definitions; 
however this was not the case. Similar trends were demonstrated by the Transition and 
Composite models: TJA waitlist and 6MWT were retained in both, though the Transition 
model also retained signal joint and did not reach statistical significance. These trends were 
not apparent when the WOMACG definition was applied.  
 
The evidence for symptomatic deterioration while waiting for TJA is conflicting. A systematic 
review (163) reported people with hip or knee OA waiting for less than six-months did not 
experience 10% deterioration in WOMAC pain or function scores. In contrast, 25% of people 
waiting for TJA longer than six-months reported a decline of ≥9.6% WOMACG scores (156). 
Only 46% of our sample was listed for TJA and these participants had been waiting for 
approximately six months. This may account for the lack of association between TJA waitlist 
status and the WOMACG definition of worsening. The participants lost to follow-up due to 
TJA and other reasons reported a higher mean WOMACG of 61.7 (SD ± 23.67), more similar 
to the previous study (156). These participants may have worsened in this time without 
surgery; however we do not have the data to support this supposition. The group reporting 
worsening according to the WOMACG definition had significantly lower baseline mean 
WOMACG scores of 38.4 (SD 16.34) compared to 50.2 (SD 17.93) for those who did not 
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(Table 5.1). One possible explanation is that there was a regression to the mean in 
participants with lower baseline WOMAC scores.  
 
In contrast to our hypothesis, 22/34 people who reported worsening on the Transition scale 
were not considered worse according to the WOMACG definition despite using “moderately 
worse” as the minimum cut-off. This contrasts with the study from which the threshold is 
derived (32). In the former study participants were not on the TJA waitlist, the intervention 
focused on physical therapy (not multidisciplinary) and was of shorter duration (3-4 weeks). 
It is possible that the thresholds we used to indicate worsening were not ideal for our study 
population. Further work is required to confirm the most appropriate threshold of worsening 
for this population. 
 
Alternatively, it is possible that discordance of worsening according to WOMACG and 
Transition scale definitions may be attributed to the attitudes and expectations of participants 
waitlisted for TJA. The act of booking a person for TJA possibly preconditions them to 
believe that their signal joint should become worse over time. The language used such as 
“end-stage”, “severe” and “bone-on-bone” may influence their response of “moderately 
worse” or “much worse” even though their WOMACG scores, a much lengthier 
questionnaire directly asking about specific symptoms, did not reflect this. The association 
between use of specific language by care-givers and patient perception of disease severity has 
received minimal research attention and is a potential area for future work. However, 
considerable paternalism persists in medical decision making about TJA (164, 165). Perhaps 
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some of our cohort believed that they needed the surgery because the surgeon said so, and 
this was sufficient evidence to report that their overall hip or knee joint health was “worse”. 
 
Participants on TJA waitlists had twice the odds of meeting the Composite criteria for 
“worsening” following participation in the OACCP. While TJA can provide good 
symptomatic relief for most people with end-stage OA (166), non-surgical management is 
efficacious in reducing the signs and symptoms of knee OA (149). It is advocated that patients 
be referred for non-surgical treatments as a first port-of-call and participation in chronic 
disease management programs should commence earlier in the OA disease course prior to 
being waitlisted for TJA. Although at this stage we can only explain a very small proportion of 
variables that predict worsening, referring participants earlier in their disease course may 
lessen their odds of worsening despite taking part in self-management programs. 
 
The absence of depression was a significant predictor of worsening according to the 
WOMACG definition. This finding is counterintuitive and a possible explanation is that of 34 
participants who worsened according to the WOMACG definition, only five reported 
depressive symptoms. This result is likely to be a type I error. The evidence for the absence of 
depression as a predictor of positive response to non-surgical interventions for hip and knee 
OA is conflicting (34, 39, 80). Further investigation of the relationship between symptoms of 
depression and outcomes following participation in the OACCP is warranted. Depression has 
been associated with non-compliance with treatment in populations with chronic disease 
(167). Compliance with OACCP interventions was not measured in this study. Exploration of 
Chapter 5 
124  
 
the association between compliance with multi-modal therapies, depression and self-reported 
worsening should also be addressed in future research. 
 
Signal joint was associated with the Transition and Composite definitions of worsening in the 
univariable analysis; participants with knee OA had lower odds of worsening following the 
OACCP. However, signal joint was not a significant predictor in the multivariate models. 
Previous research found that people waiting for hip TJA do not deteriorate compared to those 
awaiting knee TJA, however those participants were not receiving interventions for their OA 
(168). In contrast, a previous study following 26-weeks participation in the OACCP those 
with signal joint knees had twice the odds of responding as those with hips (39). Although 
exercise for hip OA may confer some reduction in pain and improvement in function, the 
treatment effect sizes are small (17). Further research into effective non-surgical management 
options for participants with hip OA is urgently required. 
 
Although previous research reports age, gender and BMI to be important characteristics in 
disease progression and response to intervention for hip and knee OA (34, 39, 76, 153, 169, 
170), they were not found to be significant predictors of worsening in our current 
investigation. The presence of comorbidities has been associated with poorer health-related 
quality of life for OA patients (171), yet a greater number of comorbidities was not associated 
with any definition of worsening. This is an important finding suggesting that non-surgical 
management may be considered for anyone with any number of concomitant conditions. 
Increasing pain over time has been associated with progression to TJA (150) and baseline 
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WOMAC pain scores independently correlated with TJA 6 years following assessment (152). 
Baseline pain-VAS was only independently associated with the Transition definition, hence 
failed to meet the criteria for entry into the multivariate models. The 6MWT was not a 
predictor of “response” in a similar OACCP cohort (38) however the self-paced 40-m walk 
test was predictive of response to physical therapy interventions for patients with hip OA 
(102). There is a gap in the research concerning the external validity of the 6MWT as 
compared to PRO’s (145). 
 
This study has several notable strengths: overall it was well-powered, potential predictor 
variables were identified a priori and care was taken to avoid over-fitting the prediction 
models. A doctor diagnosis of OA was used, which has good face validity (133). Although we 
were able to determine why participants withdrew participation from the OACCP, WOMAC 
data was missing for some who progressed to TJA, resulting in their exclusion from the 
analysis. This potentially limits the applicability of our results. Data from these participants 
would have been very useful to determine if these participants met any of the ‘worsening’ 
definitions immediately prior to their surgery. Significant predictors of worsening were 
found, however the multivariate models provide a very small proportion of the factors that 
predict worsening (Figure 5.2) and were not sensitive. 
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Figure 5.2 Variability of worsening explained by the model 
 
 
 
It is possible that stronger predictors of worsening exist that have not yet been studied, or 
perhaps the thresholds were chosen to represent the predictors affected the outcome. We 
transformed symptoms of depression and the number of comorbidities into categorical 
variables which may not have been ideal. This study did not include a control group and was 
limited to one OACCP site; both investigation into predictors of worsening compared to a 
control group and use of more heterogeneous samples of participants are important areas for 
future research.  
 
Three definitions of worsening were applied; potential predictors were identified only when 
using the Composite definition of worsening. While TJA waitlist status was associated with a 
two-fold increase in odds of reporting worsening using this definition, the model explained 
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only 5% of the total variance. Further, following 26-weeks participation in the OACCP, the 
WOMACG was largely discordant with the Transition and Composite definitions of 
worsening. Participants with similar demographic, psychological, disease-related and 
functional performance predictor variables were not consistently identified as ‘worse’ across 
the three definitions. Variables that predict worsening are largely unknown and further 
research into this area is warranted in order to present comprehensive and targeted 
management of patients with hip and knee OA. 
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Chapter Six: Instruments assessing attitudes toward or capability regarding 
self-management of osteoarthritis: a systematic review of measurement 
properties 
 
6.1. Abstract 
Objective: To make a recommendation on the “best” instrument to assess attitudes toward 
and/or capabilities regarding self-management of osteoarthritis based on available 
measurement property evidence. 
 
Methods: Electronic searches were performed in MEDLINE, EMBASE, CINAHL and 
PsychINFO (inception to 27 December 2016). Two reviewers independently rated 
measurement properties using the Consensus-based Standards for the selection of Health 
Measurement Instruments (COSMIN) 4-point scale. Best evidence synthesis was determined 
by considering COSMIN ratings for measurement property results and the level of evidence 
available for each measurement property of each instrument. 
 
Results: Eight studies out of 5653 publications met the inclusion criteria, with eight 
instruments identified for evaluation: Multidimensional Health Locus of Control, Perceived 
Behavioural Control, Patient Activation Measure, Educational Needs Assessment, Stages of 
Change Questionnaire in Osteoarthritis, Effective Consumer Scale and Perceived Efficacy in 
Patient–Physician Interactions five item (PEPPI-5) and ten item scales. Measurement 
properties assessed for these instruments included internal consistency (k=8), structural 
validity (k=8), test-retest reliability (k=2), measurement error (k=1), hypothesis testing (k=3) 
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and cross-cultural validity (k=3). No information was available for content validity, 
responsiveness or minimal important change/difference. The Dutch PEPPI-5 demonstrated 
the best measurement property evidence; strong evidence for internal consistency and 
structural validity but limited evidence for reliability and construct validity.  
 
Conclusions: Although PEPPI-5 was identified as having the best measurement properties, 
overall there is a poor level of evidence currently available concerning measurement 
properties of instruments to assess attitudes toward and/or capabilities regarding 
osteoarthritis self-management. Further well-designed studies investigating measurement 
properties of existing instruments are required. 
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6.2. Introduction 
Healthcare systems currently face a rising number of people living with chronic conditions 
leading to disability, without causing death (147). The Chronic Care Model (CCM) has been 
promoted to assist healthcare systems to meet the escalating demands attributable to chronic 
conditions (44). The CCM describes healthcare whereby patients are enabled to manage their 
condition supported by a proactive healthcare delivery system, involving a coordinated team 
of health professionals with the expertise required to provide decision support, all 
underpinned by appropriate health information systems (44). Self-management programs are 
interventions based on the tenets of the CCM; they aim to improve self-management 
capabilities. It follows that the efficacy of these programs should be measured by assessing 
change in participants’ attitudes toward and/or capabilities to manage their health. However, 
there are few recommendations guiding which instruments accurately measure self-
management (172). The widespread heterogeneity in standardised instruments measuring 
self-management programs is surprising given that the primary aim of these programs is to 
directly influence the attitudes toward and abilities to manage one’s health. 
 
This situation is apparent in a systematic review that examined the effects of self-management 
programs for arthritis. Meta-analysis showed short term small to moderate effects for pain up 
to one year and small long term effects on function for self-management programs for 
arthritis (14). The studies included in this review examined the effects of self-management 
programs that typically included the following elements: problem-solving, decision making, 
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action planning, self-tailoring, pain management strategies, exercise advice, joint protection, 
rational medication use and physician–patient communication (14). 
 
The studies included in the systematic review of self-management programs focussed on 
measures of pain and function (14). While these outcomes are obviously important to this 
population, there appears to be a disparity in the aims of self-management programs and the 
outcomes used to assess efficacy (15). Self-management programs aim to provide participants 
with the necessary tools to manage their condition rather than “cure” OA. Although these 
programs may not dramatically reduce pain and enhance functional ability, this does not 
necessarily reflect a failed strategy if the participants improve their attitudes towards and 
ability to manage symptoms and live with an acceptable quality of life despite their disease 
(15). Another systematic review reported low-to-moderate quality evidence of no or small 
benefits to participants of OA self-management education programs (15). The authors 
highlighted the heterogeneity of outcomes used to quantify the effects of self-management 
programs and that work is needed to establish which outcomes are important to patients. 
This review recommended rigorous evaluation of OA self-management programs with 
validated instruments fit to measure attitudes towards/capabilities to self-manage OA, and 
advised that to achieve this, the measurement properties of the existing instruments need 
further investigation (15). It is important to note that unlike most of the studies in these 
systematic reviews, modern OA management programs deliver education and self-
management strategies in combination with exercise and weight loss (27, 28, 39). Programs 
combining these additional treatment modalities should theoretically produce larger 
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treatment effects, but this is yet to be quantified in a systematic review. Regardless of this, 
self-management attitudes and capabilities are also important aspects of modern OA 
management programs and further information regarding the measurement properties of 
instruments measuring these constructs is required to guide the choice of the ‘best’ 
instrument to use.  
 
Measurement properties refer to the ability of the instrument to truthfully and 
comprehensively measure the specified construct (37). In addition, it is necessary to 
demonstrate that the instrument is discriminative, sensitive, reliable and deemed feasible in 
terms of cost and time constraints (36). It is important to consider that the measurement 
properties of an instrument are not universal across different populations; hence, it cannot be 
assumed that one with good measurement properties in a specific population will 
demonstrate the same results in a different population (56). Therefore, the measurement 
properties of an instrument must be considered within the specific context of the population 
of interest.  
 
The aims of this systematic review were to: i) identify studies reporting measurement 
properties of instruments assessing attitudes toward and/or capabilities regarding self-
management of OA; ii) systematically critique the studies evaluating instruments using the 
Consensus-based Standards for the selection of Health Measurement Instruments (COSMIN) 
tool: and iii) synthesize the evidence available with the possibility of making rudimentary 
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recommendations concerning the best evidence-based instruments to assess attitudes toward 
and/or capabilities regarding self-management of OA.  
 
6.3. Methodology 
6.3.1. Terminology 
Self-management was defined as the individual’s ability to manage their physical and 
psychological symptoms, treatments, consequences and lifestyle changes required to live with 
their OA (35). Attitudes toward and/or capabilities regarding self-management of OA 
included the following constructs: knowledge, skills, beliefs, behaviours, activation, self-
efficacy, health locus of control, readiness to change healthcare behaviours, healthcare 
navigation, participation, engagement, and motivation. This list of possible constructs was 
developed a priori using existing content knowledge about available instruments by the 
authors, and new constructs identified during the review were also included. 
 
 
6.3.2. Review protocol 
The review protocol was developed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement and prospectively registered 
with PROSPERO on 24 November 2015 (CRD42015019074). 
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6.3.3. Literature search 
The review search strategy was developed and refined by the study authors according to the 
PRISMA statement and recommendations made for conducting systematic reviews of 
measurement properties (56, 173). Electronic searches were conducted of the following four 
bibliographic databases from inception to 27 December 2016: MEDLINE (PubMed), 
EMBASE (OvidSP), CINAHL (Ebsco), PsychINFO (OvidSP). An initial search was conducted 
using four main filters containing key search terms as briefly summarised below (see 
Appendix 1 PubMed search strategy): 
I. Construct- attitudes toward and capabilities regarding self-management of OA using 
terms such as: “self-treatment OR self-management OR patient education…” Names of 
known instruments measuring attitudes and/or capabilities regarding self-management 
were added using ‘OR’: “health education impact questionnaire OR patient activation 
measure OR effective consumer scale …”  
II. Target population- osteoarthritis OR osteoarth* OR degenerative arthritis OR arthrosis. 
III. Measurement instrument filter- designed for PubMed to retrieve more than 97% of 
publications related to measurement properties (59) using terms such as: 
“instrumentation OR methods OR validation studies…” The filter was translated into the 
language of the other databases used.  
IV. Exclusion filter- An exclusion filter was used to improve the precision of the 
measurement instrument filter (59). 
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Secondary searching was conducted for all instruments measuring attitudes toward and 
capabilities regarding self-management of OA identified during the initial search. The name 
of each instrument was used as the keyword combined (AND) with the target population 
filter in PubMed. Targeted hand searching of reference lists was also used. Results of the 
database searches were imported into Endnote X7 (Thomson Reuters, Philadelphia, USA). 
 
6.3.4. Eligibility criteria 
Study titles were screened by one reviewer (JE). Two reviewers (JE & SM) independently 
screened abstracts, followed by the full text of potentially eligible studies. Disagreements were 
discussed and resolved with a third reviewer (KM). Studies were included if they met the 
following criteria: 
1. Construct- at least one instrument attempted to measure the participants’ attitudes 
and/or capabilities regarding self-management of their OA.  
2. Target Population- adults diagnosed with any stage of OA according to the American 
College of Rheumatology guidelines, clinical diagnosis of OA from examination findings, 
patients’ symptoms or radiographic evidence of disease. Studies with mixed disease 
populations were excluded if the proportion of participants with a main diagnosis of OA 
was less than 80% and the results for OA participants were not reported separately. 
3. Measurement Instrument- patient-reported outcomes (PROs) (completed by the 
participant) in the form of questionnaires or scales.  
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4. Measurement Properties- the study was required to explicitly state a primary or 
secondary aim to develop an instrument or examine at least one measurement property of 
the instrument involved. 
5. Setting- the instrument was required to have been utilised in a clinic, field or community 
setting using readily available equipment. Instruments with a license fee were included.  
6. Publication type- full-text studies published as original articles in peer-reviewed journals. 
7. Language- English language studies were included. Non-English language studies were 
noted, and data extraction performed when possible, however, these were excluded from 
COSMIN rating due to lack of access to translation resources, and the high level of detail 
required for a COSMIN review. 
 
6.3.5. Data extraction 
Two reviewers (JE & SM) independently extracted data to a predefined spreadsheet with a 
third reviewer (KM) available to resolve differences. The generalisability of the included 
studies was considered by extracting characteristics such as mean age, gender distribution, 
OA stage, setting and language. Relevant data regarding interpretability issues was extracted 
including the distribution of scores, floor and ceiling effects, change scores, and minimal 
important change (MIC) or minimal important difference (MID) (174). 
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6.3.6. Methodological quality evaluation of the studies 
Two raters (JE & NC) independently assessed the methodological quality of the included 
studies, with a third rater (FD) available to resolve discrepancies. Included studies were 
assessed according to the COSMIN taxonomy of the following measurement properties: 
internal consistency, reliability, measurement error, content validity, structural validity, 
hypotheses testing (a form of construct validity), cross-cultural validity, and responsiveness 
(58). The definitions of these measurement properties are summarised in Table 6.1 (174). 
Each measurement property featured within a particular study was rated separately according 
to the COSMIN tool; a robust quality evaluation tool using a 4-point scoring system: “poor”, 
“fair”, “good” or “excellent” (60, 174). An overall quality score was given for each 
measurement property in each study using the “worst score counts” method that accounted 
for the lowest rating of any item within that measurement property section (60).  
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Table 6.1 Definitions of measurement properties 
 
Measurement property Definition 
 
Internal consistency The degree to which items of an instrument are related to 
each other  
 
Reliability The proportion of the total variance of “true differences” 
measured by the instrument that is not attributed to 
measurement error 
 
Measurement error 
  
The component of a patient’s score that is not due to real 
changes of the construct measured by the instrument, but 
attributed to systematic and/or random error 
 
Content validity The degree to which the content of the instrument 
measures the construct it intends to measure  
 
Structural validity The extent to which the scores of an instrument conform to 
the dimensionality of the construct intended  
 
Hypotheses testing An aspect of construct validity; when questions are 
formulated a priori about the expected relationships with 
instruments measuring related constructs  
 
Cross-cultural validity The extent to which the translated or culturally adapted 
instrument reflects  the performance of  the original 
version of the instrument  
 
Criterion validity When the scores of an instrument are compared to 
determine if they are reflective of the outcomes of another 
instrument considered to be the “gold standard”  
 
Responsiveness 
 
The measurement of the ability of the instrument to detect 
changes in scores that reflect change in the construct over 
time  
 
Floor and ceiling effects 
 
The proportion of participants who responded with the 
lowest or highest possible score on the instrument 
Definitions adapted from Mokkink et al. J Clin Epidem 36 (2010) and de Vet, H., et al., “Measurement in 
Medicine: A Practical Guide to Biostatistics and Epidemiology” (2010). 
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6.3.7. Evaluation of measurement property result 
An overall quality rating of the measurement property results for each instrument was 
performed using a checklist of criteria for good measurement properties (61)(Appendix 2). 
Two raters determined the quality rating using this additional tool (JE & SM) with 
disagreements resolved with a third reviewer (NC).  
 
6.3.8. Data synthesis 
Qualitative analysis: To summarise the level of evidence of each measurement property for 
each instrument, a “best evidence synthesis” was performed. The “best evidence synthesis” 
was derived by triangulating the methodological quality of the studies (174) (using the 
COSMIN score), the quality criteria for rating the results of measurement properties 
(Appendix 2) (61), and the level of evidence for the measurement properties of the 
instruments according to the following: “strong”, “moderate”, “limited”, “conflicting”, or 
“indeterminate” (56, 61); (Table 6.2).  
 
Quantitative analysis: Meta-analysis of data was planned for studies of fair or better 
methodological quality and of sufficient homogeneity (56).  
 
6.4. Results 
The initial search strategy identified 5653 studies (Figure 6.1). Following title and abstract 
screening, 44 studies were identified for full-text review. Following full-text review, eight 
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studies were included (175-182). Each study assessed a different instrument, therefore it was 
not possible to pool data for quantitative analyses. The content of instruments varied widely 
with respect to the constructs of self-management they represented. Table 6.3 provides a 
content comparison of the constructs represented in the eight instruments, their 
characteristics are summarised in Table 6.4. The Patient Activation Measure (PAM) (175) 
required a license fee; all others were freely available online or following contact with the 
authors. Many instruments were translated into a language other the original, including 
Korean (175), Dutch (176, 179-181), Austrian-German, Finnish, Norwegian, Portuguese, 
Spanish, Swedish (179) and Chinese (182).  
 
Study characteristics such as cohort descriptors, sample sizes and instrument scores are 
provided in Table 6.4. The OA sites captured within the studies included hand, hip and knee 
(176, 179), hip and knee (177), knee (182)or were not specified (175, 178, 180, 181). Stage or 
duration of OA was generally unreported. Participants were predominantly female across all 
studies and representative of the age of the wider OA population, with mean age ranging 
from 62-72.2 years.  
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Table 6.2 Levels of evidence for the quality of the measurement property 
 
Level of evidence Rating Criteria 
Strong +++ OR --- Consistent ﬁndings in multiple studies of good 
methodological quality OR in one study of excellent 
methodological quality 
 
Moderate ++   OR -- Consistent ﬁndings in multiple studies of fair 
methodological quality OR in one study of good 
methodological quality 
 
Limited +     OR - One study of fair methodological quality 
 
Conflicting ± Conﬂicting ﬁndings 
 
Indeterminate ? Only studies of poor methodological quality 
   
Adapted from Terwee et al. J Clin Epidemiol 2007;60(1):34-42  
+ = positive rating, ? =  unknown rating, - = negative rating. 
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Figure 6.1 Flowchart of the selection and inclusion of studies 
 
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
 
Exclusion Criteria   
i) Population: the proportion of participants with a main diagnosis of OA was less than 80% and the results for 
OA participants were not reported separately 
ii) Construct: Not an instrument that measures attitudes or abilities pertaining to self-management of OA 
iii) Instrument: Not a patient-reported outcome in the form of questionnaire or scale 
iv) Setting: Not used in a clinic setting/field 
v) Measurement study: No primary or secondary aim to examine at least one measurement property    
vi) Publication type: Not a full-text article 
vii) Language: Not English (only excluded from COSMIN review) 
 
Additional full text 
studies assessed for 
eligibility from hand 
searching              
6 
 
PubMed 
4201 references 
Embase 
2136 references 
Cinahl 
190 references 
PsychINFO 
217 references 
Following removal of duplicates 
5653 
 
 
Excluded based on 
title/abstract 
5622 
 
 
Full-text articles assessed for eligibility 
31 
Additional full text 
studies from single 
instrument with 
population filter search  
7 
 
 Total included in the review 
8 
Excluded based on full 
text review 
i) 19 
ii) 15 
iii) 0 
iv) 0 
v) 1 
vi) 1 
vii) 0 
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Table 6.3 Content comparison of instruments  
 
 
 
Construct 
Attitudes/ 
beliefs 
pertaining to 
self-
management 
of OA  
Attitudes/ 
beliefs 
pertaining to 
changing 
health 
behaviour 
Knowledge 
required for 
self-
management 
 
Capability to 
perform 
skills 
required for 
self-
management  
Educational 
needs for 
self-
management 
of OA 
Interactions 
with health 
care 
providers 
assisting with 
management 
of OA  
Overall 
capability to 
self-manage 
OA  
MHLC173 
 
•        
PBC174 
 
•    •   •   
PAM-13171 
 
•   •  •   •  •  
ENAT175 
 
•  •  •   •    
PEPPI-5176 
 
  •  •   •   
SCQOA172 
 
•  •       
EC-17177 
 
•   •  •   •   
PEPPI-10178  
 
 •  •   •   
MHLC= Multidimensional Health Locus of Control, IHLC= Internal Health Locus of control, PBC= Perceived 
behavioural control, PAM13= Patient activation measure, ENAT= Educational needs assessment, PEPPI-5= 
Perceived Efficacy in Patient–Physician Interactions Scale, SCQOA= The Stages of Change Questionnaire in 
Osteoarthritis, EC-17= Effective Consumer Scale. 
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Table 6.4 Characteristics of included studies 
 
Authors/ 
Instrument 
 
Construct 
described  
Time to 
administer 
Availability Language 
& country 
Number, type of 
questions & scoring 
Proport 
-ion 
with OA 
(%) 
OA site 
& stage 
% other 
diseases in 
sample 
N with > 
80% OA 
(response 
rate 
%) 
Age: mean age 
years (SD) or 
age groups (%) 
Female 
% 
Mean (standard 
deviation), 
possible score 
range, 
distribution 
Kelly  
(2007)/ 
MHLC173 
Measures beliefs 
about who or 
what controls 
the patient’s 
health status 
Not stated Freely 
available at: 
http://www.
nursing.van
derbilt.edu/f
aculty/kwall
ston/mhlcsc
ales.htm 
 
English, 
USA & 
Canada 
Three scales of 6 items 
each, using 6-point Likert 
scale measuring the 
following dimensions: 
‘‘Internal’’ ‘‘Chance’’ and 
‘‘Powerful Others’’.  
Sum the individual item 
scores for each subscale. 
86.2 Hip & 
knee 
Control 
sample: 
13.8 
1040 (100) Study I: 65 (9) 
Study II: 64 (16) 
Study III: 62 (6) 
Study I:  
(66) 
Study 
II:  (59) 
Study 
III: (63) 
IHLC: 26.44 
(5.61) 
PHLC: 20.22 
(6.64) 
CHLC: 16.96 
(6.05) 
Each subscale 
has range 6- 36 
Liu (2007)/ 
PBC 174 
Survey of OA 
patients' drug 
information 
seeking from 
physicians and 
pharmacists. 
Not stated In published 
paper 
English 
USA 
8 statements with 7-point 
Likert responses 
Perceived difficulty:3 
Self-efficacy: 3 
Controllability: 2 
Answer for physicians & 
pharmacists separately  
 
100 Not 
stated 
- 1000 (61.9) 18-24: 1.8% 
25-34: 3.8% 
35-44: 11.9% 
45-54: 27.6% 
55-64: 28.3% 
>64:  26.6% 
72.8 PDP: 5.10 (1.60) 
PDPh: 5.27 
(1.49) 
SEP: 5.62 (1.62) 
SEPh: 5.62 (1.60) 
CP: 5.63 (1.36)       
CPh: 5.62 (1.37) 
 
Ahn (2015)/ 
PAM-13171 
Patient 
activation: 
patient’s 
knowledge, skill, 
and confidence 
regarding the 
self- 
management of 
a chronic 
disease 
 
Not stated Insignia 
Health 
provides 
licenses for 
the PAM at 
a cost 
Korean, 
South 
Korea 
13-statements, with 
responses on a 4-point 
Likert scale. Raw score: 
sum responses to the 13 
items. Scores ranging 
from 13 to 52. converted 
to a 0–100 interval scale. 
Higher total PAM scores 
reflect higher levels of 
patient activation. 
 
100 Not 
stated 
- 270 (100) 72.2 (8.3) 82.4 50.0 (13.5)  0-
100, 
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Ndosi 
(2014)/ 
ENAT175 
Assesses the 
educational 
needs 
(priorities) of 
patients with 
rheumatic 
diseases 
Not stated Contact 
authors 
Austrian 
German 
Finnish 
Dutch 
Norwei-
gian 
Portu-
guese 
Spanish 
Swedish 
Austria 
Finland 
Nether-
lands 
Norway 
Portugal 
Spain 
Sweden 
 
39 items with 4-point 
Likert scale in 7 domains: 
managing pain (6 items), 
movement 
(5 items), feelings (4 
items), arthritis process 
(7 items), treatments (7 
items), self-help measures 
(6 items) and support 
systems (4 items) 
14.4 Hand, 
hip or 
knee in 
discussi
on. 
Stage 
not 
stated 
AS: 22.5% 
FM:  12% 
PsA: 
26.8% 
SLE:  
12.3% 
SS:  12.0% 
433 
(response 
rate not 
stated) 
Not stated for 
OA sample: 
pooled sample is 
52.6(13.1) 
Not 
stated 
for OA 
but 
across 
pooled 
sample 
66.2 
Not stated for 
OA group 
ten 
Klooster 
(2012)/ 
PEPPI-5176 
Self-efficacy in 
both obtaining 
medical 
information and 
attention to 
chief health 
concern from a 
physician 
Not stated Dutch 
version 
freely 
available on 
web. English 
version 
published 
Dutch, 
Nether-
lands 
5 questions with 
responses on a 5-point 
numerical rating scale. 
Total scores are summed 
to range from 5 to 25, 
higher total scores reflect 
higher perceived self-
efficacy in patient–
physician interactions. 
100 Not 
stated 
- 224 (55.4) 62.9 (10.2) 81.3 18.8 (4.3) 
5- 25, 
Slightly 
negatively 
skewed. 
Heuts 
(2005)/ 
SCQOA172 
People move 
from low to 
high level of 
participation. 
Stages:  no 
intention to 
change to 
optimal 
3-5 min Published in 
paper as 
appendix 
(in English) 
Unclear 
(Dutch or 
English), 
Nether-
lands 
21 items scored on 5-
point likert scale. 
3 subscales: 7 questions 
for precontemplation, 7 
for contemplation, 7 for 
action. 
100 In 
results 
hip, 
knee & 
hand. 
Stage 
not 
stated 
- 273 (100) Range 40-60 
years for 
inclusion 
criteria 
59.7 Using highest 
score method: 
10.3% was in the 
'pre-
contemplation 
stage', 22.3% in 
the 
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active 
participation 
with 
internalization 
of new behavior 
 
'contemplation 
stage', 67.0% was 
'in action', 
ten 
Klooster 
(2013)/ 
EC-17177 
Measures 
knowledge, 
attitudes, and 
behaviours 
regarding self-
management 
skills 
Not stated Available in 
published 
paper & on 
web 
http://www.
cgh.uottawa.
ca/assets/do
cuments/Su
rvey.pdf 
Dutch 
Nether-
lands 
17 items with 5-point 
Likert scale. Item scores 
are summed when items 
are completed and 
converted to range from 0 
to 100, where 100 is the 
best possible score. 
 
85.6 Not 
stated 
FM: 14.4 209 (55.8% 
of combined 
OA & FM 
sample) 
62.6 (10.1) 80.9 68.9 (16.3), 
0-100, 
Near normal 
distribution 
(Kolmogorov-
Smirnov, P= 
0.058) 
 
Zhao (2016) 
PEPPI-10178 
 
Self-efficacy in 
both obtaining 
medical 
information and 
attention to 
chief health 
concern from a 
physician 
Not stated Supplement 
link from 
paper:  
https://www
.dovepress.c
om/get_sup
plementary_
file.php?f=1
10883.pdf 
Chinese, 
China 
10 items with 10 point 
Numerical Rating Scale: 
Not confident to 
extremely confident. Sum 
ten scores from 0 to 100 
(100 best self-efficacy) 
100 Knee - 115 (100) 63.42 (6.7) 59 90.07 ( 12.9), 
0- 100 
Negatively 
skewed 
distribution 
MHLC= Multidimensional Health Locus of Control, IHLC= Internal Health Locus of control, PHLC= Powerful Others Health Locus of control, CHLC= Chance Health Locus of Control, PBC= 
Perceived behavioural control, PDP= Perceived diﬃculty for physicians, PDPh= Perceived diﬃculty for pharmacists, SEP= Self-eﬃcacy for physicians, SEPh= Self-eﬃcacy for pharmacists, CP= 
Controllability for physicians, CPh= Controllability for pharmacists, PAM13= Patient activation measure, ENAT= Educational needs assessment, PEPPI-5= Perceived Efficacy in Patient–
Physician Interactions scale, SCQOA= The Stages of Change Questionnaire in Osteoarthritis, EC-17= Effective Consumer Scale. RA: Rheumatoid arthritis, FM: Fibromyalgia, AS: Ankylosing 
spondylitis, PsA: Psoriatic arthritis, SLE: Systemic Lupus Erythematosus, SS: Systemic sclerosis. 
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6.4.1. Measurement property results and “best evidence synthesis” 
Findings for measurement properties are summarised in Tables 6.5 and 6.6, qualitative data 
synthesis in Table 6.7.  
 
 Internal Consistency 
Internal consistency was estimated for all instruments. Strong evidence (excellent rating) for 
internal consistency (Cronbach’s α = 0.92) was found for the Perceived Efficacy in Patient–
Physician Interactions 5 item scale (PEPPI-5) (180), satisfying requirements for 
unidimensionality (Appendix 2). Moderate evidence (good rating) of adequate internal 
consistency was demonstrated for the Perceived Efficacy in Patient–Physician Interactions  10 
item scale (PEPPI-10) (182) (Cronbach’s α = 0.91). Limited evidence (fair rating) of adequate 
internal consistency was found for three instruments: Perceived Behavioural Control (PBC) 
(178), PAM-13 (175) and The Stages of Change Questionnaire in Osteoarthritis (SCQOA) 
(176). There was indeterminate evidence (poor rating) of internal consistency for three 
instruments: Multidimensional Health Locus of Control (MHLC) (form C) (177), 
Educational Needs Assessment Tool (ENAT) (179) and Effective Consumer Scale (EC-17) 
(181). 
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Table 6.5 Measurement property results: internal consistency, reliability, measurement error and structural validity. 
 
Instrument #Requirements  
IRT  
Internal consistency Reliability Measurement error Structural validity 
  Result 
Cronbach’s alpha 
COSMIN 
score 
Result COSMIN 
score 
Result COSMIN 
score 
Result COSMIN score 
MHLC173 
 
Good IHLC: 0.75; 
PHLC: 0.70; 
CHLC: 0.65 
Poor - - - - Confirmatory FA, 3 factor 
model: χ2= 904.50 , 135 df, 
(P<0.01), RMSEA 0.0, GFI = 
0.96, CFI=  0.79, ECVI= 
0.81,PCA, FA & Rasch 
analysis supported  item 
reduction: removed 2 items  
Poor 
PBC174 
 
- PDP: α= 0.77 
PDPh: α= 0.72 
SEP: α= 0.83 
SEPh: α= 0.83 
 
Fair - - - - PCA & exploratory FA with 
Factor loading.  
Data reduction & data 
detection 
Fair 
PAM-13171 
 
Good α= 0.88 Fair - - - - Confirmatory PCA 
GFI= 32 (11.9%) misfits 
MNSQ 0.68 to 1.42 
Rasch analysis: person 
reliability was between .87 
(real) and .89 (model), and the 
item reliability was .99. The 
separation index for persons 
was 2.57 and that for items 
was 10.56. 
57.5% variance of data 
explained. 
 
Fair 
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ENAT175 
 
Good IRT: Person 
separation index 
> 0.9 
 
Poor - - - - Confirmatory FA, structure 
detection & 
Rasch analysis 
OA group was a misfit 
 
Fair 
PEPPI-5176 
 
- α= 0.92 Excellent Test-retest: 
ICC 0.68 (95% 
CI 0.56, 0.78) 
Bland–Altman 
analysis LOA 
6.83 -6.35 
(mean 
difference  -
0.24, t(99) = - 
0.71, p = 0.48) 
Fair LOA -6.83-  
6.35 
differences 
_ weakly 
related to 
the  
magnitude 
of the 
measurem
ent (r2 = 
0.04, p = 
0.049), 
indicating 
little to no 
systematic 
bias. 
Fair Confirmatory FA, factor 
loading & structure detection 
(1 factor) 
SB χ2 (5) = 17.43, NNFI = 0.98, 
CFI = 0.99, 
SRMR = 0.03, RMSEA (90% 
CI) = 0.11 (0.05–0.16) 
Excellent 
SCQOA172 
 
- action α= 0.74 
precontemplation 
α= 0.70 
contemplator α= 
0.77 
After removal of 5 
items: 
action α= 0.79  
precontemplation 
α= 0.72 
contemplation α= 
0.76 
Fair - - - - Confirmatory FA, factor 
loading & date reduction: 
removal of items 3, 7, 12, 16, 
18 and 20 
PCA. 
Repeated FA with 15 item 
scale: 3 factors explained 45% 
of variance 
 
Fair 
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EC-17177 Good person reliability:  
0.92 
Poor test-retest 
ICC= 0.71 (95 
% CI: 0.60–
0.80) 
Poor - - Confirmatory FA 
Apart from RMSEA, 1-factor 
model 
good fit  
SB χ2 (119) = 488.70,  
NNFI = 0.96, 
CFI = 0.96, SRMR = 0.08, 
RMSEA (90 % CI) = 0.11 
(0.10–0.12). 
Poor 
PEPPI-10178 - α= 0.91 Good - - - - Confirmatory FA: two-factor 
model good fit (df=33, P-value 
=0.000) except  RMSEA=0.164 
above cutoff 
Good 
NOTE: Content validity, criterion validity and responsiveness were not reported on in any included articles, hence do not appear in the table. 
#This field was only completed for those instruments based on Item Response Theory (IRT). MHLC= Multidimensional Health Locus of Control, IHLC= Internal Health 
Locus of control, PHLC= Powerful Others Health Locus of control, CHLC= Chance Health Locus of Control, PBC= Perceived behavioural control, PDP= Perceived diﬃculty 
for physicians, PDPh= Perceived diﬃculty for pharmacists, SEP= Self-eﬃcacy for physicians, SEPh= Self-eﬃcacy for pharmacists, CP= Controllability for physicians, CPh= 
Controllability for pharmacists, PAM13= Patient activation measure, ENAT= Educational needs assessment, PEPPI-5= Perceived Efficacy in Patient–Physician Interactions 5 
item scale, SCQOA= The Stages of Change Questionnaire in Osteoarthritis, EC-17= Effective Consumer Scale. FA= Factor Analysis, PCA= Principal Components Analysis, 
GFI= Goodness of fit index, MNSQ= Infit & outfit mean square statistics, NRS= numerical rating score, NS= non-significant, NNFI= Non-normed Fit Index, CFI= 
comparative fit index, SRMR= standardized root mean square residual, RMSEA=  root mean square error of approximation,  SB χ2= Satorra-Bentler chi-squared statistic, 
LOA = limits of agreement, MFES= modified fall efficacy scale, OSES= osteoporosis self-efficacy scale, PEPPI-10= Perceived Efficacy in Patient–Physician Interactions 10 
item  scale; SEE-C= self-efficacy for exercise scale. 
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Table 6.6 Measurement property results: construct validity, cross-cultural validity, and floor and ceiling effects. 
 
Instrument Construct validity (Hypothesis testing) 
 
Cross-cultural validity 
 
 Floor & ceiling effects 
 Hypothesis Result COSMIN 
score 
Result COSMIN 
score 
Result 
MHLC173 
 
- - - - -  Seven items, including all six 
items of the IHLC scale, exhibited 
skewness that exceeded -1.00 (i.e., 
a ‘‘ceiling effect’’). No floor effect. 
PBC174 
 
- - - - - - 
PAM-13171 
 
- - - Items 1 and 4 were 
adjusted to make more 
sense in Korean 
translation. PCA 
indicated 
unidimensionality 
 
Fair* - 
ENAT175 
 
- - - - - - 
PEPPI-5176 
 
Expected correlations: 
Strongly positively 
correlated with EC-17, 
moderately positively with 
GSES, weakly positively with 
AIMS2 family & friends 
scale and SF-36 MCS and 
not correlated with SF- 36 
PCS and pain NRS  
EC-17: r=0.52, p<0.01 
GSES: r= 0.07 (not sig) 
AIMS2 F & F: r=0.23, 
p<0.05 
SF-36 MCS: R= 0.26, 
p<0.01 
SF- 36 PCS: r= 0.05 
(NS) 
Pain NRS: r=-0.12 (NS) 
 
 
 
Fair - - No floor and ceiling effects:  no 
patients scored five and 26 
patients (11.6%) scored 25. 
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SCQOA172 
 
- - - - - - 
EC-17177 Expected correlations: 
Strongly correlated PEPPI-5, 
moderately correlated GSES 
and AIMS2 F & f, moderate 
correlation SF-36 MCS, 
weak correlations SF-36 PCS 
& pain NRS 
PEPPI-5: r=0.55, 
P<0.01, 
GSES: r=0.26, P<0.01 
AIMS2 F & F: r=-0.34, 
P<0.01 
SF-36 MCS: r=0.39, 
p<0.01 
SF-36 PCS: r=0.14, 
p<0.05, 
Pain NRS: r=-0.21, 
p<0.01 
Poor Following pretests 
small wording changes 
made in six items. CFA 
supported 
unidimensional 
structure of the scale 
Poor* No ceiling or floor effect found: 
no participants scored zero and 
only 1.3% achieved maximum 
score 
PEPPI-10178 No hypothesis and expected 
correlations not stated 
SEE-C: r=0.292, 
p<0.01, 
MFES: r= 0.220, 
p<0.05, 
OSES: r=0.315, p<0.01 
Poor Following pretests, two 
items were modified to 
suit Chinese language. 
FA showed Chinese 
version of PEPPI-10 
has two common 
factors; different to 1 
factor reported 
previously for the 
English version.  
Fair* Ceiling effect found for 28.2% of 
participants. No floor effect. 
NOTE: Content validity, criterion validity and responsiveness were not reported on in any included articles, hence do not appear in the table. Floor and ceiling effects were 
not evaluated using the COSMIN Checklist.*Paper did not assess cross-cultural validity however did translate the questionnaire into other language(s) hence quality of 
translation items of COSMIN checklist were rated (Box G items 4-11).MHLC= Multidimensional Health Locus of Control, IHLC= Internal Health Locus of control, PBC= 
Perceived behavioural control, PAM13= Patient activation measure, ENAT= Educational needs assessment, PEPPI-5= Perceived Efficacy in Patient–Physician Interactions 5 
item scale, SCQOA= The Stages of Change Questionnaire in Osteoarthritis, EC-17= Effective Consumer Scale, GSES= General Self Efficacy scale, AIMS2 F & F= Dutch 
Arthritis Impact Measurement Scales 2 Family and Friends scale, SF-36 MCS= Short form 36 mental component summary score, SF- 36 PCS=  Short form 36 mental 
component summary score, MFES= modified fall efficacy scale, OSES= osteoporosis self-efficacy scale, PEPPI-10= Perceived Efficacy in Patient–Physician Interactions 10 
item  scale; SEE-C= self-efficacy for exercise scale. 
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Table 6.7 Measurement property synthesis using COSMIN rating, quality criteria and levels of evidence 
Instrument Internal 
consistency 
Reliability Measurement 
error 
Structural 
validity 
Hypothesis 
testing 
Cross-cultural 
validity 
Floor and 
ceiling effects 
MHLC173 
 
? 0 0 ? 0 0 ? 
PBC174 
 
+ 0 0 ? 0 0 0 
PAM-13171 
 
+ 0 0 + 0 *+ 0 
        
ENAT175 
 
? 0 0 - 0 0 0 
PEPPI-5176 
 
+++ - ? +++ + 0 +++ 
SCQOA172 
 
+ 0 0 - 0 0 0 
EC-17177 
 
? ? 0 ? ? *? ? 
PEPPI-10178 ++ 0 0 ++ ? *+ 
 
- 
NOTE: Content validity and responsiveness were not reported on in any included studies, hence do not appear in the table.  
*Paper did not assess cross-cultural validity hence the quality criteria for rating the results of measurement properties (Appendix 2) were not applied to the 
overall measurement property result, however the translation items of COSMIN checklist were rated (Box G items 4-11).   
+++ or --- strong evidence, ++ or -- moderate evidence, + or – limited evidence, ± conflicting evidence, ? indeterminate, 0 no information [+ positive, - 
negative rating (results)]. MHLC= Multidimensional Health Locus of Control, IHLC= Internal Health Locus of Control, PBC= Perceived Behavioural 
Control, PAM13= Patient Activation Measure, ENAT= Educational Needs Assessment, PEPPI-5= Perceived Efficacy in Patient–Physician Interactions 5 item 
Scale, SCQOA= The Stages of Change Questionnaire in Osteoarthritis, EC-17= Effective Consumer Scale, PEPPI-10= Perceived Efficacy in Patient–Physician 
Interactions 10 item Scale  
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Reliability 
Adequate test-retest reliability required intraclass correlation coefficient (ICC)> 0.7 (see 
Appendix 2). There was limited evidence (fair rating) of inadequate test-retest reliability for 
the PEPPI-5 (ICC= 0.68) (180). Indeterminate evidence (poor rating) of adequate test-retest 
reliability was found for the EC-17 (181) (ICC= 0.71). 
 
Measurement error 
Although data for test-retest reliability can be used to calculate measurement error, only one 
study reported this. There was indeterminate evidence of measurement error for the PEPPI-5 
(180) (limits of agreement -6.83 to 6.35) because the MIC was not defined (see Appendix 2). 
 
Structural Validity 
To demonstrate adequate structural validity, the factors identified should explain at least 50% 
of the variability of responses (see Appendix 2). There was strong evidence (excellent rating) 
that the PEPPI-5 featured an appropriate 1-factor structure (180). There was moderate 
evidence (good rating) that the PEPPI-10 demonstrated a two factor structure (182). There 
was limited evidence (fair rating) of positive structural validity for the PAM (175) and limited 
evidence (fair rating) that the factor structure of the SCQOA did not explain 50% of the 
variance (176) . There was also limited evidence (fair rating) of a negative result for structural 
validity of the ENAT (179). The level of evidence for the structural validity of the EC-17, 
MHLC and PBC (177, 178, 181) was indeterminate (poor rating).  
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Hypothesis Testing 
The demonstration of adequate construct validity through hypothesis testing required that 
specific hypotheses were formulated a priori AND at least 75% of the results were in 
accordance with these (61). There was limited evidence (fair rating) for adequate construct 
validity for the PEPPI-5 (180) which was evaluated against; General Self Efficacy scale, 
Arthritis Impact Measurement Scales 2 Family and Friends scale, Short Form 36 mental 
component summary score, and pain numerical rating score. The EC-17 was compared with 
the same instruments as the PEPPI-5, however there was indeterminate evidence (poor 
rating) for the hypotheses tested (see Table 6.6) (181) . The study assessing PEPPI-10 did not 
formulate a priori hypotheses therefore the evidence for hypotheses testing was indeterminate 
(182). 
 
Cross-cultural Validity 
Cross-cultural validity is established following specified translation procedures, then 
comparison of two cohorts differing only in language/cultural background to test if the 
translated instrument accurately reflects the measurements made in the original (174). There 
was limited evidence (fair rating) for adequate translation of the English PAM(183) into 
Korean (175). The Korean PAM was not compared with the English version. There was 
indeterminate evidence (poor rating) for the translation of the English EC-17  (184) into 
Dutch (181) and no formal cross-cultural validation. There was limited evidence (fair rating) 
of adequate translation of the English PEPPI-10 (185) into Chinese (182) with no cross-
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cultural validation. Cross-cultural comparisons were not made for the ENAT because the 
structural validity was inadequate in the OA group (179). 
  
Floor and ceiling effects 
Floor and ceiling effect results were rated using the quality criteria for rating the results of 
measurement properties in Appendix 2. There was strong evidence of absence of floor and 
ceiling effects for the PEPPI-5 (180), limited evidence of a ceiling effect for the PEPPI-10 
(182) and indeterminate evidence for floor and ceiling effect for the EC-17 (181). 
 
Best evidence synthesis 
The instrument with the most promising level of evidence for the measurement properties 
available was the PEPPI-5. Of note is that these results are applicable only to the Dutch 
language version of the PEPPI-5. There was strong evidence for internal consistency, 
structural validity, and lack of floor/ceiling effects, however there was limited positive 
evidence for construct validity (hypothesis testing) and limited evidence of negative findings 
for test-retest reliability (Tables 6.6 and 6.7). There was indeterminate evidence for 
measurement error and no information for content validity, or responsiveness. 
 
6.5. Discussion 
Osteoarthritis self-management programs are not curative but aim to equip participants with 
the tools to manage their disease. It is important to measure the changes in attitudes towards 
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and/or capabilities regarding OA self-management to determine whether participants achieve 
this aim and to demonstrate the efficacy of programs. Further, it may be possible to predict 
the outcomes of participants by measuring attitudes towards and/or capabilities in regard to 
OA self-management at baseline. This may provide a basis on which to appropriately allocate 
healthcare resources to those that will likely benefit from such a program. Participants 
reporting a positive attitude toward self-management and good self-management capabilities 
may be prioritised for immediate engagement in a program. Conversely, individuals 
reporting poorer attitudes and capabilities may be targeted for supplementary therapies such 
as motivational coaching to improve the likelihood of successful participation in such a 
program. In order to test whether this is possible, we first need to identify a suitable 
instrument measuring attitudes towards and/or abilities regarding self-management of OA 
that demonstrates good measurement properties. 
 
This systematic review is the first to synthesize the measurement property evidence for 
instruments assessing attitudes towards and/or capabilities regarding self-management of 
OA. There were a very small number of studies identified; only eight studies reported 
measurement properties of such instruments, each for a separate instrument. The scope of 
measurement properties assessed by the included studies was very limited. Internal 
consistency and structural validity were estimated for all instruments. Test-retest reliability 
(180, 181), and hypothesis testing (180, 181) were each assessed for two instruments, cross-
cultural validity was addressed in three studies (175, 181, 182). Measurement error was 
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reported in one study (180), responsiveness and content validity were not evaluated for any of 
the instruments.  
 
Given the limited measurement property evidence for the included instruments, we cannot 
provide a definitive, evidence-based recommendation for a particular instrument to measure 
attitudes towards and capabilities regarding OA self-management on the basis of good 
measurement properties. On balance, the instrument with the “best” measurement properties 
was the Dutch version of the PEPPI-5 (180). There was strong evidence that the PEPPI-5 
satisfied requirements for internal consistency and structural validity. There was limited 
evidence for the hypotheses specified comparing PEPPI-5 scores against several other 
PROMs. The test-retest reliability findings were sub-optimal (i.e. ICC<0.7) which has 
implications regarding the standard error of the measure. Greater standard error may require 
larger change scores to represent ‘real’ change (vs error inherent in the measure) between 
groups over time. The evidence for measurement error of the PEPPI-5 was indeterminate 
because the MIC was not provided. Measurement property evidence for content validity and 
responsiveness of the PEPPI-5 remains unknown. The remaining instruments identified in 
the review demonstrated moderate evidence of positive measurement properties at best.  
 
The PEPPI-5 was originally developed in a sample of “older people” with mixed medical 
diagnoses; measurement property results for internal consistency, structural and construct 
validity were reported for this population (185). Given the PEPPI-5 was developed for a 
different group of patients it may be that it has limited content validity for OA. The PEPPI-5 
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measures self-efficacy in obtaining both medical information and attention to chief health 
concern from a physician hence includes limited aspects of a patient’s ability to self-manage 
OA. Although effective communication with a physician is important, it may not be a key 
outcome used to indicate the efficacy of such programs. OA self-management programs are 
often multidisciplinary, with input from a team of health professionals including 
physiotherapists, dietitians and occupational therapists (39), and some programs do not 
include a medical physician (186). Hence, there is a clear need to develop tools that have 
adequate content validity for participants of OA self-management programs. 
 
A previous systematic review synthesized the measurement property evidence for 
instruments measuring self-efficacy in participants with rheumatic conditions (187). Self-
efficacy is defined as the confidence that one possesses the ability to influence events that 
affect aspects of one’s life (188). Self-efficacy is potentially an important aspect of self-
management, however additional constructs may be considered such as how motivated or 
activated participants are to self-manage (183), or beliefs about who controls their health 
(177).  
 
The previous review included participants of mixed disease groups with different rheumatic 
conditions (187). Given that measurement property evidence is specific to the population 
studied, these measurement property results cannot be extrapolated to the OA population. 
The population-specific nature of measurement properties also placed limitations on the 
studies available for this current review. Often studies were excluded at the full-text stage 
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because they comprised mixed disease cohorts and did not report the OA participant results 
separately. This limited the number of studies included. 
  
The methodologies of the included studies were limited to the investigation of a small range 
of measurement properties. Internal consistency and structural validity were reported for all 
studies. This is a similar finding to the previous systematic review of self-efficacy in patients 
with rheumatic conditions (187). Although these are valuable measurement properties to 
establish, many measurement properties remain untested in the instruments of our 
systematic review. Test-retest reliability estimates the relative consistency of a measure in 
otherwise stable patients so that when any change is detected by the instrument, it can be 
attributed to the intervention rather than from measurement error of the instrument. 
Unfortunately, the test-retest reliability and measurement error for the included instruments 
are yet to be established in OA patients. Test-retest reliability was tested in a larger proportion 
of studies included in the systematic review on rheumatic conditions, however, the quality of 
the evidence was generally poor and measurement error was unreported (187). Hypothesis 
testing is a further property that was neglected by the majority of studies in our review. 
Hypothesis testing establishes whether an instrument measures the intended construct by 
testing the internal relationships with scores of other instruments measuring similar or 
different constructs (58). There is much need for future studies evaluating test-retest 
reliability, measurement error and construct validity of instruments measuring OA self-
management attitudes and capabilities. 
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 Cross-cultural validation was attempted in three studies that translated questionnaires; 
however, true cross-cultural validation comparing language versions was not conducted. This 
was also found in the previous review of instruments measuring self-efficacy (187). We found 
no evidence pertaining to content validity, responsiveness, or MID/MIC. Similar to previous 
conclusions (187), the recommendations arising from the present review are limited due to 
the small number of studies, their poor methodology, and the limited scope of measurement 
properties assessed. Further studies concerned with all measurement properties of existing 
instruments assessing self-management of OA is the only way to remedy this situation. 
 
Some existing instruments measuring attitudes towards and/or capabilities regarding OA 
self-management were not featured in the systematic review because there was no 
measurement property evidence available. The Health Education Impact Questionnaire 
(heiQ) (189) evaluates the efficacy of patient education programs and has been used to 
evaluate OA self-management programs (15, 190). Also, the Arthritis Self Efficacy Score 
(ASES) measures patients’ perceived self-efficacy to cope with the symptoms and limitations 
attributed to chronic arthritis (191) and is a published outcome of existing OA self-
management programs (130, 192). The measurement properties of the heiQ and ASES 
remain untested in the OA population. Given the current popularity of these instruments, the 
measurement properties of heiQ and ASES are an important area of future research. 
 
There were possible limitations of this systematic review; the inclusion criteria requiring 
studies to be published as original articles may have introduced publication bias. Unpublished 
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studies may have been more likely to contain evidence of negative results about measurement 
properties of the instruments under study. However, the inclusion of only peer-reviewed 
articles likely enhanced the quality of included studies, given the basic level of scrutiny 
required to publish. This may have improved the quality of the review rather than biasing it. 
While excluding non-English language studies may have introduced bias, no such studies 
were identified by the comprehensive search strategy. 
 
6.6. Conclusion 
This review highlights the paucity of evidence available for the measurement properties of 
instruments assessing attitudes towards and/or capabilities regarding OA self-management. 
There were many gaps in the measurement property evidence for the instruments identified. 
The instrument with the “best” properties assessed self-efficacy in communication with a 
physician; a very discrete aspect of self-management. Therefore, we were unable to make 
recommendations concerning instruments to assess attitudes toward and/or capabilities 
regarding OA self-management. Further well-designed studies of measurement properties of 
available instruments are required. This review may provide a starting point for researchers to 
identify the instruments that are currently used for this purpose in the OA population and the 
evidence for measurement properties available. Once we are able to identify instruments with 
adequate measurement properties for use in this population, we will be able to better compare 
the efficacy of different OA self-management programs and inform best practice for care of 
our patients. 
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Chapter Seven: Is the Patient Activation Measure a valid measure of 
osteoarthritis self-management attitudes and capabilities? Results of a 
Rasch analysis 
 
7.1. Abstract: 
Objective: The Patient Activation Measure (PAM-13) was developed using Rasch analysis to 
assess knowledge, skills, and confidence in the management of one’s health. Previous studies 
report positive relationships between PAM-13 scores, self-management behaviours and 
longitudinal health outcomes in adults with chronic disease. There is little extant 
measurement property evidence for the use of PAM-13 in specific osteoarthritis (OA) 
populations. This study tested measurement properties of the PAM-13 in people living with 
hip and knee OA. 
 
Methods: Item response analysis demonstrated data quality. Rasch analysis evaluated the fit 
of the PAM-13 data to the Rasch model. Model-data fit was evaluated using infit and outfit 
statistics Person/item reliability and person separation indices were computed. 
Unidimensionality was evaluated using Principal Components Analysis of Rasch residuals 
and the data were assessed for item redundancy. Differential Item Functioning (DIF) 
examined bias in respondent subgroups and correlations tested relationships between PAM-
13 and other patient-reported outcomes.  
Results: Two-hundred-and-seventeen PAM-13 surveys were completed, there were no 
missing responses, floor or ceiling effects. Person and item reliability were acceptable (0.98 
and 0.87 respectively) with good separation (person separation index 2.58). 
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Unidimensionality was evaluated, with 49.4% of the variance explained. There was evidence 
of potential local response-dependence. The Rasch fit statistics were acceptable (except for 
item-2). There were some issues identified with targeting of the PAM-13 items to people with 
higher ability and the item difficulty order was different to that proposed in original 
American cohorts. Significant DIF was identified for sex and educational level for a small 
number of items. PAM-13 scores were moderately correlated with depressive symptoms on 
the Depression Anxiety Stress Scale and Assessment of Quality of Life-6D. There were small 
correlations between PAM-13 and Knee injury and Osteoarthritis Outcome Score pain and 
activities of daily living (ADL) scores.  
 
Conclusions: This study provides some evidence of adequate person and item reliability, 
unidimensionality, and construct validity to support the use of PAM-13 to measure patient 
activation in people living with hip and knee OA. Possible limitations regarding targeting, 
different item difficulty order, DIF and local response dependence should be investigated in 
future research. 
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7.2. Background: 
Osteoarthritis (OA) is a prevalent, painful condition and a leading cause of global disability 
(147). As a costly (9), chronic, incurable disease, self-management interventions are 
recommended for the management of osteoarthritis (OA) (13). Two systematic reviews have 
evaluated the effects of self-management interventions that included OA patients. The first 
demonstrated evidence of small to moderate effects in terms of pain and functional 
improvements conferred by arthritis self-management interventions (14). The second was 
concerned specifically with OA self-management education programs and found no or small 
benefits from these programs (15). These reviews highlight that measures of pain and 
function are the most common primary outcomes for self-management interventions (14, 
15). Whilst pain and function are obviously important to this population, there is a disparity 
between the aims of self-management programs and the outcomes used to assess efficacy. A 
more meaningful measurement of program efficacy would be to measure OA self-
management attitudes and capabilities (15), which have been recognised as comparatively 
neglected domains (193). 
 
The measurement of OA self-management attitudes and capabilities requires validated 
instruments that have demonstrated adequate measurement properties in populations with 
OA (56). Measurement properties refer to the ability of the instrument to accurately and 
comprehensively measure the specified construct (37) (e.g. internal consistency, reliability, 
validity). A recent systematic review of instruments assessing OA self-management attitudes 
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and capabilities found that there was very little measurement property evidence available and 
that further research was needed to fill this knowledge gap (41).  
 
An instrument identified in the review was the Patient Activation Measure (PAM-13); a 
patient- reported outcome assessing knowledge, skill and confidence in the management of 
one’s health (42). The measurement properties of the PAM-13 have been studied in 
populations with varying chronic conditions including: mental illness (194); neurological 
disorders (195) and multimorbidity (196, 197). Two previous studies investigated 
measurement properties of the PAM-13 in OA populations. The first translated the PAM-13 
into Korean and provided some evidence of adequate internal consistency and structural 
validity (175). The second examined the responsiveness of PAM-13 in a sample of people 
with “arthritis”, not specifically OA (198). This study aims build and extend on this prior 
research to provide more comprehensive evidence of measurement properties of the PAM-13 
in people living with OA. 
 
Several large cohort studies report that higher levels of patient activation measured by the 
PAM-13 predict better self-management behaviours and longitudinal health outcomes in 
adults with chronic disease (199-201). This considered, it may be possible to predict patient 
outcomes following OA management programs using PAM-13 scores. This would enable the 
identification of people likely to experience a positive treatment effect. These people could 
then be prioritised for participation in these programs. Conversely, people reporting poorer 
self-management attitudes and capabilities may be identified and targeted for supplementary 
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therapies (e.g. motivational coaching). Further, the efficacy of OA management programs 
could be measured in terms of change in patient activation. Before these potential uses of the 
PAM-13 are tested, it is important to establish that the measurement properties are 
acceptable in the OA population.  
 
The PAM-13 developers used Rasch analysis to construct the instrument according to the 
Rasch measurement model (42). The Rasch model determines the measurement 
requirements for the construction of interval level measurement scales (202). A major 
advantage of using instruments developed using Rasch analysis is that the measurements can 
be assumed to produce interval level variables, hence, statistical tests requiring interval level 
variables can be used to report the results of clinical studies (203). Rasch analysis also 
provides a unified measurement approach to test the validity of an instrument developed 
using this method when it is tested in a different population of patients (56). This study had 
the following aims: 
i) To test the measurement properties (including reliability (internal consistency), 
unidimensionality (structural validity) and construct validity and floor/ceiling effects) of the 
PAM-13 in people with hip and knee OA. 
ii) To examine the relationships between PAM-13 scores and psychological, quality of life and 
disease-specific outcomes.  
 
7.3. Methods: 
7.3.1. Participants 
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This cohort study comprised participants of the Osteoarthritis Chronic Care Program 
(OACCP). Participants were recruited directly from Royal North Shore, Ryde (major 
teaching hospitals), Hunter’s Hill Private and Mount Wilga (private metropolitan hospitals) 
hospitals in Australia via referral from rheumatologists, orthopaedic surgeons and general 
practitioners or joint arthroplasty waiting lists. People with symptomatic and radiographic 
hip and knee OA were eligible if they reported pain in the affected knee/hip on most days of 
the past month. Details of the program are published elsewhere (39).  
 
Ethical approval for this study in accordance with the Declaration of Helsinki was provided 
by Human Research Ethics Committees: 
NSPHEC 2016-LNR-007; NSPHEC 2017-LNR-005 and LNRl16/HAWKE/14. Participants 
provided written consent to take part in this study.  
 
7.3.2. Data 
All data were collected at the baseline assessment of OACCP as part of the normal clinical 
pathway. Signal joint (the predominant site of OA) was determined by clinical and 
radiographic examination. Anthropometric measurements were undertaken using a 
standardised protocol (47). Participants rated their average pain on the day of assessment 
using a Numeric Rating Scale (0 indicated no pain and 10 the most pain imaginable) (157). 
Patient-reported outcomes were collected electronically as described below. 
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Patient Activation Measure-13: Participants rated their level of agreement with 13 statements 
(Table 7.1) using a 4-point Likert scale: Totally Disagree, Disagree, Agree, Totally Agree and 
Not Applicable (N/A). This outcome assumes that Item-1 is the easiest to endorse, and each 
subsequent item is more difficult to endorse than the one before (42). The response (range 1–
4) to the items are added to calculate a raw score. Responses of “not applicable” (N/A) are 
treated as missing. A continuous activation score is computed from the raw score using an 
empirically derived calibration table by Insignia Health (after January 2014). Total scores 
range from 0 (no activation) to 100 (high activation) (42). PAM-13 score thresholds are used 
to assign four stages of activation in order of ascending activation: 1. “Believes active role is 
important”; 2. “Confidence and knowledge to take action”; 3. “Taking action”; 4. “Staying the 
course under stress” (42).  
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Table 7.1 PAM-13 items and mean response scores  
 
PAM-13 items N Mean# (SD) 
1. When all is said and done, I am the person who is responsible for taking care of my health 217 3.4 (0.73) 
2. Taking an active role in my own health care is the most important thing that affects my health 217 3.4 (0.77) 
3. I am confident I can help prevent or reduce problems associated with my health 217 3.3 (0.77) 
4. I know what each of my prescribed medications do 200 3.3 (0.70) 
5. I am confident that I can tell whether I need to go to the doctor or whether I can take care of a health problem myself 215 3.2 (0.70) 
6. I am confident that I can tell a doctor concerns I have even when he or she does not ask 217 3.3 (0.65) 
7. I am confident that I can follow through on medical treatments I may need to do at home 216 3.2 (0.67) 
8. I understand my health problems and what causes them 215 3.1 (0.71) 
9. I know what treatments are available for my health problems 212 2.8 (0.75) 
10. I have been able to maintain (keep up with) lifestyle changes, like eating right or exercising 210 2.8 (0.70) 
11. I know how to prevent problems with my health 208 2.6 (0.70) 
12. I am confident I can figure out solutions when new problems arise with my health 212 2.8 (0.70) 
13. I am confident that I can maintain lifestyle changes, like eating right and exercising, even during times of stress 216 2.8 (0.70) 
#PAM items are scored using “Totally Disagree”=1, “Disagree”=2, “Agree”=3, “Totally Agree”=4  
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The Hip disability and Osteoarthritis Outcome Score (HOOS) and Knee injury and  
 
Osteoarthritis Outcome Score (KOOS): The HOOS (135) and KOOS (158) are disease-specific 
measures that have been validated in people with OA. Participants rate their symptoms, 
stiffness, pain, physical function, recreational activities and quality of life on a 5-point Likert 
scale (0- 4). The responses for the six subscales are summed and transformed to comprise six 
independent subscores; lower scores indicate worse problems. 
 
The Depression, Anxiety and Stress Scale (DASS-21): Participants rate their level of agreement 
with 21 statements using a 4-point Likert scale (0-3). The DASS-21 subscores indicate the 
presence/absence of symptoms of depression, anxiety and stress (159). Higher scores indicate 
worse symptoms.  
 
Assessment of Quality of Life (AQoL-6D): Participants respond to questions or statements 
rated using four-, five- or six-point scales. Six dimensions are reported separately including: 
independent living, relationships, mental health, coping, pain and senses which are combined 
for a standardised AQoL index. Higher scores indicate a worse quality of life (204). 
 
7.3.3. Statistical analysis 
Descriptive statistics and correlations were processed using SPSS (Version 22.0, Armonk 
NY: IBM Corp, USA) software. The PAM-13 responses were compared to the Rasch model 
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with Rasch analysis  (202) using Winsteps (version 4.0.1 Linacre, J. M. (2017) Winsteps® 
Rasch measurement computer program. Beaverton, Oregon: Winsteps.com).  
 
Item response frequency analysis: 
Item response analysis was conducted to demonstrate data quality (174). The frequencies of 
each response option and missing responses were reported for each item. Floor and ceiling 
effects were confirmed if ≥15% of respondents answered “totally disagree” or “totally agree” 
to all items respectively (61).  
 
Rasch Model Overview: 
The PAM-13 was originally developed using Rasch analysis (42). A Rasch analysis compares 
individual items or responses of a patient reported outcome measure with a Rasch model 
(RM) (203). Comparison to a Rasch Model provides insight into whether scores obtained for 
individual items of the outcome measure can be added together to create an overall score. 
More specifically, it assists in determining whether the outcome measure possesses the 
properties of an interval scale or whether each item is stand-alone (203).  
 
The RM assumes that responses to the items of an outcome scale are affected by the ability of 
the person and the difficulty of the item (62). In Rasch analysis, metrics are calculated to 
determine whether the relationships between ability of the person and the difficulty of the 
item in the study data are consistent with what would be expected to fit the RM and that the 
assumptions of the RM are met. ‘Person ability’ is calculated using the number of items of the 
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instrument that a person agreed with. ‘Item difficulty’ is estimated using the number of 
persons in the sample who agreed with an item. The relationship between person ability and 
item difficulty is clearly depicted on a person-item map. Measures of fit are used to assess 
whether the instrument conforms to RM requirements; infit and outfit statistics are used to 
indicate how accurately or predictably data fit the model (63). There is not complete 
agreement about the influence of sample size on fit statistics however, a sample of 200 
participants has been recommended (205). For this study we aimed to recruit 250 to account 
for 20% non-completion rate.  
 
Reliability and separation: 
In Rasch analysis the person reliability index estimates the probability that the ordering of 
persons (based on their abilities) is preserved when they respond to further items measuring 
the same construct. The Item reliability index indicates the probability that the order of the 
items (based on difficulty) would be the same if the same construct was measured in a similar 
but discrete sample of people (62). The person separation index tests if the instrument is 
sensitive enough to distinguish between people with high and low abilities. Thresholds for 
acceptable indices were set at >0.8 for item reliability, >0.8 for person reliability and >2 for 
the person separation index (61, 63). The person-item map was used as a pictorial 
representation of how well the difficulty of the items aligned with the abilities of the persons 
who completed the survey. The alignment between item difficulty and person ability is 
referred to as ‘targeting’ (62). In addition to the Rasch analysis, internal consistency was 
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estimated using Cronbach’s Alpha from Classical Test Theory (CTT). The threshold for 
Cronbach’s alpha was set at 0.8.  
 
Rasch model fit analysis: 
The partial credit model was used to examine model-data fit; it was chosen because the 
PAM13 had four response options demonstrating different patterns of usage (62). Point-
measure correlations were estimated to determine whether item responses aligned with 
person abilities. Point measure correlations >0.5 were considered acceptable. Infit and outfit 
statistics (expressed in mean square (MnSq)) indicated how well the data fit the RM. Values 
between 0.5 and 1.5MnSq were considered acceptable (62). An approximate global log-
likelihood chi-squared statistic for overall goodness of fit was computed to indicate if the 
misfit of the data was large enough to be problematic (63). 
 
Instrument performance improvement: 
Rasch analysis can be used to identify overlapping items measuring similar aspects of the 
construct and/or items that do not fit the model well; termed item redundancy. Fit statistics 
(MnSq values) indicated whether an item might be redundant and considered for removal 
from the model (62). Overlapping items were also identified using the Rasch person-item 
map as those occupying the same location on the map. To confirm item redundancy as 
identified using fit statistics and/or the person-item map, it was also necessary to assess 
whether the content of the item overlapped with any aspect of another item. If two or more 
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items were similar in content, this might indicate redundancy. Following item removal, fit 
statistics and person-item maps confirmed whether model fit was improved. 
 
Unidimensionality: 
In Rasch analysis, structural validity is determined by confirming the unidimensionality of 
the construct (174). Winsteps uses a Principal Components Analysis (PCA) to create 
potential secondary dimensions (termed contrasts) based on the unexplained variance of the 
residuals, measured in eigenvalue units. The Winsteps PCA of residuals is not interpreted in 
the same way as Factor Analysis (FA) of the original data in CTT. For this analysis, the 
threshold for good evidence of unidimensionality was provided by an eigenvalue of less than 
2.0 on the first contrast; (larger eigenvalues indicated the need for further investigation)(63). 
Where eigenvalues exceeded 2.0, a CTT factor analysis of the original data (FA) was used to 
evaluate unidimensionality further. The Kaiser-Meyer-Olkin measure tested sampling 
adequacy and Bartlett's Test of Sphericity was used to detect the presence of multiple factors. 
 
An important assumption of the RM is that there is no local response dependency. Local 
response dependency can occur when items are related to each other in a way that is outside 
the latent trait the outcome scale is measuring (206). Local response dependency was 
evaluated through the calculation of Yens Q3 statistics. It is commonly recommended that 
these values do not exceed r= 0.7 (63). Christensen et al. (2017) proposed that a single critical 
threshold for Q3 statistics was not appropriate for all situations and that a Q3 value of 0.2 
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above the average correlation was appropriate (63). Local response dependency was assessed 
using both thresholds. 
 
Differential item functioning (DIF): 
DIF tested whether subgroups responded differently to items of the instrument compared 
with the rest of the sample. There is evidence of DIF when an item’s difficulty estimate 
location on the latent trait varies between subgroups by more than the modelled error (62). 
There are two types of DIF. Uniform DIF provides information about whether the outcome 
scale performs similarly in subgroups while the item difficulties and person measures are held 
constant. Non-uniform DIF tests the performance of the outcome scale across subgroups at 
different levels of ability. To evaluate DIF Winsteps uses the Mantel Chi-Squared testwith 
(log-)odds estimates of DIF size and tests significance from a comparison of the two groups 
(63). DIF that exceeds 0.64 logits is considered to be moderate to large (63). The following 
demographic variables were used for DIF testing: gender, highest educational level (secondary 
vs tertiary) and signal joint (hip vs knee). 
 
Construct validity:  
Previous studies in different populations indicated PAM-13 scores were associated with the 
presence of depressive symptoms and health-related quality of life (207-209); hence we 
expected moderate correlations between DASS and AQoL scores with PAM-13 (r>0.3). We 
hypothesized that weak correlations (if any) would be observed between PAM-13 and 
HOOS/KOOS ‘Pain’ and ‘Function in daily living’ subscale scores (r<0.2). Pearson’s 
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correlations were used for normally distributed variables, Spearman’s correlations for those 
that were non-parametric. The thresholds for correlation size were defined as the following: 
0.5 was large, 0.3 moderate, and 0.1 small (210). 
 
7.4. Results: 
Study population 
Out of the 238 participants consecutively enrolled in the OACCP February 2016 to June 2017 
and approached to take part in the study, 21 participants declined to participate. The 
characteristics of the participants who completed the PAM-13 are summarised in Table 7.2. 
The group excluded based on non-completion was not large enough to make statistical 
comparisons.  
 
Item response frequency analysis 
Of 217 attempted PAM-13 surveys, there were no missing responses, however, the N/A 
responses were not included in the scoring and were treated as missing data (211). The 
distribution of responses to the questions is depicted in Figure 7.1. The questions most 
commonly responded to with N/A were PAM-13 item-4 (I know what each of my prescribed  
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Table 7.2 Participant characteristics  
Characteristics 
 
Included n=217 Excluded n=21 
Sex female, n (%) 148 (68) 10 (48) 
 
Age years, (SD) 65.5 (10.8) 68.7 (10.3) 
 
Signal joint knee n (%) 183 (84) 15 (71) 
 
Body mass index kg/m2(SD) 30.3 (6.1) 30.0 (5.1) 
 
PAM raw score 
PAM score mean (SD)∞ 
PAM level 1 n (%) 
PAM level 2 n (%) 
PAM level 3 n (%) 
PAM level 4 n (%) 
 
 
60.5 (11.0) 
10 (4.6) 
47 (21.7) 
123 (56.7) 
28 (12.9) 
 
Highest level of education 
Year 10 or equivalent n (%) 
Year 12 or equivalent n (%) 
Graduate degree n (%) 
Post graduate degree n (%) 
Missing n (%) 
 
57 (26) 
28 (13) 
104 (48) 
22 (10) 
6 (3) 
 
4 (19) 
1 (5) 
11 (52) 
1 (5) 
4 (19) 
 
Work status 
Home duties n (%) 
Full time n (%) 
Part-Time n (%) 
Retired n (%) 
Volunteer n (%) 
Other n (%) 
Missing n (%) 
 
6 (3) 
56 (26) 
21 (10) 
100 (46) 
4 (2) 
25 (12) 
5 (1) 
 
 
0 
3 (14) 
3 (14) 
8 (38) 
1 (5) 
2 (10) 
4 (19) 
Private hospital n (%) 
Public hospital n (%) 
160 (74) 
57 (26) 
21 (100) 
0 
Average pain in last week on VASα  
VAS mean (SD) 
n = 214 
4.0 (2.3) 
n = 17 
3.4 (2.5) 
 
KOOS*  
Pain mean (SD) 
Function in daily living mean (SD) 
n = 179 
52.3 (17.7) 
58.0 (19.8) 
n = 12 
53.6 (14.1) 
59.3 (19.1) 
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HOOS^ 
Pain mean (SD) 
Function in daily living mean (SD) 
n = 32 
57.7 (19.2) 
59.5 (18.1) 
n = 3 
61.7 (16.7) 
48.3 (20.2) 
 
DASS-21± 
Depression mean (SD) 
Anxiety mean (SD) 
Stress mean (SD) 
n = 214 
7.2 (8.66) 
5.1 (7.3) 
8.8 (8.5) 
 
n = 16 
5.2 (6.8) 
3.8 (4.3) 
7.5 (5.2) 
AQoL#  
Independent living mean (SD) 
Social relationships mean (SD) 
Mental health mean (SD) 
Coping mean (SD) 
Pain mean (SD) 
Physical senses mean (SD) 
AQoL summed index mean (SD) 
n = 198 
68.4 (19.3) 
75.4 (20.0) 
69.8 (21.9) 
65.3 (20.3) 
45.8 (22.3) 
81.8 (10.9) 
68.4 (14.9) 
n = 6 
68.5 (15.5) 
86.7 (10.3) 
74.0 (11.6) 
69.3 (8.8) 
55.0 (18.7) 
79.7 (6.5) 
72.1 (8.6) 
∞PAM: Patient Activation Measure- 0= worst, 100= best, however participants with scores of 0 or 100 were 
excluded from having a final score. PAM level 1 = least activated, 4 = most activated. 
α VAS: Visual analogue scale- average pain over the last week 0 = no pain, 10 = worst pain imaginable. 
* KOOS: Knee injury and Osteoarthritis Outcome Score- 0=worst, 100=best 
^ HOOS: Hip disability and Osteoarthritis Outcome Score- 0=worst, 100=best 
± DASS: Depression Anxiety Stress Scales- 0= best, 42 = worst. 
# Assessment of Quality of Life Instrument- Standardised scores- 0=worst, 100=best. 
 
 
medications do) and item-11 (I know how to prevent problems with my health), although 
N/A responses only comprised 2% (49/2821) of the total responses to these items. The most 
frequent response category overall was “agree” which comprised 1458/2821 (52%) of the total 
responses, followed by “totally agree” with 813/2921 (29%) responses. The “disagree” and 
“totally disagree” categories were much less frequent comprising 403/2821 (14%) and 98/2821 
(3%) of all responses, respectively. 
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Figure 7.1 Responses across items of the PAM-13; agreement and not applicable categories 
 
 
 
The mean response scores (range 1-4) for each item decreased from 3.4 (SD 0.73) for item-1 
to 2.6 (SD 0.70) for item-11 (see table 7.1). Although the mean response demonstrated an 
overall trend of decreasing as the questions became more difficult with subsequent items, the 
individual item order did not follow the originally established order of the questions (42): for 
example, the mean for item-11 (mean 2.6, SD 0.70) was smaller than the means for item-12 
and item-13 ( mean 2.8, SD 0.70). Floor and ceiling effects were not detected; one percent 
(2/217) and three percent (7/217) of participants answered with ‘totally disagree” and “total 
agree” to all items respectively.  
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Reliability and separation 
The person and item reliability of the PAM-13 was adequate as indicated by; person reliability 
index 0.87, item reliability index 0.98. The person separation index was 2.58 indicating good 
separation. In addition Cronbach’s Alpha indicated adequate internal consistency; α= 0.92. 
 
Rasch model fit analysis 
There were high positive point measure correlations of r= 0.58-0.78 for all PAM-13 items. 
The relationship between the difficulty of the items and the ability of participants expressed 
in logits is depicted in Figure 7.2. Overall, the mean difficulty of the PAM-13 questions was 
lower than the mean ability of this sample. The mean PAM-13 item difficulty was shown at 0 
logits, and the mean response of participants was almost 2 logits higher, 37% (81/217) people 
had abilities that exceeded the two most difficult items. Figure 7.2 also shows that the items 
were not evenly-spread with several items having very similar item difficulty (see items 3,6 
and 7; items 9, 10 and 12). Moreover, the item difficulty did not ascend uniformly with each 
subsequent item. This is confirmed by item difficulty calibrations (Table 7.3) which showed 
item difficulty order was different to the original PAM-13. Fit statistics are summarised in 
Table 7.3. Items fit the RM apart from item-2 with infit and outfit statistics of 1.58 and 1.97 
Msq respectively, indicating under-fit. However, the global fit statistic indicated overall 
adequate fit of the data to the model (log-likelihood χ 2 = 3901.0644, 3927 +- 5 degrees of 
freedom, P = 0.612). 
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Figure 7.2 Person-item map of study participants and PAM-13 items 
Patients          Items 
 Good Activation         Item “least agreed with” by participants 
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                  .#  │  Item 5 can tell need doctor 
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 Poor Activation        Item “Most agreed with” by participants 
Rasch variable map of item agreement and participants’ activation as measured on the Patient Activation 
Measure-13. This relationship is plotted on a logit scale indicating person ability (-6 to 7), with 0 indicating the 
item with the mean (Mi) difficulty, Mp indicates the mean person ability; S one standard deviation and; T two 
standard deviations.  Each "#" represents three participants; each "." represents one or two participants. 
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Table 7.3 Item fit statistics for the PAM-13 
PAM items 
(in order of 
difficulty) 
Difficulty 
calibration 
(logits) 
Mean ability 
logits (SD) 
Infit 
Mean squared 
Outfit 
Mean squared 
1 -1.52 -2.65 (3.26) 1.21 1.13 
2 -1.50 -2.09 (3.58) 1.58 1.97 
4 -1.07 1.95 (1.80) 1.27 1.16 
6 -0.75 -5.17 (1.92) 0.80 0.75 
3 -0.75 -4.02 (2.70) 0.95 0.89 
7 -0.55 1.68 (0) 0.95 1.04 
5 -0.40 1.36 (1.01) 0.85 0.80 
8 0.11 1.93 (0.26) 0.74 0.70 
13 1.14 1.68 (0) 1.12 1.44 
9 1.17 2.54 (1.87) 0.91 0.95 
10 1.19 2.34 (2.01) 0.96 0.97 
12 1.23 2.54 (2.17) 0.96 0.96 
11 1.68 2.55 (1.62) 0.93 1.29 
Note: Results in bold indicate values that are beyond the ideal cutoffs for infit and outfit statistics (i.e. Msq of 
0.5- 1.5) 
 
 
Unidimensionality and structural validity 
The Rasch dimension demonstrated that the persons and items within the analysis explained 
49.4% of the variance (49.8% was expected if the sample fit model perfectly), with an 
eigenvalue of 12.70. The first contrast gave an eigenvalue of 2.5. Unidimensionality was 
further assessed using CTT FA. The data was adequate for the FA (Kaiser-Meyer-Olkin value 
= 0.88 and Bartlett's Test of Sphericity χ2=1404.0, df 78, p <0.001). Using a scree plot and 
principal axis factoring, the PAM-13 loaded on one factor which explained 45.0% of the 
variance and suggested unidimensionality. In the assessment of local response dependence, 
the Yens Q3 values did not exceed the first common threshold of r=0.7 suggesting the 
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absence of local response-dependence. According to the second threshold, five items 
exceeded the Q3 value of 0.2 above the average correlation indicating the presence of local 
response-dependence. 
 
Differential item functioning 
No significant uniform DIF was found for people with hip OA compared with those with 
knee OA. There was significant uniform DIF for item-13 which was more easily endorsed by 
women; (DIF contrast = 0.98 logits, Mantel chi-squared statistic χ2M= 11.83, p = 0.001) 
compared to men. Item-7 was easier to endorse for people who reported their highest 
educational level was tertiary vs those whose highest level was high school (DIF contrast 
=0.85 logits, χ2MH= 4.67, p = 0.031). Conversely, people whose highest level of education was 
high school found Item-11 easier to endorse than those with tertiary level education (DIF 
contrast= 0.68 logits, χ2M= 6.25, p=0.012). The subgroups tested in this sample were not large 
enough to test for non-uniform DIF.  
 
Instrument performance improvement 
The person ability and item responses were assessed on person-item maps that depicted the 
logit values for all possible response options. The person-item map in figure 2 summarises the 
mean logit response across all response options. Although there were overlapping and similar 
item difficulties for items 3, 6 and 7 (Figure 7.2 and Table 7.3), these items measured different 
aspects of the construct and were deemed inappropriate for removal. Similarly, items 9, 10 
and 12 were overlapping (Figure 7.2), however, measured different aspects of the construct 
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and were retained. Item-2 demonstrated poor fit statistics and was similar in item difficulty 
and content to item-1 (Table 7.3) so was removed. Removal of item-2 resulted in a slight 
improvement in the spread of the PAM-13 items (Figure 7.3). Reliability remained adequate 
(person and item reliability 0.87 and 0.98, respectively) and there were high positive point 
measure correlations (r = 0.61 to r = 0.79). The fit statistics for the revised model (Table 7.4) 
revealed item-1 outfit statistic 1.56 MnSq, while the remaining items were acceptable. The 
PCA showed 49.9% of the variance was explained by the model (compared with 50.0% 
expected) with an eigenvalue of 12.0. The first contrast resulted in an eigenvalue of 2.2. The 
analysis following removal of item-2 did not improve the performance of the instrument 
adequately to recommend removal of this item in this population. 
 
Table 7.4 Item fit statistics for the PAM-13 following removal of items 
PAM items 
(in order of 
difficulty) 
Difficulty 
calibration 
Mean ability 
logits (SD) 
Infit 
Mean squared 
Outfit 
Mean squared 
1 -1.73 -2.45 (3.63) 1.40 1.56 
4 -1.25 1.94 (2.07) 1.32 1.19 
6 -0.92 -5.25 (2.02) 0.83 0.78 
3 -0.92 -4.10 (2.77) 1.04 0.99 
7 -0.72 2.80 (0) 1.00 1.11 
5 -0.55 1.28 (0. 97) 0.88 0.84 
8 -0.02 2.40 (0.40) 0.75 0.7 
13 1.07 2.80 (0) 1.14 1.42 
9 1.10 2.98 (2.37) 0.90 0.93 
10 1.13 2.43 (2.04) 0.95 0.95 
12 1.17 2.78 (2.15) 0.97 0.97 
11 1.65 2.64 (1.62) 0.92 1.23 
Note: Results in bold indicate values that are beyond the ideal cutoffs for infit and outfit statistics (i.e. Msq of 
0.5- 1.5) 
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Figure 7.3 Person-item map of study participants and PAM-13: removal of item-2 
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 Rasch variable map of item agreement and participants’ activation as measured on the Patient Activation 
Measure-13 with item-2 removed. This relationship is plotted on a logit scale indicating person ability (-6 to 7), 
with 0 indicating the item with the mean (Mi) difficulty, Mp indicates the mean person ability; S one standard 
deviation and; T two standard deviations.  Each "#" represents three participants; each "." represents one or two 
participants. 
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Construct validity 
The correlations between the PAM-13 scores and other variables are summarized in Table 
7.5. Lower activation scores were moderately correlated with the presence of depressive 
symptoms on the DASS; r=-0.26, (95% Confidence interval (CI) -0.38, -0.14). Higher 
activation scores correlated moderately with higher health-related quality of life score as 
measured on the AQoL; r=0.32 (95% CI 0.18, 0.47). There were small correlations between 
PAM-13 and KOOS pain and ADL scores (r=0.13 (95% CI 0.03, 0.29) and r=0.15 (95% CI 
0.03, 0.31). There were no significant correlations between PAM-13 and HOOS pain or 
function scores. 
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Table 7.5 Correlations between Patient Activation Measure-13 scores and other variables 
 Expected 
correlation* 
Actual  
correlation 
95% Confidence 
interval 
DASS depression 
(n=205) 
<-0.3 -0.26 -0.38, -0.14 
AQoL (n=190) >0.5  0.32 0.18, 0.47 
KOOS Pain (n=171) <0.2  0.13 0.03, 0.29 
KOOS ADL (n=171) <0.2  0.15 0.03, 0.31 
HOOS Pain (n=31) <0.2 -0.06 -0.47, 0.39 
HOOS ADL (n=31) <0.2 -0.23 -0.54, 0.15 
Pearson’s correlations were used for normally distributed variables, Spearman’s correlations for those that were 
non-parametric. DASS: Depression Anxiety Stress Scales- 0= best, 42 = worst. AQoL: Assessment of Quality of 
Life Instrument- Standardised scores- 0=worst, 100=best. KOOS: Knee injury and Osteoarthritis Outcome 
Score- 0=worst, 100=best. HOOS: Hip disability and Osteoarthritis Outcome Score- 0=worst, 100=best 
 
 
7.5. Discussion: 
Adequate person and item reliability was demonstrated for the PAM-13 and 
unidimensionality was evaluated. There were some issues with targeting items to people with 
higher abilities and the item-order was different to that expected for the PAM-13. Rasch 
analysis revealed that Item-2 under-fit the model and its removal resulted in a very slightly 
improved model fit, but not enough to recommend its removal. There was evidence of a 
difference in item response based on sex and educational status, though this was limited to a 
small number of items. The presence of depressive symptoms and AQoL scores correlated 
moderately with PAM-13 as expected.  
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International studies commonly report a different item difficulty order to the original order 
for PAM-13 published in American cohorts (42, 175, 195, 212-214). This was consistent with 
the findings of our study with the exception of three items: -1 (When all is said and done, I 
am the person who is responsible for taking care of my health); -2 (Taking an active role in 
my own health care is the most important thing that affects my health) and -12 (I am 
confident I can figure out solutions when new problems arise with my health) (42). These 
were also the only items consistent with the original order in a Canadian study of participants 
with neurological conditions (195). Items-1 and -2 alone followed the original order of item 
difficulty in a study of adults in Korea living with OA. Item-1 was the ‘easiest’ item in a 
Danish study (213), but not in studies of the German and Italian PAM-13 in people with 
chronic conditions (212, 214). Differences in item-difficulty order seen in our study and other 
populations may be attributed to specific disease and cultural factors. The differences in self-
management tasks required and the corresponding difficulty of these should be considered in 
the context of the health conditions and populations in which the PAM-13 is used.  
 
Unidimensionality of the PAM-13 was assessed, almost 50% of the variance was explained by 
the items and participant responses. This percentage of explained variation was higher than 
reported in other disease populations (212-214), but not as high as that reported for the 
Korean version of PAM-13 tested in an OA sample (57.5%) (175). The limited proportion of 
variance explained suggests there may be other additional factors that comprise this construct 
that are not captured by the items of the instrument. On the other hand, it may indicate 
simply that the items were of similar difficulty and the participants in the study were of 
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similar ability (63). This study relied on the PCA of Rasch residuals and conventional factor 
analysis. Further information on the unidimensionality of PAM-13 in this population using 
other statistical tests such as confirmatory factor analysis based on polychoric correlations or 
further Rasch based tests may be valuable in future research to explore this further.  
 
The assessment of local response dependence using two different thresholds of Q3 values 
yielded conflicting results. The conventional threshold Q3 value indicated the absence of local 
response dependence. The second threshold of the mean Q3 + 0.2 suggested the presence of 
local response dependence. To confirm these results, it would be helpful to attempt to 
replicate these results in future studies. This could also provide further evidence regarding the 
potential for different results produced by commonly recommended thresholds versus 
thresholds that are influenced by the characteristics of the dataset being analysed.  
 
There were issues identified with the targeting of the PAM-13 items. Specifically, there was a 
lack of items of sufficient difficulty for the participants with greater ability. This could affect 
the precision of the measure in these people. A possible way of dealing with both the low 
proportion of explained variance and limited targeting of items to people with higher abilities 
may be to develop an OA-specific version of the PAM-13 in a similar way the version was 
developed for mental health (PAM-MH) (215). An important implication of modifying the 
PAM-13 to be condition-specific would be a loss of the ability to compare populations and 
the relative impact of different medical conditions and/or treatments. Further, people with 
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OA commonly report the presence of several chronic comorbidities (216); it is arguably more 
useful to use a generic instrument and consider self-management of health in general. 
 
There were a few incidences of significant DIF in this study, however, it is important to 
recognise that the size of the subgroups used in the DIF analysis were low, which may have 
increased the type I error rate in these analyses (217). Sample sizes of 200 per subgroup have 
been recommended for DIF analyses (217). Significant DIF was found for item-13 suggesting 
women find it more difficult to endorse this item. This is consistent with one study in a 
different population (212) however, there was no significant DIF identified for gender in the 
OA Korean PAM-13 study (175). Our analysis found that PAM Item-7 was easier to endorse 
for those people with higher formal educational level, yet, an Italian study found the opposite, 
reporting that people with higher education levels found this item more difficult to endorse 
(212). In our study, item-11 was harder to endorse for participants with higher education 
levels, this was not reported in other studies.  
 
Given the concerns that low sample size may have increased the incidence of type I error in 
this analysis and the lack of consistency of DIF reported for the different items of PAM-13 in 
other studies we did not further evaluate the DIF in this study. To further evaluate DIF for 
PAM-13 in this population, studies with larger subgroup sizes should be used. If DIF is found 
for the same items in future studies, there are several ways this could be managed such as 
removal of those items (218).  
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This is the first time, to our knowledge that a study, has examined measurement properties of 
the English language version PAM in a sample of people living with OA. There is growing 
interest in the utility of the PAM-13, particularly in the United Kingdom where the PAM-13 
is being appraised as a tool used to evaluate care for chronic conditions in the National 
Health Service (219). It is important to improve our understanding of the measurement 
properties of PAM-13 in different disease populations and this study is a valuable 
contribution to this growing body of evidence. 
 
There are some limitations to the applicability of this study which included a fairly 
homogenous population from a higher socio-demographic region of Australia. Future studies 
should aim to include a less geographically and socio-demographically homogenous sample. 
There was also a large proportion of people in our study with knee OA so that the sample was 
less representative of people with hip OA. Future studies should assess larger groups of 
participants with hip OA to ensure that accurate measurement properties are available for 
people with this disease.  
 
7.6. Conclusion 
There is limited extant measurement property evidence available to support the use of any 
instrument assessing OA self-management attitudes and capabilities. This study provides 
evidence of adequate person and item reliability, unidimensionality, and construct validity to 
support the use of PAM-13 to measure patient activation in people living with OA. Potential 
areas for concern regarding the PAM-13 responses from this sample include possible local 
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response dependence, DIF and issues with targeting. Studies in larger cohorts of people with 
OA is recommended to provide further information on measurement properties not just for 
the purposes of research, but to provide information about how the PAM-13 can be used with 
individual OA patients in the clinic. 
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Chapter Eight: Examining patient activation as a predictor of short-term 
outcomes following an osteoarthritis chronic disease management 
program 
 
8.1. Abstract  
Objective: To examine baseline patient activation as a predictor of short-term symptomatic 
outcomes and quantify the change in Patient Activation Measure (PAM-13) scores following 
participation in the Osteoarthritis Chronic Care Program (OACCP). We also assessed the 
relationship between PAM-13 and Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) longitudinal scores. 
 
Methods: One-hundred-and-ten OACCP participants with knee osteoarthritis were followed 
with assessments at 0-, 12- and 26-weeks. Demographic variables (e.g. sex, age, employment 
status), timed-up-and-go (TUG), PAM-13, Depression Anxiety Stress Scale and WOMAC 
were collected. Multivariable linear regression examined the relationships between baseline 
PAM-13 scores and WOMAC pain and function change scores at 12- and 26-weeks.  
 
Results: Complete 12- and 26-week data were available for 89 and 66 participants 
respectively: mean age 67.1 years; 75% female; 14% waitlisted for total joint arthroplasty. 
Baseline PAM-13 did not predict pain (β=0.10 (95%CI-0.12, 0.31) p=0.50) or function 
(β=0.08 (95%CI-0.11, 0.28), p=0.40) scores at 12- or 26-weeks. Employment status and TUG 
were independently associated with 12-week change in pain and function. No significant 
predictors of changes in 26-week pain or function were identified. Following 26-weeks of the 
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OACCP, PAM-13 scores improved by 5.8 points (n= 66, 95%CI 1.89, 9.78). PAM-13 change 
scores were not significantly correlated with pain or function change scores. 
 
Conclusions: Although improvements in pain, function and PAM-13 scores were achieved 
following participation in the OACCP, baseline and change PAM-13 scores did not predict 
changes in pain and function. Employment status and TUG were independent predictors of 
changes in pain and function. 
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8.2. Introduction  
Osteoarthritis (OA) is a leading cause of global disability (8). International guidelines for the 
management of OA recommend a combination of non-surgical, non-pharmacological and 
pharmacological treatments (13). Despite the availability of concordant, high-quality, 
evidence-based management guidelines, these have not been implemented sufficiently into 
clinical practice (12). Considerable discrepancy persists between recommended OA care, and 
the actual care that is received by patients (24, 220). To address this discrepancy, a number of 
OA management programs (OAMPs) have been implemented internationally (22). Some 
studies have reported that a substantial proportion of participants achieve clinically 
important improvements from these programs; however, some do not achieve such benefits 
(27, 29, 30). Further, some people report worsening symptoms despite their participation 
(40). Identifying participants most likely to benefit from OAMPs would enable clinicians to 
prioritise these individuals for entry to these programs. The people identified as unlikely to 
benefit may be referred for adjunctive therapies (e.g. motivational counselling) to improve 
their outcomes.  
 
Several studies have attempted to identify predictors of response to OAMPs (30, 33, 34, 39, 
130). There were two studies that identified higher log-odds of women improving than men 
(34, 39). Another two studies associated poorer outcomes with total joint arthroplasty (TJA) 
waitlist status (33, 40). Otherwise, the predictors in these studies were inconsistent. Given this 
inconsistent evidence, it is necessary to consider alternative explanatory variables that are 
plausible predictors of outcome to intervention. 
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Published international OAMPs consistently provide participants with: support for self-
management; education; and exercise as core treatments (22). Additional optional 
interventions are offered by some programs including: weight loss; medication review; 
provision of assistive devices; psychosocial support; or orthotics (22). Participants of OAMPs 
are often prescribed complex multimodal treatment including lifestyle interventions 
(particularly weight loss and exercise). These complex interventions require a considerable 
commitment and substantial, sustained health behaviour change.   
 
Given the importance of health behaviour change to the success of lifestyle interventions, it is 
necessary to consider the influencers of behaviour change. A scoping review with systematic 
searches examined barriers and facilitators to exercise participation in people with hip and 
knee OA (221). Some of the important barriers to exercise participation identified in the 
review included; lack of knowledge about exercise for OA; negative attitudes to health and 
exercise; and low motivation (221). Conversely, education or knowledge about OA, positive 
expectations of exercise effects, strong levels of motivation and determination were identified 
as facilitators to exercise participation (221). A systematic review of the determinants of 
adherence to lifestyle interventions in obese adults identified several barriers to behaviour 
change including: poor motivation and gaps in knowledge/lack of awareness (222). Both of 
these reviews suggest that knowledge, attitudes and motivation play a critical role in health 
behaviour change for lifestyle interventions.  
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The knowledge, attitudes and motivation of participants towards OA self-management and 
health behaviour can be regarded as a similar concept to ‘patient activation’. Patient 
activation is described as the self-reported confidence, knowledge and skills regarding self-
management of one’s health (42). This construct is quantified using the Patient Activation 
Measure-13 (PAM-13). Previous studies report that higher scores on the PAM-13 are 
associated with better self-management behaviours and outcomes including: participation in 
regular exercise; attending to the fat content of foods; medication and physical therapy 
adherence; self-management knowledge; and appropriate care-seeking behaviours (199, 200, 
223). Much of the existing PAM-13 evidence is derived from large North American primary 
care cohorts (199). As PAM-13 is now being implemented elsewhere, e.g. the United 
Kingdom’s National Health Service, there is recognition of the need to understand the utility 
of PAM-13 within different contexts (219).  
 
This study examined the relationships between PAM-13 scores and symptomatic 
improvements in participants of an OAMP. An important aspect to consider when 
investigating patient activation as a predictor is the timepoint at which most improvements 
are gained from OAMPs. Previous studies have demonstrated that symptomatic 
improvements gained in the first three to six months of OAMPs tend to decline over time (27, 
130). It is also important to consider that the changes in symptoms achieved in the early 
months of a program may greatly influence the long-term success of participants (130). For 
these two reasons, the present cohort study examined PAM-13 scores as a predictor of short-
term symptomatic outcomes. Our primary aim was to determine if baseline PAM-13 scores 
Chapter 8 
212  
 
predicted change in Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) pain and function scores following 12 weeks of an OAMP. Secondary outcomes 
included; to examine PAM-13 scores as a predictor of change in symptoms at 26 weeks, to 
quantify the change in ‘Patient Activation’ between baseline and 26 weeks and assess the 
relationship between PAM-13 and WOMAC change scores. 
 
8.3. Methods 
Participants and data collection 
This study comprised a clinical cohort of consecutive participants with symptomatic and 
radiographic knee OA recruited for OAMPs at a major teaching hospital and a private 
metropolitan hospital in New South Wales, Australia. These OAMPs were based on the same 
model of care (134), the main difference being one was in a public hospital and one a private 
hospital setting. Both programs henceforth will be referred to as Osteoarthritis Chronic Care 
Program (OACCP). Participants were recruited through referral by rheumatologists, 
orthopaedic surgeons, general practitioners and TJA waiting lists. People with a diagnosis of 
knee OA were eligible if they reported pain in the affected knee on most days of the past 
month (39), there were no exclusion criteria. Participants provided consent to participate in 
this study. Ethical approval for this study in accordance with the Declaration of Helsinki was 
provided by Human Research Ethics Committees (HREC): 
NSPHEC 2017-LNR-005 and RESP/16/11, HREC reference: LNRl16/HAWKE/14. 
Participants provided consent to take part in this study and were given the opportunity to opt 
out of having their data included in this research. 
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The objectives of the OACCP were to: reduce OA pain, increase functional abilities and 
quality of life of participants through the provision of tailored interventions delivered by a 
multidisciplinary team and referral to appropriate community-based services. At initial 
assessment, a musculoskeletal (MSK) coordinator (experienced physical therapist/exercise 
physiologist) provided participants with education about their OA and associated 
comorbidities, set patient-oriented goals, prescribed behavioural change strategies and an 
individually tailored exercise program. The exercise program comprised of strength and 
cardiovascular training; and was evaluated and progressed at reassessments (12, 26 and 52 
weeks). Participants also attended a multidisciplinary clinic for consultations with a 
rheumatologist, dietitian, occupational therapist, social worker or orthotist according to their 
individual clinical needs. 
 
Outcome Measures 
As per standard clinical practice for the OACCP, demographic data were recorded at baseline 
including: age; educational level (finished/did not finish high school); and employment status 
(engaged/ not engaged in paid employment). Standardised outcomes collected at each 
OACCP assessment stage included the following: 
i) Measures of height and weight were performed using a standardised protocol (47).  
ii) Participants rated their average pain on the day of assessment using an 11-point Numerical 
Rating Scale - NRS (0 no pain, 10 worst pain imaginable) (157). 
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iii) The Knee injury and Osteoarthritis Outcome Score (KOOS)(158) requires participants to 
rate their: Symptoms; Stiffness; Pain; Physical Function; Recreational Activities; and Quality 
of Life on 5-point Likert scales. The KOOS subsumes the WOMAC questions enabling 
calculation of WOMAC pain, stiffness and function subscales (137) which has demonstrated 
acceptable measurement properties for people living with OA (224). Higher scores indicate 
worse symptoms of pain, stiffness or function.  
iv) The Depression, Anxiety and Stress Scale 21 item version (DASS-21) requires participants 
to rate how much 21 separate statements applied to them over the past week using a 4-point 
Likert scale (0: Did not apply to me at all – never; 3: Applied to me very much, or most of the 
time - almost always). DASS depression responses were added, doubled and dichotomised 
according to thresholds indicating symptoms of moderate depression or worse (scores ≥ 
14/42) and no symptoms to mild symptoms of depression (scores < 14) (159). 
vi) The Timed Up and Go (TUG) measures the time taken for participants to stand from a 
chair (with arms), walk in a straight line for three metres, turn around 180 degrees and walk 
back to the chair and sit down (142).  
vi) A modified version of the Self-Administered Comorbidity Questionnaire estimates a 
commodity score based on participant responses to ‘has your doctor told you that you have 
any of the following problems?’, 21 commonly reported conditions were listed plus an ‘other’ 
category (141). The comorbidity count was categorised into low (0-1), moderate (2-3) and 
high (≥4) groups.  
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In addition to the standard OACCP outcomes, participants were asked to complete the PAM-
13 at baseline and 26-week assessments. The PAM-13 requires participants to rate their 
agreement with 13 statements using a 4-point Likert scale. Responses to the items were added 
to calculate a raw score. A continuous activation score was calculated using an empirically 
derived calibration table by Insignia Health (after January 2014) ranging from 0= no 
activation to 100= high activation (42).  
 
Statistical Analyses 
Statistical analyses were conducted in SPSS (Version 24.0, Armonk NY: IBM Corp, USA). 
The distribution of variables was assessed before analysis through visual 
inspection of histograms and Q-Q plots. Descriptive statistics including frequencies 
(percentage), means and standard deviations summarised participant characteristics. Paired 
t-tests compared PAM-13, WOMAC pain and function scores between baseline, 12- and 26 
weeks. Pearson’s correlation coefficient was used to measure the strength of linear association 
between change scores of the PAM-13, WOMAC pain and function. The thresholds used to 
define correlation size were; 0.5 strong, 0.3 moderate, and 0.1 weak (210). 
 
Potential independent predictor variables were identified a priori through literature review 
and consensus of the authors. These included: PAM-13 scores; age; sex; level of comorbidity; 
presence of depressive symptoms; TJR waitlist status; educational level; employment status; 
and TUG. First, the unadjusted analysis was performed using simple linear regression to 
study relationships between potential baseline predictors and WOMAC pain and function 
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change scores. In the second step, models included an adjustment for baseline WOMAC 
pain/function scores. Variables with a P-value of ≤ 0.1 were included as candidate variables in 
multivariable models which were built using a backward selection, forced entry technique. At 
each step, the least significant variable (p-value<0.05) was removed from the model and the 
beta coefficients were checked; if the coefficients changed by ≥ 10% the variable was retained 
in the model as a confounder, if not it was removed. The underlying assumptions of the linear 
regression model were tested (54). 
 
Power calculations for this study were based on accommodating six predictors at 10-15 cases 
per predictor which is a conservative estimate for multivariable linear regression and takes 
into account the degrees of freedom required for the univariable pre-screening (55). 
Therefore we aimed to include approximately 90 participants in the analysis. With knowledge 
of the expected loss-to-follow-up of participants of this clinical program, we aimed to recruit 
112 participants to accommodate a 20% drop-out rate.  
 
8.4. Results 
Of 117 participants with knee OA recruited to the OACCPs between February- December 
2017, 110 consented to take part in the study and completed baseline PAM-13 questionnaires 
in addition to the standard outcomes (see Figure 8.1). The cohort was predominantly female 
(75%), 61.1 (Standard Deviation [SD] 10.0) years of age, overweight with mean BMI 31.5 (SD 
6.2) kg/m2, not currently employed (73%) with an education level finished high school or 
higher (71%) (Table 8.1). Fourteen percent of these participants were on TJA waitlists at a 
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Figure 8.1 Flow diagram of study participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recruited participants 
February- December 2017 
n = 110 
Included participants secondary 
timepoint 26 weeks: 
Complete Wk26 KOOS data 
n=66 
Included participants primary 
timepoint 12 weeks: 
Complete Wk12 KOOS data  
n = 89 
 
Excluded participants 12 week 
analysis: n=21 
Lost to follow-up; n=7 
Ceased program; moved away n=2 
Pain-free so didn’t continue; n=1 
Referred to private program; n=1  
Missed wk12 appointment; 
medical/carer/other reason; n=10 
 
 
 Excluded participants 26 week 
analysis: n=44 (-21 lost wk12) =23 
Did not complete wk26 KOOS; n= 2 
Ceased: work commitments; n=1 
Missed wk26 appointment; 
medical/carer/other reason; n= 17  
Total Joint Arthroplasty; n=3 
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Table 8.1 Characteristics of participants.  
Numbers are n (%) unless otherwise stated. 
Characteristic n = 110 
Female 83 (75) 
Age (years, mean [SD]) 67.1 (10.0) 
Residence‡: Lives alone  24 (27) 
Currently employed^  30 (27) 
Finished secondary school or higher∞  78 (71) 
Did not finish secondary school˚ 32 (29) 
On elective joint arthroplasty waitlist  15 (14) 
BMIϱ, (mean [SD]) 31.5 (6.2) 
Pain NRS, (mean [SD], range 0-10) 3.8 (2.5) 
TUG (units, mean [SD]) 10.3 (4.4) 
DASS Depression (mean [SD]) 8.7 (9.9) 
DASS depression ≥14 28 (25) 
Anxiety (mean [SD]) 6.6 (8.8) 
Stress (mean [SD]) 9.6 (9.6) 
Number of comorbidities Low (0-1)  35 (32) 
Number of comorbidities Moderate (2-3)  40 (36) 
Number of comorbidities High (≥4)  25 (23) 
Number of comorbidities Missing 10 (9) 
Baseline PAM-13 Score (mean [SD])                                                                             59.1 (13.0)
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PAM-13 Activation Level 1 19 (17) 
PAM-13 Activation Level 2 20 (18) 
PAM-13 Activation Level 3 56 (51) 
PAM-13 Activation Level 4 15 (14) 
KOOS converted to WOMAC Pain mean (mean [SD]) 45.0 (19.2) 
KOOS converted to WOMAC Function (mean [SD]) 46.4 (18.1) 
‡ Lives alone reported by participants. Living with others included living with able/non-able bodied person, 
hostel or aged care residential facility. ^ Currently employed includes participants who reported engaging in 
full/part-time paid work. ∞Included participants who reported finishing secondary school (final year), or 
university degree. ° Includes participants who did not finish secondary school and those who reported no formal 
schooling. KOOS: Knee injury and Osteoarthritis Outcome Score; WOMAC: Western Ontario and McMaster 
Universities Arthritis Index: 0 indicates no problems and 100 indicates extreme problems. Pain NRS: Numerical 
rating scale (0-10); BMIϱ: body mass index(kg/m2). TUG: Timed Up and Go (seconds); DASS: Depression 
Anxiety Stress Scale: each subscale 0 best, 42 worst. PAM-13: Patient Activation Measure score 0 worst- 100 best. 
 
 
 
public hospital. Baseline mean WOMAC pain and function scores were 45.0 (SD 19.2) and 
46.4 (SD 18.1) respectively, and mean PAM-13 was 59.1 (SD 13.0). Of the 110 participants, 21 
did not complete their 12-week reassessment (see Figure 8.1 for reasons for loss to follow up). 
The mean change in WOMAC pain and function scores at 12 weeks was -5.8 (95% CI 9.11, 
p<0.01) and -6.4 (95%CI -9.93, -3.39 p<0.01) points respectively (Table 8.2). Sixty-six 
participants returned for their 26-week assessment, (see Figure 8.1 reasons for loss to follow 
up). The mean change from baseline to 26-weeks WOMAC pain and function scores were -
4.4 (95% CI -8.52, -0.27), p=0.04) and -4.4 (95%CI -8.05, -0.82, p=0.02) respectively. The 
mean improvement in baseline to 26-week PAM-13 scores was 5.8 (95%CI 1.89, 9.78, p<0.01) 
(Table 8.2). 
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Table 8.2 Change in PAM-13, pain and function baseline to 12 and 26- weeks 
Variable Baseline mean (SD) 
n=89 
12-week mean (SD) Difference 12-week - 
baseline (95% CI), Pv 
Baseline mean (SD) 
n=66 
26-week mean (SD) Difference 26-week -  
baseline (95% CI), Pv, 
KOOS 
WOMAC pain  
44.6 (19.5), n=89 38.8 (2.5) -5.8 (9.11, 2.57) 
p<0.01 
45.5 (20.2) 41.1 (22.5) -4.4 (-8.52, -0.27), p=0.04 
KOOS 
WOMAC 
function 
45.5 (20.2) n=89 40.6 (20.8) -6.4 (-9.23, -3.49,) 
p<0.01 
46.2 (19.0) 41.8 (21.7) -4.4 (-8.05, -0.82,) p=0.02 
PAM-13  - - - 58.7 (13.3), n=66 64.5 (16.0) 5.8 (1.89, 9.78) p<0.01 
Results in bold significant to alpha level 0.05. KOOS: Knee injury and Osteoarthritis Outcome Score; WOMAC: Western Ontario and  
McMaster Universities Arthritis Index: 0 indicates no problems and 100 indicates extreme problems. PAM-13: Patient Activation Measure score 0 
worst- 100 best. 
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Unadjusted and baseline pain/function adjusted linear regression models 
Tables 8.3 and 8.4 summarise the unadjusted and baseline pain/function adjusted linear 
regression models for change in pain and function at 12-weeks. PAM-13 scores were not 
significantly associated with changes in WOMAC pain and function at 12-weeks. Adjusted 
and unadjusted employment status and TUG were associated with WOMAC pain and 
function at 12-weeks. There was an association between age and change in WOMAC pain at 
12-weeks which was not significant when adjusted for baseline. 
 
The unadjusted and adjusted models for change in week-26 pain and function are presented 
in Tables 8.5 and 8.6. At the 26-week assessment, baseline PAM-13 were not associated with a 
change in WOMAC pain and function scores. Adjusted and unadjusted employment status 
was associated with a change in WOMAC function at 26-weeks. It was associated with a 
change in WOMAC pain only when adjusted for baseline. Baseline TUG results were 
associated with a change in WOMAC Function at 26-weeks when adjusted for baseline 
function. 
 
Multivariable linear regression models 
Baseline PAM-13 scores were not predictive of changes in WOMAC pain or function in the 
12- or 26-week multivariable models (Tables 8.3, 8.4, 8.5, 8.6). Employment status (β=8.90 
(95% CI 2.48, 15.30), p<0.01) and TUG (-1.32 (-1.20, -0.65), p<0.01) were predictive of week-
12 WOMAC pain change scores when adjusted for baseline pain, PAM-13 and TJA waitlist 
status (F statistic= 9.065, p≤0.001, adjusted R2= 0.32). Employment status (β= 11.01 (95%CI  
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5.05, 16.96), p<0.01) and TUG (β= -1.07 (95%CI -1.72, -0.42), p< 0.01) were also predictive of 
change in WOMAC function scores at 12-weeks when adjusted for baseline, PAM-13 scores, 
the DASS depression, age and TJA waitlist status (F statistic=7.063, p<0.01, adjusted R2= 
0.33). There were no significant predictors (p ≤0.05) in the multivariable models for change 
in baseline to 26-weeks WOMAC pain or function. There were no statistically significant 
correlations between baseline to 26-weeks change scores of PAM-13 and WOMAC pain (r= -
0.14, p= 0.311) and function (r= -0.06, p= 0.636). 
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Table 8.3 Linear regression analyses; change in WOMAC pain Wk0 to Wk12 
 (n=89) 
Variable  β (95% CI) (crude) P β (95% CI) (adjusted)* P Final multivariable model P 
Baseline PAM-13 score -0.01 (-0.26, 0.24) 0.94 0.08 (-0.16, 0.33) 0.50 0.10 (-0.12, 0.31) 0.50 
male reference      
female 2.90 (-4.59, 10.39) 0.44 2.42 (-4.70, 9.55) 0.50 -  
Age (per year) -0.4 (-0.72, -0.04) 0.03 -0.3 (-0.62, 0.05) 0.09 -  
  R2= 0.05     
Didn’t finish high school reference      
High School/higher  5.18 (-2.23, 12.59) 0.17 5.21 (-1.86, 12.28) 0.15 -  
No paid employment reference      
Paid employment 10.00 (2.80, 17.21) 0.01 11.57 (4.81, 18.32) <0.01 8.90 (2.48, 15.30) 0.006 
  R2= 0.08  R2= 0.20   
DASS Depression score <14 reference      
DASS Depression score ≥14 -1.52 (-9.16, 6.13) 0.69 -7.75 (-15.56, 0.06) 0.05 -  
Comorbidity count: 0-1 reference  reference  -  
Comorbidity count: 2-3 -0.57 (-9.00, 7.86) 0.89 -1.22 (-9.18, 6.73) 0.76 -  
Comorbidity count: ≥4 -4.55 (-14.33, 5.23) 0.36 -5.80 (-15.06, 3.46) 0.22 -  
Not on waitlist reference  reference    
On waitlist -8.27 (-18.54, 2.00) 0.11 -8.84 (-18.56, 0.88) 0.07 -5.07 (-14.02, 3.88) 0.26 
TUG -0.97 (-1.69, -0.26) 0.01 -1.51 (-2.18, -0.84) <0.01 -1.32 (-1.20, -0.65) <0.01 
  R2= 0.08  R2= 0.28   
KOOS WOMAC pain 0.26 (0.10, 0.42) <0.01   0.40 (0.25, 0.55) <0.01 
       
Results in bold significant to alpha level 0.05. KOOS: Knee injury and Osteoarthritis Outcome Score; WOMAC:  
Western Ontario and McMaster Universities Arthritis Index: 0 indicates no problems and 100 indicates extreme problems. 
PAM-13: Patient Activation Measure score 0 worst- 100 best. TJA: total joint arthroplasty; TUG: Timed Up and Go (seconds);  
DASS: Depression Anxiety Stress Scale: each subscale 0 best, 42 worst. P= p-value. *Adjusted for Wk0 WOMAC Pain score 
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Table 8.4 Linear regression analyses; change in WOMAC function Wk0 to Wk12  
(n=89) 
Variable  β (95% CI) (crude) P β (95% CI) 
(adjusted)* 
P Final multivariable model P 
Baseline PAM-13 score 0.03 (0.19, 0.25) 0.79 0.07 (-0.16, 0.29) 0.54 0.08 (-0.11, 0.28) 0.40 
Male reference      
Female 3.75 (-2.80, 10.30) 0.26 3.34 (-3.25, 9.92) 0.32 -  
Age -0.40 (-0.70, -0.11) <0.01 -0.38 (-0.68, -0.08) 0.01 -0.14 (-0.42, 0.14) 0.32 
  R2= 0.08  R2= 0.06   
Didn’t finish high school reference  reference    
High School/higher  1.9 (-4.82, 8.39) 0.54 2.27 (-4.35, 8.89) 0.50 -  
No paid employment reference  reference    
Paid employment 14.44 (8.60, 20.28) <0.01 14.72 (8.94, 20.51) <0.01 11.01 (5.05, 16.96) <0.01 
  R2= 0.22  R2= 0.23   
DASS Depression score <14 reference  reference    
DASS Depression score ≥14 -3.48 (-10.18, 3.23) 0.31 -6.71 (-14.11, 0.70) 0.08 -4.86 (-11.24, 1.52) 0.13 
Low (0-1) reference  reference    
Moderate (2-3) 1.10 (-5.99, 8.17) 0.76 0.93 (-6.12, 7.98) 0.79 -  
High (≥4) -0.56 (-8.78, 7.66) 0.89 -1.41 (-9.69, 6.86) 0.74   
Not on waitlist reference  reference    
On waitlist -8.00 (-16.98, 1.00) 0.08 -8.25 (-17.21, 0.70) 0.07 -4.42 (-12.28, 3.45) 0.27 
TUG -0.91 (-1.53, -0.28) <0.01 -1.44 (-2.12, -0.76) <0.01 -1.07 (-1.72, -0.42) <0.01 
  R2=0.09  R2= 0.17   
KOOS WOMAC function 0.10 (-0.06, 0.27) 0.21   0.31 (0.13, 0.48) <0.01 
 
Results in bold significant to alpha level 0.05. KOOS: Knee injury and Osteoarthritis Outcome Score; WOMAC: Western Ontario 
and McMaster Universities Arthritis Index: 0 indicates no problems and 100 indicates extreme problems. PAM-13: Patient  
Activation Measure score 0 worst- 100 best. TJA: total joint arthroplasty; TUG: Timed Up and Go (seconds); DASS: Depression  
Anxiety Stress Scale: each subscale 0 best, 42 worst. P= p-value. *Adjusted for Wk0 WOMAC function score 
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Table 8.5 Linear regression analyses; change in WOMAC pain Wk0 to Wk26 
(n=66) 
Variable β (95% CI) (crude), Pv β (95% CI) (adjusted)*, Pv Final multivariable model, Pv 
Baseline PAM-13 0.03 (-0.28, 0.34), 0.85 0.09 (-0.22, 0.40), 0.60 0.10 (-0.20, 0.40), 0.49 
male reference reference  
female 1.50 (-8.67, 11.67) 0.77 0.14 (-9.81, 10.10),0.98 - 
Age 0.08 (-0.35, 0.51) 0.71 0.16 (-0.26, 0.57), 0.46 - 
Not finished high school reference reference  
High School/higher 3.54 (-5.76, 12.83),0.45 3.54 (-5.45, 12.52),0.43 - 
No paid employment reference reference  
Paid employment 7.69 (-2.06, 17.43),0.12 10.14 (0.66, 19.62), 0.04 9.10 (-0.36, 18.62), 0.06 
DASS Depression <14 reference reference  
DASS Depression ≥14 4.27 (-5.01, 13.55),0.36 0.53 (-9.26, 10.31), 0.92 - 
Comorbidity count: 0-1 reference reference  
Comorbidity count: 2-3 2.67 (-7.28, 12.62),0.59 3.45 (-6.16, 13.06), 0.48 - 
Comorbidity count: ≥4 0.55 (-10.48,11.58), 0.92 0.2 (-10.46,10.80), 0.97 - 
Not on TJA waitlist reference reference  
On TJA waitlist 3.08 (-10.42,16.57), 0.65 0.13 (-13.25, 3,52), 0.98 - 
TUG -0.41 (-1.48, 0.66), 0.44 -0.98 (-2.07, 0.12), 0.08 -0.94 (-2.03, 0.15), 0.09 
KOOS WOMAC  0.23 (0.03, 0.43), 0.03  0.34 (0.13, 0.55), 0.01 
  
Results in bold significant to alpha level 0.05. KOOS: Knee injury and Osteoarthritis Outcome Score; WOMAC: 
 Western Ontario and McMaster Universities Arthritis Index: 0 indicates no problems and 100 indicates extreme 
 problems. PAM-13: Patient Activation Measure score 0 worst- 100 best. TJA: total joint arthroplasty; TUG: Timed 
 Up and Go (seconds); DASS: Depression Anxiety Stress Scale: each subscale 0 best, 42 worst. Pv= p-value.  
*Adjusted for Wk0 WOMAC pain/function score 
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Table 8.6 Linear regression analyses; change in WOMAC function Wk0 to Wk26 
(n=66) 
Variable β (95% CI) (crude), Pv β (95% CI) (adjusted)*, Pv Final multivariable model, Pv 
Baseline PAM-13 -0.01 (-0.28, 0.27), 0.97 0.03 (-0.24, 0.31), 0.82 0.06 (-0.21, 0.32), 0.67 
male reference reference  
female 4.03 (-4.83, 12.88),0.37 3.35 (-5.47, 12.18), 0.45 - 
Age -0.04 (-0.41, 0.34), 0.84 0.01 (-0.38, 0.37), 0.98 - 
Not finished high school reference reference  
High School/higher 4.15 (-4.06, 12.35), 0.32 5.08 (-3.03,13.20), 0.215 - 
No paid employment reference reference  
Paid employment 9.74 (1.40, 18.09), 0.02 10.25 (2.03, 18.48), 0.02 8.10 (-0.24, 16.43), 0.06 
DASS Depression <14 reference reference  
DASS Depression ≥14 -4.30 (-12.41, 3.81), 0.29 -7.61 (-16.10, 0.87), 0.08 -6.20 (-14.47, 2.07), 0.14 
Comorbidity count: 0-1 reference reference  
Comorbidity count: 2-3 3.68 (-5.03, 12.39), 0.40 4.51 (-4.12, 13.14), 0.30 - 
Comorbidity count: ≥4 1.50 (-8.16, 11.14), 0.76 0.80 (-8.73, 10.33), 0.87  
Not on TJA waitlist reference reference  
On TJA waitlist -7.08 (-18.77, 4.62), 0.23 -8.90 (-20.57, 2.77), 0.13 - 
TUG -0.47 (-1.40, 0.46), 0.32 -1.0 (-2.07, -0.02), 0.05 -0.93 (-1.94, 0.09), 0.07 
KOOS WOMAC  0.1 (-0.04, 0.34), 0.12  0.31 (0.09, 0.53), 0.01 
  
Results in bold significant to alpha level 0.05. KOOS: Knee injury and Osteoarthritis Outcome Score; WOMAC: 
 Western Ontario and McMaster Universities Arthritis Index: 0 indicates no problems and 100 indicates extreme 
 problems. PAM-13: Patient Activation Measure score 0 worst- 100 best. TJA: total joint arthroplasty; TUG: Timed 
 Up and Go (seconds); DASS: Depression Anxiety Stress Scale: each subscale 0 best, 42 worst. Pv= p-value.  
*Adjusted for Wk0 WOMAC pain/function score 
Chapter 8 
227  
 
8.5. Discussion 
The main purpose of this study was to examine the relationships between baseline patient 
activation and changes in pain and function following 12 weeks of an OACCP. Baseline 
PAM-13 scores were not associated with WOMAC pain and function in any of the models. 
Other variables such as employment status, TUG and the confounders depression, TJA 
waitlist status and age were independently associated with WOMAC pain and function scores 
at 12 weeks. Employment status and TUG results were associated with a change in WOMAC 
pain and function scores at 26 weeks. There were no significant predictors of change in 
symptoms at 26 weeks identified in the multivariable models. The mean change in PAM-13 
scores was 5.8 (95%CI 1.89, 9.78) points following 26 weeks of the OACCP. The correlations 
between changes in PAM-13 and WOMAC pain/function scores at 26 weeks were weak. 
 
Several previous studies have demonstrated that higher activation is associated with better 
longitudinal health outcomes in people living with chronic diseases (199-201). Most of the 
outcomes in these studies were comprised of general health behaviours such as healthy eating, 
managing medications or testing glucose levels. Few studies have examined the relationship 
between PAM-13 and aggregated change scores of outcomes to intervention.  
 
One study examined the association between baseline PAM-13 scores and weight-loss 
following an incentive-based weight-loss intervention for obese individuals (225). Consistent 
with our findings, there was no association between PAM-13 and change scores (225). 
Conversely, another study reported that higher pre-operative PAM-13 scores predicted 
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greater improvement in Pain and Symptoms subscales of KOOS and Hip Disability and 
Osteoarthritis Outcome Scores (HOOS) following TJA for patients with advanced arthritis 
(226). These conflicting findings may be explained by the magnitude of the change scores. 
Changes in symptoms following non-surgical management are expected to be smaller than 
TJA particularly in people with end-stage OA (227). The change scores in our study may have 
been too subtle to detect an association.  
 
Other independent predictors of changes in pain and function were identified. Employment 
status independently accounted for over 20% of the variability in change in 12-week 
WOMAC Function scores and 20% of the variability of change in pain scores when adjusted 
for baseline. Employment status has been associated with age and the severity of OA 
symptoms in previous studies (228, 229). It could be argued that employment status was 
acting as a proxy for disease severity and/or age in this analysis, however, we adjusted the 
models for these variables, so this should not be the case. The relationship between 
employment status and improved outcomes following OAMPs warrants further attention. 
 
Timed Up and Go accounted for 28% and 17% of the variability in change of WOMAC pain 
and function scores at 12 weeks respectively, when adjusted for baseline. A possible 
explanation for this finding is that people with higher functional ability may have found it 
easier to fully engage with their exercise program, and hence were more able to achieve the 
potential beneficial treatment effects associated with the intervention. Better TUG times may 
reflect higher levels of physical activity and/or exercise of participants in their everyday lives. 
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Previous experience with exercising has been identified in a scoping review as a facilitator of 
exercise participation (221); this may also have improved the engagement of these higher 
functioning participants with the program and led to better treatment effects.  
 
The mean change in PAM-13 scores following 26 weeks of the OACCP (5.8 (95%CI 1.89, 
9.78) points) was small considering that the PAM-13 is a 100- point scale. This change was 
similar to the mean change reported in a previous randomised trial (200). This trial included 
participants with at least one of several chronic diseases: arthritis; diabetes; hypertension; 
heart disease; chronic obstructive pulmonary disease, or hyperlipidaemia. Participants 
randomised to the Chronic Disease Self-Management Program reported a mean change of 4.7 
PAM-13 points at 26-weeks (200). However, the authors identified two trajectories of change 
in activation: i) an increased PAM trajectory, and ii) a stable PAM trajectory. The participants 
with increased PAM trajectory membership reported a mean change in PAM-13 of 15.4 
points at six months, while those with the stable PAM trajectory had a slightly worse mean 
PAM-13 scores at six months (compared to baseline). Although all study participants 
increased their desirable self-management behaviours, the participants with increased PAM 
trajectory membership demonstrated greater improvements across more self-management 
behaviours (200). This present study did not examine different trajectories in change of 
PAM-13 scores following the OACCP. This could be explored further in larger cohorts of 
OACCP participants.  
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Changes in PAM-13 scores were not correlated with changes in pain and function. It is 
possible that the symptomatic benefits from lifestyle interventions requiring substantial 
behaviour change take longer to result in improvements that are noticeable and important to 
patients. The analyses at 12 and 26 weeks may not have allowed adequate time for 
participants to harness their activation to change behaviour and experience noticeable 
changes in pain and function. In addition, to reduce participant burden attributed to multiple 
tests, PAM-13 was not routinely administered at 12-weeks. We were unable to determine 
whether changes in PAM-13 scores at 12 weeks were correlated with changes in pain and 
function. Also, there was loss to follow up throughout this clinical cohort study (follow-up 
rates were 81% and 60% at 12- and 26-weeks respectively). This may have contributed to the 
lack of association between baseline measures and changes in symptoms at the 26-week time 
point.  
 
Although improvements in pain and function scores were achieved following participation in 
OACCPs, these were not associated with PAM-13 baseline or change scores. Other 
independent predictors of changes in symptoms including employment status and TUG were 
more helpful predictors of change in pain and function. 
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Chapter Nine: Thesis discussion and future directions 
 
9.1. Summary of Thesis findings 
This aim of this Thesis was to identify clinical characteristics that were associated with 
positive responses and worsening following participation in the OACCP. A range of disease-
specific, psychological, physical and demographic variables were examined. However, an 
overall finding was that the variables that were significantly associated with OACCP 
outcomes only explained a small amount of the variability of the outcome. 
 
This Thesis has confirmed previous evidence that not all participants respond favourably 
following an OAMP (27, 29, 30). The mean improvements of people with knee OA, who had 
participated in 12-weeks of the OACCP in Chapter Eight, was approximately 6/100 points for 
both WOMAC Pain and Function scores respectively. Although these improvements were 
small, they were comparable to the results of other OAMPs (30, 34). In Chapter Four only 
28% Of OACCP participants reached the MCID for ‘response’ (39) . While this response rate 
seems low, it aligns with the results reported in most of the previous literature (29, 34). The 
exception was the ESCAPE-Knee Pain program where 61% and 54% of participants reached 
the threshold for response at six weeks and six months respectively. An important difference 
in the ESCAPE-Pain study was that the threshold of change in WOMAC scores used to 
indicate response was lower than the one used in Chapter Four: this probably explains the 
higher proportion of responders compared with our study.  
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The low response rates found in this Thesis and in the literature according to disease-specific 
measures such as the WOMAC, prompts consideration of whether these variables are the 
most meaningful outcomes to measure the effectiveness of OAMPs. It was argued in Chapter 
Six (41) that the measurement of OA self-management capabilities is important to indicate 
the success of OAMPs. The authors of a systematic review on the effectiveness of OA self-
management education programs reported a “mismatch between the aims of self-
management education programs and the outcomes used to measure success” (15). They 
argued further that pain is often used as the main outcome for non-surgical treatments for 
OA, and although a reduction in pain is desirable for patients, it may not fully reflect the aims 
of treatments centred on enabling patients to self-manage their condition (15). Most often, 
the main aim of OAMPs is to support patients to live well with their OA, despite their 
ongoing pain and other symptoms. Hence, it is arguable that self-management capability is an 
important indicator of efficacy (15).  
 
Osteoarthritis self-management knowledge, attitudes and capabilities have not been widely 
assessed in previous OAMP literature. Following the systematic review in Chapter Six, we 
were unable to recommend a suitable instrument with demonstrated adequate measurement 
properties to measure these constructs. In the absence of a suitable instrument, the 
measurement properties of the PAM-13 were evaluated in a cohort of OACCP participants in 
Chapter Seven. The PAM-13 was then evaluated further in a longitudinal cohort in Chapter 
Eight.  
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The study in Chapter Eight demonstrated that patient activation is positively modifiable in an 
OA population, potentially more so than for several other chronic conditions (200). This is an 
important finding because the improvements in PAM-13 scores have previously been 
associated with increased desirable self-management behaviours (200). We did not investigate 
the relationship between patient activation and desirable health-related behaviours in this 
Thesis. However, an important future research question may be to determine whether 
longitudinal PAM-13 scores and specific health behaviours, such as meeting the requirements 
of physical activity recommendations or adhering to prescribed daily calorific intake to 
achieve weight loss, concurrently improve in people participating in OAMPs. If PAM-13 
scores were found to reflect changes in health-specific behaviours, this would provide 
important evidence to support the construct validity of PAM-13 in this population. 
 
We hypothesised that people with higher patient activation at enrolment in the OACCP 
would have better outcomes. In Chapter Eight neither patient activation nor change in 
activation, were associated with changes in WOMAC pain and function following 
participation in the OACCP. This finding was surprising, especially given the findings of a 
previous study on the Good Living with Osteoarthritis Denmark (GLA:D) program. The 
GLA:D study reported that self-efficacy measured on the Arthritis self-efficacy scale (ASES) at 
three months; and the change in ASES from baseline to three months; were significantly 
associated with improvements in pain at 12 months (130). These conflicting results may be 
related to differences in the specificity of the constructs measured by the PAM-13 and the 
ASES. The PAM-13 items are not targeted to specific OA management tasks, but ask about 
Chapter 9 
236  
 
the management of general health e.g. “I am confident I can help prevent or reduce problems 
associated with my health”. On the other hand, self-efficacy refers to the belief that one can 
achieve a specific task or behaviour (230). The items of the ASES start with the prefix: “How 
certain are you that you can…” and then list specific tasks to manage arthritis e.g. “make a 
large reduction in your arthritis pain by using methods other than taking extra medication?” 
(191). The ASES contains specific questions that ask about OA self-management. These items 
may have a stronger statistical relationship with improvements in measures of pain and 
function because they relate more specifically to OA. Whereas, the PAM-13 items are 
directed at management of general health (42). This may explain why baseline and changes in 
PAM-13 scores were not associated with changes in pain and function in Chapter Eight. 
 
Several other characteristics were significantly associated with changes in pain and function 
following the OACCP. Some of these variables were non-modifiable such as gender and index 
joint (hip vs knee), and other variables were potentially modifiable such as TJA waitlist status, 
functional performance (TUG) and employment status.  
 
Non-modifiable characteristics 
i) Index joint 
Participants who presented with the knee as the index joint had twice the log odds of being 
responders compared to those with hip OA in Chapter Four (39). A possible explanation for 
this result was that the size of the treatment effects observed following exercise were higher 
for people with knee OA compared to those with hip OA. Evidence from systemic reviews 
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suggests that the clinical efficacy of exercise differs for people with hip OA compared with 
knee OA for both pain and physical function. In a meta-analysis investigating interventions 
for knee OA, the pooled treatment effect was 0.5 standardised mean difference immediately 
following treatments (16). For those with hip OA, this effect was smaller (0.38) and the 
confidence intervals was less precise, indicating more variability in the treatment effect (17). 
Based on these findings, it is not surprising that people with hip OA had lower odds of being 
considered responders in Chapter Four (39). 
 
There are potential clinical implications of participants with knee OA having twice the log 
odds of being responders following 26-weeks of the OACCP. First, this finding needs to be 
replicated in other large sample size clinical cohort studies. If this finding is confirmed in 
further research, this evidence may alter the expectations of participants and their clinicians 
regarding the magnitude of symptomatic relief that participants with hip OA achieve. This is 
not to say that people with hip OA will worsen. There was no significant association between 
index joint and worsening in Chapter Five (40). Furthermore, several studies have 
demonstrated that index joint was not a stable predictor of response (29, 30, 34). This 
underscores the need for caution when interpreting differences between knee and hip OA 
responders. Given the evidence for significant, small to moderate effects on pain and function 
derived from exercise therapy for hip OA (17), it would be inappropriate to exclude people 
with hip OA from entry to OACCP based on their index joint. 
 
ii) Sex 
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Based on findings from Chapter Four, female participants had twice the log odds of being 
responders compared to males (39). Sex was not significantly associated with worsening in 
Chapter Five (40), nor with a change in WOMAC pain and function in Chapter Eight of this 
Thesis. The evidence in the literature of the association between sex and outcomes of OAMPs 
is conflicting (29, 30, 34). The clinical utility of using sex as a predictor of response is limited. 
It would be considered unacceptable to triage participants for entry to the OACCP based on 
sex even if there were stronger evidence to support this finding. 
 
Modifiable factors 
i) Total joint arthroplasty waitlist status 
Total joint arthroplasty (TJA) waitlist status was significantly associated with increased odds 
of worsening in Chapter Five following 26 weeks participation in the OACCP (OR 1.91 
[95%CI 1.04, 3.51]) when adjusted for baseline 6-minute-walk-test results (40). However, this 
model only explained 5% of the variance in demonstrating worsening (40), suggesting that 
there are other unknown factors that need to be considered. In addition, the relationship 
between TJA waitlist status and worsening changed depending on the definition of worsening 
that was used (40). There was a similar finding in a previous longitudinal observational 
cohort study of people on hip and knee joint replacement waitlists. Using similar thresholds 
of clinically important worsening and improvement in WOMAC scores as Chapters Four and 
Five, half of the cohort reported unchanged WOMAC score, approximately a 25% reported 
worsening and 25% reported improvement while waiting for TJA (156). In addition, 
participants were asked transition questions about self-perceived change in wellbeing 
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(including: pain, fatigue, overall quality of life, overall health). Over half of the participants 
reported they were ‘worse’ on the transition questions. An obvious difference between this 
cohort and the one in Chapter Five was that the participants did not receive any intervention. 
However, the study did identify different trajectories of people on TJA waitlists; and similar 
to Chapter Five, the proportion of participants who reported they were ‘worse’ was dependent 
on the threshold used to indicate worsening (156).   
 
In Chapter Eight TJA waitlist status was not an independent predictor of change in WOMAC 
pain and function. However, it was included as a confounder in the final multivariable 
models for WOMAC pain and function at 12-weeks. When TJA waitlists status was removed 
from the model, the regression coefficients of the other variables changed (>10%) such that it 
suggested TJA waitlist status bore some influence on the relationships between the other 
variables in the model. TJA waitlist status was included in the final multivariable models of 
the studies in both Chapters Five and Eight, and both studies suggested that there is a 
relationship between TJA waitlist status and outcomes following the OACCP (40). This 
evidence lends weight to the recommendation in OA management guidelines that TJA should 
only be considered in cases where the patient has disabling symptoms, and all non-surgical 
treatments (non-pharmacologic and pharmacologic) have been exhausted (13). Further, early 
recruitment for participation in OAMPs, prior to referral for consultation with orthopaedic 
surgeons, may enable people with OA to derive the greater benefits from non-surgical 
treatments.  
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ii) Functional performance measures 
The TUG assesses a multitask activity that includes transitions between sitting, standing and 
walking (142). Baseline TUG was associated with of changes in pain and function, explaining 
28% and 17% of the variability in change of WOMAC pain and function scores at 12 weeks 
respectively, when adjusted for baseline. Although the TUG is a test of functional 
performance for hip and knee OA recommended by OARSI (142), there is little literature 
available detailing biomechanical forces at the knee during this test. One previous study from, 
over 30 years ago, demonstrated that standing from sitting causes loading across the different 
joint compartments of the knee (231). The forces at the patellofemoral joint were 
approximately 15x bodyweight which were almost twice the magnitude of those at the 
tibiofemoral joint (231). By vigorously loading the different compartments of the knee, the 
TUG may provide a comprehensive outcome that reflects the overall health of the OA knee. 
This may explain why the TUG was associated with changes in pain and function found in 
Chapter Eight. 
 
The ability of the TUG to discriminate OA functional severity may have important clinical 
implications. Participants with higher functional ability, indicated by lower TUG times may 
find it easier to fully engage with their OACCP interventions, especially their exercise 
program, and hence be enabled to achieve the potential beneficial treatment effects associated 
with the interventions. Assessment using the TUG may therefore identify patients most likely 
to respond to OACCP interventions and enable OAMP resources to be targeted towards 
those individuals. While this hypothesis would need to be tested in future research, this 
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finding could modify patient and health professional expectations regarding the likely 
benefits derived from OACCP participation. Our findings suggest that better improvements 
in pain and function could be expected from participants with higher baseline functional 
performance measured using TUG.  
 
iii) Employment status 
Another potentially modifiable variable and independent predictor of change in WOMAC 
pain and function scores in Chapter Eight was employment status. Employment status 
independently accounted for over 20% of the variability in change in 12-week WOMAC 
Function scores and 20% of the variability of change in pain scores when adjusted for baseline 
in Chapter Eight. This relationship between employment status, pain and function has not 
been previously examined within the context of an OAMP. One possible explanation for this 
finding is that employment was acting as a proxy for OA symptom severity. A previous 
Australian population-based study suggested that people living with lower limb joint disease 
who had very low health quality of life indicated by their WOMAC scores, had more than 
three times the odds of not being engaged in paid employment (229). In our study, people 
who were engaged in paid employment may have presented to the OACCP with lower levels 
of OA disease severity; and being at an earlier stage of the condition they may have responded 
to treatment more favourably. The relationship between employment status, disease severity 
and improved outcomes following the OACCP warrants further attention in longitudinal 
cohort studies. 
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iii) Depressive symptoms 
The presence/absence of depressive symptoms was not significantly associated with either 
improvement or worsening in Chapters Four (39), Five (40) or Eight. Our findings contrasted 
with some previous studies. The absence of depression was identified previously as a 
predictor of response or improvement following a 3-4 week inpatient multimodal 
rehabilitation intervention (34) and a weight loss program in overweight veterans with knee 
OA (80). A “depressive knee OA” phenotype was identified in previous two large cross-
sectional cohort studies: people classified as the depressive knee OA phenotype reported 
significantly worse self-reported pain and function outcomes than most of the other 
phenotypes (232). 
 
The absence of any significant association between baseline depressive symptoms and 
OACCP clinical outcomes in this Thesis may be explained by the effect of the OACCP 
intervention on depression itself. All participants of the OACCP were screened for symptoms 
of mental health conditions using the Depression, Anxiety and Stress Scale (DASS) (159). The 
participants of the OACCP who indicated that they had experienced depressive symptoms on 
the DASS depression subscale, were referred for consultation with a social worker (or less 
frequently a psychologist) as required.  
 
The evidence for the clinical efficacy of treatment for OA sufferers with comorbid depression 
is conflicting. There is some RCT evidence that the treatment of depression in people with 
arthritis reduced their pain, depressive symptoms and improved function and quality of life 
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(92). Subsequent analyses found that depression management (compared to usual care) was 
effective in reducing pain severity among people with arthritis with lower levels of baseline 
pain, but these benefits were not observed in people with higher initial pain severity (233). A 
more recent cluster RCT in primary care practices in the United Kingdom compared two 
methods of screening for and managing depressive symptoms. One group of general practices 
were randomised to a point-of-care screening form to identify people presenting with OA 
who were experiencing comorbid symptoms of depression and/or anxiety; and provided 
management of depression/anxiety when required. The other group of practices were 
randomised to usual care. Compared with usual care, the group who received the screening 
and depression/anxiety intervention reported worse pain outcomes and no improvement in 
their depression/anxiety symptoms (234). Together, these studies demonstrate that the 
relationship between the management of depression and the impact on OA symptoms 
remains unclear. Further RCTs are required to determine the effects of treatment of 
depression on OA symptoms.  
 
iv) Number of comorbidities 
The presence of depression and other comorbidities have been previously associated with 
poorer health-related quality of life for OA patients waiting for TJA (171). Low comorbidity 
counts were associated with improvements in OA symptoms following a 3-4 week inpatient 
multimodal rehabilitation intervention for hip and knee OA (34). In contrast, our study 
found higher comorbidity counts were not significantly associated with improving or 
worsening following the OACCP in Chapters Four or Five of this Thesis (39, 40). The 
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OACCP model of care aims to include assessment, education and interventions to support 
the management of comorbidities (134). The assessment and management of comorbidities, 
within the context of this chronic care model, may have reduced the negative impact of 
higher comorbidity counts on OACCP outcomes. This is an important clinical finding as it 
suggests that OACCP may be considered suitable for anyone with any number of 
concomitant conditions.  
 
9.2. Strengths and limitations of this Thesis 
The clinical cohort designs of the studies of this Thesis brought both strengths and limitations 
to the findings of this Thesis. A clinical cohort study generally includes a sample of 
individuals who are actively receiving health care in a clinic setting, for a specified condition, 
and uses their health data to assess outcomes. The data collection intervals are determined by 
the nature of the healthcare services provided (235). The clinical cohorts in this Thesis were 
comprised of real-life OACCP clinics and the data were collected at program assessments 
according to standard clinical practice. Although this had implications on the timing and 
completeness of the data, this was a strength of our study as it also increased the applicability 
of the study findings to real-world clinical settings (235).  
 
It is important, however, to consider the nature of the real-world settings that the clinical 
cohorts were drawn from. The study data were drawn from a limited number of OACCPs in 
socio-demographically similar regions of NSW, Australia. The resulting study samples 
represented homogenous, metropolitan geographic areas of Australia with higher socio-
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economic and educational status. This was a limitation of the findings of this Thesis. A 
previous multicentre randomised controlled trial suggested that sociodemographic and 
geographic characteristics have an impact on the availability and uptake of some components 
of OA treatment (236). The homogenous samples used in this Thesis may have diminished 
the applicability of these studies and this needs consideration when interpreting the results.  
 
A further limitation is the applicability of our findings to people living with hip OA due to the 
low number of hip OA participants in our studies. There were much larger proportions of 
people with knee OA, compared to hip OA in the studies reported in Chapters Four (39), Five 
(40), and Seven. Chapter Eight only included people with the knee as the index treatment 
joint. The lower proportions of participants with hip OA in Chapters Four, Five and Seven 
reflected the lower prevalence of hip compared with knee OA (237) and referral patterns of 
the OACCP. The low hip OA participation rate should be considered when interpreting the 
results of this Thesis in relation to hip OA. 
 
Despite some limitations to the applicability of the findings of the studies, the clinical cohort 
study design provided an important strength to this Thesis. This design enabled recruitment 
of large sample sizes for the studies in Chapters Four, Five and Eight. This allowed for 
adequate statistical power to detect associations between the variables and the dependent 
outcomes, which imbues confidence in the results of the studies overall. Although the study 
design enabled large study sample sizes, it was also prone to problems with loss-to-follow-up 
that is typical of clinical practice (235). Participants left the OACCP for various reasons 
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including: they reached the top of the TJA waitlists and underwent surgery; withdrew on 
medical advice; moved interstate; or suffered illness or death. The earlier studies of this Thesis 
(Chapters Four (39) and Five (40)) saw larger losses to follow-up than the later studies. This 
could be attributed to larger proportions of participants referred to the OACCP from TJA 
waitlists at that earlier time.  
 
This censoring due to TJA may have introduced selection bias because the participants with 
the worst disease severity may have been lost to follow up as they left the OACCP to have 
TJA. The participants who attended the OACCP at the later data collection timepoints may 
have been those who were responding most favourably to the intervention. This may have 
resulted in overestimation of the mean changes in symptoms following the OACCP for the 
population. However, we used techniques to mitigate the risk of selection bias such as 
imputation of data for participants lost to follow up in these chapters (39, 40).  
 
A further strength of our studies was that the follow-up periods for the longitudinal studies 
were clearly defined and clinically meaningful. The follow-up period for the primary analyses 
in Chapters Four and Five was at 26-weeks. This was chosen to allow for sufficient 
opportunity for OACCP participants to achieve changes in their symptoms to achieve the 
MCID used to indicate response or worsening (32). The follow-up time chosen for the 
primary analysis in Chapter Eight was at 12-weeks. This timepoint was chosen considering 
that the changes in symptoms achieved in the early months of a program may greatly 
influence the long-term success of participants. The association between early success and 
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better long-term outcomes was demonstrated in a previous study of GLA:D participants 
(130). A further advantage of using the 12-week follow up was it avoided some of the loss to 
follow-up that was seen at the 26-week follow-up timepoint in Chapters Four and Five. In 
maximizing the sample of complete data by using the earlier 12-week timepoint, the models 
had more statistical power to examine the associations between baseline characteristics and 
outcomes of the OACCP because we had a larger sample size. 
 
The variables examined in relation to their association with OACCP outcomes in Chapters 
Four, Five and Eight were identified ‘a priori’ through literature and peer review. A broad mix 
of disease, psychological, physical and demographic variables were included, while giving due 
consideration to the number of variables examined, to avoid overfitting the regression models 
with excessive degrees of freedom (53, 55). This is considered an important strength: 
however, we acknowledge a potential limitation of the clinical cohort study design was that 
the effect of these variables on treatment outcomes were not compared with a control group. 
It was only possible to identify prognostic factors that were associated with a treatment 
outcome. To truly identify subgroups of people who experience a different effect of treatment 
compared with another group, it would be necessary to use a RCT trial design (238). An RCT 
was not a feasible study design for this Thesis and was unnecessary for the exploratory nature 
of the research question. We understand that the variables that explained larger amounts of 
the variation in outcomes (i.e. employment status and TUG), need to be validated in similar 
but different samples of OACCP participants and that ideally, this would be compared with 
people not participating in such programs (239).  
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A further potential methodological limitation of this Thesis was the categorisation of some of 
the independent variables. Categorising data inevitably leads to loss of information; however, 
it was necessary to reflect the clinical utility of some outcome measures by using established 
cut-offs taken from clinical practice. For example, DASS depression scores were 
dichotomised to indicate the presence/absence of depressive symptoms in Chapters Four 
(39), Five (40) and Eight. In treating DASS depression as a categorical variable, we may have 
diminished the ability of the models to detect relationships with the outcome. There were also 
limitations regarding the methods used to describe and quantify comorbidities in this Thesis. 
These were limited to simple counts of diagnosed conditions that did not take into 
consideration the seriousness or impact each comorbidity may have on overall health. This 
may have overlooked implications that certain comorbidities may have for people with OA 
e.g. cardiovascular disease, diabetes or obesity (11).   
 
9.3. Future directions 
Osteoarthritis is now widely recognised as an heterogenous, inflammatory disease with 
distinct observable characteristics, also known as phenotypes (240). A well-documented 
limitation of extant clinical trials investigating the effectiveness of OA treatments is that 
sample populations ‘lump’ patients with different pathoaetiologies together and expect to find 
a significant overall treatment effect (238, 241-243). Grouping together subgroups which both 
respond and don’t respond to interventions in RCTs potentially masks the overall treatment 
effect and this may lead to diminished or even negative findings from the RCT (242). This 
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phenomenon probably contributed to the relatively underwhelming small to moderate 
treatment effects of interventions recommended as effective therapies for OA (68).  
 
As our understanding of OA grows, it is crucial that this knowledge is used to conduct 
research that enable clinicians and researchers to better target treatments to individuals 
according to their clinical presentation (238).Doing so should enable us to direct limited 
clinical resources to individuals most likely to derive benefit from them. Whilst our studies 
investigated associations between patient reported outcomes, and subgroups identified using 
functional performance variables, personal factors, demographic and psychosocial variables, 
there have been a range of alternative clinical features studied in the literature that could 
potentially indicate different subgroups of OA. Suggested features include: the site (joint 
compartments), extent and structural subtypes of OA, injury history, range of motion, 
radiographic features (e.g. effusion/synovitis and bone marrow lesions), and specific 
comorbidities (e.g. cardiovascular disease) (238). There has also been great interest in 
phenotypes defined by cellular features and biomarkers such as: inflammatory and 
autoimmune markers; cell senescence; metabolic, genetic and hormonal features; and signs 
associated with mechanical overload (242, 243).  
 
Work emerging in this field includes a recent systematic review that examined phenotypes of 
knee OA and their relationship with clinical and structural outcomes (244). The review 
identified substantial heterogeneity in the types of variables used to define OA phenotypes in 
observational studies (244). Once the characteristics of these subgroups have been identified 
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and validated, the associations of subgroup memberships with clinical outcomes following 
OACCP participation will need to be determined. 
 
9.4. Final Remarks 
• This Thesis identified some significant predictors of outcomes following the OACCP 
which included gender, index joint and TJA waitlist status. However, the models were 
not adequate to explain much of the variability in these outcomes. 
• In the absence of strong predictors of improvement or worsening, we sought to 
examine the association between OA self-management attitudes and capabilities and 
outcomes. 
• There was no instrument recommended to measure OA self-management attitudes 
and capabilities. We conducted a systematic review that revealed a paucity of 
measurement property evidence for instruments measuring this construct. 
• We evaluated the measurement properties for PAM-13 using Rasch analysis in an OA 
population. 
• Patient activation was not significantly associated with changes in measures of pain 
and function, however there were other characteristics that were associated with these 
outcomes. 
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Appendices 
Appendix 1. Search strategy 
i) Construct 
generalized self efficacy scale[tiab] OR adaptive behavior[tiab] OR multidimensional 
health locus of control[tiab] OR pain self efficacy questionnaire[tiab] OR health literacy 
management scale[tiab] OR stages of change questionnaire in osteoarthritis[tiab] OR 
health education impact questionnaire[tiab] OR patient activation measure[tiab] OR 
effective consumer scale[tiab] OR arthritis self-efficacy scale[tiab] OR internal-external 
control[MH] OR locus of control[tw] OR attitude to health[MH] OR health locus of 
control[tiab] OR adaptation, psychological[MH] OR health behavior[MH] OR health 
knowledge, attitudes, practice[MH] OR self management behavio*[tiab] OR patient 
activation[tiab] OR self concept[MH] OR self efficacy[MH] OR confidence[tiab] OR 
activation[tiab] OR consumer participation[MH] OR patient education as topic[MH] OR 
Patient Participation[MH] OR individualized medicine[MH] OR patient-centered 
care[MH] OR goals[MH] OR patient preference[MH] OR choice behavior[MH] OR 
decision making[MH] OR patient care planning[MH] OR personalised care 
planning[tiab] OR patient led[tiab] OR selftreatment[tiab] OR self treat*[tiab] OR self 
manage*[tiab] OR self care[tiab] OR self care[MH] 
 
ii) Target population  
osteoarthritis[MH] OR osteoarth*[tiab] OR degenerative arthritis[tiab] OR arthrosis[tiab] 
iii) Measurement instrument filter 
instrumentation[sh] OR methods[sh] OR validation studies[pt] OR Comparative 
Study[pt] OR psychometrics[MH] OR psychometr*[tiab] OR clinimetr*[tw] OR 
clinometr*[tw] OR “outcome assessment (health care)”[MH] OR “outcome 
assessment”[tiab] OR “outcome measure*”[tw] OR “observer variation”[MH] OR 
“observer variation”[tiab] OR “Health Status Indicators”[MH] OR “reproducibility of 
results”[MH] OR reproducib*[tiab] OR “discriminant analysis”[MH] OR reliab*[tiab] OR 
unreliab*[tiab] OR valid*[tiab] OR coefficient[tiab] OR homogeneity[tiab] OR 
homogeneous[tiab] OR “internal consistency”[tiab] OR (cronbach*[tiab] AND 
(alpha[tiab] OR alphas[tiab])) OR (item[tiab] AND (correlation*[tiab] OR 
selection*[tiab] OR reduction*[tiab])) OR agreement[tiab] OR precision[tiab] OR 
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imprecision[tiab] OR “precise values”[tiab] OR test–retest[tiab] OR (test[tiab] AND 
retest[tiab]) OR (reliab*[tiab] AND (test[tiab] OR retest[tiab])) OR stability[tiab] OR 
interrater[tiab] OR inter-rater[tiab] OR intrarater[tiab] OR intra-rater[tiab] OR 
intertester[tiab] OR inter-tester[tiab] OR intratester[tiab] OR intra-tester[tiab] OR 
interobserver[tiab] OR inter-observer[tiab] OR intraobserver[tiab] OR 
intraobserver[tiab] OR intertechnician[tiab] OR inter-technician[tiab] OR 
intratechnician[tiab] OR intra-technician[tiab] OR interexaminer[tiab] OR inter-
examiner[tiab] OR intraexaminer[tiab] OR intra-examiner[tiab] OR interassay[tiab] OR 
inter-assay[tiab] OR intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR 
inter-individual[tiab] OR intraindividual[tiab] OR intra-individual[tiab] OR 
interparticipant[tiab] OR inter-participant[tiab] OR intraparticipant[tiab] OR intra-
participant[tiab] OR kappa[tiab] OR kappa’s[tiab] OR kappas[tiab] OR repeatab*[tiab] 
OR ((replicab*[tiab] OR repeated[tiab]) AND (measure[tiab] OR measures[tiab] OR 
findings[tiab] OR result[tiab] OR results[tiab] OR test[tiab] OR tests[tiab])) OR 
generaliza*[tiab] OR generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND 
correlation*[tiab]) OR discriminative[tiab] OR “known group”[tiab] OR factor 
analysis[tiab] OR factor analyses[tiab] OR dimension*[tiab] OR subscale*[tiab] OR 
(multitrait[tiab] AND scaling[tiab] AND (analysis[tiab] OR analyses[tiab])) OR item 
discriminant[tiab] OR interscale correlation*[tiab] OR error[tiab] OR errors[tiab] OR 
“individual variability”[tiab] OR (variability[tiab] AND (analysis[tiab] OR values[tiab])) 
OR (uncertainty[tiab] AND (measurement[tiab] OR measuring[tiab])) OR “standard 
error of measurement”[tiab] OR sensitiv*[tiab] OR responsive*[tiab] OR ((minimal[tiab] 
OR minimally[tiab] OR clinical[tiab] OR clinically[tiab]) AND (important[tiab] OR 
significant[tiab] OR detectable[tiab]) AND (change[tiab] OR difference[tiab])) OR 
(small*[tiab] AND (real[tiab] OR detectable[tiab]) AND (change[tiab] OR 
difference[tiab])) OR meaningful change[tiab] OR “ceiling effect”[tiab] OR “floor 
effect”[tiab] OR “Item response model”[tiab] OR IRT[tiab] OR Rasch[tiab] OR 
“Differential item functioning”[tiab] OR DIF[tiab] OR “computer adaptive testing”[tiab] 
OR “item bank”[tiab] OR “cross-cultural equivalence”[tiab] 
iv) Exclusion filter 
“addresses”[PT] OR “biography”[PT] OR “case reports”[PT] OR “comment”[PT] OR 
“directory”[PT] OR “editorial”[PT] OR “festschrift”[PT] OR “interview”[PT] OR 
“lectures”[PT] OR ”legal cases”[PT] OR “legislation”[PT] OR “letter”[PT] OR “news”[PT] 
OR “newspaper article”[PT] OR “patient education handout”[PT] OR “popular 
works”[PT] OR “congresses”[PT] OR “consensus development conference”[PT] OR 
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“consensus development conference, nih”[PT] OR “practice guideline”[Publication 
Type]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms] 
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Appendix 2: Quality criteria for rating the results of measurement properties  
 
Measurement 
property 
Rating Quality criteria 
Internal 
Consistency 
+ 
 
 
? 
- 
 
0 
Factor analyses performed on adequate sample size (7 * # 
items and >100) AND Cronbach’s alpha(s) calculated per 
dimension AND Cronbach’s alpha(s) between 0.70 and 
0.95 
No factor analysis OR doubtful design or method 
Cronbach’s alpha(s) ≤ 0.70 or ≥ 0.95, despite adequate 
design and method 
No information found on internal consistency 
Reliability + 
? 
- 
0 
ICC or weighted Kappa > 0.70 
Doubtful design or method (e.g., time interval not 
mentioned) 
ICC or weighted Kappa < 0.70, despite adequate design and 
method 
No information found on reliability 
Measurement error + 
? 
- 
0 
MIC > SDC OR MIC outside the LOA 
MIC not defined or doubtful design 
MIC < SDC OR MIC equals or inside LOA 
No information found on measurement error 
Structural validity + 
? 
- 
0 
Factors should explain at least 50% of the variance 
Explained variance not mentioned 
Factors explain <50% of the variance 
No information found on structural validity 
Hypothesis testing + 
 
? 
- 
 
0 
Specific hypotheses were formulated AND at least 75% of 
the results are in accordance with these hypotheses 
Doubtful design or method (e.g., no hypotheses) 
Less than 75% of hypotheses were confirmed, despite 
adequate design and methods 
No information found on hypothesis testing 
Cross-cultural 
validity 
+ 
 
? 
- 
 
0 
Original factor structure confirmed or no important DIF 
found between language versions 
Confirmatory factor analysis not applied & DIF not 
assessed 
Original factor structure not confirmed or important DIF 
found between language versions 
No information found on cross-cultural validity 
Floor and ceiling 
effects 
+ 
 
? 
≤15% of the respondents achieved the highest or lowest 
possible scores 
Doubtful design or method 
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- 
 
0 
>15% of the respondents achieved the highest or lowest 
possible scores despite adequate design and methods 
No information found on interpretation 
Adapted from Terwee et al J Clin Epidemiol 2007; 60(1): 34-42. and F. Dobson et al. 
Osteoarthritis and Cartilage 20 (2012) 1548-1562. Content and criterion validity, 
responsiveness, & interpretability were not reported on in any included studies; hence have 
been omitted.  
ICC= intraclass correlation coefficient, LOA= limits of agreement, MIC= minimal important 
change, SDC= smallest detectable change. 
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Appendix 3: Targeting care: tailoring non-surgical management according to clinical 
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Targeting Care
Tailoring Nonsurgical Management According to
Clinical PresentationJillian Eyles, BAppSc(Physiotherapy)a,*,
Barbara R. Lucas, BAppSc(Physiotherapy), MEd, MPHa,
David J. Hunter, MBBS, MSc, PhD, FRACPb,cKEYWORDS
 Osteoarthritis  Clinical predictors  Treatment response
KEY POINTS
 Numerous studies have explored patient characteristics, including body mass index,
psychological factors, muscle strength, tibiofemoral alignment, radiographic changes,
and signs of inflammation, as potential predictors of response to nonsurgical interventions
for the management of osteoarthritis (OA) of the hip and knee.
 Often the sample sizes used by these studies have been inadequate in yielding sufficient
numbers of responders to the interventions to allow for analysis of the potential predictors
identified.
 Several well-designed studies have been adequately powered to provide some evidence
for clinical characteristics that do or do not predict response to nonsurgical interventions
for participants with hip and knee OA.INTRODUCTION
The activity limitation attributed to osteoarthritis (OA) places it within the world’s top 10
most disabling conditions.1 Globally, OA affects approximately 18.0% of women and
9.6% of men older than 60 years.2 In 2003 the annual costs to the United States
economy of OA and other rheumatic conditions was an estimated $128 billion.3 These
enormous costs are projected to rise steeply with the steadily increasing prevalence of
rheumatic conditions.3
This prevalent, expensive, disabling disease is incurable, so it follows that current
treatments focus on symptomatic relief. Commonly reported treatment goals for thisDisclosures: None.
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Dowgroup include reductions in joint pain, stiffness, activity limitation, participation restric-
tion, and improvements in quality of life and well-being. To assist clinicians in
achieving these goals with their patients, numerous international evidence-based
guidelines for management of hip and knee OA have become available.4–10 There is
uniformity in most of the recommendations made by the guidelines,11 and agreement
that conservative management of hip and knee OA should combine both nonpharma-
cologic and pharmacologic treatment modalities.4–10
The recommendations made in the guidelines for the management of hip and knee
OA are broad. The evidence-based, expert consensus guidelines from the Osteoar-
thritis Research Society International (OARSI) (2008) include no fewer than 20 recom-
mendations for the nonsurgical management of hip and knee OA4; however, the
treatments are not arranged systematically to indicate the order of priority in which
they should be undertaken. With so many recommended management options tabled,
it would be advantageous to know which treatments are most likely to be effective for
the individual with hip or knee OA according to clinical presentation.
This review examines the evidence available for the identification of clinical charac-
teristics that predict patient response to nonsurgical treatments for hip and knee OA.
The summation of this evidence may assist clinicians to target treatments most likely
to benefit patients according to clinical presentation, and identify areas for further
research.BODY MASS INDEX
Obesity is a known risk factor for the development of arthritis12 and is a strong
predictor for long-term progression of the disease.13 There is evidence that obesity
is a risk factor for knee OA, but the relationship between obesity and the risk of devel-
oping hip OA is less clear.14,15 International guidelines nonetheless recommend
weight reduction in individuals with hip and knee OA who are overweight or
obese.8,9,11,16 There is strong evidence that weight loss is an effective treatment for
knee OA, yet little evidence exists regarding weight loss as an effective treatment
for obese patients with hip OA.
It seems reasonable that body mass index (BMI) may be a clinical characteristic that
predicts response to weight-loss interventions but, surprisingly, evidence exists that it
does not. A post hoc analysis of a randomized controlled trial (RCT) involving 111 over-
weight veterans with knee OA investigated 9 clinical characteristics as possible
predictors of weight change between baseline, 16 weeks, and 32 weeks. The
minimum amount of weight loss required to define a treatment responder was not
provided. Multiregression analysis revealed that BMI was not predictive of weight
loss in response to the interventions for overweight veterans with knee OA.17 The
external validity of this study is limited by confining the recruitment of participants
to veterans.
Two studies found that BMI was not predictive of response to a Dutch multimodal,
stepped-care model of pain management for hip and knee OA. Snijders and
colleagues18 investigated the efficacy of the Dutch model in a cohort of 183 partici-
pants with hip and knee OA. The model combined pharmacologic and nonpharmaco-
logic treatments. Two possible definitions of positive treatment response were
described: (1) Outcome Measures in Rheumatoid Arthritis Clinical Trials/Osteoarthritis
Research Society International (OMERACT-OARSI) Responder Criteria, and (2)
patient-reported numeric rating scale (NRS) for pain of 4 or less. At 12-week reassess-
ment, 86 patients were responders according to definition (1), and 71 fulfilled definition
(2). BMI was 1 of 11 potential predictors of response included in analyses, and was notnloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
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predictors of response the study was underpowered. A more recent study used the
same Dutch model, focusing specifically on a stepped-care protocol used to progress
the use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) at stan-
dardized intervals according to patient-reported pain levels.19 The definition of treat-
ment responder was a patient-reported NRS pain 4 or less, and 100 participants met
this target. The study was underpowered in analyzing 13 patient characteristics,
including BMI, as possible predictors of response. Further research is required to
determine whether BMI can predict a positive treatment response in this multimodal
stepped-care model of pain management.
Two well-powered studies examined the potential of BMI as a predictor of response
to cyclooxygenase-2 (COX-2) inhibitors. Bingham and colleagues20 pooled the results
of 2 similar RCTs comparing the efficacy of etoricoxib and celecoxib with that of
placebo. The OMERACT-OARSI Responder Criteria determined that 562 participants
were responders to the COX-2 inhibitors following 12 weeks of the intervention. BMI,
one of 16 variables analyzed as potential predictors of response, failed to predict
a positive treatment response to the COX-2 inhibitors.20 Similar results were found
by Detora and colleagues,21 who combined the results of 3 6-week RCTs comparing
the COX-2 inhibitor rofecoxib with placebo in 1501 patients with hip and knee OA.
Responder criteria were not defined. Patient data were analyzed according to
subgroups representing 14 baseline characteristics including BMI. Analysis of covari-
ance failed to identify any baseline measures associated with treatment response.21
To date, good evidence exists that baseline BMI does not predict a response in
patients with hip and knee OA treated with COX-2 inhibitors.
A single study explored BMI as a predictor of response to intra-articular corticoste-
roid injection (CSI) for the management of hip OA. Robinson and colleagues22 followed
120 patients with hip OA for 12 weeks following CSI. Participants were classified as
responders to the CSI at 12 weeks if a reduction in baseline Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) pain subscale of greater than
15% was achieved; 48 participants met this criterion. Logistic regression determined
that BMI, one of 14 variables analyzed, was not a significant predictor of response to
hip CSI22; however, the study was underpowered in detecting true predictors of treat-
ment response.
Four cohort studies explored possible predictors of response to intra-articular (IA)
hyaluronic acid derivatives for hip and knee OA. Short-term efficacy and tolerability
of IA Hylan G-F 20 were assessed in 4253 patients with symptomatic knee OA.23
Responder criteria were not defined, and the primary outcome was pain measured
at baseline and 3 weeks on a 4-point Likert scale. At 3 weeks after IA Hylan G-F 20,
88.4% of patients assessed their pain as better or much better. Logistic regression
of 7 potential predictors of short-term pain reduction determined that underweight
patients were more likely than their obese counterparts to report reduced knee
pain. The method of recruitment threatens the validity of this evidence; the investiga-
tors invited 840 orthopedic surgeons to report on at least 5 consecutive patients
receiving Hylan G-F 20 for relief of knee OA pain, introducing significant selection bias.
Longer-term outcomes of patients with knee OA receiving IA Hylan G-F 20 were
explored in 3 cohort studies.24–26 A retrospective cohort of 155 patients with knee
OA was reassessed 7 to 14 months following IA Hylan G-F 20.24 The definition of
responder was not specified. Analysis of 16 possible predictors found that BMI was
not a significant predictor of patient satisfaction, although this study was underpow-
ered in identifying the possible predictors, and the retrospective design was prone
to significant recall bias. Longer-term outcomes of Hylan G-F 20 were also studiedDownloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
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Dowin a small cohort of 32 patients with mild to moderate knee OA 6 months following IA
Hylan G-F 20.25 Clinical response was defined using the OMERACT-OARSI “high
improvement” criterion. Only 15 participants were responders, and 8 variables,
including BMI, were investigated as predictors of response, leaving the study under-
powered for the detection of significant predictors. BMI was not significantly corre-
lated with patient response. A prospective cohort study examining 84 patients with
knee OA for 6 months following knee IA Hylan G-F 20 found that Short-Form-36
(SF-36) health survey scores were significantly improved at 6 months after injection.26
The responder criteria were not described. Three factors, including the subjects’
percentage above ideal body weight, were analyzed for correlations with positive
treatment outcomes seen in the SF-36 health survey categories Physical Function,
Role-Physical, and Role-Emotional. The subjects’ percentage above ideal body
weight was not predictive of improvement. The high number of patients lost to
follow-up (23%) affected the validity of this study. Evidence for BMI and percentage
above ideal body weight as clinical characteristics predictive of longer-term response
to knee IA Hylan G-F 20 was inconclusive, owing to low validity and power.
BMI was not a significant predictor of response to IA Hylan G-F 20 in people with hip
OA. Migliore and colleagues27 evaluated 250 patients with hip OA who received IA
Hylan G-F 20. Treatment response was defined as a 30% or greater improvement
in baseline Lequesne scores or NSAID usage at 6 months, but the number of partic-
ipants classified as responders was unclear. Ten possible predictors of treatment
response were analyzed; BMI was not a significant predictor of response to hip IA
Hylan G-F 20.27 The large number of dropouts (42%) affected the validity of this study.
Patients with a lower BMI may be more likely to experience a reduction in chronic
knee pain following treatment with glucosamine sulfate. A prospective correlational
study of 39 participants with chronic knee pain followed patients receiving 1.5 g
glucosamine sulfate daily for 12 weeks.28 Participants were not required to have
been diagnosed specifically with OA, which affected the external validity of this study.
The definition of treatment responder was not described, and 7 patient characteristics
were examined as potential predictors of reduction of pain rated on a visual analog
scale (VAS). The study was underpowered in determining the effects of 7 potential
predictors.
To date, most of the evidence suggests that BMI is not a consistent predictor of
response to nonsurgical treatments for people with hip and knee OA. Some evidence
exists that BMI is not predictive of response to a weight-loss program in overweight
veterans with knee OA.17 There is good evidence that BMI does not predict response
to COX-2 inhibitors for the management of hip and knee OA.20,21 The evidence is weak
that BMI is not predictive of treatment response to either a multimodal stepped-care
pain management model,18,19 hip CSI,22 hip IA Hylan G-F 20,27 or glucosamine for
chronic knee pain.28 The evidence for BMI as a predictor of response to knee IA Hylan
G-F 20 is weak and conflicting.23–26 Further research is required to determine whether
BMI is a clinical characteristic that can foretell a response to nonsurgical treatments
for people with hip and knee OA.PSYCHOLOGICAL FACTORS
Complex interactions exist between psychological factors and perceived symptoms
of OA. Compared with their peers, people with OA report an increased prevalence
of depression and depressed mood.29 The intensity of perceived OA pain has been
demonstrated to be predictive of depression severity in this cohort.29 Poor mental
health has been associated with worse overall hip and knee OA pain, and deteriorationnloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
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Treatment of depression in people with arthritis appears to improve depressive symp-
toms, reduce OA pain, and improve function and quality of life,31 and therefore is an
important consideration in the management of OA.
Many treatments prescribed for hip and knee OA management, particularly exer-
cise, weight-loss programs, and medications; require active participation from the
patient. The compliance with and efficacy of these treatments may be influenced by
the individual’s mental state as to how rehabilitation outcomes are affected. The
prospective cohort study “Predictors for response to rehabilitation in patients with
hip or knee OA”32 featured 250 patients with hip and knee OA who participated in
a 3- to 4-week multimodal rehabilitation program combining exercise therapy, hydro-
therapy, relaxation strategies, distraction techniques, patient education, manual
therapy, thermotherapy, and electrotherapy. Participants were assessed at baseline
and 6months following the program. Three different definitions of treatment responder
were used: (1) the minimal clinically important difference (MCID) (18%) improvement
shown on the WOMAC, (2) improvement on the Transition scale, and (3) MCID
improvement on WOMAC and improvement on the Transition scale. The transition
scale was described as a measure of the current state of health of the OA joint
compared with its state 6 months earlier.32 There were 21 personal, lifestyle, and
psychological measures investigated as potential predictors of the 3 definitions of
responder. Depression and anxiety were evaluated using the Hospital Anxiety and
Depression Scale, and mental health was assessed using the mental component of
the SF-36. The absence of depressive symptoms was determined to be a strong
predictor of all 3 of the responder definitions, suggesting that depression may hinder
the achievement of positive treatment outcomes of patients with hip and knee OA
following a 3- to 4-week rehabilitation program. This study did not attempt to answer
the question as to why patients did not achieve the same results as their nonde-
pressed counterparts, but one may hypothesize that perhaps those patients with
depression have more difficulty complying with a comprehensive rehabilitation
program. This area is an interesting one for further research.32
The presence of depression may affect the ability of overweight people with OA to
lose weight. A post hoc analysis of an RCT aimed to identify predictors of positive
treatment response resulting from weight-loss interventions for 111 overweight
veterans with knee OA.17 Veterans were randomized into groups receiving 24 weeks
of nutritional counseling, a home exercise program, a combination of both, or usual
care. There were no differences in weight loss between intervention groups, and 9
variables were investigated as possible predictors of weight change between base-
line, 16 weeks, and 32 weeks of the RCT. The amount of weight loss required to indi-
cate successful treatment response was not indicated. Symptoms of depression were
evaluated using The Center for Epidemiologic Studies Depression Scale, which
measured 20 items to achieve a score out of 60. The presence of depression was indi-
cated by a score of 16 or greater. The absence of depression was the only indepen-
dent predictor of weight loss at 16 weeks and 32 weeks.17 This study is limited by its
failure to define treatment responders; however, it does suggest that depressive
symptoms may limit the ability of veterans to lose weight.
Depression and anxiety did not seem to predict the treatment response of patients
with knee OA to CSI. A small study of 59 patients with knee OA receiving CSI exam-
ined 10 possible predictors of a favorable response, defined as a 15% or greater
reduction of pain rated on VAS, to injection of methylprednisolone acetate.33 The
Hospital Anxiety and Depression score at baseline was not found to consistently
predict treatment response. Given that 59 patients were used to investigateDownloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
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effects of the potential predictors.
Mental health scores do not seem to predict response to a combined nonpharma-
cologic and pharmacologic pain-management program. Predictors for response to
analgesics were explored in relation to a cohort study of 347 patients investigating
treatment outcomes of a stepped model of care for hip and knee OA. The model
initially offered education, lifestyle and weight-loss advice, physiotherapy, and acet-
aminophen, then progressed to other medications at intervals as guided by a pain
NRS.19 Treatment response was defined as achievement of pain NRS of 4 or greater,
and there were 100 responders. Thirteen possible predictors of response were
explored, including mental health. The SF-36 questionnaire was used to assess
health-related quality of life, and the mental component summary (MCS) scores of
the SF-36 were used to reflect mental health. Mental health rated by the MCS was
not a significant predictor of response to the stepped model of pharmacologic pain
management for patients with hip and knee OA; however, this study was underpow-
ered regarding the analysis of 13 possible predictors.
Self-reported participant mood failed to predict treatment outcome in a small cross-
over RCT of 11 patients with osteoarthritis receiving 2 different NSAIDs.34 During
2 treatment periods of 4 weeks’ duration, participants received ketoprofen and pirox-
icam. A 4-week washout period followed the initial drug treatment before commence-
ment of the second drug. Participants were classified as treatment responders if they
showed 30% or better improvement of 5 of the 7 variables measured at baseline,
including pain, tenderness, swelling, patient and physician global assessments,
acute-phase protein levels, and disability. There were 20 baseline variables explored
as possible predictors of response including mood, assessed using an 18-item ques-
tionnaire. Mood was not a significant predictor of treatment outcome; however, the
small sample size of this study leaves it underpowered for the detection of meaningful
effects of the predictors investigated.
In summary, 2 well-designed, adequately powered studies used specific measures
of depression that were predictive of response to intervention.17,32 Both studies
demonstrated the relationship between the absence of depressive symptoms and
positive nonpharmacologic treatment outcomes. The treatments investigated in these
studies included a comprehensive rehabilitation program and weight-loss interven-
tions. These treatment modalities require high levels of active participation of the
patients involved, which may be affected by the presence of depressive symptoms.
Of interest, the 3 studies investigating drug-therapy regimes, perhaps not requiring
such a high level of active participation by the subjects, consistently found different
measures of psychological factors incapable of predicting treatment response.19,33,34
Two of these studies were underpowered33,34 and the third, which was inadequately
powered, did not measure depression specifically.MUSCLE STRENGTH
In view of the biomechanical influence and protective functions of skeletal muscles
surrounding joints, muscle weakness is considered to be an important possible factor
in the development and progression of OA. Evidence for the significance of muscle
strength in the pathogenesis of OA remains unclear.35,36 Higher quadriceps strength
may have a protective effect against the development of symptomatic OA.36 Whether
muscle weakness precedes the onset of OA, or if it is a feature of already established
disease seen on radiography, or is only related to the onset of pain and other symp-
toms, is an area for further research.nloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
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Limited evidence exists to support muscle strength as a predictor of progression of
knee OA.13 Nevertheless, over time people with knee OAwho have greater quadriceps
strength report less pain and superior functional ability compared with their weaker
counterparts.37 Quadriceps strength has been studied widely in relation to knee OA;
however, muscles around the hip that stabilize the pelvis also have an effect on adduc-
tion forces around the knee, which may result in increased compression of the medial
compartment38 and influence the pathogenesis and progression of OA. Hip OA has
also been associated with significantly reduced lower limb muscle strength39;
however, limited evidence is available to explain the role of hip and thigh musculature
in the development and progression of the disease. Further research is required to
explain this possible relationship.
Treatments for hip and knee OA have long included specific exercises designed to
strengthen muscles surrounding the joints involved. High-level evidence exists
regarding the reduction of pain and dysfunction in knee OA through therapeutic exer-
cises.40 The evidence to date for the efficacy of exercise in hip OA is less convincing,41
yet exercise is often prescribed. Wright and colleagues42 published a study aiming to
identify baseline characteristics of patients with hip OA likely to respond favorably to
physical-therapy interventions. As part of a larger RCT, 91 patients were randomized
to groups receiving manual therapy, exercise therapy, a combination of both, or usual
care. The OMERACT-OARSI Responder Criteria determined treatment responders.
Ten variables were analyzed as predictors of treatment response. Measures of muscle
strength using a hand-held dynamometer were not predictive of treatment success.
Only 22 of the 68 participants were responders, which left the study underpowered
in identifying predictors of response.42
There has been recent interest in the nature of lower limb muscle weakness in
people with knee OA. Decreased quadriceps strength in knee OA has been attributed
to both loss of muscle cross-sectional area43 and reduced ability to activate the
muscles.44 In a cohort of 111 subjects taken from a larger RCT, baseline ability to acti-
vate quadriceps was examined as 1 of 9 possible predictors of changes in strength of
the muscle following a 6-week exercise program for subjects with knee OA. Primary
outcome measures were quadriceps strength and quadriceps activation, measured
using a burst-superimposition maximum isometric quadriceps torque test; however,
a definition of treatment response was not identified. Although activation of lower
quadriceps was associated with lower strength, baseline activation of quadriceps
did not predict the magnitude of gain in quadriceps strength following exercise
therapy.45 These results suggest that patients with OA should benefit from strength-
ening exercises regardless of baseline activation of quadriceps.
Baseline muscle strength does not seem to predict the degree of symptomatic
relief achieved following a weight-loss program in obese people with knee OA.
The 192 participants, who were part of a larger RCT, were randomized to 2
different dietary interventions. Significant response to the interventions included
the OMERACT-OARSI Responder Criteria and improvement on Knee Injury and
Osteoarthritis Outcome (KOOS) scores. Although weight loss was achieved in
most of the subjects, only 64% achieved the OMERACT-OARSI responder crite-
rion. There were 23 variables investigated as possible predictors of response to
the weight-loss programs, including measurements of baseline hamstrings and
quadriceps strength using isometric dynamometry. Baseline muscle strength was
not predictive of symptomatic relief in response to the weight-loss program.46
The study was underpowered in detecting significant predictors from a possible
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logic agent. Jones and Doherty33 performed a crossover RCT comparing CSI with
saline (placebo) in 59 subjects with knee OA. Ten possible predictors of treatment
response were analyzed. Treatment response, defined as a decrease of 15% or
more in pain rated on a VAS, was not predicted by baseline quadriceps strength
measured using a commercial strain gauge. This study was significantly underpow-
ered for the analysis of 10 predictors of response.
Further research into the role of muscle strength in the pathogenesis of OA and
subsequent progression of the disease may be helpful in refining recommendations
for therapies aimed at OA prevention and further joint deterioration as a consequence
of OA. To date, muscle strength has not been demonstrated to predict response to
nonsurgical interventions for hip and knee OA.TIBIOFEMORAL JOINT ALIGNMENT
Varus (bow-legged) or valgus (knock-kneed) tibiofemoral joint alignments are clinical
characteristics observed in some people with knee OA. Joint alignment affects the
distribution of load borne by the medial and lateral compartments of the articular
surface of the knee. Static knee alignment is conventionally determined using
full-length weight-bearing radiographs of the lower limb with knees extended. Lines
are drawn from the center of the femoral head to the talus through the middle of the
femoral and tibial shafts to indicate the load-bearing mechanical axis, then measure-
ments are made of various angles subtended from where those lines intersect.47–49
Neutral alignment is commonly defined as 0 to 2 of varus,50 meaning that in a normal
knee the mechanical axis passes medial to the knee joint, resulting in 60% to 70% of
weight-bearing forces passing through the medial articular surface.51 Varus malalign-
ment results in higher loads borne through the medial compartment of the knee,
whereas increased compressive forces through the lateral articular surface accom-
pany valgus malalignment.
Dynamic knee alignment can be assessed using 3-dimensional gait analysis. In
varus knees the measurement of knee-adduction moment during the stance phase
of walking is an indirect measure of joint compressive forces sustained within the
medial tibiofemoral joint compartment.49,52,53 Static and dynamic alignment is an
important consideration, given that altered distribution of forces placed through the
joint surface may lead to damage of articular structures, possibly increasing the risk
for development of OA or worsening existing disease.
It remains unclear as to whether knee-joint malalignment precedes incident knee
OA47,48; however, varus alignment is considered to be a significant predictor of
knee OA disease progression.13 Knee malalignment has been demonstrated to
interact with other risk factors for OA progression, increasing the likelihood of disease
acceleration. Possible interactive factors include greater quadriceps strength,54 the
stage of disease observed in the individual,55 and obesity.48
The evidence for the relationship between knee malalignment and reported OA
symptoms remains unclear.55,56 Nevertheless, some nonsurgical treatments in OA
management guidelines aim to reduce pain and dysfunction associated with tibiofe-
moral malalignment. Orthotic bracing, shoe wedges, and muscle strengthening are
recommended with a view to improving the biomechanics of the joint.4,6,7,9,10 Several
studies have investigated knee-joint alignment as a predictor response to nonsur-
gical management of OA. An RCT by Lim and colleagues57 examined the effect of
a 12-week quadriceps-strengthening program on knee-adduction moment, pain,
and function in 107 subjects with knee OA. Knee alignment was assessed onnloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
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neutral (<5) or more varus (5) alignment. Specific responder criteria were not
described. Patients in the strengthening group achieved significant improvements
in strength regardless of alignment. Self-reported function, performance measures,
and knee-adduction moment determined using 3-dimensional gait analysis were
unchanged by the intervention in both alignment groups. Pain, assessed using the
WOMAC pain subscale, was significantly improved in the strengthening group
subset that was more neutrally aligned. Neutral knee-joint alignment may mediate
improvements in knee OA pain following a 12-week quadriceps-strengthening
program.
Immediate changes in static alignment and knee-adduction moment were not
predictive of response to lateral-wedge insoles at 3 months. A cohort of 40 volun-
teers with knee OA were provided with laterally wedged insoles to assess the imme-
diate effects of the insoles on knee OA pain, knee-adduction moment, and static
alignment.49 The lateral wedges immediately reduced knee-adduction moment
calculated using 3-dimensional gait analysis and walking pain measured using the
WOMAC pain subscale, but had no effect on static alignment as determined on
full-length leg radiographs. Alignment was defined as the angle subtended by the
intersection of the femoral and tibial mechanical axes. Varus malalignment was
determined when the angle was less than 180, with valgus indicated by an angle
of greater than 180. After 3 months of wearing the insoles, significant improvements
in pain and function persisted. A definition of treatment responder was not specified;
nevertheless, 10 predictors at baseline of outcome after 3 months were explored.
Neither immediate changes in static alignment nor knee-adduction moment were
predictive of decreased pain and improvement in function 3 months following the
intervention.49 The size of this cohort limited the ability of the study to identify true
predictors of response to the intervention.
A larger RCT of 192 obese subjects with knee OA allocated patients to 2 different
weight-loss interventions.46 Knee-joint alignment was assessed using a “Plug-in-
Gait” model with a 6-camera stereophotogrammetric system and markers on
anatomic landmarks. A knee was categorized as varus when alignment was greater
than 0, and valgus if less than 0. Baseline knee alignment was one of 23 variables
examined as possible predictors; however, it failed to predict improvements in
KOOS or achievement of OMERACT-OARSI Responder Criteria following weight-
loss interventions.46 In view of the fact that only 64% of patients were treatment
responders according to OMERACT-OARSI criteria, the study was underpowered in
detecting effects of significant predictors.
It is interesting to consider the definitions of knee malalignment used in the 3 studies
discussed above. Lim and colleagues57 used a more extreme definition of 5 or more
to indicate varus malalignment. By contrast, the 2 other studies categorized subjects
to knee-malalignment groups if the mechanical axis did not appear as a straight
line.46,49 This disparity may have increased the severity of malalignment observed
within the participants assigned to the varus group investigated by Lim and
colleagues, compared with the subjects categorized to knee-malalignment groups
in the other studies. Participants with varus malalignment studied by Lim and
colleagues57 did not experience improvements in pain following strength training,
whereas neutrally aligned subjects reported significant pain reduction. Perhaps the
higher severity of varus malalignment was key to the determination of knee-joint align-
ment as a predictor of outcome after intervention in this study. Future research consid-
ering knee malalignment as a predictor of treatment response to conservative
treatments should consider carefully the definition of joint alignment.Downloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
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The presence of radiographic osteophytes (OP) and joint-space narrowing are
commonly used to diagnose OA. These features are combined to determine radio-
graphic disease severity according to scoring systems such as the Kellgren-
Lawrence grade (KLG).58 Despite known limitations, radiographs are inexpensive,
accessible, and easy to interpret, so are commonly used in research for the classifica-
tion of subjects to determine eligibility, and for stratification of samples according to
radiographic severity. Radiographic joint-space width (JSW) or minimum joint-space
width (mJSW) is recommended for use in clinical trials; however, magnetic resonance
imaging (MRI) is preferred particularly for the assessment of cartilage morphology.59
Relatively few articles analyze radiographic severity of hip and knee OA as possible
predictors of response to nonsurgical, nonpharmacologic treatments. Two of the 3
articles doing so examined the ability of radiologic and MRI OA severity to predict
response to weight-loss interventions. A small RCT of 30 obese female participants
with knee OA compared 2 dietary weight-loss interventions.60 Within the intervention
group 90% of participants achieved a clinically significant weight reduction of greater
than 10%, and 33% had a 50% improvement in symptoms of knee OA. A strict defi-
nition of treatment responder was not provided. Structural joint damage was assessed
at baseline using both the KLG classification and low-field MRI (0.2 T) to assess
various measures of cartilage abnormalities, bone marrow lesions, effusions, and
synovitis of the medial, lateral, and patellofemoral compartments of the knee. Five
baseline radiographic characteristics and clinical outcomes following the weight-
loss interventions were investigated for correlations. None of the imaging variables
were able to forecast symptomatic response to treatment60; however, this study
was likely underpowered in identifying significant predictors.
A second RCT randomized 192 obese patients with knee OA into 8 weeks of 2
experimental dietary interventions.46 Results were calculated for the entire cohort,
as the method of weight loss was not relevant for this analysis. OA symptoms were
evaluated at baseline and at 16 weeks using the OMERACT-OARSI Responder
Criteria and changes in KOOS. High-field MRI was assessed using the Boston-
Leeds Osteoarthritis of the Knee Score (BLOKS) to measure joint damage at baseline.
Conventional radiography determined the baseline KLG and mJSW. MRI and radio-
graphic measures failed to find any relationship between variables assessing struc-
tural damage to the knee and symptomatic improvements following the dietary
interventions.46 Only 64% of patients were treatment responders according to
OMERACT-OARSI criteria, therefore this study may also be insufficiently powered
to detect the effects of 23 potential predictors.
A third study examining the ability of radiographic features to predict response to
nonsurgical, nonpharmacologic interventions was conducted by Hinman and
colleagues.49 A cohort of 40 patients with knee OA wore full-length 5 lateral-wedge
insoles for 3 months. Improvements were observed in WOMAC pain and function
subscales following the intervention. Tibiofemoral OA severity was assessed at base-
line using the KLG scoring system. Following analysis of 10 possible predictors of
outcome, greater disease severity indicated by higher KLG scores was predictive of
worse pain at 3 months. This study does not define responder criteria, and the small
sample size reduced the ability to identify predictors of response to lateral-wedge
insoles.
Two studies examined radiographic severity using KLG as potentially predictive of
response to interventions combining both nonpharmacologic and drug therapies for
hip and knee OA. Both investigated cohorts of patients with hip and knee OAnloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
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During the 12-week program subjects received standardized nonpharmacologic
management and pain-relieving medications, prescribed and altered at set intervals
depending on self-reported pain at reassessment. The definition of positive treatment
response in the initial cohort of 183 patients was fulfillment of either the OMERACT-
OARSI Responder Criteria or NRS of 4 or less.18 The later study of 347 subjects
required NRS of 4 or less at 12 weeks to indicate successful response to the interven-
tion.19 Both studies analyzed OA severity as determined by KLG scores as possible
predictors of positive treatment outcomes. The first study tested 11 possible predic-
tors of response to intervention, and found that disease severity did not forecast
improvements in overall pain and function as a result of the 12-week pain manage-
ment program.18 In the second study, 13 predictors were tested for correlation with
treatment response at the 4 different steps of the treatment model. Greater OA
severity was independently associated with a higher chance of pain relief achieved
in response to the use of acetaminophen.19 This correlation was discovered because
unlike in the first study, the predictors of response were tested at each of the separate
steps of the program. There were 59 responders to acetaminophen, so the study was
underpowered for the testing of 13 predictors. Although the evidence is tenuous, this
finding lends support to the recommendations made by international OA management
guidelines to trial acetaminophen as a first-line pharmacologic treatment of hip and
knee OA,4–10 even in those patients with severe disease.
Evidence to the contrary was presented by Case and colleagues61 in the results
from a double-blind, placebo-controlled RCT comparing the efficacy of acetamino-
phen and diclofenac sodium for the management of pain in knee OA. Eighty-two
patients were randomized to 3 groups receiving either one of the drugs or placebo.
The primary outcome at baseline, 2 weeks, and 12 weeks was the WOMAC scale.
The diclofenac sodium group alone achieved significant improvement (20%) in all
3WOMAC subscales following the intervention. The subjects were stratified according
to prestudy medication, baseline pain, and disease severity indicated by KLG to iden-
tify subsets of patients who were consistent in their response to the treatments. None
of the subgroups consistently demonstrated preferential response to acetaminophen
or diclofenac sodium. This study suffered from a high number of dropouts (>25%).
Three of the 5 subjects who withdrew from the diclofenac sodium treatment arm
(n 5 25) did so as a result of adverse effects. Despite the evidence presented in this
study for the superior efficacy of diclofenac sodium, the relatively high risk of
unwanted side effects lends further weight to the OA treatment guidelines that recom-
mend a trial of acetaminophen before commencing NSAID therapy,4–10 and it can be
presumed that this follows regardless of radiographic severity.
Four articles investigated radiologic predictors of response to CSI for hip OA. Of
these, only one reported that radiographically determined disease severity was
a significant predictor of positive response to steroid injection.62 This retrospective
cohort study reviewed radiographs, radiology reports, and medical records of 361
patients who had received fluoroscopically guided IA methylprednisolone acetate
80 mg, or methylprednisolone with bupivacaine. The definition of treatment responder
was a 50% decrease in pain reported on a VAS. An immediate positive response to
injection was evident in 68.2% of hips and a delayed response was apparent in
71.4%. OA severity was measured at baseline using KLG classification, and the
grades were split into groups for analysis. Multivariate regression determined that
radiographic severity of OA was an independent predictor of treatment response.
Patients with advanced disease were much more likely to experience both immediate
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moderate disease.62 Although a sizable number of participants was recruited, these
inferences should be considered cautiously in view of the inherent risk of bias associ-
ated with the retrospective cohort design of this study.
By contrast, Robinson and colleagues,22 using a similar fluoroscopically guided
injection of methylprednisolone and bupivacaine into the hip joint of 120 people with
hip OA, concluded that radiographically determined OA severity was not predictive
of response to intervention. This cohort study assessed symptomatic response to
40-mg and 80-mg doses of the steroid. A decrease in the WOMAC pain by greater
than 15% was considered to indicate positive treatment response, and 75 patients
were classified as responders at 6 weeks. The investigators concluded that the higher
dose (80 mg) of methylprednisolone was more effective and lasted longer. Twelve
possible predictors of treatment response included KLG scoring. Forward logistic
regression found that KLG was incapable of predicting reduced pain in response to
hip CSI.22 This study was underpowered in detecting predictors of response among
12 variables.
Similar conclusions were made regarding a small prospective cohort of 27 patients
with hip OA assessed at baseline and 2, 12, and 26 weeks following hip IA lignocaine
and methylprednisolone.63 The main outcome measure was pain measured on VAS.
The degree of radiologic severity according to KLG classification and mJSW had no
significant bearing on the reported pain relief following steroid injection to the hip;
however, the small sample size decreased the power to detect significant predictors.
The fourth RCT compared ultrasound-guided CSI with IA hyaluronic acid, saline
(control), and standard care (no injection) in 77 subjects with hip OA.64 Response to
treatment was delineated by the OMERACT-OARSI Responder Criteria, and there
were 14 responders to steroid injection. CSI was significantly more effective than
the 3 other treatments. Univariate regression analysis determined that of 5 predictors
analyzed, radiographic severity using Croft grading and mJSW were not predictive of
treatment response to CSI; however, the study was underpowered in analyzing 5
predictors.64 Further research is required to explore the value of radiographic and
MRI clinical characteristics indicating disease severity as potential predictors of
response to hip CSI.
Three cohort studies attempted to identify radiographic characteristics of patients
with hip and knee OA that were predictive of treatment response to IA Hylan G-F
20.24,25,27 Migliore and colleagues27 followed 250 patients who received ultrasound-
guided IA Hylan G-F 20 into OA hips. Treatment response was defined as improve-
ment of greater than 30% or more in Lequesne index or NSAID use. Significant
improvements were reported for all outcome measures at 3, 6, 9, and 12 months
when compared with baseline. Multiregression analysis of 8 baseline variables deter-
mined that KLG was unable to predict treatment response.27 A high number of drop-
outs limited the validity of this study. The second study followed a small cohort of 32
patients with mild to moderate knee OA for 6 months following IA Hylan G-F 20.25 The
OMERACT-OARSI “High Improvement” responder criteria for OA were used to define
responders to treatment. Fifteen participants met the responder criteria. Eight predic-
tors of treatment response were explored, including mJSW, which was not predictive
of positive response to Hylan G-F 20 injection.25 The study was underpowered and
limited by the exclusion of patients with severe OA. Conrozier and colleagues24
studied a cohort of 155 patients across the spectrum of mild through severe knee
OA. Knee joint-space loss in a single compartment seen on radiographs and meniscal
calcinosis noted on MRI scans were predictive of a good outcome after IA Hylan
GF-20. The definition of treatment responder was not adequately described in thisnloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
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these measures.24 Nevertheless, weak evidence exists that knee joint-space loss in
a single compartment and meniscal calcinosis may predict response to IA Hylan
G-F 20, and this warrants further research.
Bennett and colleagues28 investigated the symptomatic response of 39 subjects
with chronic knee pain treated with 1.5 g oral glucosamine sulfate for 12 weeks.
Primary outcome measures at baseline and 3 months included pain VAS rated on
movement, VAS for restriction in function, and patient-rated global change score.
These outcomes were all found to be significantly improved at 12 weeks, but the
responder criteria were not specified. Seven possible predictors of reduced pain
and improved functional ability were analyzed using regression modeling. The inves-
tigators concluded that lower levels of osteophytes in the patellofemoral joint, BMI,
and functional self-efficacy were predictors of successful glucosamine treatment.
The presence of osteophytes within the medial and lateral compartments of the tibio-
femoral joint was not correlated with response to the intervention.28 The study was
underpowered for the identification of true predictors of response, and the participants
did not require formal diagnosis of OA, so these results must be viewed accordingly.
Overall, there was weak evidence that radiographic measures of OA severity may
have predictive value in the identification of potential responders to lateral-wedge
insoles,49 CSI,62 and glucosamine sulfate. MRI assessment was predictive of
response in a single study concerned with Hylan G-F 20 injections in the knee.24 A
greater number of studies exist that were unable to predict response to treatment
based on radiographic disease severity or MRI. There is good evidence that KLG
scores are not predictive of response to hip CSI.22 Further research is required to
clarify the roles performed by radiography and MRI regarding clinical characteristics
that predict response to the nonsurgical treatment of hip and knee OA.INFLAMMATION
Abnormal progressive remodeling of joint tissues occurs in response to local inflam-
matory processes arising within osteoarthritic joints.65 Physical examination may
reveal clinical signs such as presence of joint swelling, effusion, and heat. With recent
improvements in imaging techniques, synovial hypertrophy has become a surrogate
marker of local inflammation within a joint.
Signs of inflammation were examined as potential predictors of response to weight-
loss interventions for participants with knee OA. The clinical cohort described by
Gudbergsen and colleagues46 participated in a 4-month dietary intervention.
Responders were required to fulfill the OMERACT-OARSI Responder Criteria. Joint-
damage severity was assessed on MRI using the BLOKS, which included scoring
for synovitis and effusion. Although synovitis and effusion were not predictive of
OMERACT-OARSI response, there was some evidence that the effusion score corre-
lated with changes in the KOOS activities of daily living score from baseline to
4 months. Responder criteria for the KOOS score were not provided. There were 23
variables assessed as potential predictors of response; 123 patients were responders,
therefore this study was insufficiently powered for this many predictors. The presence
of inflammatory markers such as effusion and synovitis requires further investigation
as predictors of symptomatic response to weight-loss interventions for overweight
patients with OA.
Systemic pharmacologic agents such as NSAIDs and COX-2 inhibitors are
prescribed for their analgesic properties and also to reduce inflammatory activity in
affected joints. Two studies found that the presence of swelling was not predictiveDownloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
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Dowof response to these drug therapies. The data of 3 6-week RCTs comparing rofecoxib
with placebo were combined to analyze the consistency of response of patients with
hip or knee OA classified into subgroups determined by 14 demographic and disease
factors.21 Three outcome measures were analyzed in relation to the subgroups: pain
walking on a flat surface (WOMAC), patient global assessment of response to therapy,
and global assessment of disease status. The definition of treatment responder was
not provided. Overall, the subgroups did not show consistent interactive effects
with all 3 outcome measures. The absence of knee swelling in participants with
knee OA significantly correlated with improved scores on the patient global assess-
ment of response to therapy, but not the 2 remaining outcome measures.21 Another
study investigated swelling among numerous possible predictors of response of
patients with OA and rheumatoid arthritis to ketoprofen and piroxicam.34 The trial
was very small with only 11 participants with OA, so was underpowered in determining
significant predictors of response.34 Further investigation into signs of inflammation as
possible predictors of response to NSAIDs and COX-2 inhibitors would be helpful to
the clinician attempting to tailor pharmacologic management according to clinical
presentation.
IA corticosteroids aim to directly reduce inflammatory processes occurring within
joint tissues. An RCT by Chao and colleagues66 examined inflammatory characteris-
tics assessed on ultrasonography as predictors of response to IA corticosteroid injec-
tion for knee OA. Participants were categorized as inflammatory if synovial
hypertrophy (synovitis) with or without effusion was detected on gray-scale ultrasound
examination of the affected knee(s) at baseline. Within the intervention group, 16
patients presented with synovitis on ultrasonography and 18 did not. At 4 weeks there
were no significant differences between the inflammatory and noninflammatory
subgroups. Significantly lower WOMAC pain scores of the noninflammatory subgroup
at 12 weeks suggested that those without inflammatory characteristics experienced
prolonged beneficial effects from corticosteroids. The presence of effusion had no
influence on response to corticosteroid injection.66
The presence of hip-joint synovitis on ultrasound assessment of patients with hip OA
was predictive of treatment response to CSI. An RCT compared standard care (no
injection), injection of normal saline (placebo), nonanimal stabilized hyaluronic acid,
and methylprednisolone acetate.64 Of the participants receiving CSI, 14 participants
were classified as responders according to the OMERACT-OARSI criteria. The inves-
tigators concluded that synovitis was predictive of response at 4 and 8weeks following
injection; however, this study was underpowered in establishing clear associations
between the 5 variables analyzed as possible predictors. By contrast, Robinson and
colleagues22 found that evidence of hip synovitis and effusion on ultrasonography
were not predictive of clinical response to IA methylprednisolone injection. The cohort
study defined response to intervention as greater than 15% reduction in baseline
WOMAC pain score at 6 and 12 weeks following injection. This study was also under-
powered in identifying predictors of response. Further research using greater numbers
of subjects is required to explore ultrasound-determined inflammatory characteristics
as predictors of response to CSI of osteoarthritic hips.
Inflammatory characteristics identified on physical examination of patients with
knee OA failed to predict response to CSI. The presence of local inflammation indi-
cated by knee-joint fluid, local heat, synovial thickening, and stiffness were explored
as possible predictors of response to IA methylprednisolone in an RCT of 59 partici-
pants with symptomatic knee OA.33 No predictors of response were identified,
perhaps as a result of this study being underpowered. Pendleton and colleagues67
examined similar clinical signs of inflammation, namely presence of heat, effusion,nloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
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Targeting Care 227and synovial thickening, in addition to the presence of effusion and synovitis on knee
ultrasonography, as predictors of improvements in baseline WOMAC pain scale 1 and
6 weeks following CSI. The presence of heat was associated with a 29% greater
reduction in night pain; otherwise, clinical and ultrasonographic inflammatory signs
were not predictive of response. The study was underpowered and did not publish
any measures of data variability. Adequately powered, well-designed research is
necessary to determine whether clinical and ultrasonographic signs of inflammation
are predictive of outcomes following CSI for knee OA.
Moderate effusion was associated with a good outcome following IA injection with
Hylan G-F 20 in patients with symptomatic OA. Conrozier and colleagues24 followed
a cohort of 155 patients who received 3 IA Hylan G-F 20 injections and were evaluated
7 to 14 months later. Treatment outcomes included patient satisfaction, safety, and
changes in pain and function, which were assessed on 4-point Likert scales. This
study was limited by the lack of validated outcome measures and the retrospective
study design.
Only one study investigated signs of inflammation as predictive of outcome to nonsur-
gical, nonpharmacologic intervention. There is weak evidence that that synovitis and
effusion seen on MRI are unable to predict response to weight loss in patients with
OA.46 Numerous studies were concerned with signs of inflammation as predictors of
outcomes to pharmacologic agents, but fewwere sufficiently powered. Some evidence
exists that knee-joint swelling may predict good outcomes from rofecoxib21 and that
patientswithout synovitis observedonultrasonographyexperienceprolongedpain relief
following CSI injection in comparison with patients with knee OA presenting with syno-
vitis.66 The evidence for synovitis on ultrasonography as a predictor of response for
outcomes following hip CSI is conflicting.22,64 There is little evidence to support the
use of clinical inflammatory signs as predictors of response to CSI for knee OA.33,67
Further research is required to determine whether signs of inflammation are useful
predictors of response to conservative therapies for people with hip and knee OA.OTHER CLINICAL CHARACTERISTICS THAT MAY PREDICT RESPONSE TO INTERVENTION
For the purposes of this review, the authors have selected patient characteristics
deemed worthy of examination as potential predictors of response to interventions
for those with hip and knee OA. There is a wider range of presenting features than
those covered here, analyzed as potential predictors of response and further dis-
cussed in the literature. Among the articles identified through literature searches for
the predictors chosen, age and gender were commonly analyzed as potential predic-
tors of response to intervention, but appeared to hold little predictive capacity overall.
Four well-powered studies investigating predictors of response to COX-2 inhibi-
tors,20,21 a rehabilitation program,32 and exercise therapy45 provided moderate to
good evidence that age was not a powerful predictor of response to these interven-
tions. Further investigation of age as a predictor of response to alternative interven-
tions for patients with hip and knee OA is justified.
One adequately powered study determined female gender to be a characteristic
predictive of treatment success following participation in a rehabilitation program.32
By contrast, 3 well-powered studies found that gender was not predictive of treatment
success for COX-2 inhibitors and exercise therapy.20,21,45 Additional research into
gender as a predictor of treatment response to different nonsurgical modalities is
required.
WOMAC subscales of pain and function are often used as primary outcome
measures in OA research. Of the studies extracted from literature searches performedDownloaded for Anonymous User (n/a) at University of Sydney from ClinicalKey.com.au by Elsevier on October 11, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
Fig. 1. Summary of evidence available for particular features of clinical presentation
shown by people with hip and knee osteoarthritis. BMI, body mass index; CSI, intra-
articular corticosteroid injection; KLG, Kellgren-Lawrence Grade; mJSW, minimum joint
space width; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-inflammatory
drugs.
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Targeting Care 229around the chosen predictors, 2 well-designed studies examined WOMAC pain and
function scores as predictors of response to COX-2 inhibitors. One found that that
baseline WOMAC pain was not predictive of response to etoricoxib and celecoxib.
Lower levels of function on the WOMAC decreased the odds of response to the drugs,
but the difference in WOMAC function scores between responders and nonre-
sponders was not clinically significant.20 The second study concluded that baseline
WOMAC function was not predictive of response to rofecoxib.21 Although baseline
WOMAC pain and function scores were not predictive of response to COX-2 inhibi-
tors, these measures may prove to be interesting predictors of response to different
nonsurgical interventions in other research.
SUMMARY
This review identified and summarized the evidence available for particular features of
clinical presentation shown by individuals with hip and knee OA that were predictive of
response to nonsurgical interventions. The studies are summarized in Fig. 1. Good
evidence exists that BMI is not predictive of response to COX-2 inhibitors for hip and
knee OA,20 and there is moderate evidence that BMI does not predict weight reduction
following weight-loss interventions for overweight people with knee OA.17 There is
someevidence to suggest that the absence of depressive symptomspredicts success-
ful outcomes from both weight-loss interventions in overweight people with knee OA17
and a 3- to 4-week rehabilitation program for participants with hip and knee OA.32
Moderate evidence was cited that activation of quadriceps muscle was not predictive
of improvements in quadriceps strength attained by participants with knee OA during
a strengthening program.45 Patients with medial knee OA who were neutrally aligned
were more likely than their more varus-aligned counterparts to achieve significant
pain relief following a quadriceps-strengthening program.57 Evidence was lacking for
any radiographic or MRI changes that were significant predictors of response to
nonsurgical interventions; however, patients with knee OA presenting without inflam-
matory characteristics on ultrasonography (synovitis) were more likely to experience
prolonged benefit from CSI than were inflammatory patients.66
The practice of analyzing patient characteristics as potential predictors of response
to interventions is becoming increasingly popular. Researchers attempting to identify
predictors of clinical response to nonsurgical treatments for hip and knee OA require
the use of larger sample sizes, or restriction of the number of variables analyzed such
that 10 to 15 responders are studied per possible predictor.68 Identification of further
characteristics capable of predicting response to intervention would indeed provide
clinicians with additional tools to tailor the nonsurgical care of patients with hip and
knee OA according to their clinical presentation.
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Does Clinical Presentation Predict Response to a
Nonsurgical Chronic Disease Management Program
for Endstage Hip and Knee Osteoarthritis? 
Jillian P. Eyles, Barbara R. Lucas, Jillian A. Patterson, Matthew J. Williams, Kate Weeks,
Marlene Fransen, and David J. Hunter
ABSTRACT. Objective. To identify baseline characteristics of participants who will respond favorably following
6 months of participation in a chronic disease management program for hip and knee osteoarthritis
(OA).
Methods. This prospective cohort study assessed 559 participants at baseline and following 6
months of participation in the Osteoarthritis Chronic Care Program. Response was defined as the
minimal clinically important difference of an 18% and 9-point absolute improvement in the Western
Ontario and McMaster Universities Arthritis Index global score. Multivariate logistic regression
modeling was used to identify predictors of response.
Results. Complete data were available for 308 participants. Those who withdrew within the study
period were imputed as nonresponders. Three variables were independently associated with
response: signal joint (knee vs hip), sex, and high level of comorbidity. Index joint and sex were
significant in the multivariate model, but the model was not a sensitive predictor of response. 
Conclusion. Strong predictors of response to a chronic disease management program for hip and
knee OA were not identified. The significant predictors that were found should be considered in
future studies. (First Release Sept 15 2014; J Rheumatol 2014;41:2223–31; doi:10.3899/
jrheum.131475)
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Osteoarthritis (OA) is one of the world’s top 10 most
disabling conditions1. According to global burden of disease
estimates, musculoskeletal (MSK) disorders rank second
only to mental and behavioral disorders in overall contri-
bution to years lived with a disability (YLD)2. A large
proportion of YLD attributed to MSK disorders results from
hip and knee OA, estimated at over 17 million YLD
worldwide2.
Treatments for this disabling, prevalent, and incurable
disease focus on symptomatic relief. Numerous interna-
tional evidence-based guidelines for management of hip and
knee OA have become available3,4,5,6,7,8,9. There is consis-
tency in most of the recommendations made by the guide-
lines10 and agreement that nonsurgical management of hip
and knee OA should combine both nonpharmacological and
pharmacological treatment modalities3,4,5,6,7,8,9. However,
the recommendations are numerous and are not arranged
systematically to indicate the order of priority in which
treatments should be undertaken or which combinations of
modalities should be used. Faced with a plethora of choices,
it would be helpful for clinicians to be able to base treatment
decisions on the identification of specific clinical presenta-
tions that foretell greater likelihood of success following
implementation of an individual or combination of treat-
ments. In an era when the delivery of quality care is being
promoted coupled with finite resources, the ability to predict
outcome/s to intervention would allow clinicians to prior-
itize those who will get the greatest benefit.
There is a growing body of evidence for clinical charac-
teristics that predict response to nonsurgical interventions
for participants with hip and knee OA11. Four previous
studies attempted to identify predictors of response to
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programs involving combinations of nonsurgical interven-
tions12,13,14,15; however, consistent predictors of response
were not found. All 4 treatment protocols involved strategies
for self-management of OA including dietary advice; 2
studies provided weight loss advice if indicated13,14, and all
were of relatively short duration, ranging from 3 to 12
weeks12,13,14,15. To our knowledge, studies reporting
outcomes or predictors of response to longer duration self-
management programs do not exist. The aim of our research
was to determine participant characteristics predictive of
favorable outcomes following participation in a longer-term
nonsurgical chronic disease management program for hip
and knee OA. We hypothesized that it would be possible to
predict participants likely to respond to the program using
baseline demographic, psychological, disease-related, and
functional performance variables. 
MATERIALS AND METHODS
Study design. This observational clinical cohort study followed consecutive
participants of the Osteoarthritis Chronic Care Program (OACCP) from 2
teaching hospitals in New South Wales (NSW), Australia, over a period of
6 months. The OACCP was developed by the Agency for Clinical
Innovation MSK Network in response to the growing recognition of the
need for a nonsurgical care program for people awaiting elective hip or
knee joint replacement surgery (JRS). Participants with symptomatic and
radiographic hip and knee OA were recruited for the OACCP at Royal
North Shore/Ryde and Wollongong Hospitals from JRS waiting lists or
referral by rheumatologists, orthopedic surgeons, and general practitioners.
This equates to a doctor diagnosis of OA, which provides good face
validity16. People with a diagnosis of knee or hip OA were eligible for the
OACCP at initial assessment if they had pain in the affected knee/hip on
most days of the past month17. Participants who had completed a
reassessment at 26 weeks (within 140–225 days following initial
assessment) were included in the analysis (Figure 1). There were no
exclusion criteria for the OACCP, but participants who did not return for
their 26-week assessment, or who were reassessed outside 140–225 days
following initial assessment, were considered for imputation as non-
responders. Participants imputed as nonresponders included those who
underwent JRS more than 90 days (and less than 225 days) following initial
assessment, those discharged on medical advice, or participants who cited
dissatisfaction with the program as their reason for discharge. Those
receiving JRS within 90 days of initial assessment were excluded from
analysis on the basis that there was insufficient time to determine whether
they responded to the OACCP. The remaining participants without a
complete 26-week assessment within 140-225 days were excluded from the
regression analysis.
Intervention. The OACCP aimed to reduce pain, increase function, and
improve the quality of life of participants with hip and knee OA through
provision of access to relevant health professionals to support
self-management and longterm behavior change. At initial assessment, the
MSK Coordinator engaged participants to set goals around the
management of their OA and comorbidities18. The MSK Coordinator was
a specialized MSK physical therapist; all participants were prescribed an
individualized exercise program that focused on strengthening muscles
around affected joints, increasing physical activity levels, and other
exercises depending on clinical presentation. These programs were
reviewed at 12 and 26 weeks. All participants were provided with education
about their OA and any identified comorbidities.
Following initial assessment, participants were referred to members of
the multidisciplinary team (MDT) according to clinical need. If participants
required medication review they were referred to a rheumatologist or pain
clinical nurse consultant. Intraarticular injections were not part of the
treatment provided. A dietitian provided interventions when indicated to
assist participants with weight loss and/or comorbidity management.
Participants requiring assessment of efficiency and safety of functional
tasks were referred to an occupational therapist. Psychosocial interventions
and linkage with community support services were provided by a social
worker as required. Some participants with tibiofemoral or patellofemoral
joint malalignment were referred to an orthotist for application of knee
bracing or foot orthoses. Participants were also referred to healthcare
providers outside the MDT for other interventions (e.g., hydrotherapy,
diabetes education, psychology, etc.) as required.
Outcome measures. During a structured interview at initial assessment, the
MSK coordinator recorded demographic and comorbidity data.
Demographic data included sex, date of birth, referral source, residential
status, language spoken at home, employment, and level of education.
Signal joint, the predominant site of OA, was determined by clinical exami-
nation, patients’ symptoms, and radiographic evidence of disease. All
physical measures performed at initial and 26-week assessments were
performed using a standardized protocol17, including height, weight, waist
and hip circumferences, and body mass index (BMI). Disease-specific
self-report measures administered at 0 and 26 weeks included the Hip
Dysfunction and Osteoarthritis Score (HOOS) or Knee Injury and
Osteoarthritis Score (KOOS), according to the signal joint. The Depression
Anxiety Stress 21 Scale (DASS 21) was used to measure these 3 negative
emotional states at initial and 26-week assessments. The Six-minute Walk
Test (6MWT) was completed at baseline and 26 weeks. 
The validated, disease-specific HOOS19 and KOOS20 require partici-
pants to use 5-point Likert scales to rate their symptoms, stiffness, pain,
physical function, recreational activities, and quality of life. The HOOS and
KOOS subsume all of the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) questions, enabling conversion into
WOMAC scores21,22. The WOMAC subscales for pain, stiffness, and
function were calculated by summation of the numerical responses
provided by the WOMAC questions within the HOOS and KOOS. The
WOMAC subscores were combined to calculate a WOMAC global score =
100– (sum of pain + stiffness + function items) × 100/96. Normalized
WOMAC global scores were used, reflecting the convention that 100
indicated no problems and 0 indicated severe problems21,22.
Using a 4-point Likert scale, the DASS 21 asks participants to rate how
much 21 separate statements applied to them over the past week. The
DASS 21 provides subscores to indicate the presence or absence of
symptoms of depression, anxiety, and stress and has previously been shown
to predict the diagnostic presence of depression and anxiety in older
adults23. We were concerned primarily with the depression subscores; with
0–9 indicating no depressive symptoms, 10–13 mild, 14–20 moderate,
21–27 severe, and greater than 28, extremely severe symptoms. The DASS
depression subscores were categorized into low depressive (0–13) versus
high depressive (≥ 14) groups for the regression analyses.
The Modified Self-Administered Comorbidity Questionnaire asks
participants, “Has your doctor told you that you have any of the following
problems?” and then lists 21 commonly reported conditions plus an “other”
category to indicate comorbidities not included on the list. Response is
“yes” or “no”. This questionnaire was adapted from The Self-Administered
Comorbidity Questionnaire24 and is scored by counting “yes” responses to
indicate the number of comorbidities experienced by the participant. The
number of comorbidities variable was categorized into low (0–2), high
(3–5), and very high (≥ 6) groups for the analyses.
The 6MWT is recommended by the Osteoarthritis Research Society
International to assess long-distance walking and aerobic capacity for
participants with hip and knee OA25. Participants were asked to walk as
quickly as they could for 6 min on a flat 25-m track with no corners26 and
the distance walked was recorded in meters. Baseline measurement of
oxygen saturation, heart rate, and perceived exertion (Borg Scale) were
taken prior to and at test completion. Participants with respiratory or
cardiac concerns had measures taken at 1-min intervals during the test,
2224 The Journal of Rheumatology 2014; 41:11; doi:10.3899/jrheum.131475
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which was discontinued for the following: chest pain or discomfort, mental
confusion, lack of coordination, dizziness, intolerable dyspnea, leg cramps,
extreme muscle fatigue, persistent oxygen saturation < 85%, or other clini-
cally warranted reasons.
Participants were asked to rate their average pain on the day of
assessment using a visual analog scale (VAS; 0 indicated no pain and 10 the
most pain imaginable). The pain VAS was categorized into low pain (VAS
0–5) and high pain (VAS 6–10) for the regression analyses.
Statistical analyses. Participants were dichotomized according to response
or non-response at the 26-week assessment according to treatment based on
2225Eyles, et al: Nonsurgical OA management
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Figure 1. Study flowchart. Ø Participants with incomplete 26-week assessment or 26-week assessment outside 140–225 days or receiving joint replacement
surgery (JRS) within 90 days of initial assessment. ØØ Participants who underwent JRS more than 90 days (and less than 225 days) following initial
assessment, or were discharged on medical advice or who cited dissatisfaction with the program as the reason for their discharge. *HOOS or KOOS at either
0 or 26 weeks were incomplete so that WOMAC global scores could not be calculated. #6MWT results were unavailable because participants were unable to
complete the test: 5 because of high blood pressure and 1 with back pain. HOOS: Hip Dysfunction and Osteoarthritis Score; KOOS: Knee Injury and
Osteoarthritis Score; WOMAC: Western Ontario and McMaster Universities Arthritis Index; 6MWT: Six-minute Walk Test. 
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the notion of minimal clinically important difference (MCID), which can
be defined as the smallest difference in scores of the variable concerned
that is considered beneficial by participants of the intervention27. The
MCID used was first developed by Angst, et al28 to reflect the treatment
effect considered to be clinically relevant to a comprehensive rehabilitation
intervention for participants with OA of the lower extremities. This MCID
required a relative change greater than or equal to 18% (100 × change of
score/baseline score) and an absolute change of 9 points improvement of
WOMAC global scores at the 26-week assessment compared to baseline.
Using an MCID comprising both relative and absolute change standardized
the amount of improvement required to achieve response across the
spectrum of disease severity. Hence participants with very low global
WOMAC scores were not classified as responders for small absolute
changes in score compared with those whose baseline scores were higher.
Participants who demonstrated improvements in WOMAC global scores at
26 weeks of ≥ 18% with an absolute change in score ≥ 9 were categorized
as responders28; those who did not were nonresponders. 
Participants censored at their 26-week followup because of JRS
performed at least 90 days after their initial assessment and within the
26-week assessment window (≤ 225 days) were imputed into the analysis
as nonresponders. Participants who withdrew from the OACCP owing to
dissatisfaction with the program or following medical advice were also
imputed as nonresponders. 
The potential predictor variables were chosen following literature
review11 and discussion among this study’s authors. The MSK coordinators
collecting the data at both study sites were blinded to which variables were
to be analyzed as predictors of response. Eight baseline predictor variables
were identified a priori for consideration in the model: BMI, pain VAS,
DASS subscore, signal joint, 6MWT, age, sex, and number of comor-
bidities. The power calculation was set to include at least 10 “responders”
per predictor variable29,30. Previous studies have reported 34%–47% of
participants with hip or knee OA may be expected to satisfy responder
criteria following nonsurgical multimodal interventions14,15. A sample of
267 was considered sufficient to accommodate 8 predictor variables. 
Univariate logistic regression analyses examined the association
between each of the predictor variables and response, and continuous
variables were categorized when necessary to meet linearity requirements.
All variables were entered into a multivariate binary logistic regression
model; the least significant predictor was removed at each step of the
modeling until only significant variables remained. To control for
confounding, when any variables associated with response in the univariate
analyses were removed from the model, the regression coefficients of the
remaining variables were checked for a change in 10% or more and if so
were retained. Testing for interactions was performed by combining
variables of interest. SPSS version 21 was used for all statistical analyses. 
Ethics approval was granted by the NSW Population and Health
Services Research Ethics Committee (AUREI Reference HREC/12/
CIPHS/63); Cancer Institute NSW Reference Number 2012/08/413. 
RESULTS
Of 559 patients consecutively referred to the Wollongong
and Royal North Shore/Ryde Hospitals OACCP from July
2011 to December 2013, 475 participants had completed
their 26-week assessment as shown in Figure 1. There were
145 participants who were excluded because their 26-week
assessment occurred outside the assessment range. A further
16 participants were excluded with incomplete HOOS or
KOOS, 6 were unable to complete the 6MWT because of
high blood pressure or back pain, and 84 did not return for
followup assessment. That left 308 participants with
complete datasets remaining for the analysis. A further 74
were imputed as nonresponders: 55 discharged from the
OACCP after JRS 90–225 days following initial assessment,
16 withdrew because of dissatisfaction with the program,
and 3 stopped as a result of medical advice.
The baseline demographics of included participants,
those excluded because of missing assessments or assess-
ments outside the 26-week range (n = 167), and those who
did not return for followup assessment (n = 84) are summa-
rized in Table 1. The included and excluded groups were
homogeneous in most respects. About 90% were referred
from elective JRS waiting lists; the wait time for JRS in
NSW Hospitals is around 12 months. The majority of partici-
pants were of similar age, lived at home with an able person,
spoke English, were retired, and overweight. Participants
reported similar baseline pain. The majority had 0–5 comor-
bidities and did not finish high school.
There were proportionally more males in the excluded
group with no followup assessment (p = 0.07) and the
included group reported a higher proportion of OA knees to
hips than did the excluded groups (p = 0.02). The mean
baseline WOMAC global scores were significantly different
(p = 0.03); however, the greatest difference in mean scores
was 5.2 points, which is not very clinically important. 
The referrals to healthcare providers recorded for
included and excluded participants are summarized in Table
2. All participants were assessed by a physical therapist and
provided with a graded exercise program; around half were
referred to a dietitian; 30-40% to a rheumatologist; and
20–30% to an occupational therapist or a social worker.
About 20% of participants were referred to providers within
and 40% outside the local health district. 
Of 308 included participants with complete datasets, 9
were omitted from analysis because their baseline WOMAC
was too high (> 84) or 0, and so were unable to achieve
response. Of the 299 participants with complete datasets, 84
(28%) were responders according to the MCID. Results of
the univariate regression analyses are shown in Table 3.
Compared to females, males were less likely to be
responders (OR 0.5, 95% CI 0.31, 0.88). There was strong
evidence that participants with knee OA were more likely to
be responders than those with hip OA (OR 2.1, 95% CI 1.10,
3.88). Compared to those with a low number (≤ 2) there was
evidence that participants with a very high number of
comorbidities (≥ 6) were more likely to be responders (OR
2.2, 95% CI 0.99, 4.95). The other baseline variables were
not independently associated with response.
All potential predictor variables were entered into the
base multivariate model. No significant interactions
between the variables were found. Following elimination of
nonsignificant variables, the final model (Table 4) contained
both signal joint (chi squareLR = 4.49, p < 0.05) and sex (chi
squareLR = 4.95, p < 0.05). Participants with the knee as the
signal joint were more likely to be responders compared
with those with hip as the signal joint (adjusted OR 1.92,
95% CI 1.02, 3.62). Compared to women, men were less
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likely to be responders (adjusted OR 0.55, 95% CI 0.32,
0.94). The group with a very high number of comorbidities
was not significantly associated with response in the multi-
variate model (p = 0.07) and removal did not have a
confounding effect on the remaining variables. The model
fit the data well using the Hosmer-Lemeshow goodness-of-
fit test (chi square = 3.03, 3 DF, p = 0.21); however, the
model was unable to predict any participants as responders
(sensitivity 0%, specificity 100%). 
DISCUSSION 
To our knowledge, this was the first study attempting to
identify predictors of response following longer-term (6
mos) participation in a chronic disease management
2227Eyles, et al: Nonsurgical OA management
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Table 1. Demographics of included and excluded participants at baseline.
Baseline Characteristics Included, Excluded: Excluded: No p v
n = 313 26 Weeks Not Followup 
Within 140–225 Days, Assessment, 
or Missing Data, n = 84
n = 162
Female (%) 62 59 48 0.067
Age, yrs, mean (SD) 68.5 (9.25) 69.0 (9.92) 68.0 (10.85) 0.76
Signal joint knee (%) 77 65 68 0.022
Signal joint knee (%) responders 83
Signal joint knee (%) nonresponders 75
On elective joint replacement list (%) 88 90 86 0.68
Residence
At home with able person (%) 64 68 68 0.46
Home alone (%) 28 22 21
Other‡ (%) 8 10 11
Speaks English* (%) 90 92 88 0.61
Employment (%) 0.60
Not currently employed† 86 82 84
Currently employed^ 14 18 16
Education (%) 0.94
Finished secondary school or higher¤ 30 29 32
Did not finish secondary school°  60 71 68
BMI, mean (SD) 31.9 (6.88) 32.0 (6.57) 31.7 (6.36) 0.94
BMI knees, mean (SD) 32.52 (7.12)
BMI hips, mean (SD) 30.03 (5.84)
Pain VAS, mean (SD) 5.5 (1.84) 5.7 (1.74) 5.7 (2.20) 0.65
No. comorbidities (%)
Low (0–2) 54 44 43
High (3–5) 39 51 42
Very high (≥ 6) 8 5 10
Missing (no.) 5
WOMAC global score#, mean (SD), 43.4 (19.39), 38.4 (17.17), 41.3 (21.72), 
range 0–100 0–90 3–98 0.027
WOMAC global score, knees, mean (SD) 44.2 (19.66) 40.8 (18.59) 41.5 (21.23)
WOMAC global score, hips, mean (SD) 40.7 (18.34) 33.6 (12.96) 40.8 (23.23)
WOMAC global score for responders, 33.8 (18.06), 
mean (SD), range 1–79
WOMAC global score for nonresponders, 47.4 (18.51), 
mean (SD), range 4–100
6 Minute Walk Test, m, mean (SD) 337.4 (118.52) 324.3 (120.51) 323.5 (114.51) 0.44
Data in bold face are statistically significant. ‡ Other includes residence at hostel or residence with non-able
person. * Participants who did not speak English (about 10%) required the use of an interpreter. † Not currently
employed includes participants who reported they were retired, performed home duties, and other. ^ Currently
employed includes participants who reported engaging in full/part time/volunteer work. ¤ Includes participants
who reported finishing secondary school, tertiary certificate, or university graduate. ° Includes participants who
did not finish secondary school, and those who reported no formal schooling. # The WOMAC global scores are
a transformed score calculated from the HOOS and KOOS: 100 indicates no problems and 0 indicates extreme
problems. v Independent ANOVA or chi-squared statistic comparing included participants with the 2 other
groups. VAS: visual analog scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index; BMI:
body mass index.
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program for hip and knee OA. The relatively low response
rate (28%) was not surprising considering the severity of
disease in this sample indicated by the large proportion of
participants on JRS waiting lists (around 90%). Assuming
that participants on JRS waiting lists would have clinically
and radiographically significant disease, it may be expected
that given the natural history of the disease, without inter-
vention the majority of participants would stay the same or
worsen over a period of 6 months. A similar response rate
was reported by Weigl, et al using a less stringent definition
of response (≥ 18% improvement in global WOMAC score)
6 months following a 3–4 week rehabilitation program for
participants with hip and knee OA15. 
The univariate analysis and the multivariate model
adjusting for sex found participants with the knee as signal
joint were almost twice as likely to be responders compared
to those referred with hip OA (OR 1.92, 95% CI 1.02, 3.62).
Although signal joint is not a significant predictor of
response in the literature13,14,15, this finding makes sense in
the clinic. A central aim of the OACCP was to increase
physical activity. There is evidence that participants with
knee OA experience reduced pain and improvement in
physical function following land-based therapeutic
exercise31; however, the evidence for such benefits is
weaker in those with hip OA32. Perhaps the participants
with knee OA derived higher levels of therapeutic benefit
from the exercise prescribed by the physical therapist of the
OACCP and so were more likely to respond than were those
with hip OA. Included participants with knee OA had a
higher mean BMI (32.52 kg/m2) than those with hip OA
(30.03 kg/m2; Table 1). Given that a common goal for
OACCP participants was to lose weight, and that partici-
pants with knee OA were more overweight, it was hypothe-
sized that knees would be more likely to respond to inter-
ventions that involved weight loss. Interestingly, BMI was
not an independent predictor of response, and it was not
significant in the multivariate model when adjusted for
signal joint. This confirms previous findings that BMI was
not predictive of responsiveness to weight loss or multi-
modal nonpharmacological and pharmacological interven-
tions for participants with hip and knee OA13,14,33.
Sex was a univariate predictor of response that remained
significant in the multivariate model adjusting for signal joint
(OR 0.54, 95% CI 0.31, 0.95). Men were half as likely to be
responders as women, a result that is difficult to explain. The
literature yields conflicting results: being female was
predictive of response to a rehabilitation program for hip and
knee OA15, but sex was not significantly associated with
response in other previous predictor studies13,14. 
Compared to participants with a low number of comor-
bidities (0–2), participants with a very high number of
comorbidities (> 6) were independently associated with
response (OR 2.2, 95% CI 0.99, 4.95). A very high number
of comorbidities was not significantly associated with
response when adjusting for sex and signal joint, so number
of comorbidities was removed from the model. 
The absence of depression has been identified previously
as a predictor of response to a 3–4 week inpatient multi-
2228 The Journal of Rheumatology 2014; 41:11; doi:10.3899/jrheum.131475
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Table 2. Percentage of OACCP participants referred to health providers within and outside the OACCP.
Healthcare Provider Type Included Participants, Participants Without Followup, Excluded 
n = 300 Imputed as Nonresponders, Participants,
n = 74 n = 185
OACCP multidisciplinary team
OACCP physical therapist* (%) 100 100 100
OACCP dietitian* (%) 53.7 55.7 41.3
OACCP rheumatologist# (%) 40.4 46.3 31.1
OACCP occupational therapist* (%) 28.4 36.6 30.5
OACCP social worker# (%) 19.4 28.5 13.8
OACCP orthotist# (%) 23.7 17.8 13.5
Other** (%) 16 12.9 10.7
Other health providers within the local 
health district± (e.g., hydrotherapy, 
exercise groups; %) 21 20.3 19.4
Other health providers outside the local 
health district‡ (e.g., GP, hydrotherapy, 
diabetes educator, exercise groups; %) 42 39.2 39.2
* Available at both OACCP sites. # Available at Royal North Shore Hospital OACCP (only this rheumatologist
saw patients in the OACCP clinic, they did not refer participants to the OACCP). **Other may include pain CNC
at Wollongong Hospital and education sessions at both sites. ± Other healthcare providers within the local health
district may include hydrotherapy, exercise groups, falls clinic, physiotherapist, pulmonary rehabilitation,
smoking cessation, or geriatrician. ‡Other healthcare providers outside the local health district may include
general practitioner (GP), hydrotherapy, exercise groups, diabetes clinic, orthopedic surgeon, psychologist,
geriatrician, physiotherapist, dietitian, falls clinic, pain clinic, social worker, orthotist, smoking cessation,
pulmonary and cardiac rehabilitation. OACCP: Osteoarthritis Chronic Care Program; CNC: clinical nurse
consultant.
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modal rehabilitation intervention15 and positive outcomes
from a weight loss program in overweight veterans with
knee OA33. The absence of depression was not a significant
predictor of response in the present study. Participants
reporting depressive symptoms on the DASS depression
subscale were referred for treatment as required. The
treatment of depression in people with arthritis has been
shown to reduce pain and depressive symptoms, and
improve function and quality of life34. The treatment of
depression as an adjunct to the other multidisciplinary inter-
ventions in our study may have diminished the negative
effect depressive symptoms had on response to treatment.
Age was not a predictor of response to the OACCP. Most
studies include age in their list of potential predictor
variables to control for the effects of confounding. Previous
evidence for age as a predictor of response is conflicting.
Higher age was a predictor of response to a multimodal
stepped-care model for participants with hip and knee OA13
and a physical therapy intervention for patients with hip
OA35 but was insignificant in other predictor studies14,15.
The 6MWT was not predictive of response and while
functional performance measures have not been widely used
in previous prediction studies, 1 study found the self-paced
40-m walk test predictive of response to physical therapy
interventions for patients with hip OA35. A recent systematic
review rated the 40-m walk test as the best walk test based
on the limited evidence available36 and perhaps it would
have been a more useful predictor of response for our study.
This is an interesting area for future research.
Notable strengths of this study design included the large
sample size, the clinically meaningful followup period, and
that the potential predictor variables were identified a priori
through literature and peer review, with due consideration to
not overfitting the model with excessive degrees of freedom.
The potential predictors included a broad mix of disease,
psychological, physical, and demographic variables. To
minimize bias, the data were collected prospectively by the
MSK coordinators, who were blinded to which variables
were to be analyzed as predictors. 
This clinical cohort study used data from a real-life
clinic. The participants required doctor diagnosis of OA,
which provides good face validity but may present potential
limitations because different symptom labels for OA may
exist between independent medical practitioners16. Recruited
largely from JRS waiting lists, many participants of the
OACCP were censored when their date for JRS came up.
Excluded participants reported worse global WOMAC
scores at baseline compared to included participants. To
control for selection bias, participants who had experienced
at least 90 days in the OACCP and had surgery within the
26-week window (≤ 225 days) were imputed as non-
responders, in addition to those who discontinued the
OACCP citing dissatisfaction with the program or who
withdrew under medical advice. The transformed baseline
global WOMAC score (100 indicates no problems and 0
indicates extreme problems) was significantly lower in
responders compared to nonresponders (p < 0.05), and
2229Eyles, et al: Nonsurgical OA management
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Table 3. Univariate analyses of potential predictors of response to the OACCP. 
Variable Unadjusted OR (95% CI) p
Age 0.9 (0.071, 1.20) 0.539
Sex Female Reference
Male 0.5 (0.31, 0.88) 0.015
Signal joint Knee 2.1 (1.10, 3.88) 0.023
Hip Reference
Comorbidity Low (0–2) Reference
High (3–5) 0.8 (0.47, 1.37) 0.414
Very high (≥ 6) 2.2 (0.99, 4.95) 0.053
Depression* ≤ 13 Reference
≥ 14 1.2 (0.68, 1.98) 0.592
Pain † 0–5 Reference
6–10 1.2 (0.72, 1.92) 0.526
BMI 1.0 (0.98, 1.05) 0.329
6MWT** 1.0 (1.0, 1.0) 0.755
*Depression measured using the Depression component of the Depression Anxiety Stress Scales. †Pain
measured using visual analog scale (self-rated; 0 no pain, 10 worst pain). **Distance participants are able to
walk on flat ground during Six-minute Walk Test. OACCP: Osteoarthritis Chronic Care Program; BMI: body
mass index.
Table 4. Final multivariate# prediction model for response to the
Osteoarthritis Chronic Care Program.
Variable β Coefficient p Adjusted OR 95% CI
Constant –1.496
Sex –0.594 0.029 0.55 0.32, 0.94
Signal joint knee 0.651 0.045 1.92 1.02, 3.62
# The base adjusted or multivariate model included age, sex, index joint,
comorbidity, depression, pain, body mass index, and Six-minute Walk Test. 
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although there is marked overlap between groups, the mean
difference of 10 points may suggest some regression toward
the mean.
A control group was not used in this study, so it could be
argued that it is impossible to distinguish between predictors
of response to the chronic disease management program and
natural progression of the disease. Previous studies con-
cerned with progression of OA indicate a slow evolution and
progression of the disease over time37. Given that the vast
majority of patients were on the waiting list for JRS
indicating endstage disease, it would be unlikely that the
natural course of OA in these participants would allow
improvement in symptoms sufficient to achieve the MCID
over a period of 6 months. However, this does limit the
generalizability of the results of our study to those with
severe OA. A previous study reported that compared to
participants not waiting for surgery, patients on the waitlist
for knee JRS experienced smaller improvements that were
not as lasting in response to participation in a chronic
disease management program12. It would be interesting in
future research to investigate a more heterogeneous sample
of participants to enable analysis of referral for JRS as a
potential predictor of response. 
We can only assume that referral for JRS was a proxy
measure of disease severity in this study. Future research
should include a standardized measure of structural disease
severity. Higher radiographic severity of knee and hip OA
measured using the Kellgren-Lawrence (KL) Grading Scale
was a predictor of response to acetaminophen as part of a
Dutch multimodal stepped-care model13. Conversely, an
earlier study investigating predictors of response to the same
intervention found that KL grade was not associated with a
more stringent definition of response14. It would be inter-
esting to investigate whether radiographic severity is
associated with response to the longer-term chronic disease
management program. Another predictor variable in the
literature associated with response was history of previous
nonsurgical interventions. Two studies reported history of
previous nonsurgical therapies as associated with good
response to rehabilitation programs for participants with hip
or knee OA12,15. This should be addressed in future studies
concerned with prediction of response to chronic disease
management programs for hip and knee OA.
Response to intervention could not be predicted using the
variables studied in this sample following 6 months of partic-
ipation in the OACCP. Although significant predictors of
response were identified, the model was not sensitive. The
significant predictors of our study should be considered for
future research, and alternative variables for investigation
have been highlighted. It is possible that an alternative
battery of variables could be more useful for prediction of
response to this intervention. If response can be predicted, it
may enable clinicians to better tailor management of hip and
knee OA according to clinical presentation.
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Can We Predict Those With Osteoarthritis Who
Will Worsen Following a Chronic Disease
Management Program?
JILLIAN P. EYLES,1 KATHRYN MILLS,2 BARBARA R. LUCAS,3 MATTHEW J. WILLIAMS,3
JOANNA MAKOVEY,1 LAURENCE TEOH,4 AND DAVID J. HUNTER1
Objective. To identify predictors of worsening symptoms and overall health of the treated hip or knee joint following
26 weeks of a nonsurgical chronic disease management program for hip and knee osteoarthritis (OA) and to examine
the consistency of these predictors across 3 definitions of worsening.
Methods. This prospective cohort study followed 539 participants of the program for 26 weeks. The 3 definitions of
worsening included symptomatic worsening based on change in the Western Ontario and McMaster Universities Oste-
oarthritis Index Global score (WOMAC-G) measuring pain, stiffness, and function; a transition scale that asked about
overall health of the treated hip or knee joint; and a composite outcome including both. Multivariate logistic regres-
sion models were constructed for the 3 definitions of worsening.
Results. Complete data were available for 386 participants: mean age was 66.3 years, 69% were female, 85% reported
knee joint pain as primary symptom (signal joint), 46% were waitlisted for total joint arthroplasty (TJA). TJA waitlist
status, signal joint, 6-Minute Walk Test (6MWT), depressive symptoms, pain, and age were independently associated
with at least 1 definition of worsening. TJA waitlist status and 6MWT remained in the multivariate models for the
transition and composite definitions of worsening.
Conclusion. Participants reporting worsening on the transition scale did not consistently meet the WOMAC-G defini-
tion of worsening symptoms. TJA waitlist status was predictive of the composite definition of worsening, a trend
apparent for the transition definition. However, variables that predict worsening remain largely unknown. Further
research is required to direct comprehensive and targeted management of patients with hip and knee OA.
INTRODUCTION
Osteoarthritis (OA) is a well-known cause of significant
disability (1,2). Current evidence promotes tailored treat-
ments combining nonpharmacologic and pharmacologic
nonsurgical modalities for symptomatic management of
knee and hip OA (3–5). It would be naive to assume that
everybody will benefit from a similar program of nonsurgi-
cal interventions, hence it is important to identify partici-
pants likely to report symptomatic worsening despite
“usual” nonsurgical regimens so that alternative therapeu-
tic options may be considered.
Longitudinal studies have examined predictors of hip
and knee OA progression, i.e., deterioration in radio-
graphic features, symptoms, or progression to total joint
arthroplasty (TJA) (6–10). Attempts have been made to
identify thresholds of pain, function, and structural sever-
ity to provide a surrogate measure of need for TJA for use
in clinical trials (11,12). Elusive thus far, these thresholds
could be useful to triage participants of nonsurgical self-
management programs so that those who may potentially
derive more benefit from TJA may be escalated to surgery.
Extant thresholds indicative of symptomatic worsening fol-
lowing a rehabilitation program for hip and knee OA (13)
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have not been applied extensively in the literature. Yet the
ideal threshold for “worsening” may be useful by 1) inter-
preting clinical findings of individual patients and 2) deriv-
ing predictors of worsening in groups of nonsurgical
program participants. Predictors may be used to triage refer-
rals for interventions unlikely to confer benefit, placing
unnecessary burden on the health care system and patients.
In the absence of a robust clinical definition of “worsening,”
we have compared 2 definitions existing in the literature.
The first is based on a threshold of change in the Western
Ontario and McMaster Universities Osteoarthritis Index glob-
al score (WOMAC-G) derived from participants of a rehabili-
tation intervention (13). The second is the response to a
transition question measuring the overall amount and direc-
tion of change the individual has undergone regarding their
joint following the intervention (14). This method has been
suggested following recent questioning of the utility of pre-
and post–patient-reported outcomes (PROs) to measure effi-
cacy of self-management education programs, possibly due
to a response shift prompted by change in the participant’s
perspective following engagement in such programs (14). A
third definition of worsening was used in this study, i.e., a
composite outcome including either or both WOMAC-G and
transition definitions. The composite outcome was chosen to
reflect the dual importance of the 2 clinical outcomes and to
increase the power of the analysis by combining 2 outcomes
of common etiology (15).
The objective of this study was to identify baseline par-
ticipant characteristics predictive of 3 different definitions
of symptomatic worsening following 26 weeks of partici-
pation in a nonsurgical chronic disease management pro-
gram for hip and knee OA and to examine the consistency
of predictors for the definitions. Previous studies have
identified age, body mass index (BMI), and pain intensity
as predictors of radiographic progression and TJA of knee
(6–9) and hip OA (9,10). As such, these were pragmatical-
ly chosen as potential predictors of worsening following
participation in the Osteoarthritis Chronic Care Program
(OACCP). TJA waitlist status was also selected based on
evidence that some patients report deterioration in health
status following a$6 months wait for TJA (16). Additional
predictors included signal joint, sex, number of comorbid-
ities, a functional performance measure (6-Minute Walk
Test [6MWT]), and presence of depression, which have all
been previously associated with response to nonsurgical
rehabilitation programs for hip and knee OA (17–19). We
hypothesized that the same participants with similar
demographic, psychological, disease-related, and func-
tional performance predictor variables would be identified
as “worse” across 3 definitions of worsening.
PATIENTS AND METHODS
Participants and data collection. This study comprised
a cohort of consecutive participants with symptomatic and
radiographic hip and knee OA recruited for the OACCP at
Royal North Shore Hospital (RNSH). Participants were
recruited directly from RNSH and Ryde Hospital (New
South Wales, Australia) TJA waitlists or referral by rheuma-
tologists, orthopedic surgeons, and general practitioners.
People with a diagnosis of knee or hip OA were eligible if
they reported pain in the affected knee/hip on most days of
the past month (18). Data were included from participants
who had completed at least 140 days in the program, and
there were no exclusion criteria. Ethics approval for analysis
of OACCP clinical data was provided by the New South
Wales Population and Health Services Research Ethics
Committee (AUREI reference HREC/12/CIPHS/63, Cancer
Institute NSW, reference 2012/08/413).
The objectives of the OACCP were to reduce pain and
increase function and quality of life of participants through
the provision of tailored interventions delivered by a multi-
disciplinary team, including a physical therapist, rheumatol-
ogist, dietitian, occupational therapist, social worker, and
orthotist. At the initial assessment, an experienced musculo-
skeletal physical therapist (MJW) provided participants with
education about their OA and associated comorbidities, set
patient-oriented goals, and prescribed behavioral modifica-
tion strategies and an exercise program. The exercise program
was comprised of strength and cardiovascular training and
was progressed at 12-, 26-, and 52-week reassessments. Par-
ticipants then attended a multidisciplinary clinic for consul-
tation with a rheumatologist and a selection of other health
professionals according to their individual clinical needs.
Outcome measures. Demographic data were recorded
at baseline. The signal joint, i.e., the predominant site of
OA, was determined by clinical and radiographic exami-
nation. Anthropometric measures were performed using a
standardized protocol (20), including height, weight,
waist and hip circumferences, and BMI. Participants rated
their average pain on the day of assessment using a 10-cm
visual analog scale (VAS; where 0 indicated no pain and
10 indicated the most pain imaginable) (21).
The validated, disease-specific Hip Disability and Oste-
oarthritis Outcome Score (22) and the Knee Injury and
Osteoarthritis Outcome Score (23) require participants to
rate their symptoms, stiffness, pain, physical function,
recreational activities, and quality of life on 5-point Likert
Significance & Innovations
 Three different definitions of worsening were
applied to a cohort participating in a chronic disease
management program for hip and knee osteoarthritis.
 Participants who were “moderately” or “much”
worse on the transition scale were not consis-
tently worse, according to the minimal impor-
tant difference using the Western Ontario and
McMaster Universities Osteoarthritis Index global
(WOMAC-G) scores.
 Predictors of worsening were similar between
the transition and composite definitions, but not
the WOMAC-G definition of worsening.
 Total joint arthroplasty waitlist status was signifi-
cantly associated with the composite definition of
worsening; however, variables that predict worsen-
ing remain largely unknown.
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scales. These questionnaires subsume the WOMAC ques-
tions, enabling conversion as follows:
WOMAC-G5 (sum of pain1 stiffness1
function items)3 100/96 (24,25)
The 21-item version of the Depression, Anxiety and Stress
Scale, using a 4-point Likert scale, asks participants to rate
how much 21 separate statements applied to them over the
past week. Subscores indicate the presence/absence of symp-
toms of depression, anxiety, and stress (26). Participants
were dichotomized into those with depression subscores of
0–9 with no depressive symptoms, and those with subscores
$10 with signs of depression (26).
A modified version of the Self-Administered Comorbi-
dity Questionnaire (27) quantified the number of comorbi-
dities experienced by each participant. Participants were
asked to respond yes or no to the question, “Has your doc-
tor told you that you have any of the following problems?”
followed by a list of 21 commonly reported conditions,
plus an “other” category. We categorized the number of
comorbidities into groups of low (0–1), moderate (2–3), and
high ($4).
The 6MWT is recommended to assess long-distance walk-
ing and submaximal aerobic capacity (28). Participants were
asked to walk as quickly as possible for 6 minutes on a flat
25-meter track with no corners (29), with the distance
walked recorded in meters. Measurement of oxygen satura-
tion, heart rate, and perceived exertion were taken prior to
and at test completion. Participants with respiratory or car-
diac comorbidity had measures at 1-minute intervals; the
test was discontinued if participants reported concerning
symptoms.
At reassessments, participants were asked a transition
question (“Compared with when I started this program,
my hip/knee has. . .”) to rate their signal joint health status
compared with prior to starting the program, with the fol-
lowing choices on a 7-point scale: much improved, mod-
erately improved, slightly improved, not changed, slightly
worse, moderately worse, or much worse.
Definitions of worsening. WOMAC-G definition of wor-
sening. The minimal important difference (MID) is the
smallest difference in scores of the variable considered to
be beneficial or detrimental by participants (30). MID
thresholds for worsening of 9.6 points absolute and 21%
relative change in WOMAC-G were previously determined
for a comprehensive rehabilitation intervention for hip and
knee OA (13). We termed this threshold the “WOMAC-G
Figure 1. Study flow diagram. OACCP5Osteoarthritis Chronic Care Program; WOMACG5Western
Ontario and McMaster Universities Osteoarthritis Index global score; DASS5Depression, Anxiety and
Stress Scale.
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definition of worsening.” A similar threshold has been
used previously to indicate meaningful symptomatic wors-
ening of participants on TJA waitlists (16).
Transition definition of worsening. In addition to pre-
and postintervention assessment questionnaires, a transi-
tion scale is recommended to assess efficacy of self-
management education programs (14). Therefore, the sec-
ond definition of worsening was defined by the transition
scale participant response of “moderately worse” or “much
worse.” In the absence of evidence for an ideal cutoff for
change on the transition question that is meaningful to par-
ticipants (31), we decided that “slightly worse” was not an
adequate threshold for worsening, in an attempt to ensure
that participants were reporting a change that was important
to them.
Composite definition of worsening. The final definition
of worsening was based on combined criteria of 9.6 points
absolute and 21% relative change in WOMAC-G scores or
“moderately worse” or “much worse” on the transition
scale. This was chosen to reflect the dual importance of self-
reported worsening of symptoms and self-reported overall
deterioration of the signal joint.
Statistical analysis. Power calculations were based on
evidence that 25% of patients waitlisted for TJA wors-
ened $9.6 WOMAC-G points over 6 months (16). Given
that only half of the OACCP participants were on TJA
waitlists, we extrapolated that around 12.5% of the sam-
ple would report worsening. Further, because all partici-
pants received interventions for their OA, we expected
that the majority of participants would report no change
or improvements following the intervention and there-
fore estimated 10% of participants would “worsen.” A
sample of 500 participants was considered sufficient to
include 3–5 variables in the final model, assuming 10
participants reported worsening per predictor variable
(32,33).
A series of regression analyses were conducted in SPSS
(version 22.0). For each model, the dependent variable
was “worsening” and was based on dichotomization of
participants into 2 groups: worse and not worse using
each definition of worsening. Independent predictor vari-
ables were identified a priori, and the physical therapist
collecting data was blinded to which variables were ana-
lyzed as predictors of worsening. Missing 26-week assess-
ment data from patients who were not lost to followup
had their 12-week assessment data carried forward, simi-
lar to intent-to-treat analysis. Further, the 6MWT results
were standardized to ensure the scale (meters) was compa-
rable with the other variables (34).
Univariate logistic regression analyses examined the
odds of an OACCP participant worsening when each pre-
dictor variable was present. Subsequently, multivariate
regression models were built for each definition of wors-
ening. Variables exhibiting odds with P less than 0.2 that
trended in the same direction across a minimum of 2 defi-
nitions were included in the base model for all 3 defini-
tions of worsening. This method enabled interpretation
and comparison of results between the composite defini-
tion and the single-outcome definitions (WOMAC-G and
transition definitions) (15). The least significant predictor
was removed at each step of the modelling until only sig-
nificant variables remained. The regression coefficients of
the remaining variables were checked on removal of each
variable from the model, and in the presence of a change of
$10% the variable was retained. Testing for interactions
was performed by combining variables of interest. The
validity of each model was assessed using Hosmer-
Lemeshow goodness-of-fit, and the predictive ability of
the model was assessed by calculation of sensitivity and
specificity.
RESULTS
Of 539 participants consecutively enrolled in the OACCP
from March 2012 to July 2014, 153 were excluded due to
missing data or the presence of a floor/ceiling effect
whereby they could not achieve the WOMAC-G definition
(Figure 1). Reasons for missing data included undergoing
TJA, medical advice, moving interstate, and illness or
death.
Included and excluded participants were of similar age,
were overweight, and reported a low to moderate number
(0–3) of comorbidities (Table 1). Higher proportions of
excluded participants were on TJA waitlists, presented
with hips as the signal joint, and demonstrated depressive
symptoms. Fewer excluded participants finished second-
ary school (P5 0.018) and their mean WOMAC-G scores
were higher (P,0.001). Excluded patients exhibited
worse 6MWT results and higher baseline pain-VAS,
although the mean difference was within measurement
error for both outcomes (35). In the multidisciplinary
OACCP clinic, most participants (95%) saw a rheumatolo-
gist, 75% were referred to a dietitian, 55% to an occupa-
tional therapist, 50% to a social worker, and 50% to an
orthotist.
Definition of worsening outcomes. The 386 participants
with complete data sets were included in the regression
analyses. Of these, 34 (9%) reported worsening according
to the WOMAC-G definition, 34 (9%) met the criteria for
worsening for the transition definition, and 56 (15%) for the
composite definition. Only 12 participants met all 3 defini-
tions of worsening. According to both the transition defini-
tion (odds ratio [OR] 2.7 [95% confidence interval (95% CI)
1.26, 5.62]) and the composite definition (OR 2.2 [95% CI
1.22, 3.91]), OACCP participants waitlisted for TJA had
more than twice the odds of reporting worsening. There
was a trend that those with signal joint knees had lower
odds of reporting worsening (Table 2). The standardized
6MWT was significantly associated with the transition defi-
nition and trended towards significance for the composite
definition of worsening whereby farther walking distance
indicated reduced odds of worsening (OR 0.7 [95% CI 0.46,
0.70]). The results of the univariate analyses differed when
the WOMAC-G worsening definition was applied; partici-
pants reporting depressive symptoms were less likely to
worsen.
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Multivariate models. The final model for the WOMAC-G
definition retained only presence of depressive symp-
toms (OR 0.30 [95% CI 0.11, 0.79]) (Table 3). The final
multivariate model for the transition definition contained
TJA waitlist, 6MWT, and signal joint; however, these pre-
dictors did not attain statistical significance (Table 3).
The final multivariate composite definition model
retained TJA waitlist (OR 1.91 [95% CI 1.04, 3.51]) and
6MWT (OR 0.83 [95% CI 0.60, 1.13]). According to the
composite definition, participants on TJA waitlists had
almost twice the odds of worsening. The 6MWT was a
confounder, although as the CI crossed zero, we can
interpret this as having little or no effect. The composite
definition model fit the data well using the Hosmer-
Table 1. Baseline characteristics of OACCP participants*
Baseline characteristics
Included
(n5 386)
Excluded:
missing data
(n5 153)† P‡
Female 69 63 0.242
Age, mean6SD years 66.369.97 65.86 11.35 0.620
Signal joint knee 85 73 0.006
On TJA waitlist 46 59 0.008
Residence
Lives alone§ 28 29 0.694
Speaks English¶ 93 89 0.146
Engaged in paid employment# 31 28 0.573
Education 0.018
Finished secondary school or higher** 57 46
Did not finish secondary school†† 43 54
BMI, mean6SD kg/m2 30.066.47 32.16 7.17 0.001
Pain VAS (range 0–10), mean6SD 4.16 2.17 5.46 2.58 , 0.001
6MWT, mean6SD meters 421.66 111.72 380.76 129.13 0.001
Depressive symptoms: DASS depression
subscale ($14) (%)
35 48 0.005
Number of comorbidities 0.233
Low (0–1) 39 32
Moderate (2–3) 39 41
High ($4) 22 27
Baseline WOMAC-G, mean6SD (range)‡‡ 49.16 18.09 (3.1–82.3) 61.76 23.67 (0–97.9) , 0.001
Baseline WOMAC-G for those who worsened
vs. didn’t worsen, mean6SD§§
WOMAC-G
Worse, mean6SD (n5 34) 38.46 16.34
Not worse, mean6SD (n5 352) 50.26 17.93
(CI difference in means) P (218.02, 25.45), 0.01
Transition¶¶
Worse, mean6SD (n5 34) 58.36 17.31
Not worse, mean6SD (n5 352) 48.36 17.94
(CI difference in means) P (3.69, 16.32) 0.002
Composite##
Worse, mean6SD (n5 56) 49.36 19.91
Not worse, mean6SD (n5 330) 49.16 17.79
(CI difference in means) P (24.91, 5.38) 0.929
* Values are the percentage unless indicated otherwise. OACCP5Osteoarthritis Chronic Care Program; TJA5 joint replacement arthroplasty;
BMI5 body mass index; VAS5 visual analog scale; 6MWT5 6-Minute Walk Test; DASS5Depression, Anxiety and Stress Scale; WOMAC-G5
Western Ontario and McMaster Universities Osteoarthritis Index global scores; CI5 confidence interval.
† Missing data include those participants with missing 0-, 12-, or 26-week WOMAC-G data (n5 126), those whose week 0 WOMAC-G score
equaled 0 (n5 2), those with week 0 WOMAC-G .82.6, and missing DASS depression data (n5 1).
‡ Independent analysis of variance or chi-square statistic comparing included and excluded participants.
§ Lives alone reported by participants. Living with others included living with abled/disabled person, in hostel or aged-care residential facility.
¶ Participants who did not speak English (;7%) required the use of an interpreter.
# Currently employed includes participants who reported engaging in full-/part-time paid work.
** Included participants who reported finishing secondary school (final year) or university degree.
†† Includes participants who did not finish secondary school and those who reported no formal schooling.
‡‡ WOMAC-G scores are calculated from the Hip Disability and Osteoarthritis Outcome Score and the Knee Injury and Osteoarthritis Outcome
Score, where 0 indicates no problems and 100 indicates extreme problems.
§§ WOMAC-G minimum clinically important difference for worsening is 9.6 points absolute and 21% relative change in WOMAC-G compared to
baseline.
¶¶ Transition definition of worsening; participant response was “moderately worse” or “much worse.”
## Composite definition of worsening; 9.6 points absolute and 21% relative change in WOMAC-G scores compared to baseline OR transition ques-
tion response as “moderately worse” or “much worse.”
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Lemeshow goodness-of-fit test (x25 8.68, 2 df, P5 0.37);
however, it was only capable of explaining 5% of the
variance in demonstrating worsening (Figure 2). No
model could predict worsening on all 3 definitions
together. Although the best model was specific, i.e., cor-
rectly identified participants who did not worsen, it
lacked sensitivity, so failed to identify those who had
worsened.
Table 2. Univariate logistic regression analyses of predictors for 3 definitions of worsening*
WOMAC-G† Transition‡ Composite§
Independent variable
Unadjusted
OR (95% CI) P
Unadjusted
OR (95% CI) P
Unadjusted
OR (95% CI) P
Age 1.0 (0.99, 1.08) 0.062 1.0 (0.99, 1.10) 0.114 1.0 (1.00, 1.07)¶ 0.028¶
Sex
Male Reference Reference Reference
Female 1.1 (0.50, 0.23) 0.895 1.6 (0.78, 3.29) 0.199 1.3 (0.70, 2.28) 0.477
Signal joint
Hip Reference Reference Reference
Knee 1.0 (0.39, 2.84) 0.922 0.5 (0.20, 1.04) 0.063 0.5 (0.27, 1.07) 0.078
Pain VAS 1.0 (0.83, 1.15) 0.820 1.2 (1.04, 1.45)¶ 0.017¶ 1.1 (1.00, 1.24) 0.203
Number of comorbidities
Low Reference 0.274 Reference 0.605 Reference 0.365
Moderate 1.3 (0.63, 2.88) 0.443 0.9 (0.43, 1.1) 0.845 1.1 (0.60, 2.05) 0.753
High 0.5 (0.17, 1.73) 0.302 0.6 (0.21, 1.68) 0.323 0.6 (0.26, 1.41) 0.244
Depression
No depression Reference Reference Reference
Any depression 0.3 (0.11, 0.79)¶ 0.015¶ 1.4 (0.66, 2.77) 0.409 0.6 (0.35, 1.22) 0.180
6MWT 1.1 (0.72, 1.50) 0.791 0.7 (0.46, 0.70)¶ 0.033¶ 0.8 (0.57, 1.03) 0.079
BMI 1.0 (0.95, 1.06) 0.989 1.0 (0.91, 1.02) 0.226 1.0 (0.93, 1.02) 0.351
TJA waitlist
On list Reference Reference Reference
Not on list 1.4 (0.67, 2.73) 0.404 2.7 (1.26, 5.62)¶ 0.011¶ 2.2 (1.22, 3.91)¶ 0.009¶
* WOMAC-G5Western Ontario and McMaster Universities Osteoarthritis Index global score; OR5odds ratio; 95% CI5 95% confidence interval;
Reference5 reference category for logistic regression; VAS5 visual analog scale; 6MWT5 standardized 6-Minute Walk Test; BMI5 body mass
index; TJA5 total joint arthroplasty.
† WOMAC-G minimum clinically important difference for worsening: 9.6 points absolute and 21% relative change in WOMAC-G compared to
baseline.
‡ Transition question definition of worsening: participant response as “moderately worse” or “much worse.”
§ Composite definition of worsening: 9.6 points absolute and 21% relative change in WOMAC-G compared to baseline OR transition question
response as “moderately worse” or “much worse.”
¶ P, 0.2, one of the criteria for entry into multivariate model.
Table 3. Final multivariate logistic regression models for 3 definitions of worsening*
Definition
of worse Worse, no. (%) Predictors b coefficient P
Adjusted
OR 95% CI
WOMAC-G† 34 (9) Constant 22.04
Depression 21.21 0.015 0.30 0.11, 0.79
Transition‡ 34 (9) Constant 21.14
TJA waitlist 0.65 0.114 1.91 0.86, 4.29
Signal joint knee 20.54 0.238 0.58 0.24, 1.43
6MWT 20.34 0.092 0.071 0.48, 1.06
Composite§ 56 (14.5) Constant 21.47
TJA waitlist 0.65 0.036 1.91 1.04, 3.51
6MWT 20.19 0.231 0.83 0.60, 1.13
* OR5 odds ratio; 95% CI5 95% confidence interval; WOMAC-G5Western Ontario and McMaster Universities
Osteoarthritis Index global score; TJA5 total joint arthroplasty; 6MWT5 6-Minute Walk Test.
† WOMAC-G minimum clinically important difference for worsening: 9.6 points absolute and 21% relative change
in WOMAC-G compared to baseline.
‡ Transition question definition of worsening: participant response was “moderately worse” or “much worse.”
§ Composite definition of worsening: 9.6 points absolute and 21% relative change in WOMAC-G compared to base-
line OR transition question response as “moderately worse” or “much worse.”
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DISCUSSION
This study aimed to identify participant characteristics pre-
dictive of 3 definitions of worsening following 26 weeks of
participation in the OACCP. We hypothesized that the same
participants with similar demographic, psychological,
disease-related, and functional performance predictor vari-
ables would be identified as “worse” across 3 definitions;
however, this was not the case. Similar trends were demon-
strated by the transition and composite models; TJA waitlist
and 6MWT were retained in both, though the transition
model also retained signal joint and did not reach statistical
significance. These trends were not apparent when the
WOMAC-G definition was applied.
The evidence for symptomatic deterioration while wait-
ing for TJA is conflicting. A systematic review (36) reported
people with hip or knee OA waiting for less than 6 months
did not experience 10% deterioration in WOMAC pain or
function scores. In contrast, 25% of those waiting for TJA
longer than 6 months reported a decline of $9.6%
WOMAC-G scores (16). Only 46% of our sample was listed
for TJA and these participants had been waiting for approxi-
mately 6 months. This may account for the lack of associa-
tion between TJA waitlist status and the WOMAC-G
definition of worsening. The participants lost to followup
due to TJA and other reasons reported a higher mean6SD
WOMAC-G of 61.7623.67, which is more similar to the pre-
vious study (16). These participants may have worsened in
this time without surgery; however, we do not have the data
to support this supposition. The group reporting worsening
according to the WOMAC-G definition had significantly
lower baseline mean6SD WOMAC-G scores of 38.46
16.34, compared to 50.26 17.93 for those who did not
(Table 1). One possible explanation is that there was a
regression to the mean in participants with lower baseline
WOMAC scores.
In contrast to our hypothesis, 22 of 34 people who
reported worsening on the transition scale were not con-
sidered worse according to the WOMAC-G definition
despite using “moderately worse” as the minimum cutoff.
This contrasts with the study from which the threshold is
derived (13). In the former study participants were not on
the TJA waitlist, the intervention focused on physical
therapy (not multidisciplinary), and was of shorter dura-
tion (3–4 weeks). It is possible that the thresholds we used
to indicate worsening were not ideal for our study popula-
tion. Further work is required to confirm the most appro-
priate threshold of worsening for this population.
Alternatively it is possible that discordance of worsen-
ing according to WOMAC-G and transition scale defini-
tions may be attributed to the attitudes and expectations
of participants waitlisted for TJA. The act of booking a per-
son for TJA possibly preconditions them to believe that
their signal joint should become worse over time. The lan-
guage used, such as “end-stage,” “severe,” and “bone-on-
bone,” may influence their response of “moderately worse”
or “much worse,” even though their WOMAC-G scores, a
much lengthier questionnaire directly asking about specific
symptoms, did not reflect this. The association between
use of specific language by caregivers and patient percep-
tion of disease severity has received minimal research
attention and is a potential area for future work. However,
considerable paternalism persists in medical decision-
making about TJA (37,38). Perhaps some of our cohort
believed that they needed the surgery because the surgeon
said so, and this was sufficient evidence to report that their
overall hip or knee joint health was “worse.”
Participants on TJA waitlists had twice the odds of meet-
ing the composite criteria for “worsening” following partici-
pation in the OACCP. While TJA can provide good
symptomatic relief for most people with end-stage OA (39),
nonsurgical management is efficacious in reducing the
signs and symptoms of knee OA (5). It is advocated that
patients be referred for nonsurgical treatments as a first
port-of-call, and participation in chronic disease manage-
ment programs should commence earlier in the OA disease
course prior to being waitlisted for TJA. Although at this
stage we can only explain a very small proportion of vari-
ables that predict worsening, referring participants earlier
in their disease course may lessen their odds of worsening
despite taking part in self-management programs.
The absence of depression was a significant predictor of
worsening according to the WOMAC-G definition. This
finding is counterintuitive; a possible explanation is that of
34 participants who worsened according to the WOMAC-G
definition, only 5 reported depressive symptoms. This result
is likely to be a type I error. The evidence for the absence of
depression as a predictor of positive response to nonsurgical
interventions for hip and knee OA is conflicting (18,19,40).
Further investigation of the relationship between symptoms
of depression and outcomes following participation in the
OACCP is warranted. Depression has been associated with
noncompliance with treatment in populations with chronic
disease (41). Compliance with OACCP interventions was
not measured in this study. Exploration of the association
between compliance with multimodal therapies, depres-
sion, and self-reported worsening should also be addressed
in future research.
Signal joint was independently associated with the transi-
tion and composite definitions of worsening; participants
with knee OA had lower odds of worsening following the
OACCP. However signal joint was not a significant predictor
in the multivariate models. Previous research found that
people waiting for hip TJA do not deteriorate compared to
those awaiting knee TJA; however, those participants were
not receiving interventions for their OA (42). In contrast, a
Figure 2. Summary of how much we can explain worsening in
response to a nonsurgical program. OACCP5Osteoarthritis
Chronic Care Program.
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previous study following 26 weeks of participation in the
OACCP for those with signal joint knees had twice the odds
of responding as those with signal joint hips (18). Although
exercise for hip OA may confer some reduction in pain and
improvement in function, the treatment effect sizes are
small (43). Further research into effective nonsurgical man-
agement options for participants with hip OA is urgently
required.
Although previous research reports age, sex, and BMI to be
important characteristics in disease progression and response
to intervention for hip and knee OA (6,10,18,19,44,45), they
were not found to be significant predictors of worsening
in our current investigation. The presence of comorbidities
has been associated with poorer health-related quality of life
for OA patients (46), yet greater number of comorbidities was
not associated with any definition of worsening. This is an
important finding suggesting that nonsurgical management
may be considered for anyone with any number of concomi-
tant conditions. Increasing pain over time has been associ-
ated with progression to TJA (7), and baseline WOMAC pain
scores independently correlated with TJA 6 years following
assessment (9). Baseline pain-VAS was only independently
associated with the transition definition, and therefore failed
to meet the criteria for entry into the multivariate models.
The 6MWT was not a predictor of “response” in a similar
OACCP cohort (47); however, the self-paced 40-meter walk
test was predictive of response to physical therapy interven-
tions for patients with hip OA (17). There is a gap in the
research concerning external validity of the 6MWT as com-
pared to PROs (48).
This study has several notable strengths: overall it was
well-powered, potential predictor variables were identified
a priori, and care was taken to avoid overfitting the predic-
tion models. A physician’s diagnosis of OA was used,
which has good face validity (49). Although we were able
to determine why participants withdrew participation from
the OACCP, WOMAC data were missing for some who pro-
gressed to TJA, resulting in their exclusion from the analy-
sis. This potentially limits the applicability of our results.
Data from these participants would have been very useful to
determine if these participants met any of the “worsening”
definitions immediately prior to their surgery. Significant
predictors of worsening were found; however, the multivari-
ate models provide a very small proportion of the factors
that predict worsening (Figure 2) and were not sensitive.
It is possible that stronger predictors of worsening exist
that have not yet been studied, or perhaps the thresholds
chosen to represent the predictors affected the outcome. We
transformed symptoms of depression and number of comor-
bidities into categorical variables, which may not have been
ideal. This study did not include a control group and was
limited to 1 OACCP site; both investigation into predictors
of worsening compared to a control group and use of more
heterogeneous samples of participants are important areas
for future research.
Three definitions of worsening were applied; potential
predictors were identified only when using the composite
definition of worsening. While TJA waitlist status was
associated with a 2-fold increase in odds of reporting
worsening using this definition, the model explained only
5% of the total variance. Further, following 26 weeks of
participation in the OACCP, the WOMAC-G was largely
discordant with the transition and composite definitions of
worsening. Participants with similar demographic, psycho-
logical, disease-related, and functional performance predic-
tor variables were not consistently identified as “worse”
across the 3 definitions. Variables that predict worsening
are largely unknown and further research into this area is
warranted in order to present comprehensive and targeted
management of patients with hip and knee OA.
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Objective: To make a recommendation on the “best” instrument to assess attitudes toward and/or ca-
pabilities regarding self-management of osteoarthritis (OA) based on available measurement property
evidence.
Methods: Electronic searches were performed in MEDLINE, EMBASE, CINAHL and PsychINFO (inception
to 27 December 2016). Two reviewers independently rated measurement properties using the
Consensus-based Standards for the selection of Health Measurement Instruments (COSMIN) 4-point
scale. Best evidence synthesis was determined by considering COSMIN ratings for measurement prop-
erty results and the level of evidence available for each measurement property of each instrument.
Results: Eight studies out of 5653 publications met the inclusion criteria, with eight instruments iden-
tiﬁed for evaluation: Multidimensional Health Locus of Control (MHLC), Perceived Behavioural Control
(PBC), Patient Activation Measure (PAM), Educational Needs Assessment (ENAT), Stages of Change
Questionnaire in Osteoarthritis (SCQOA), Effective Consumer Scale (EC-17) and Perceived Efﬁcacy in
PatientePhysician Interactions ﬁve item (PEPPI-5) and ten item scales. Measurement properties assessed
for these instruments included internal consistency (k ¼ 8), structural validity (k ¼ 8), testeretest reli-
ability (k ¼ 2), measurement error (k ¼ 1), hypothesis testing (k ¼ 3) and cross-cultural validity (k ¼ 3).
No information was available for content validity, responsiveness or minimal important change (MIC)/
minimal important difference (MID). The Dutch PEPPI-5 demonstrated the best measurement property
evidence; strong evidence for internal consistency and structural validity but limited evidence for reli-
ability and construct validity.
Conclusion: Although PEPPI-5 was identiﬁed as having the best measurement properties, overall there is
a poor level of evidence currently available concerning measurement properties of instruments to assess
attitudes toward and/or capabilities regarding osteoarthritis self-management. Further well-designed
studies investigating measurement properties of existing instruments are required.
© 2017 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.J. Eyles, 7C Clinical Adminis-
ital, St Leonards, NSW 2065,
Eyles), david.hunter@sydney.
(S.R.F. Meneses), n.collins1@
(F. Dobson), Barbara.Lucas@
.au (K. Mills).
ternational. Published by Elsevier LIntroduction
Healthcare systems currently face a rising number of people
living with chronic conditions leading to disability, without causing
death1. The Chronic Care Model (CCM) has been promoted to assist
healthcare systems to meet the escalating demands attributable to
chronic conditions2. The CCM describes healthcare whereby pa-
tients are enabled to manage their condition supported by atd. All rights reserved.
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of health professionals with the expertise required to provide de-
cision support, all underpinned by appropriate health information
systems2. Self-management programmes are interventions based
on the tenets of the CCM; they aim to improve self-management
capabilities. It follows that the efﬁcacy of these programmes
should be measured by assessing change in participants' attitudes
toward and/or capabilities to manage their health. However, there
are few recommendations guiding which instruments accurately
measure self-management3. The widespread heterogeneity in
standardised instruments measuring self-management programs is
surprising given that the primary aim of these programs is to
directly inﬂuence the attitudes toward and abilities to manage
one's health.
This situation is apparent in self-management programmes for
osteoarthritis (OA). Research examining the efﬁcacy of OA self-
management programmes has focussed on measures of pain and
function4. While these outcomes are obviously important to this
population, there appears to be disparity in the aims of self-
management programmes and the outcomes used to assess efﬁ-
cacy5. Self-management programs aim to provide participants with
the necessary tools to manage their own condition rather than
“cure” OA. Although these programmes may not dramatically
reduce pain and enhance functional ability, this does not neces-
sarily reﬂect a failed strategy if the participants improve their at-
titudes towards and ability to manage symptoms and live with an
acceptable quality of life despite their disease5.
A systematic review reported low-to-moderate quality evidence
of no or small beneﬁts to participants of OA self-management ed-
ucation programmes5. The authors highlighted the heterogeneity of
outcomes used to quantify the effects of self-management pro-
grammes and that work is needed to establish which outcomes are
important to patients. This review recommended rigorous evalua-
tion of OA self-management programmes with validated in-
struments ﬁt to measure attitudes towards/capabilities to self-
manage OA, and advised that to achieve this, the measurement
properties of the existing instruments need further investigation5.
Measurement properties refer to the ability of the instrument to
truthfully and comprehensively measure the speciﬁed construct6.
In addition, it is necessary to demonstrate that the instrument is
discriminative, sensitive, reliable and deemed feasible in terms of
cost and time constraints7. It is important to consider that the
measurement properties of an instrument are not universal across
different populations; hence, it cannot be assumed that one with
good measurement properties in a speciﬁc population will
demonstrate the same results in a different population8. Therefore,
the measurement properties of an instrument must be considered
within the speciﬁc context of the population of interest.
The aims of this systematic review were to: (1) identify studies
reporting measurement properties of instruments assessing atti-
tudes toward and/or capabilities regarding self-management of OA;
(2) systematically critique the studies evaluating instruments using
the Consensus-based Standards for the selection of Health Mea-
surement Instruments (COSMIN) tool; and (3) synthesize the evi-
dence available with the possibility of making rudimentary
recommendations concerning the best evidence-based in-
struments to assess attitudes toward and/or capabilities regarding
self-management of OA.
Methodology
Terminology
Self-management was deﬁned as the individual's ability to
manage their physical and psychological symptoms, treatments,consequences and lifestyle changes required to live with their OA9.
Attitudes toward and/or capabilities regarding self-management of
OA included the following constructs: knowledge, skills, beliefs,
behaviours, activation, self-efﬁcacy, health locus of control, readi-
ness to change healthcare behaviours, healthcare navigation,
participation, engagement, and motivation. This list of possible
constructs was developed a priori using existing content knowledge
about available instruments of the authors, and new constructs
identiﬁed during the review were also included.
Review protocol
The review protocol was developed in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement and prospectively registered with
PROSPERO on 24 November 2015 (CRD42015019074).
Literature search
The review search strategy was developed and reﬁned by the
study authors according to the PRISMA statement and recom-
mendations made for conducting systematic reviews of measure-
ment properties8,10. Electronic searches were conducted of the
following four bibliographic databases from inception to 27
December 2016: MEDLINE (PubMed), EMBASE (OvidSP), CINAHL
(Ebsco), PsychINFO (OvidSP). An initial search was conducted using
four main ﬁlters containing key search terms as brieﬂy summarised
below (see Appendix 1 PubMed search strategy):
I. Constructe attitudes toward and capabilities regarding self-
management of OA using terms such as: “self-treatment OR
self-management OR patient education…” Names of known
instruments measuring attitudes and/or capabilities
regarding self-management were added using ‘OR’: “health
education impact questionnaire OR patient activation mea-
sure OR effective consumer scale…”
II. Target population e osteoarthritis OR osteoarth* OR
degenerative arthritis OR arthrosis.
III. Measurement instrument ﬁlter e designed for PubMed to
retrieve more than 97% of publications related to measure-
ment properties11 using terms such as: “instrumentation OR
methods OR validation studies…” The ﬁlter was translated
into the language of the other databases used.
IV. Exclusion ﬁltere an exclusion ﬁlter was used to improve the
precision of the measurement instrument ﬁlter11.
Secondary searching was conducted for all instruments
measuring attitudes toward and capabilities regarding self-
management of OA identiﬁed during the initial search. The name
of each instrument was used as the keyword combined (AND) with
the target population ﬁlter in PubMed. Targeted hand searching of
reference lists was also used. Results of the database searches were
imported into Endnote X7 (Thomson Reuters, Philadelphia, USA).
Eligibility criteria
Study titles were screened by one reviewer (JE). Two reviewers
(JE & SM) independently screened abstracts, followed by the full
text of potentially eligible studies. Disagreements were discussed
and resolved with a third reviewer (KM). Studies were included if
they met the following criteria:
1. Construct e at least one instrument attempted to measure the
participants' attitudes and/or capabilities regarding self-
management of their OA.
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according to American College of Rheumatology guidelines,
clinical diagnosis of OA from examination ﬁndings, patients'
symptoms or radiographic evidence of disease. Studies with
mixed disease populations were excluded if the proportion of
participants with a main diagnosis of OA was less than 80% and
the results for OA participants were not reported separately.
3. Measurement instrumente patient-reported outcomes (PROs)
(completed by the participant) in the form of questionnaires or
scales.
4. Measurement properties e the study was required to explicitly
state a primary or secondary aim to develop an instrument or
examine at least one measurement property of the instrument
involved.
5. Settinge the instrument was required to have been utilised in a
clinic, ﬁeld or community setting using readily available
equipment. Instruments with a license fee were included.
6. Publication type e full text studies published as original arti-
cles in peer-reviewed journals.
7. Language e English language studies were included. Non-
English language studies were noted and data extraction per-
formed when possible, however these were excluded from
COSMIN rating due to lack of access to translation resources, and
the high level of detail required for a COSMIN review.Data extraction
Two reviewers (JE & SM) independently extracted data to a
predeﬁned spreadsheet with a third reviewer (KM) available to
resolve differences. The generalisability of the included studies was
considered by extracting characteristics such as mean age, gender
distribution, OA stage, setting and language. Relevant data
regarding interpretability issues was extracted including distribu-
tion of scores, ﬂoor and ceiling effects, change scores, and minimal
important change (MIC) or minimal important difference (MID)12.Methodological quality evaluation of the studies
Two raters (JE & NC) independently assessed the methodolog-
ical quality of the included studies, with a third rater (FD) available
to resolve discrepancies. Included studies were assessed according
to the COSMIN taxonomy of the following measurement proper-
ties: internal consistency, reliability, measurement error, content
validity, structural validity, hypotheses testing (a form of construct
validity), cross-cultural validity, and responsiveness13. The deﬁni-
tions of these measurement properties are summarised in Table I12.Table I
Deﬁnitions of measurement properties
Measurement property Deﬁnition
Internal consistency The degree to which items of an instrument are relat
Reliability The proportion of the total variance of “true differenc
Measurement error The component of a patient's score that is not due to
systematic and/or random error
Content validity The degree to which the content of the instrument m
Structural validity The extent to which the scores of an instrument conf
Hypotheses testing An aspect of construct validity; when questions are fo
measuring related constructs
Cross-cultural validity The extent to which the translated or culturally adap
Criterion validity When the scores of an instrument are compared to d
considered to be the “gold standard”
Responsiveness The measurement of the ability of the instrument to
Floor and ceiling effects The proportion of participants who responded with t
Deﬁnitions adapted from Mokkink et al. J Clin Epidem 36 (2010) and de Vet, H. et al., “MEach measurement property featured within a particular study was
rated separately according to the COSMIN tool; a robust quality
evaluation tool using a 4-point scoring system: “poor”, “fair”,
“good” or “excellent”12,14. An overall quality score was given for
each measurement property in each study using the “worst score
counts” method that accounted for the lowest rating of any item
within that measurement property section14.
Evaluation of measurement property result
An overall quality rating of the measurement property results
for each instrument was performed using a checklist of criteria for
good measurement properties15 (Appendix 2). Two raters deter-
mined the quality rating using this additional tool (JE & SM) with
disagreements resolved with a third reviewer (NC).
Data synthesis
Qualitative analysis
To summarise the level of evidence of each measurement
property for each instrument, a “best evidence synthesis” was
performed. The “best evidence synthesis” was derived by triangu-
lating the methodological quality of the studies12 (using the COS-
MIN score), the quality criteria for rating the results of
measurement properties (Appendix 2)15, and the level of evidence
for the measurement properties of the instruments according to
the following: “strong”, “moderate”, “limited”, “conﬂicting”, or
“indeterminate”8,15 (Table II).
Quantitative analysis
Meta-analysis of data was planned for studies of fair or better
methodological quality and of sufﬁcient homogeneity8.
Results
The initial search strategy identiﬁed 5653 studies (Fig. 1).
Following title and abstract screening, 44 studies were identiﬁed
for full-text review. Following full-text review, eight studies were
included16e23. Each study assessed a different instrument, there-
fore it was not possible to pool data for quantitative analyses.
The content of instruments varied widely with respect to the
constructs of self-management they represented. Table III provides
a content comparison of the constructs represented in the eight
instruments, their characteristics are summarised in Table IV. The
Patient Activation Measure (PAM)16 required a license fee; all
others were freely available online or following contact with the
authors. Many instruments were translated into a language othered to each other
es” measured by the instrument that is not attributed to measurement error
real changes of the construct measured by the instrument, but attributed to
easures the construct it intends to measure
orm to the dimensionality of the construct intended
rmulated a priori about the expected relationships with instruments
ted instrument reﬂects the performance of the original version of the instrument
etermine if they are reﬂective of the outcomes of another instrument
detect changes in scores that reﬂect change in the construct over time
he lowest or highest possible score on the instrument
easurement in Medicine: A Practical Guide to Biostatistics and Epidemiology” (2010).
Table II
Levels of evidence for the quality of the measurement property
Level of evidence Rating Criteria
Strong þþþ OR  Consistent ﬁndings in multiple studies of good methodological quality OR
in one study of excellent methodological quality
Moderate þþ OR  Consistent ﬁndings in multiple studies of fair methodological quality OR
in one study of good methodological quality
Limited þ OR  One study of fair methodological quality
Conﬂicting ± Conﬂicting ﬁndings
Indeterminate ? Only studies of poor methodological quality
þ ¼ positive rating, ? ¼ unknown rating,  ¼ negative rating.
Adapted from Terwee et al. J Clin Epidemiol 2007;60(1):34e42.
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Finnish, Norwegian, Portuguese, Spanish, Swedish20 and Chinese23.
Study characteristics such as cohort descriptors, sample sizes
and instrument scores are provided in Table IV. The OA sites
captured within the studies included hand, hip and knee17,20, hip
and knee18, knee23or were not speciﬁed16,19,21,22. Stage or duration
of OA was generally unreported. Participants were predominantlyExclusion Criteria i) PopulaƟon: proporƟon of parƟcipants with a m
results for OA parƟcipants were not reported sepa
ii) Construct: Not an instrument that measures aƫ
management of OA
iii) Instrument: Not a paƟent-reported outcome in
iv) Seƫng: Not used in a clinic seƫng/field
v) Measurement study: No primary or secondary a
property
vi) PublicaƟon type: Not a full-text arƟcle
vii) Language: Not English (only excluded from CO
AddiƟon
studies a
eligibility
sear
PubMed
4201 references
Embase
2136 references
Following remo
56
Full-text arƟcles as
3
AddiƟon
studies f
instrum
populaƟon
Total include
Fig. 1. Flowchart of the selectifemale across all studies and representative of the age of the wider
OA population, with mean age ranging from 62 to 72.2 years.
Measurement property results and “best evidence synthesis”
Findings for measurement properties are summarised in
Tables V and VI, qualitative data synthesis in Table VII.ain diagnosis of OA was less than 80% and the 
rately
tudes or abiliƟes pertaining to self-
 form of quesƟonnaire or scale
im to examine at least one measurement
SMIN review)
al full text 
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Table III
Content comparison of instruments measuring self-rated attitudes towards and capabilities to self-manage OA
Construct Attitudes/beliefs
pertaining to
self-management
of OA
Attitudes/beliefs
pertaining to
changing health
behaviour
Knowledge required
for self-management
Capability to
perform skills required
for self-management
Educational
needs for
self-management
of OA
Interactions with
health care providers
assisting with
management of OA
Overall capability
to self-manage OA
MHLC18 ✓
PBC19 ✓ ✓ ✓
PAM-1316 ✓ ✓ ✓ ✓ ✓
ENAT20 ✓ ✓ ✓ ✓
PEPPI-521 ✓ ✓ ✓
SCQOA17 ✓ ✓
EC-1722 ✓ ✓ ✓ ✓
PEPPI-1023 ✓ ✓ ✓
MHLC ¼ Multidimensional Health Locus of Control, IHLC ¼ Internal Health Locus of control, PBC ¼ Perceived behavioural control, PAM-13 ¼ Patient Activation Measure,
ENAT ¼ Educational needs assessment, PEPPI-5 ¼ Perceived Efﬁcacy in PatientePhysician Interactions Scale, SCQOA ¼ The Stages of Change Questionnaire in Osteoarthritis,
EC-17 ¼ Effective Consumer Scale.
The ✓ indicated the presence of the construct of the instrument listed.
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Internal consistency was estimated for all instruments. Strong
evidence (excellent rating) for internal consistency (Cronbach's
a ¼ 0.92) was found for the Perceived Efﬁcacy in PatientePhysician
Interactions 5 item scale (PEPPI-5)21, satisfying requirements for
unidimensionality (Appendix 2). Moderate evidence (good rating)
of adequate internal consistency was demonstrated for the
Perceived Efﬁcacy in PatientePhysician Interactions 10 item scale
(PEPPI-10)23 (Cronbach's a¼ 0.91). Limited evidence (fair rating) of
adequate internal consistency was found for three instruments:
Perceived Behavioural Control (PBC)19, PAM-1316 and The Stages of
Change Questionnaire in Osteoarthritis (SCQOA)17. There was
indeterminate evidence (poor rating) of internal consistency for
three instruments: Multidimensional Health Locus of Control
(MHLC) (form C)18, Educational Needs Assessment Tool (ENAT)20
and Effective Consumer Scale (EC-17)22.
Reliability
Adequate test-retest reliability required intraclass correlation
coefﬁcient (ICC) >0.7 (see Appendix 2). There was limited evidence
(fair rating) of inadequate test-retest reliability for the PEPPI-5
(ICC ¼ 0.68)21. Indeterminate evidence (poor rating) of adequate
testeretest reliability was found for the EC-1722 (ICC ¼ 0.71).
Measurement error
Although data for testeretest reliability can be used to calculate
measurement error, only one study reported this. There was inde-
terminate evidence of measurement error for the PEPPI-521 (limits
of agreement (LOA)6.83 to 6.35) because theMIC was not deﬁned
(see Appendix 2).
Structural validity
To demonstrate adequate structural validity, the factors identi-
ﬁed should explain at least 50% of the variability of responses (see
Appendix 2). There was strong evidence (excellent rating) that the
PEPPI-5 featured an appropriate 1-factor structure21. There was
moderate evidence (good rating) that the PEPPI-10 demonstrated a
two factor structure23. There was limited evidence (fair rating) of
positive structural validity for the PAM16 and limited evidence (fair
rating) that the factor structure of the SCQOA did not explain 50% of
the variance17. There was also limited evidence (fair rating) of a
negative result for structural validity of the ENAT20. The level of
evidence for the structural validity of the EC-17, MHLC and
PBC18,19,22 was indeterminate (poor rating).Hypothesis testing
The demonstration of adequate construct validity through hy-
pothesis testing required that speciﬁc hypotheses were formulated
a priori AND at least 75% of the results were in accordance with
these15. There was limited evidence (fair rating) for adequate
construct validity for the PEPPI-521 which was evaluated against;
General Self Efﬁcacy scale (GSES), Arthritis Impact Measurement
Scales 2 Family and Friends scale (AIMS2 F & F), Short Form 36
mental component summary score, and pain numerical rating
score (NRS). The EC-17was comparedwith the same instruments as
the PEPPI-5, however there was indeterminate evidence (poor
rating) for the hypotheses tested (see Table IV)22. The study
assessing PEPPI-10 did not formulate a priori hypotheses therefore
the evidence for hypotheses testing was indeterminate23.
Cross-cultural validity
Cross-cultural validity is established following speciﬁed trans-
lation procedures, then comparison of two cohorts differing only in
language/cultural background to test if the translated instrument
accurately reﬂects the measurements made in the original12. There
was limited evidence (fair rating) for adequate translation of the
English PAM24 into Korean16. The Korean PAM was not compared
with the English version. There was indeterminate evidence (poor
rating) for the translation of the English EC-1725 into Dutch22 and
no formal cross-cultural validation. There was limited evidence
(fair rating) of adequate translation of the English PEPPI-1026 into
Chinese23 with no cross-cultural validation. Cross-cultural com-
parisons were not made for the ENAT because the structural val-
idity was inadequate in the OA group20.
Floor and ceiling effects
Floor and ceiling effect results were rated using the quality
criteria for rating the results of measurement properties in
Appendix 2. There was strong evidence of absence of ﬂoor and
ceiling effects for the PEPPI-521, limited evidence of a ceiling effect
for the PEPPI-1023 and indeterminate evidence for ﬂoor and ceiling
effect for the EC-1722.
Best evidence synthesis
The instrument with the most promising level of evidence for
the measurement properties available was the PEPPI-5. Of note is
that these results are applicable only to the Dutch language version
of the PEPPI-5. There was strong evidence for internal consistency,
structural validity, and lack of ﬂoor/ceiling effects, however there
Table IV
Characteristics of included studies of instruments measuring attitudes toward and/or capabilities regarding self-management of OA
Authors/
Instrument
Construct
described
Time to
administer
Availability Language &
country
Number, type of questions & scoring Proportion
with OA (%)
OA site &
stage
% Other
diseases in
sample
N with >80%
OA (response
rate %)
Age: mean
age years (SD)
or age groups
(%)
Female % Mean (standard
deviation),
possible score
range, distribution
Kelly (2007)/
MHLC18
Measures beliefs
about who or what
controls the
patient's health
status
Not stated Freely available at:
http://www.nursing.
vanderbilt.edu/faculty/
kwallston/mhlcscales.
htm
English, USA &
Canada
Three scales of six items each, using
6-point Likert scale measuring the
following dimensions: ‘‘Internal’’
‘‘Chance’’ and ‘‘Powerful Others’’. Sum
the individual item scores for each
subscale.
86.2 Hip & knee Control
sample: 13.8
1040 (100) Study I: 65 (9)
Study II: 64
(16)
Study III: 62
(6)
Study I: (66)
Study II: (59)
Study III: (63)
IHLC: 26.44 (5.61)
PHLC: 20.22 (6.64)
CHLC: 16.96 (6.05)
Each subscale has
range 6e36
Liu (2007)/PBC19 Survey of OA
patients' drug
information
seeking from
physicians and
pharmacists.
Not stated In published paper English
USA
Eight statements with 7-point Likert
responses Perceived difﬁculty: 3
Self-efﬁcacy: 3 Controllability: 2
Answer for physicians & pharmacists
separately
100 Not stated e 1000 (61.9) 18e24: 1.8%
25e34: 3.8%
35e44: 11.9%
45e54: 27.6%
55e64: 28.3%
>64: 26.6%
72.8 PDP: 5.10 (1.60)
PDPh: 5.27 (1.49)
SEP: 5.62 (1.62)
SEPh: 5.62 (1.60)
CP: 5.63 (1.36)
CPh: 5.62 (1.37)
Ahn (2015)/PAM-
1316
Patient activation:
patient's
knowledge, skill,
and conﬁdence
regarding the self-
management of a
chronic disease
Not stated Insignia health
provides licenses for
the PAM at a cost
Korean, South
Korea
13-statements, with responses on a 4-
point Likert scale. Raw score: sum
responses to the 13 items. Scores
ranging from 13 to 52. converted to a
0e100 interval scale. Higher total
PAM scores reﬂect higher levels of
patient activation.
100 Not stated e 270 (100) 72.2 (8.3) 82.4 50.0 (13.5) 0e100
Ndosi (2014)/
ENAT20
Assesses the
educational needs
(priorities) of
patients with
rheumatic
diseases
Not stated Contact authors Austrian German
Finnish
Dutch
Norweigian
Portuguese
Spanish
Swedish
Austria
Finland
Netherlands
Norway
Portugal
Spain
Sweden
39 items with 4-point Likert scale in
seven domains: managing pain (six
items), movement (ﬁve items),
feelings (four items), arthritis process
(seven items), treatments (seven
items), self-help measures (six items)
and support systems (four items)
14.4 Hand, hip or
knee in
discussion.
Stage not
stated
AS: 22.5%
FM: 12%
PsA: 26.8%
SLE: 12.3%
SS: 12.0%
433 (response
rate not
stated)
Not stated for
OA sample:
pooled
sample is 52.6
(13.1)
Not stated for
OA but across
pooled sample
1111111111112066.2
Not stated for OA
group
ten Klooster
(2012)/PEPPI-
521
Self-efﬁcacy in
both obtaining
medical
information and
attention to chief
health concern
from a physician
Not stated Dutch version freely
available on web.
English version
published
Dutch, Nether-
lands
Five questions with responses on a 5-
point numerical rating scale. Total
scores are summed to range from 5 to
25, higher total scores reﬂect higher
perceived self-efﬁcacy in patient
ephysician interactions.
100 Not stated e 224 (55.4) 62.9 (10.2) 81.3 18.8 (4.3)
5e25
Slightly negatively
skewed
Heuts (2005)/
SCQOA17
People move from
low to high level of
participation.
Stages: no
intention to
change to optimal
active
participation with
internalization of
new behavior
3e5 min Published in paper as
appendix (in English)
Unclear (Dutch or
English),
Netherlands
21 items scored on 5-point Likert
scale.
Three subscales: seven questions for
precontemplation, seven for
contemplation, seven for action.
100 In results hip,
knee & hand.
Stage not
stated
e 273 (100) Range 40e60
years for
inclusion
criteria
59.7 Using highest
score method:
10.3% was in the
‘pre-
contemplation
stage’, 22.3% in the
‘contemplation
stage’, 67.0% was
‘in action’
ten Klooster
(2013)/EC-1722
Measures
knowledge,
attitudes, and
behaviours
regarding self-
management skills
Not stated Available in published
paper & on web http://
www.cgh.uottawa.ca/
assets/documents/
Survey.pdf
Dutch
Netherlands
17 items with 5-point Likert scale.
Item scores are summed when items
are completed and converted to range
from 0 to 100, where 100 is the best
possible score.
85.6 Not stated FM: 14.4 209 (55.8% of
combined OA
& FM sample)
62.6 (10.1) 80.9 68.9 (16.3), 0e100,
near normal
distribution
(Kolmogorov
eSmirnov,
P ¼ 0.058)
(continued on next page)
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J.P. Eyles et al. / Osteoarthritis and Cartilage 25 (2017) 1210e12221216was limited positive evidence for construct validity (hypothesis
testing) and limited evidence of negative ﬁndings for test-retest
reliability (Tables VI and VII). There was indeterminate evidence
for measurement error and no information for content validity, or
responsiveness.
Discussion
OA self-management programmes are not curative, but aim to
equip participants with the tools to manage their disease. It is
important to measure the changes in attitudes towards and/or ca-
pabilities regarding OA self-management to determine whether
participants achieve this aim and to demonstrate efﬁcacy of pro-
grammes. Further, it may be possible to predict outcomes of partici-
pants by measuring attitudes towards and/or capabilities in regards
toOAself-managementatbaseline. Thismayprovideabasisonwhich
to appropriately allocate healthcare resources to those thatwill likely
beneﬁt from such a programme. Participants reporting a positive
attitude toward self-management and good self-management capa-
bilities may be prioritised for immediate engagement in a pro-
gramme. Conversely, individuals reporting poorer attitudes and
capabilities may be targeted for supplementary therapies such as
motivational coaching to improve the likelihood of successful
participation in such a programme. In order to test whether this is
possible, we ﬁrst need to identify a suitable instrument measuring
attitudes towards and/or abilities regarding self-management of OA
that demonstrates good measurement properties.
This systematic review is the ﬁrst to synthesize the measure-
ment property evidence for instruments assessing attitudes to-
wards and/or capabilities regarding self-management of OA. There
were a very small number of studies identiﬁed; only eight studies
reported measurement properties of such instruments, each for a
separate instrument. The scope of measurement properties
assessed by the included studies was very limited. Internal con-
sistency and structural validity was estimated for all instruments.
Test-retest reliability21,22, and hypothesis testing21,22 were each
assessed for two instruments, cross-cultural validity was addressed
in three studies16,22,23. Measurement error was reported in one
study21, responsiveness and content validity were not evaluated for
any of the instruments.
Given the limited measurement property evidence for the
included instruments we cannot provide a deﬁnitive, evidence-
based recommendation for a particular instrument to measure at-
titudes towards and capabilities regarding OA self-management on
the basis of good measurement properties. On balance, the in-
strument with the “best” measurement properties was the Dutch
version of the PEPPI-521. There was strong evidence that the PEPPI-
5 satisﬁed requirements for internal consistency and structural
validity. There was limited evidence for the hypotheses speciﬁed
comparing PEPPI-5 scores against several other PROMs. The
testeretest reliability ﬁndings were sub-optimal (i.e., ICC < 0.7)
which has implications regarding the standard error of the mea-
sure. Greater standard error may require larger change scores to
represent ‘real’ change (vs error inherent in the measure) between
groups over time. The evidence for measurement error of the
PEPPI-5 was indeterminate because the MIC was not provided.
Measurement property evidence for content validity and respon-
siveness of the PEPPI-5 remains unknown. The remaining in-
struments identiﬁed in the review demonstrated moderate
evidence of positive measurement properties at best.
The PEPPI-5 was originally developed in a sample of “older
people” with mixed medical diagnoses; measurement property
results for internal consistency, structural and construct validity
were reported for this population26. Given the PEPPI-5 was devel-
oped for a different group of patients it may be that it has limited
Table V
Measurement properties instruments measuring self-management of OA according to the COSMIN checklist with 4-point scale: internal consistency, reliability, measurement error and structural validity
Instrument *Requirements
IRT
Internal consistency Reliability Measurement error Structural validity
Result Cronbach's alpha COSMIN
score
Result COSMIN score Result COSMIN score Result COSMIN
score
MHLC18 Good IHLC: 0.75; PHLC: 0.70;
CHLC: 0.65
Poor e e e e Conﬁrmatory FA, three factor model:
c2 ¼ 904.50, 135 df, (P < 0.01), RMSEA 0.0,
GFI ¼ 0.96, CFI ¼ 0.79, ECVI ¼ 0.81, PCA, FA &
Rasch analysis supported item reduction:
removed two items
Poor
PBC19 e PDP: a ¼ 0.77
PDPh: a ¼ 0.72
SEP:a ¼ 0.83
SEPh: a ¼ 0.83
Fair e e e e PCA & exploratory FA with Factor loading. Data
reduction & data detection
Fair
PAM-1316 Good a ¼ 0.88 Fair e e e e Conﬁrmatory PCA
GFI ¼ 32 (11.9%) misﬁts
MNSQ 0.68 to 1.42
Rasch analysis: person reliability was between
.87 (real) and .89 (model), and the item
reliability was 0.99. The separation index for
persons was 2.57 and that for items was 10.56
57.5% variance of data explained
Fair
ENAT20 Good IRT: Person separation
index >0.9
Poor e e e e Conﬁrmatory FA, structure detection & Rasch
analysis
OA group was a misﬁt
Fair
PEPPI-521 e a ¼ 0.92 Excellent Test-retest: ICC 0.68
(95% CI 0.56, 0.78)
BlandeAltman analysis
LOA 6.83e6.35 (mean
difference 0.24,
t(99) ¼ 0.71, P ¼ 0.48)
Fair LOA 6.83 to 6.35
differences e weakly
related to the
magnitude of the
measurement
(r2 ¼ 0.04, P ¼ 0.049),
indicating little to no
systematic bias
Fair Conﬁrmatory FA, factor loading & structure
detection (1 factor)
SB c2 (5) ¼ 17.43, NNFI ¼ 0.98, CFI ¼ 0.99,
SRMR ¼ 0.03, RMSEA (90% CI) ¼ 0.11 (0.05
e0.16)
Excellent
SCQOA17 e Action a ¼ 0.74
Precontemplation
a ¼ 0.70
Contemplator a ¼ 0.77
After removal of 5
items:
Action a ¼ 0.79
Precontemplation
a ¼ 0.72
Contemplation a ¼ 0.76
Fair e e e e Conﬁrmatory FA, factor loading & date
reduction: removal of items 3, 7, 12, 16, 18 and
20 PCA
Repeated FA with 15 item scale: 3 factors
explained 45% of variance
Fair
EC-1722 Good Person reliability: 0.92 Poor Test-retest
ICC ¼ 0.71 (95% CI: 0.60
e0.80)
Poor e e Conﬁrmatory FA
Apart from RMSEA, 1-factor model good ﬁt
SB c2 (119) ¼ 488.70, NNFI ¼ 0.96, CFI ¼ 0.96,
SRMR ¼ 0.08, RMSEA (90% CI) ¼ 0.11 (0.10
e0.12)
Poor
PEPPI-1023 e a ¼ 0.91 Good e e e e Conﬁrmatory FA: two-factor model good ﬁt
(df ¼ 33, P-value ¼ 0.000) except
RMSEA ¼ 0.164 above cutoff
Good
Note: Content validity, criterion validity and responsiveness were not reported on in any included articles, hence do not appear in the table.
IHLC ¼ internal health locus of control, PHLC ¼ powerful others health locus of control, CHLC ¼ chance health locus of control, PDP ¼ perceived difﬁculty for physicians, PDPh ¼ perceived difﬁculty for pharmacists, SEP ¼ self-
efﬁcacy for physicians, SEPh ¼ self-efﬁcacy for pharmacists, CP ¼ controllability for physicians, CPh ¼ controllability for pharmacists, PAM-13 ¼ patient Activation Measure-13. FA ¼ factor analysis, PCA ¼ principal components
analysis, GFI¼ goodness of ﬁt index, MNSQ¼ inﬁt & outﬁt mean square statistics, NRS¼ numerical rating score, NS¼ non-signiﬁcant, NNFI¼ non-normed ﬁt index, CFI¼ comparative ﬁt index, SRMR ¼ standardized root mean
square residual, RMSEA ¼ root mean square error of approximation, SB c2 ¼ SatorraeBentler chi-squared statistic, LOA ¼ limits of agreement, MFES ¼ modiﬁed fall efﬁcacy scale, OSES ¼ osteoporosis self-efﬁcacy scale, SEE-
C ¼ self-efﬁcacy for exercise scale.
* This ﬁeld was only completed for those instruments based on Item Response Theory (IRT).
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Table VI
Measurement properties of instruments measuring self-management: construct validity, cross-cultural validity, and ﬂoor and ceiling effects
Instrument Construct validity (Hypothesis testing) Cross-cultural validity Floor & ceiling effects
Hypothesis Result COSMIN
score
Result COSMIN
score
Result
MHLC18 e e e e e Seven items, including all six
items of the IHLC scale,
exhibited skewness that
exceeded 1.00 (i.e., a ‘‘ceiling
effect’’). No ﬂoor effect
PBC19 e e e e e e
PAM-1316 e e e Items 1 and 4 were adjusted to
make more sense in Korean
translation. PCA indicated
unidimensionality
Fair* e
ENAT20 e e e e e e
PEPPI-521 Expected correlations: Strongly
positively correlated with EC-
17, moderately positively with
GSES, weakly positively with
AIMS2 family & friends scale
and SF-36 MCS and not
correlated with SF-36 PCS and
pain NRS
EC-17: r ¼ 0.52, P < 0.01
GSES: r ¼ 0.07 (not sig)
AIMS2 F & F: r ¼ 0.23, P < 0.05
SF-36 MCS: R ¼ 0.26, P < 0.01
SF-36 PCS: r ¼ 0.05 (NS)
Pain NRS: r ¼ 0.12 (NS)
Fair e e No ﬂoor and ceiling effects: no
patients scored ﬁve and 26
patients (11.6%) scored 25
SCQOA17 e e e e e e
EC-1722 Expected correlations: Strongly
correlated PEPPI-5, moderately
correlated GSES and AIMS2 F &
f, moderate correlation SF-36
MCS, weak correlations SF-36
PCS & pain NRS
PEPPI-5: r ¼ 0.55, P < 0.01
GSES: r ¼ 0.26, P < 0.01
AIMS2 F & F: r ¼ 0.34, P < 0.01
SF-36 MCS: r ¼ 0.39, P < 0.01
SF-36 PCS: r ¼ 0.14, P < 0.05
Pain NRS: r ¼ 0.21, P < 0.01
Poor Following pretests small
wording changes made in six
items. CFA supported
unidimensional structure of the
scale
Poor* No ceiling or ﬂoor effect found:
no participants scored zero and
only 1.3% achieved maximum
score
PEPPI-1023 No hypothesis and expected
correlations not stated
SEE-C: r ¼ 0.292, P < 0.01
MFES: r ¼ 0.220, P < 0.05
OSES: r ¼ 0.315, P < 0.01
Poor Following pretests, two items
were modiﬁed to suit Chinese
language. FA showed Chinese
version of PEPPI-10 has two
common factors; different to 1
factor reported previously for
the English version
Fair* Ceiling effect found for 28.2% of
participants. No ﬂoor effect
Note: Content validity, criterion validity and responsiveness were not reported on in any included articles, hence do not appear in the table. Floor and ceiling effects were not
evaluated using the COSMIN Checklist.
IHLC¼ internal health locus of control, PAM-13¼ Patient Activation Measure-13, GSES¼ General Self Efﬁcacy scale, AIMS2 F& F¼ Dutch Arthritis Impact Measurement Scales
2 Family and Friends scale, SF-36MCS¼ short form 36mental component summary score, SF-36 PCS¼ short form 36mental component summary score, MFES¼modiﬁed fall
efﬁcacy scale, OSES ¼ osteoporosis self-efﬁcacy scale, SEE-C ¼ self-efﬁcacy for exercise scale.
* Paper did not assess cross-cultural validity however did translate the questionnaire into other language(s) hence quality of translation items of COSMIN checklist were
rated (Box G items 4e11).
J.P. Eyles et al. / Osteoarthritis and Cartilage 25 (2017) 1210e12221218content validity for OA. The PEPPI-5 measures self-efﬁcacy in
obtaining both medical information and attention to chief health
concern from a physician, hence includes limited aspects of a pa-
tient's ability to self-manage OA. Although effective communica-
tion with a physician is important, it may not be a key outcome
used to indicate the efﬁcacy of such programmes. OA self-
management programmes are often multidisciplinary, with input
from a team of health professionals including physiotherapists,
dietitians and occupational therapists27, and some programmes do
not include a medical physician28. Hence, there is a clear need toTable VII
Summary of the assessment of measurement properties of all instruments using COSMIN
evidence
Instrument Internal consistency Reliability Measurement error Structural v
MHLC18 ? 0 0 ?
PBC19 þ 0 0 ?
PAM-1316 þ 0 0 þ
ENAT20 ? 0 0 e
PEPPI-521 þþþ e ? þþþ
SCQOA17 þ 0 0 e
EC-1722 ? ? 0 ?
PEPPI-1023 þþ 0 0 þþ
Note: Content validity and responsiveness were not reported on in any included studies
þþþ or  strong evidence,þþ ormoderate evidence, þ or limited evidence, ± c
(results)]. IHLC ¼ internal health locus of control, PAM-13 ¼ Patient Activation Measure
* Paper did not assess cross-cultural validity hence the quality criteria for rating the
measurement property result, however the translation items of COSMIN checklist weredevelop tools that have adequate content validity for participants of
OA self-management programmes.
A previous systematic review synthesized the measurement
property evidence for instruments measuring self-efﬁcacy in par-
ticipants with rheumatic conditions29. Self-efﬁcacy is deﬁned as the
conﬁdence that one possesses the ability to inﬂuence events that
affect aspects of one's life30. Self-efﬁcacy is potentially an important
aspect of self-management, however additional constructs may be
considered such as how motivated or activated participants are to
self-manage24, or beliefs about who controls their health18.rating, quality criteria for rating the results of measurement properties and levels of
alidity Hypothesis testing Cross-cultural validity Floor and ceiling effects
0 0 ?
0 0 0
0 *þ 0
0 0 0
þ 0 þþþ
0 0 0
? *? ?
? *þ e
, hence do not appear in the table.
onﬂicting evidence, ? indeterminate, 0 no information [þ positive,  negative rating
-13.
results of measurement properties (Appendix 2) were not applied to the overall
rated (Box G items 4e11).
J.P. Eyles et al. / Osteoarthritis and Cartilage 25 (2017) 1210e1222 1219The previous review included participants of mixed disease
groups with different rheumatic conditions29. Given that mea-
surement property evidence is speciﬁc to the population studied,
these measurement property results cannot be extrapolated to the
OA population. The population-speciﬁc nature of measurement
properties also placed limitations on the studies available for this
current review. Often studies were excluded at the full-text stage
because they comprised mixed disease cohorts and did not report
the OA participant results separately. This limited the number of
studies included.
The methodologies of the included studies were limited to
investigation of a small range of measurement properties. Internal
consistency and structural validity were reported for all studies.
This is similar ﬁnding to the previous systematic review of self-
efﬁcacy in patients with rheumatic conditions29. Although these
are valuable measurement properties to establish, many mea-
surement properties remain untested in the instruments of our
systematic review. Testeretest reliability estimates the relative
consistency of a measure in otherwise stable patients, so that when
any change is detected by the instrument, it can be attributed to the
intervention rather than from measurement error of the instru-
ment. Unfortunately the testeretest reliability and measurement
error for the included instruments are yet to be established in OA
patients. Testeretest reliability was tested in a larger proportion
of studies included in the systematic review on rheumatic condi-
tions, however the quality of the evidence was generally poor and
measurement error was unreported29. Hypothesis testing is a
further property that was neglected by the majority of studies in
our review. Hypothesis testing establishes whether an instrument
measures the intended construct by testing the internal relation-
ships with scores of other instruments measuring similar or
different constructs13. There is much need for future studies eval-
uating testeretest reliability, measurement error and construct
validity of instruments measuring OA self-management attitudes
and capabilities.
Cross-cultural validation was attempted in three studies that
translated questionnaires; however, true cross-cultural validation
comparing language versions was not conducted. This was also
found in the previous review of instruments measuring self-efﬁ-
cacy29. We found no evidence pertaining to content validity,
responsiveness, or MID/MIC. Similar to previous conclusions29, the
recommendations arising from the present review are limited due
to the small number of studies, their poor methodology, and the
limited scope of measurement properties assessed. Further studies
concerned with all measurement properties of existing in-
struments assessing self-management of OA is the only way to
remedy this situation.
Some existing instruments measuring attitudes towards and/or
capabilities regarding OA self-management were not featured in
the systematic review because therewas nomeasurement property
evidence available. The Health Education Impact Questionnaire
(heiQ)31 evaluates the efﬁcacy of patient education programs and
has been used to evaluate OA self-management programs5,32. Also,
the Arthritis Self Efﬁcacy Score (ASES) measures patients' perceived
self-efﬁcacy to cope with the symptoms and limitations attributed
to chronic arthritis33 and is a published outcome of existing OA self-
management programs34,35. The measurement properties of the
heiQ and ASES remain untested in the OA population. Given the
current popularity of these instruments, the measurement prop-
erties of heiQ and ASES are an important area of future research.
There were possible limitations of this systematic review; the
inclusion criteria requiring studies to be published as original ar-
ticles may have introduced publication bias. Unpublished studies
may have been more likely to contain evidence of negative results
about measurement properties of the instruments under study.However, the inclusion of only peer-reviewed articles likely
enhanced the quality of included studies, given the basic level of
scrutiny required to publish. This may have improved the quality of
the review rather than biasing it. While excluding non-English
language studies may have introduced bias, no such studies were
identiﬁed by the comprehensive search strategy.
Conclusion
This review highlights the paucity of evidence available for the
measurement properties of instruments assessing attitudes to-
wards and/or capabilities regarding OA self-management. There
were many gaps in the measurement property evidence for the
instruments identiﬁed. The instrument with the “best” properties
assessed self-efﬁcacy in communication with a physician; a very
discrete aspect of self-management. Therefore, we were unable to
make recommendations concerning instruments to assess attitudes
toward and/or capabilities regarding OA self-management. Further
well-designed studies of measurement properties of available in-
struments are required. This review may provide a starting point
for researchers to identify the instruments that are currently used
for this purpose in the OA population and the evidence for mea-
surement properties available. Once we are able to identify in-
struments with adequate measurement properties for use in this
population, we will be able to better compare the efﬁcacy of
different OA self-management programmes and inform best prac-
tice for care of our patients.
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Appendix 1. Search strategy
i) Construct
generalized self efﬁcacy scale[tiab] OR adaptive behavior[tiab]
OR multidimensional health locus of control[tiab] OR pain self
efﬁcacy questionnaire[tiab] OR health literacy management scale
[tiab] OR stages of change questionnaire in osteoarthritis[tiab] OR
health education impact questionnaire[tiab] OR patient activation
measure[tiab] OR effective consumer scale[tiab] OR arthritis self-
efﬁcacy scale[tiab] OR internal-external control[MH] OR locus of
control[tw] OR attitude to health[MH] OR health locus of control
Measurement
property
Rating Quality criteria
Internal
Consistency
þ
?

0
Factor analyses performed on adequate sample size
(7*# items and >100) AND Cronbach's alpha(s)
calculated per dimension AND Cronbach's alpha(s)
between 0.70 and 0.95
No factor analysis OR doubtful design or method
Cronbach's alpha(s) 0.70 or 0.95, despite
adequate design and method
No information found on internal consistency
Reliability þ
?

0
ICC or weighted Kappa >0.70
Doubtful design or method (e.g., time interval not
mentioned)
ICC or weighted Kappa <0.70, despite adequate
design and method
No information found on reliability
Measurement
error
þ
?

0
MIC > SDC OR MIC outside the LOA
MIC not deﬁned or doubtful design
MIC < SDC OR MIC equals or inside LOA
No information found on measurement error
Structural
validity
þ
?

0
Factors should explain at least 50% of the variance
Explained variance not mentioned
Factors explain <50% of the variance
No information found on structural validity
Hypothesis
testing
þ
?

0
Speciﬁc hypotheses were formulated AND at least
75% of the results are in accordance with these
hypotheses
Doubtful design or method (e.g., no hypotheses)
Less than 75% of hypotheses were conﬁrmed,
despite adequate design and methods
No information found on hypothesis testing
Cross-cultural
validity
þ
?

0
Original factor structure conﬁrmed or no important
DIF found between language versions
Conﬁrmatory factor analysis not applied & DIF not
assessed
Original factor structure not conﬁrmed or important
DIF found between language versions
No information found on cross-cultural validity
Floor and ceiling
effects
þ
?

0
15% of the respondents achieved the highest or
lowest possible scores
Doubtful design or method
>15% of the respondents achieved the highest
or lowest possible scores despite adequate design
and methods
No information found on interpretation
ICC ¼ intraclass correlation coefﬁcient, LOA ¼ limits of agreement, MIC ¼ minimal
important change, SDC ¼ smallest detectable change.
Adapted from Terwee et al. J Clin Epidemiol 2007; 60(1): 34e42 and F. Dobson et al.
Osteoarthritis and Cartilage 20 (2012) 1548e1562. Content and criterion validity,
responsiveness, & interpretability were not reported on in any included studies;
hence have been omitted.
J.P. Eyles et al. / Osteoarthritis and Cartilage 25 (2017) 1210e12221220[tiab] OR adaptation, psychological[MH] OR health behavior[MH]
OR health knowledge, attitudes, practice[MH] OR self manage-
ment behavio*[tiab] OR patient activation[tiab] OR self concept
[MH] OR self efﬁcacy[MH] OR conﬁdence[tiab] OR activation[tiab]
OR consumer participation[MH] OR patient education as topic
[MH] OR Patient Participation[MH] OR individualized medicine
[MH] OR patient-centered care[MH] OR goals[MH] OR patient
preference[MH] OR choice behavior[MH] OR decision making
[MH] OR patient care planning[MH] OR personalised care plan-
ning[tiab] OR patient led[tiab] OR selftreatment[tiab] OR self
treat*[tiab] OR self manage*[tiab] OR self care[tiab] OR self care
[MH]
ii) Target population
osteoarthritis[MH] ORosteoarth*[tiab] OR degenerative arthritis
[tiab] OR arthrosis[tiab]
iii) Measurement instrument ﬁlter
instrumentation[sh] OR methods[sh] OR validation studies[pt]
OR Comparative Study[pt] OR psychometrics[MH] OR psychometr*
[tiab] OR clinimetr*[tw] OR clinometr*[tw] OR “outcome assess-
ment (health care)”[MH] OR “outcome assessment”[tiab] OR
“outcome measure*”[tw] OR “observer variation”[MH] OR
“observer variation”[tiab] OR “Health Status Indicators”[MH] OR
“reproducibility of results”[MH] OR reproducib*[tiab] OR
“discriminant analysis”[MH] OR reliab*[tiab] OR unreliab*[tiab] OR
valid*[tiab] OR coefﬁcient[tiab] OR homogeneity[tiab] OR homo-
geneous[tiab] OR “internal consistency”[tiab] OR (cronbach*[tiab]
AND (alpha[tiab] OR alphas[tiab])) OR (item[tiab] AND (correla-
tion*[tiab] OR selection*[tiab] OR reduction*[tiab])) OR agreement
[tiab] OR precision[tiab] OR imprecision[tiab] OR “precise value-
s”[tiab] OR testeretest[tiab] OR (test[tiab] AND retest[tiab]) OR
(reliab*[tiab] AND (test[tiab] OR retest[tiab])) OR stability[tiab] OR
interrater[tiab] OR inter-rater[tiab] OR intrarater[tiab] OR intra-
rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR intratester
[tiab] OR intra-tester[tiab] OR interobserver[tiab] OR inter-observer
[tiab] OR intraobserver[tiab] OR intraobserver[tiab] OR inter-
technician[tiab] OR inter-technician[tiab] OR intratechnician[tiab]
OR intra-technician[tiab] OR interexaminer[tiab] OR inter-
examiner[tiab] OR intraexaminer[tiab] OR intra-examiner[tiab]
OR interassay[tiab] OR inter-assay[tiab] OR intraassay[tiab] OR
intra-assay[tiab] OR interindividual[tiab] OR inter-individual[tiab]
OR intraindividual[tiab] OR intra-individual[tiab] OR inter-
participant[tiab] OR inter-participant[tiab] OR intraparticipant
[tiab] OR intra-participant[tiab] OR kappa[tiab] OR kappa's[tiab] OR
kappas[tiab] OR repeatab*[tiab] OR ((replicab*[tiab] OR repeated
[tiab]) AND (measure[tiab] OR measures[tiab] OR ﬁndings[tiab] OR
result[tiab] OR results[tiab] OR test[tiab] OR tests[tiab])) OR gen-
eraliza*[tiab] OR generalisa*[tiab] OR concordance[tiab] OR (intra-
class[tiab] AND correlation*[tiab]) OR discriminative[tiab] OR
“known group”[tiab] OR factor analysis[tiab] OR factor analyses
[tiab] OR dimension*[tiab] OR subscale*[tiab] OR (multitrait[tiab]
AND scaling[tiab] AND (analysis[tiab] OR analyses[tiab])) OR item
discriminant[tiab] OR interscale correlation*[tiab] OR error[tiab]
OR errors[tiab] OR “individual variability”[tiab] OR (variability[tiab]
AND (analysis[tiab] OR values[tiab])) OR (uncertainty[tiab] AND
(measurement[tiab] OR measuring[tiab])) OR “standard error of
measurement”[tiab] OR sensitiv*[tiab] OR responsive*[tiab] OR
((minimal[tiab] OR minimally[tiab] OR clinical[tiab] OR clinically
[tiab]) AND (important[tiab] OR signiﬁcant[tiab] OR detectable
[tiab]) AND (change[tiab] OR difference[tiab])) OR (small*[tiab]
AND (real[tiab] OR detectable[tiab]) AND (change[tiab] OR differ-
ence[tiab])) OR meaningful change[tiab] OR “ceiling effect”[tiab]OR “ﬂoor effect”[tiab] OR “Item response model”[tiab] OR IRT[tiab]
OR Rasch[tiab] OR “Differential item functioning”[tiab] OR DIF[tiab]
OR “computer adaptive testing”[tiab] OR “item bank”[tiab] OR
“cross-cultural equivalence”[tiab]
iv) Exclusion ﬁlter
“addresses”[PT] OR “biography”[PT] OR “case reports”[PT] OR
“comment”[PT] OR “directory”[PT] OR “editorial”[PT] OR “fes-
tschrift”[PT] OR “interview”[PT] OR “lectures”[PT] OR ”legal
cases”[PT] OR “legislation”[PT] OR “letter”[PT] OR “news”[PT] OR
“newspaper article”[PT] OR “patient education handout”[PT] OR
“popular works”[PT] OR “congresses”[PT] OR “consensus develop-
ment conference”[PT] OR “consensus development conference,
nih”[PT] OR “practice guideline”[Publication Type]) NOT (“animal-
s”[MeSH Terms] NOT “humans”[MeSH Terms]Appendix 2. Quality criteria for rating the results of
measurement properties
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